
<html lang="en"     class="pb-page"  data-request-id="0f2a370b-ad88-4d3f-b332-55828b08f084"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;issue:issue:10.1021/jmcmar.2016.59.issue-3;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.5b01483;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326)" /></meta><meta name="dc.Creator" content="Timothy P.  Heffron" /></meta><meta name="dc.Creator" content="Robert A.  Heald" /></meta><meta name="dc.Creator" content="Chudi  Ndubaku" /></meta><meta name="dc.Creator" content="BinQing  Wei" /></meta><meta name="dc.Creator" content="Martin  Augistin" /></meta><meta name="dc.Creator" content="Steven  Do" /></meta><meta name="dc.Creator" content="Kyle  Edgar" /></meta><meta name="dc.Creator" content="Charles  Eigenbrot" /></meta><meta name="dc.Creator" content="Lori  Friedman" /></meta><meta name="dc.Creator" content="Emanuela  Gancia" /></meta><meta name="dc.Creator" content="Philip S.  Jackson" /></meta><meta name="dc.Creator" content="Graham  Jones" /></meta><meta name="dc.Creator" content="Aleksander  Kolesnikov" /></meta><meta name="dc.Creator" content="Leslie B.  Lee" /></meta><meta name="dc.Creator" content="John D.  Lesnick" /></meta><meta name="dc.Creator" content="Cristina  Lewis" /></meta><meta name="dc.Creator" content="Neville  McLean" /></meta><meta name="dc.Creator" content="Mario  Mörtl" /></meta><meta name="dc.Creator" content="Jim  Nonomiya" /></meta><meta name="dc.Creator" content="Jodie  Pang" /></meta><meta name="dc.Creator" content="Steve  Price" /></meta><meta name="dc.Creator" content="Wei Wei  Prior" /></meta><meta name="dc.Creator" content="Laurent  Salphati" /></meta><meta name="dc.Creator" content="Steve  Sideris" /></meta><meta name="dc.Creator" content="Steven T.  Staben" /></meta><meta name="dc.Creator" content="Stefan  Steinbacher" /></meta><meta name="dc.Creator" content="Vickie  Tsui" /></meta><meta name="dc.Creator" content="Jeffrey  Wallin" /></meta><meta name="dc.Creator" content="Deepak  Sampath" /></meta><meta name="dc.Creator" content="Alan G.  Olivero" /></meta><meta name="dc.Description" content="Inhibitors of the class I phosphoinositide 3-kinase (PI3K) isoform PI3Kα have received substantial attention for their potential use in cancer therapy. Despite the particular attraction of targetin..." /></meta><meta name="Description" content="Inhibitors of the class I phosphoinositide 3-kinase (PI3K) isoform PI3Kα have received substantial attention for their potential use in cancer therapy. Despite the particular attraction of targetin..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 20, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b01483" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01483" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b01483" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01483" /></link>
        
    
    

<title>The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01483" /></meta><meta property="og:title" content="The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0019.jpeg" /></meta><meta property="og:description" content="Inhibitors of the class I phosphoinositide 3-kinase (PI3K) isoform PI3Kα have received substantial attention for their potential use in cancer therapy. Despite the particular attraction of targeting PI3Kα, achieving selectivity for the inhibition of this isoform has proved challenging. Herein we report the discovery of inhibitors of PI3Kα that have selectivity over the other class I isoforms and all other kinases tested. In GDC-0032 (3, taselisib), we previously minimized inhibition of PI3Kβ relative to the other class I insoforms. Subsequently, we extended our efforts to identify PI3Kα-specific inhibitors using PI3Kα crystal structures to inform the design of benzoxazepin inhibitors with selectivity for PI3Kα through interactions with a nonconserved residue. Several molecules selective for PI3Kα relative to the other class I isoforms, as well as other kinases, were identified. Optimization of properties related to drug metabolism then culminated in the identification of the clinical candidate GDC-0326 (4)." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b01483"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01483">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b01483&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b01483&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b01483&amp;href=/doi/10.1021/acs.jmedchem.5b01483" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 3</span><span class="cit-fg-pageRange">, 985-1002</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/3" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01439" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b01512" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (<i>S</i>)-2-((2-(1-Isopropyl-1<i>H</i>-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[<i>f</i>]imidazo[1,2-<i>d</i>][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326)</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Timothy+P.++Heffron">Timothy P. Heffron</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+A.++Heald">Robert A. Heald</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chudi++Ndubaku">Chudi Ndubaku</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=BinQing++Wei">BinQing Wei</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Martin++Augistin">Martin Augistin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steven++Do">Steven Do</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kyle++Edgar">Kyle Edgar</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Charles++Eigenbrot">Charles Eigenbrot</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lori++Friedman">Lori Friedman</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Emanuela++Gancia">Emanuela Gancia</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Philip+S.++Jackson">Philip S. Jackson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Graham++Jones">Graham Jones</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Aleksander++Kolesnikov">Aleksander Kolesnikov</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Leslie+B.++Lee">Leslie B. Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+D.++Lesnick">John D. Lesnick</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Cristina++Lewis">Cristina Lewis</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Neville++McLean">Neville McLean</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mario++M%C3%B6rtl">Mario Mörtl</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jim++Nonomiya">Jim Nonomiya</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jodie++Pang">Jodie Pang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steve++Price">Steve Price</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wei+Wei++Prior">Wei Wei Prior</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Laurent++Salphati">Laurent Salphati</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steve++Sideris">Steve Sideris</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steven+T.++Staben">Steven T. Staben</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stefan++Steinbacher">Stefan Steinbacher</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Vickie++Tsui">Vickie Tsui</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey++Wallin">Jeffrey Wallin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Deepak++Sampath">Deepak Sampath</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alan+G.++Olivero">Alan G. Olivero</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Argenta, Early Discovery Charles River, 7-9 Spire Green Centre, Flex Meadow, Harlow, EssexCM19 5TR, United Kingdom</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Proteros Biostructures GmbH, Bunsenstr. 7aD, 82152 Martinsried, Germany</span></div><div class="corresp-info"><strong>*</strong>Phone: (650) 467-3214. Fax: (650) 225-2061. E-mail: <a href="/cdn-cgi/l/email-protection#e89c808d8e8e9a8786a88f8d868dc68b8785"><span class="__cf_email__" data-cfemail="8df9e5e8ebebffe2e3cdeae8e3e8a3eee2e0">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01483&amp;href=/doi/10.1021%2Facs.jmedchem.5b01483" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 3</span><span class="cit-pageRange">, 985–1002</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 7, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>23 September 2015</li><li><span class="item_label"><b>Published</b> online</span>20 January 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 February 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b01483" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01483</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D985%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DTimothy%2BP.%2BHeffron%252C%2BRobert%2BA.%2BHeald%252C%2BChudi%2BNdubaku%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D3%26contentID%3Dacs.jmedchem.5b01483%26title%3DThe%2BRational%2BDesign%2Bof%2BSelective%2BBenzoxazepin%2BInhibitors%2Bof%2Bthe%2B%25CE%25B1-Isoform%2Bof%2BPhosphoinositide%2B3-Kinase%2BCulminating%2Bin%2Bthe%2BIdentification%2Bof%2B%2528S%2529-2-%2528%25282-%25281-Isopropyl-1H-1%252C2%252C4-triazol-5-yl%2529-5%252C6-dihydrobenzo%255Bf%255Dimidazo%255B1%252C2-d%255D%255B1%252C4%255Doxazepin-9-yl%2529oxy%2529propanamide%2B%2528GDC-0326%2529%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1002%26publicationDate%3DFebruary%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b01483"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3441</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">51</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b01483" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;P. Heffron&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;A. Heald&quot;},{&quot;first_name&quot;:&quot;Chudi&quot;,&quot;last_name&quot;:&quot;Ndubaku&quot;},{&quot;first_name&quot;:&quot;BinQing&quot;,&quot;last_name&quot;:&quot;Wei&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;Augistin&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;Do&quot;},{&quot;first_name&quot;:&quot;Kyle&quot;,&quot;last_name&quot;:&quot;Edgar&quot;},{&quot;first_name&quot;:&quot;Charles&quot;,&quot;last_name&quot;:&quot;Eigenbrot&quot;},{&quot;first_name&quot;:&quot;Lori&quot;,&quot;last_name&quot;:&quot;Friedman&quot;},{&quot;first_name&quot;:&quot;Emanuela&quot;,&quot;last_name&quot;:&quot;Gancia&quot;},{&quot;first_name&quot;:&quot;Philip&quot;,&quot;last_name&quot;:&quot;S. Jackson&quot;},{&quot;first_name&quot;:&quot;Graham&quot;,&quot;last_name&quot;:&quot;Jones&quot;},{&quot;first_name&quot;:&quot;Aleksander&quot;,&quot;last_name&quot;:&quot;Kolesnikov&quot;},{&quot;first_name&quot;:&quot;Leslie&quot;,&quot;last_name&quot;:&quot;B. Lee&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;D. Lesnick&quot;},{&quot;first_name&quot;:&quot;Cristina&quot;,&quot;last_name&quot;:&quot;Lewis&quot;},{&quot;first_name&quot;:&quot;Neville&quot;,&quot;last_name&quot;:&quot;McLean&quot;},{&quot;first_name&quot;:&quot;Mario&quot;,&quot;last_name&quot;:&quot;Mörtl&quot;},{&quot;first_name&quot;:&quot;Jim&quot;,&quot;last_name&quot;:&quot;Nonomiya&quot;},{&quot;first_name&quot;:&quot;Jodie&quot;,&quot;last_name&quot;:&quot;Pang&quot;},{&quot;first_name&quot;:&quot;Steve&quot;,&quot;last_name&quot;:&quot;Price&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Wei Prior&quot;},{&quot;first_name&quot;:&quot;Laurent&quot;,&quot;last_name&quot;:&quot;Salphati&quot;},{&quot;first_name&quot;:&quot;Steve&quot;,&quot;last_name&quot;:&quot;Sideris&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;T. Staben&quot;},{&quot;first_name&quot;:&quot;Stefan&quot;,&quot;last_name&quot;:&quot;Steinbacher&quot;},{&quot;first_name&quot;:&quot;Vickie&quot;,&quot;last_name&quot;:&quot;Tsui&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;Wallin&quot;},{&quot;first_name&quot;:&quot;Deepak&quot;,&quot;last_name&quot;:&quot;Sampath&quot;},{&quot;first_name&quot;:&quot;Alan&quot;,&quot;last_name&quot;:&quot;G. Olivero&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;20&quot;,&quot;issue&quot;:&quot;3&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;985-1002&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b01483&quot;},&quot;abstract&quot;:&quot;Inhibitors of the class I phosphoinositide 3-kinase (PI3K) isoform PI3Kα have received substantial attention for their potential use in cancer therapy. Despite the particular attraction of targeting PI3Kα, achieving selectivity for the inhibition of this isoform has proved challenging. Herein we report the discovery of inhibitors of PI3Kα that have selectivity over the other class I isoforms and all other kinases tested. In GDC-0032 (3, taselisib), we previously minimized inhibition of PI3Kβ relative to the other class I insoforms. Subsequently, we extended our efforts to identify PI3Kα-specific inhibitors using PI3Kα crystal structures to inform the design of benzoxazepin inhibitors with selectivity for PI3Kα through interactions with a nonconserved residue. Several molecules selective for PI3Kα relative to the other class I isoforms, as well as other kinases, were identified. Optimization of properties related to drug metabolism then culminated in the identification of the clinical candidate GDC-0326 (4).&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01483&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01483" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01483&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01483" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01483&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01483" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01483&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01483&amp;href=/doi/10.1021/acs.jmedchem.5b01483" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b01483" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b01483" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b01483%26sid%3Dliteratum%253Aachs%26pmid%3D26741947%26genre%3Darticle%26aulast%3DHeffron%26date%3D2016%26atitle%3DThe%2BRational%2BDesign%2Bof%2BSelective%2BBenzoxazepin%2BInhibitors%2Bof%2Bthe%2B%25CE%25B1-Isoform%2Bof%2BPhosphoinositide%2B3-Kinase%2BCulminating%2Bin%2Bthe%2BIdentification%2Bof%2B%2528S%2529-2-%2528%25282-%25281-Isopropyl-1H-1%252C2%252C4-triazol-5-yl%2529-5%252C6-dihydrobenzo%255Bf%255Dimidazo%255B1%252C2-d%255D%255B1%252C4%255Doxazepin-9-yl%2529oxy%2529propanamide%2B%2528GDC-0326%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D3%26spage%3D985%26epage%3D1002%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290658" title="Amides">Amides</a>,</li><li><a href="/action/doSearch?ConceptID=291880" title="Crystal structure">Crystal structure</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/3" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/jmcmar.2016.59.issue-3/20160211/jmcmar.2016.59.issue-3.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01483&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Inhibitors of the class I phosphoinositide 3-kinase (PI3K) isoform PI3Kα have received substantial attention for their potential use in cancer therapy. Despite the particular attraction of targeting PI3Kα, achieving selectivity for the inhibition of this isoform has proved challenging. Herein we report the discovery of inhibitors of PI3Kα that have selectivity over the other class I isoforms and all other kinases tested. In GDC-0032 (<b>3</b>, taselisib), we previously minimized inhibition of PI3Kβ relative to the other class I insoforms. Subsequently, we extended our efforts to identify PI3Kα-specific inhibitors using PI3Kα crystal structures to inform the design of benzoxazepin inhibitors with selectivity for PI3Kα through interactions with a nonconserved residue. Several molecules selective for PI3Kα relative to the other class I isoforms, as well as other kinases, were identified. Optimization of properties related to drug metabolism then culminated in the identification of the clinical candidate GDC-0326 (<b>4</b>).</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17661" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17661" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Inhibition of the phosphoinositide 3-kinases (PI3Ks) has received significant attention for its potential in the treatment of several diseases. Within the PI3 kinase family, there are four class I PI3K isoforms (α, β, δ, and γ). Of these isoforms, PI3Kα is the most commonly associated with cancers.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> PI3Kβ has been a target for preventing or treating the formation of blood clots,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and PI3Kβ selective inhibitors are also under clinical study for the treatment of phosphatase and tensin homologue (PTEN) deficient cancers.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> PI3Kδ and PI3Kγ are expressed almost exclusively in leukocytes and have been identified as targets primarily for inflammatory, autoimmune, and respiratory indications but with recent approval of idelalisib (a PI3Kδ inhibitor) for oncology applications.<a onclick="showRef(event, 'ref5 ref6 ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7 ref8 ref9">(5-9)</a> PI3Kα remains the most extensively studied isoform for oncology, with numerous clinical inhibitors under evaluation.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10, 11)</a></div><div class="NLM_p">Despite the implicated importance of inhibiting PI3Kα in particular, achieving selective inhibition of this isoform has proved challenging and few reports of molecules with specificity for PI3Kα have appeared.<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12-14)</a> Recently, and since the conclusion of our efforts described here, very notable achievements in this area have been reported describing a successful parallel chemistry approach to the identification of highly selective PI3Kα inhibitors including the clinical inhibitor NVP-BYL719.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15, 16)</a> While we have previously disclosed approaches to achieve inhibition of PI3Kα with biochemical selectivity over PI3Kβ,<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17, 18)</a> clinical candidates GDC-0941 (<b>1</b>) and GDC-0980 (<b>2</b>) are not selective for PI3Kα relative to the other class I isoforms, and GDC-0032 (<b>3</b>, taselisib) is sparing of PI3Kβ (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21">(19-21)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of clinical candidate inhibitors of class I PI3Ks, <b>1</b>; class I PI3Ks and mTOR kinase, <b>2</b>; class I PI3Ks with selectivity for PI3Kα relative to PI3Kβ, <b>3</b>; PI3Kα isoform selective, <b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01483&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">With the advancement of <b>1</b>–<b>3</b> into clinical studies, we turned the attention of our program to identify PI3Kα inhibitors which display selectivity over each of the other class I isoforms. Improved selectivity for PI3Kα relative to the other isoforms has the potential for increased tolerability in the clinical setting. The efforts leading to the discovery of the PI3Kα-specific inhibitor clinical candidate <b>4</b> (GDC-0326, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) are described herein.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21845" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21845" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">At the onset of our efforts to achieve a PI3Kα specific inhibitor, no PI3Kα crystal structures were available, with only PI3Kγ crystal structures available publicly or internally to our team. As a result, our approach relied on sequence homology to identify key residues to target that differ between PI3Kα and the other class I isoforms to achieve selectivity.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> These initial efforts using the benzoxepin series of molecules resulted only in selectivity over PI3Kβ and little to no selectivity for PI3Kα relative to the other isoforms.<a onclick="showRef(event, 'ref17 ref18 ref23'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref23">(17, 18, 23)</a></div><div class="NLM_p">Our understanding and approach to achieving PI3Kα specific inhibitors changed when we gained access to two PI3Kα crystal structures at 3.0 Å resolution. The first structure, which does not contain a small molecule in the active site of the enzyme, appeared in the public domain.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The second structure was acquired internally in complex with benzoxepin <b>5</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>A). Greater clarity into potential α-specificity determinants was provided by these PI3Kα crystal structures. In each of the two structures, Gln859 and His855 had well-defined electron density and are seen to adopt consistent conformations (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>B). This observation suggested that these two residues, which are uniquely Gln and His in PI3Kα and appear conformationally restrained, would be suitable to target to achieve high PI3Kα specificity. Of these two residues, interaction with Gln859 presented the greater opportunity to differentiate affinity between PI3Kα and the other class I isoforms due to the possibility of achieving multiple unique hydrogen bonds with its side chain.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> In support of this, modeling suggested that the position of our benzoxepin series of molecules within the active site provided adequate vectors to contact Gln859.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Crystal structure of <b>5</b> in PI3Kα (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DXH">5DXH</a>). Probable hydrogen bond between Gln859 and backbone NH of Thr856 is labeled in red. Also indicated are the corresponding residues in the other Class I PI3K isoforms. (B) Overlay of A with the public crystal structure of PI3Kα (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RD0">2RD0</a>). (C) Structure, PI3Kα <i>K</i><sub>i,app</sub> and isoform selectivity of <b>5</b>, the PI3K inhibitor contained within crystal structure A.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01483&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With a goal of achieving the maximum enthalpic benefit through interaction with Gln859, we designed molecules which contained an amide or amide isostere as such a moiety could theoretically be able to form complementary hydrogen bonds with Gln859. To aid the design of molecules with functionality positioned to contact Gln859, we used two complementary approaches. First, we utilized the desktop modeling software Benchware3D to design from the crystal structure of <b>5</b> in PI3Kα (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>A). We also used Link and Grow computational approaches to identify linkers between the core benzoxazepin and functional groups (e.g., amides, ureas, pyrazoles) that were optimally positioned to achieve hydrogen bonding interactions with Gln859.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Primary amide functionality joined to the benzoxazepin core by a two atom spacer frequently appeared in target molecules that were identified from both design approaches, and these were prioritized for synthesis. We chose to begin our efforts with a 9-azabenzoxazepin core (see <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> and <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) to facilitate synthetic chemistry for the rapid production of analogues to evaluate our hypothesis to gain isoform selectivity.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01483&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) NIS, DMF; (b) <i>t</i>-BuONO<sub>2</sub>, TFA, MeOH; (c) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF; (d) LiHMDS, THF, −78 °C; (e) <b>19</b>, KHCO<sub>3</sub>, THF, H<sub>2</sub>O, reflux; (f) toluene, 130 °C; (g) NaH, DMF; (h) HBr, AcOH, 80 °C; (i) POCl<sub>3</sub>; (j) NaH, PhNTf<sub>2</sub>, NMP; (k) formamide 130 °C; (l) (i) <i>n</i>-BuLi, THF −15 °C, (ii) <b>20</b>, −70 °C.</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Biochemical Potency and Class I PI3K Isoform Selectivity for Aza-benzoxazepins Targeting Hydrogen Bonding with Gln859</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0013.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0014.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">All <i>K</i><sub>i,app</sub> values reported represent geometric means of a minimum of three determinations. These assays generally produced results within 2-fold of the reported mean.</p></div></div><div></div></div><div class="NLM_p">The synthetic route to 8-substituted 9-azabenzoxazepins began with regiospecific iodination of commercially available 2-amino-4-chloro-pyridine (<b>6</b>) with NIS. The amino group was then replaced with a methoxy substituent (<b>8</b>), to serve as a protecting group, via diazotization in the presence of methanol and TFA. Palladium-catalyzed cyanation followed by reaction with LiHMDS gave the fully functionalized pyridine amidine <b>10</b>. The imidazole ring was formed through reaction of chloromethylketone <b>19</b> under optimized literature conditions.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The chloroketone <b>19</b> itself was prepared from regiospecific lithiation of 1-isopropyl-1<i>H</i>-[1,2,4]triazole <b>18</b>, followed by condensation reaction with chloromethyl Weinreb amide <b>20</b>. 1-Isopropyl-1<i>H</i>-[1,2,4]triazole <b>18</b> was prepared from the reaction of isopropylhydrazine with formamide at high temperature. With <b>11</b>, the benzoxazepin ring was then formed by regiospecific reaction of the imidazole with ethylene carbonate followed by intramolecular SNAr. The methoxy group was deprotected using HBr/AcOH to reveal pyridone <b>14</b>, which subsequently allowed for the formation of the fully elaborated core with a chloro (<b>15</b>) or triflate (<b>16</b>) leaving group at the 8-position. Reaction of <b>14</b>–<b>16</b> under the specified conditions allowed for introduction of the desired ether or amine, respectively (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01483&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Alcohol, PPh<sub>3</sub>, DIAD, THF or dioxane; (b) 7 N NH<sub>3</sub>, MeOH, 50 °C; (c) (i) LiOH·H<sub>2</sub>O, MeOH, H<sub>2</sub>O, 50 °C, (ii) NH<sub>4</sub>Cl, HATU, DMF, Et<sub>3</sub>N; (d) (i) NaH, DMF, PhNTf<sub>2</sub>, (ii) <span class="smallcaps smallerCapital">l</span>-prolinamide, 70–100 °C; (e) amine, Et<sub>3</sub>N, NMP, 150 °C; (f) (i) 3,4-methoxybenzylamine, NMP, 85 °C, (ii) TFA 40 °C; (g) (i) CH<sub>3</sub>HNCH<sub>2</sub>CO<sub>2</sub>CH<sub>3</sub>, NMP, 85 °C, (ii) 7 N NH<sub>3</sub>, MeOH, 50 °C.</p></p></figure><div class="NLM_p">Using the synthetic route described in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>, we accessed both ether and amine substitutions of the pyridyl ring (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Where R is methoxy in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> (<b>13</b>), as a baseline comparison, moderate selectivity was observed for PI3Kα over PI3Kβ, but no selectivity was achieved over PI3Kδ or PI3Kγ. By extending the methoxy group to include a primary amide designed to achieve hydrogen bonding contacts with Gln859 and Ser854 (<b>24</b>), improvement in PI3Kα potency, along with improvement in selectivity over each of the other isoforms, was achieved. When the methylene of compound <b>24</b> was further substituted with a methyl group (<b>25</b>), some selectivity benefit was noted against the β and γ isoforms. However, a quaternary center (<b>26</b>) resulted in loss of potency compared to <b>24</b> and <b>25</b>. In the series of aminopyridines (<b>27</b>–<b>32</b>), the baseline comparitor selected was the primary amine (<b>27</b>), which exhibited only modest selectivity over the β isoform. SAR suggested the importance of the primary amide for potency and isoform selectivity (<b>28</b>–<b>30</b>). Tertiary amine <b>28</b> achieved high potency and isoform selectivity. With that understanding, we also investigated pyrrolidine substitution and found that <b>29</b> (derived from the <span class="smallcaps smallerCapital">d</span>-proline) was more potent than its enantiomer <b>30</b> and that both had greater isoform selectivity than the unsubstituted pyrrolidine <b>31</b>. Changing the primary amide in <b>29</b> to the NHMe amide in <b>32</b> resulted in a significant reduction in potency, consistent with the model (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>) that suggested methyl substitution would result in loss of hydrogen bonding interaction and a steric clash with Gln859.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Docking model of <b>29</b> in PI3Kα. Compound <b>29</b> is predicted to form three concerted hydrogen bonds with the protein. A two-dimensional depiction of structure <b>29</b> is shown next to the docking model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01483&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Several of the potent and selective 9-aza compounds from <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> were progressed to in vitro and in vivo metabolism and pharmacokinetics studies. In contrast to our previous experience with 8-pyrazole benzoxazepine analogues,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> clearance in rats for the PI3Kα isoform selective 9-aza benzoxepin analogues tested was high and not predicted by in vitro microsomal stability (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>) or hepatocyte stability (data not shown). Additionally, one of three compounds showed systemic clearance well above the average hepatic blood flow of a rat (<b>31</b>), suggestive of nonhepatic clearance mechanisms.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Most concerning, none of the tested compounds had systemic clearance values under liver blood flow despite moderate stability in microsomes, suggesting noncytochrome P450 mediated mechanism(s) of clearance.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Predicted Hepatic Cl from Microsomal Stability and Rat in Vivo Cl Data for Select 9-Aza-benzoxazepins</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">human liver microsomes Cl<sub>hep</sub> (mL/min/kg)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">rat liver microsomes Cl<sub>hep</sub> (mL/min/kg)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">rat Cl (mL/min/kg)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="char" char=".">62</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="char" char=".">83</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">38</td><td class="colsep0 rowsep0" align="char" char=".">125</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Hepatic clearance was predicted from liver microsome incubations using the “in vitro <i>t</i><sub>1/2</sub> method”.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Male Sprague–Dawley rats were dosed intravenously with 1 mg/kg of each compound prepared in 60%PEG400/10% ethanol.</p></div></div></div><div class="NLM_p">When considering potential contributions to extrahepatic clearance, we were initially concerned that the primary amide common to molecules with high isoform specificity (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) was prone to hydrolysis. However, compound <b>31</b> lacked this amide and still seemed to be vulnerable to extrahepatic clearance. Additionally, metabolite identification studies of <b>29</b> in both rat and human hepatocytes did not reveal any amide hydrolysis or conjugation (data not shown).</div><div class="NLM_p">While an exact site of oxidation of <b>29</b> was not determined, we considered the pyridyl ring as potentially susceptible to noncytochrome P450 mediated metabolism (e.g., aldehyde oxidase).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> In our previous experience with des-aza benzoxazepins, we had not encountered compounds with rat clearance in excess of liver blood flow and typically observed reasonable correlation with liver microsomal predictions of clearance. Therefore, we set out to synthesize analogues of the PI3Kα isoform specific compounds from <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> on the des-aza core (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0011.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01483&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) (i) amino acid, CuI, K<sub>3</sub>PO<sub>4</sub>, DMSO, 80–90 °C, (ii) NH<sub>4</sub>Cl, EDCI, HOBt, DIPEA, DMF, or NH<sub>4</sub>Cl, HATU, DMF, Et<sub>3</sub>N; (b) KOH, dioxane, water, Pd<sub>2</sub>dba<sub>3</sub>, 2-ditertbutylphosphino-2′,4′,6′-triisopropylbiphenyl, 90 °C; (c) (i) <i>t</i>-Bu-(<span class="smallcaps smallerCapital">d</span>)-lactate or <i>t</i>-Bu-(<i>R</i>)-2-hydroxybutyrate, PPh<sub>3</sub>, DIAD, THF, (ii) TFA, CH<sub>2</sub>Cl<sub>2</sub>, (iii) NH<sub>4</sub>Cl, HATU, DMF, Et<sub>3</sub>N; (d) 2-bromoacetamide, Cs<sub>2</sub>CO<sub>3</sub>, DMF; (e) (i) ethyl-(<span class="smallcaps smallerCapital">l</span>)-lactate, PPh<sub>3</sub>, DIAD, THF, (ii) LiOH·H<sub>2</sub>O, MeOH, H<sub>2</sub>O, 50 °C, (iii) NH<sub>4</sub>Cl, HATU, DMF, Et<sub>3</sub>N.</p></p></figure><div class="NLM_p">The synthesis of target molecules began with 8-bromo benzoxazepin <b>33</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Compound <b>33</b> was converted to desired anilines (<b>34</b>–<b>36</b>) via copper catalyzed coupling followed by conversion of the amino acid to the primary amide. The aryl ethers <b>4</b> and <b>38</b>–<b>40</b> were obtained via Mitsunobu reaction of phenol <b>37</b>, which was also accessed via bromide <b>33</b>.</div><div class="NLM_p">A comparison of <b>34</b> (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>) with its corresponding analogue in the 9-aza series (<b>29</b>, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) reveals comparable and desirable potency and isoform selectivity. Additionally, the improved potency of <b>34</b> relative to <b>35</b> and <b>36</b> suggests the importance of optimally positioning the primary amide. We were curious to find that 8-ether analogue <b>38</b> (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>) had little to no selectivity for PI3Kα over the other isoforms. Although the 2-ethanamide ether of <b>38</b> should be long enough to allow for the hydrogen bonds with His855 and Gln859 (see for example <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>), conformational analysis showed that the addition of a 2-methyl with an <i>S</i> chirality would help restrict the preferred C–O bond torsion (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B) to mimic the desired value of ∼79°, as predicted by modeling to allow for hydrogen bonding interactions with Gln859 (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>C). Indeed, a search of the small molecule crystallographic database (CSD) using Mogul confirmed the effect of such substitutions. Inclusion of an <i>S</i>-methyl or <i>S</i>-ethyl (<b>4</b> and <b>39</b>) led to significant improvments in selectivity over the other three class I isoforms. We have previously reported on the apparent importance of PI3Kβ inhibition to inhibit proliferation of a cancer cell that has lost PTEN function.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> We have also previously demonstrated that compounds with enhanced PI3Kα to PI3Kβ enzyme selectivity in cell proliferation assays showed a qualitative trend for weaker effect on inhibiting proliferation in the PC3 cell line (PTEN-null) relative to inhibiting proliferation in the MCF7.1 cell line (PI3Kα mutant).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Consistent with these previous studies, improvement in selectivity over PI3Kβ is apparent in the relative potency in MCF7-neo/HER2 and PC3 cell proliferation assays (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Biochemical Potency and Class I PI3K Isoform Selectivity for Benzoxazepins Targeting Hydrogen Bonding with Gln859</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0015.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0016.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">All <i>K</i><sub>i,app</sub> values reported represent geometric means of a minimum of three determinations. These assays generally produced results within 2-fold of the reported mean.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Cellular EC<sub>50</sub> values represent geometric means of a minimum of two determinations and these assays generally produced results within 3-fold of the reported mean.</p></div></div><div></div></div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Distributions of the observed torsion angles in the CSD database where −CH<sub>2</sub>– separates an amide and an aryl ether (A) or −CHMe– separates an amide and an aryl ether (B). Query structures of Mogul searches (setting: exact structures) are shown in inset with the torsional bond colored in red. The preferred angles are labeled by the red arrows. (C) Docking model <b>4</b> in PI3Kα. <b>4</b> is predicted to form three concerted hydrogen bonds with the protein. A two-dimensional depiction of <b>4</b> is shown next to the docking model. The dihedral angle along the C–O (colored in red) bond is 79°.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01483&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It is worth noting that the improved selectivity of compounds <b>4</b> and <b>39</b> compared to compound <b>38</b> came not from better potencies against PI3Kα but from decreased affinities toward the other isoforms. One rationale for this observation could be that the <i>S</i>-alkyl substitutent somehow insults the other isoforms, leading to the better selectivity. However, modeling suggests that the alkyl group points toward the solvent, not toward the protein, which is consistent with a lack of difference between the methyl (<b>4</b>) and ethyl group (<b>39</b>). We hypothesize that the affinities of compounds <b>4</b> and <b>39</b> toward the off-target isoforms were reduced due to desolvation penalties upon binding of the primary amide and the nearby protein residues, while for PI3Kα the desolvation energy is fully compensated by three, concerted hydrogen bonds formed by the amide with His855 and Gln859 (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>C). The balance between desolvation and hydrogen bonding can also account for the reduced potency and PI3Kα selectivity of <b>40</b> (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>) for which the preferred torsional angle would not allow for engagement of the residues unique to PI3Kα.</div><div class="NLM_p">After the conclusion of these studies, a crystal structure of <b>4</b> bound to PI3Kα was obtained (2.25 Å resolution, <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A, PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DXT">5DXT</a>). Consistent with our model (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>C), when bound to PI3Kα, the primary amide of compound <b>4</b> achieves three concerted hydrogen bonds with the protein as predicted (vide supra). The dihedral angle of interest is 68° and again consistent with expectations based on observed torsion angles in the CSD database. Additionally, a crystal structure of <b>4</b> bound to PI3Kδ was also obtained (2.64 Å resolution, <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B). This crystal structure shows that the primary amide of compound <b>4</b> achieves two hydrogen bonding interactions, one with Asp832 (corresponding to His855 in PI3Kα) at an apparently suboptimal bonding angle and one with the backbone carbonyl of Ser831 (corresponding to the analogous interaction with the backbone carbonyl of Ser854 in PI3Kα), which appears nonoptimal at a distance of 3.6 Å.</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Crystal structures of <b>4</b> bound to PI3Kα (A; PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DXT">5DXT</a>) and PI3Kδ (B; PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DXU">5DXU</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01483&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In vitro metabolic stability and in vivo pharmacokinetic data for two des-aza core analogues are shown in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>. A comparison of <b>34</b> (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>) with its aza-core analogue (<b>29</b>, <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>) shows that des-aza core proline-derived analogue <b>34</b> is stable in vitro and with encouraging clearance in rat, well below liver blood flow. The O-linked analogue <b>4</b>, however, is the most stable in human and rat liver microsomes, and there is a good correlation with in vivo rat clearance. Furthermore, <b>4</b> achieves high oral bioavailability and has high unbound fraction.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. In Vitro Metabolic Stability and in Vivo Rat PK Data for Key Des-aza Benzoxazepins</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">human liver microsomes Cl<sub>hep</sub> (mL/min/kg)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">rat liver microsomes Cl<sub>hep</sub> (mL/min/kg)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">rat Cl (mL/min/kg)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">rat <i>F</i>%<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">rat PPB (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="char" char=".">33</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">120</td><td class="colsep0 rowsep0" align="char" char=".">63</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Hepatic clearance was predicted from liver microsome incubations using the “<i>in vitro</i><i>t</i><sub>1/2</sub> method”.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Male Sprague–Dawley rats were dosed intravenously with 1 mg/kg of each compound prepared in 60% PEG400/10% Ethanol.</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last">Male Sprague–Dawley rats were dosed PO with 5 mg/kg of each compound in 0.5% methylcellulose with 0.2% Tween 80 (MCT).</p></div></div></div><div class="NLM_p">The balance of potency, selectivity and appealing ADME properties led us to profile <b>4</b> in further studies. Compound <b>4</b> was found to have consistently low clearance and high oral bioavailability across species tested, enabling significant sustained free drug levels (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetic Data for <b>4</b> in Preclinical Species</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0017.gif" alt="" id="fx5" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">IV (1 mg/kg)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">PO<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char=".">microsomes Cl<sub>hep</sub> (mL/min/kg)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">in vivo Cl (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">AUC (μM·h)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th><th class="colsep0 rowsep0" align="center" char=".">PPB (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">0.6</td><td class="colsep0 rowsep0" align="char" char=".">25</td><td class="colsep0 rowsep0" align="char" char=".">31</td><td class="colsep0 rowsep0" align="char" char=".">74</td><td class="colsep0 rowsep0" align="char" char=".">55</td><td class="colsep0 rowsep0" align="char" char=".">40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="char" char=".">25.4</td><td class="colsep0 rowsep0" align="char" char=".">120</td><td class="colsep0 rowsep0" align="char" char=".">63</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cyno</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">4.8</td><td class="colsep0 rowsep0" align="char" char=".">72</td><td class="colsep0 rowsep0" align="char" char=".">39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">38</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Hepatic clearance was predicted from liver microsome incubations using the “in vitro <i>t</i><sub>1/2</sub> method”.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Male Sprague–Dawley rats, female NCR nude mice, male cynomolgus monkeys, or beagle dogs were dosed intravenously with 1 mg/kg of each compound prepared in 60% PEG400/10% ethanol.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">Compound <b>4</b> was administered PO at the indicated dose in 0.5% methylcellulose with 0.2% Tween 80 (MCT).</p></div></div></div><div class="NLM_p last">In addition to achieving selectivity over the other class I isoforms, the PI3Kα specific inhibitor <b>4</b> also achieves a very high level of selectivity over other kinases. In a panel of 235 kinases evaluated at Invitrogen, only one was inhibited by >50% by <b>4</b> when tested at 1 μM (61% inhibition of the class II PI3KC2b).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Also worth noting, <b>4</b> is not an inhibitor of cytochrome P450 enzymes tested (IC<sub>50</sub> > 10 μM against 3A4, 2C9 1A2, 2C19, 2D6), is highly permeable in MDCK cells (<i>P</i><sub>app</sub> A to B: 13 × 10<sup>–6</sup> cm/s), and has thermodynamic solubility of 82 μg/mL at pH 7.4.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">In Vivo Efficacy and Pharmacodynamics</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50731" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50731" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The identification of <b>4</b> allowed us to compare this selective inhibitor of PI3Kα with <b>3</b>, which is selective over the β isoform. A head-to-head comparison of relevant data for the interpretation of in vivo efficacy is presented in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>. While <b>3</b> achieves higher total AUC than <b>4</b> in mice at the same dose, this is offset by the substantially higher free fraction of <b>4</b> in mice. Therefore, to compare the PI3Kα specific inhibitor <b>4</b> with the PI3Kβ-sparing inhibitor <b>3</b>, we advanced both into in vivo efficacy studies in tumor xenograft models.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Potency, Selectivity, and Mouse Pharmacokinetic Parameters for <b>3</b> and <b>4</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0018.gif" alt="" id="fx6" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">mouse PK (1 mg/kg iv/25 mg/kg po)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">Pl3Kα <i>K</i><sub>i,app</sub><a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">β <i>K</i><sub>i,app</sub>/α <i>K</i><sub>i,app</sub></th><th class="colsep0 rowsep0" align="center" char=".">δ <i>K</i><sub>i,app</sub>/α <i>K</i><sub>i,app</sub></th><th class="colsep0 rowsep0" align="center" char=".">γ <i>K</i><sub>i,app</sub>/α <i>K</i><sub>i</sub><sub>app</sub></th><th class="colsep0 rowsep0" align="center" char=".">MCF7-neo/HER2 EC<sub>50</sub> (μM)<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">KPL4 EC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">Cl mL/min/kg</th><th class="colsep0 rowsep0" align="center" char=".">Vss (L/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th><th class="colsep0 rowsep0" align="center" char=".">AUC (μM·h, po)</th><th class="colsep0 rowsep0" align="center" char=".">PPB (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">31</td><td class="colsep0 rowsep0" align="char" char=".">0.4</td><td class="colsep0 rowsep0" align="char" char=".">3.3</td><td class="colsep0 rowsep0" align="char" char=".">0.03</td><td class="colsep0 rowsep0" align="char" char=".">0.01</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">388</td><td class="colsep0 rowsep0" align="char" char=".">97.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">133</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">51</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">0.06</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">0.6</td><td class="colsep0 rowsep0" align="char" char=".">55</td><td class="colsep0 rowsep0" align="char" char=".">74</td><td class="colsep0 rowsep0" align="char" char=".">40</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Female NCR nude mice were dosed intravenously with 1 mg/kg of each compound prepared in 60% PEG400/10% ethanol and PO at 25 mg/kg in 0.5% methylcellulose with 0.2% Tween 80 (MCT).</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">All <i>K</i><sub>i,app</sub> values reported represent geometric means of a minimum of three determinations. These assays generally produced results within 2-fold of the reported mean.</p></div><div class="footnote" id="t6fn3"><sup>c</sup><p class="last">Cellular EC<sub>50</sub> values represent geometric means of a minimum of two determinations and these assays generally produced results within 3-fold of the reported mean.</p></div></div></div><div class="NLM_p">The in vivo efficacy of <b>4</b> was compared to the β isoform sparing clinical PI3K inhibitor <b>3</b> in two breast cancer xenograft models that were grown in nude (MCF7-neo/HER2) and scid beige (KPL-4) mice. Daily, oral administration of <b>3</b> at a maximum tolerated dose of 25 mg/kg in the MCF7-neo/HER2 xenograft model resulted in 116% tumor growth inhibition (TGI) and four partial regressions (PRs) out of 10 animals treated when compared to vehicle treated mice (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>A). Daily administration of <b>4</b> orally at 0.78, 1.56, 3.25, 6.25, or 12.5 mg/kg resulted in dose-dependent increase in TGI (73%, 79%, 83%, 101%, and 110%, respectively) and tumor regressions (6 PRs out of 10 animals at 6.25 and 12.5 mg/kg) when compared to vehicle treated mice (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>A).</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Dose–response curves of fitted tumor volumes in response to <b>3</b> and <b>4</b> at the doses shown against MCF7-neo/HER2 (A) and KPL-4 (B) breast cancer xenografts in mice relative to vehicle (MCT; 0.5% methycellulose/0.2% Tween-80) after daily (QD) oral (PO) dosing for 21 days. Rx = treatment period.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01483&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">At the maximum tolerated dose of 25 mg/kg, daily doses of <b>3</b> resulted in 125% TGI in the KPL-4 xenograft models with eight PRs and two complete regressions (CRs) out of 10 animals treated when compared to vehicle treated mice (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>B). Daily administration of compound <b>4</b> orally at 0.78, 1.56, 3.25, 6.25, or 12.5 mg/kg also resulted in dose-dependent increase in TGI (73%, 97%, 97%, 122%, and 121%, respectively) in the KPL-4 xenograft model. Notably, maximum efficacy of <b>4</b> was observed at 6.25 mg/kg in the KPL-4 model based on TGI and tumor regressions (9 PRs and 1 CR out of 10 animals treated) when compared to vehicle treated mice (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>B). Doses of <b>4</b> up to 12.5 mg/kg were well tolerated based on less than 10% body weight loss (data not shown). Thus, increased unbound concentration of <b>4</b> at doses that were approximately 4-fold lower (6.25 mg/kg) than the maximum tolerated dose of <b>3</b> (25 mg/kg) resulted in comparable TGI in both the MCF7-neo/HER2 and KPL-4 breast cancer xenograft models.</div><div class="NLM_p">The relationship between pharmacokinetics and pharmacodynamics of <b>4</b> relative to <b>3</b> was also investigated in the MCF7-neo/HER2 xenograft model (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). The phosphorylation levels of Akt in MCF7-neo/HER2 tumors, as well as plasma drug concentrations of both compounds, were evaluated 1 h after a single dose of vehicle (MCT), <b>3</b> at 25 mg/kg or <b>4</b> at 0.39, 0.78, 1.56, 3.25, 6.25, or 12.5 mg/kg. A single dose of <b>3</b> resulted in a 74% decrease of phosphorylated Akt (pAkt<sup>Ser473</sup>) levels, while a 4-fold lower dose of <b>4</b> at 6.25 mg/kg resulted in a similar decrease in Akt phosphorylation (78%) (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>).<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The comparable decreases in pAkt between these doses of <b>4</b> and <b>3</b> is likely due to similar unbound plasma drug concentrations that were achieved in mice after 1 h of dosing (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). More importantly, these doses of <b>4</b> and <b>3</b> that potently inhibited PI3K (based on robust suppression of PI3K) were sufficient to induce tumor regressions in the MCF7-neo/HER2 xenograft model.</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0008.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Quantification of pAkt<sup>Ser473</sup> levels in MCF7-neo-HER2 tumor xenografts 1 h after a single dose of MCT vehicle (0.5% methycellulose/0.2% Tween-80), <b>3</b> at 25 mg/kg or <b>4</b> at 0.39, 0.78, 1.56, 3.25, 6.25, or 12.5 mg/kg. Phosphorylated Akt (pAkt<sup>Ser473</sup>) and total Akt (tAkt) levels were measured by Mesoscale Discovery assay, and values are expressed as ratio of pAkt/tAkt. Error bars represent SEM for tumor xenograft samples from four different animals. Corresponding unbound plasma drug concentrations (closed diamonds) for each dose of <b>3</b> or <b>4</b> are plotted on the right <i>y</i>-axis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01483&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">An optimized synthetic route to <b>4</b> is shown in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. A Mitsunobu reaction employing intermediate <b>37</b> was used for installation of the ether side chain required for isoform selectivity. While not being atom efficient, this methodology is reliably stereospecific. The amide was formed directly from ester <b>47</b> by reaction with concentrated ammonia. This route provided <b>4</b> in 19% overall yield with a longest linear sequence of 7 steps.</div><figure id="sch4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0012.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01483&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) K<sub>2</sub>CO<sub>3</sub>, BnBr, KI, acetone; (b) LiHMDS, THF, −78 °C; (c) <b>19</b>, KHCO<sub>3</sub>, THF, H<sub>2</sub>O; (d) 1,3-dioxolan-2-one, toluene, 100 °C; (e) NaH, DMF; (f) H<sub>2</sub>, Pd/C, EtOAc, IMS; (g) (<i>R</i>)-2-hydroxy-propionic acid methyl ester, PPh<sub>3</sub>, DIAD, dioxane; (h) 7 N NH<sub>3</sub>, MeOH.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55363" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55363" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Structure-based drug design targeting nonconserved residues allowed for the realization of potent benzoxazepin inhibitors of PI3Kα that are remarkably selective over the other class I isoforms in enzymatic assays. Crystal structures of <b>4</b> in PI3Kα and PI3Kδ were solved which support the proposed basis for PI3Kα selectivity. Optimization of pharmacokinetics resulted in the identification of <b>4</b> which demonstrated comparable in vivo efficacy at reduced dose when compared to the clinical inhibitor <b>3</b>. The in vitro characterization and pharmacokinetic parameters estimated in preclinical species suggest <b>4</b> would have low plasma CL in human.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The overall profile of <b>4</b> led to its selection as a clinical development candidate (not currently in clinical trials) and allows for further study of a highly optimized specific inhibitor of the PI3Kα isoform.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87372" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87372" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Chemistry</h3><div class="NLM_p">All solvents and reagents were used as obtained. <sup>1</sup>H NMR spectra were recorded with a Bruker Avance DPX400 spectrometer or a Varian Inova 400 NMR spectrometer and referenced to tetramethyl silane. Chemical shifts are expressed as δ units using tetramethylsilane as the external standard (in NMR description, s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; and br, broad peak). All final compounds were purified to >95% chemical purity, as assayed by HPLC (Waters Acquity UPLC column, 21 mm × 50 mm, 1.7 μm) with a gradient of 0–90% acetonitrile (containing 0.038% TFA) in 0.1% aqueous TFA, with UV detection at λ = 254 and 210 nm, and with CAD detection with an ESA Corona detector.</div><div class="NLM_p">High pressure liquid chromatography–mass spectrometry (LC-MS) experiments to determine retention times (rt) and associated mass ions were performed using various methods which are fully described in the <a href="/doi/suppl/10.1021/acs.jmedchem.5b01483/suppl_file/jm5b01483_si_001.pdf" class="ext-link">Supporting Information</a>. Where measured, chiral purity was assessed by SFC using Chiralpak AS column, using isocratic methods of methanol with 0.1% ammonium hydroxide/carbon dioxide. All compounds were named using Autonom 1.0 (MDL Information Systems Inc.).</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> 4-Chloro-5-iodo-pyridin-2-ylamine (<b>7</b>)</h4><div class="NLM_p last">To a solution of 2-amino-4-chloropyridine (<b>6</b>) (150 g, 0.78 mol) in DMF (1.5 L) was added NIS (341 g, 1.52 mol), and the reaction mixture stirred at room temperature for 18 h before being concentrated in vacuo to 300 mL volume. The resultant residue was poured into 10% aqueous sodium thiosulfate solution (1.2 L), stirred for 15 min, and the precipitate formed collected by filtration, washed with water, and then dried at 35 °C in vacuo to give the title compound as a pale-brown solid (185 g, 62%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ ppm 8.33 (1 H, s), 6.68 (1 H, s), 4.52 (2 H, s).</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> 4-Chloro-5-iodo-2-methoxy-pyridine (<b>8</b>)</h4><div class="NLM_p last">To a solution of <b>7</b> (64.2 g, 0.25 mol) in methanol (1.1 L) and TFA (93.7 mL, 1.26 mol) was added <i>tert</i>-butyl nitrite (150 mL, 1.26 mol) so as to maintain temperature less than 3 °C. The resultant mixture was stirred at room temperature for 1 h then allowed to warm to room temperature and stirred for 16 h. The reaction was quenched by the careful addition of water then concentrated in vacuo to 1/4 volume. The resultant residue was treated with water (1 L) and the precipitate formed collected by filtration and dried in vacuo at 35 °C to give the title compound (62.3 g, 92%). Contains 16% unidentified impurity. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ ppm 8.56 (1 H, s), 7.20 (1 H, s), 3.86 (3 H, s).</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> 4-Chloro-6-methoxy-nicotinonitrile (<b>9</b>)</h4><div class="NLM_p last">A suspension of <b>8</b> (30.5 g, 0.11 mol), zinc(II) cyanide (7.97 g, 68 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (6.56 g, 5.66 mmol), and DMF (450 mL) was degassed and then heated at 120 °C for 1 h before being concentrated in vacuo. The resultant residue was treated with water then extracted with DCM, the organic extract dried (MgSO<sub>4</sub>), filtered, and then concentrated in vacuo. The resultant residue was crystallized from DCM to give the title compound (10.1 g, 54%). The mother liquors were concentrated in vacuo and the residue subjected to flash chromatography (SiO<sub>2</sub> gradient 0–100% ethyl acetate in cyclohexane) then crystallization from cyclohexane to give the title compound (5.16 g, 28%; 82% total). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ ppm 8.45 (1 H, s), 6.90 (1 H, s), 4.01 (3 H, s).</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> 4-Chloro-6-methoxy-nicotinamidine Hydrochloride (<b>10</b>)</h4><div class="NLM_p last">To a solution of <b>9</b> (10.1 g, 59.7 mmol) in THF (300 mL) at −78 °C was added LHMDS (65.7 mL) dropwise and the reaction mixture stirred for 30 min before allowing to warm to room temperature and stirring for a further 1 h. The reaction was quenched by the addition of 1 N HCl (to pH ∼ 1) and then extracted three times with ethyl acetate. The aqueous layer was concentrated in vacuo to give a brown solid which was azeotroped with toluene to give the title compound as a tan solid. Mixture with ammonium chloride, 72% title compound by weight. (15.2 g, 83%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ ppm 9.68 (4 H, d, <i>J</i> = 15.8 Hz), 8.46 (1 H, s), 7.47 (5 H, t, <i>J</i> = 50.7 Hz), 7.27 (1 H, s), 3.95 (3 H, s).</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> 4-Chloro-5-[4-(2-isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-1<i>H</i>-imidazol-2-yl]-2-methoxy-pyridine (<b>11</b>)</h4><div class="NLM_p last">A suspension of <b>10</b> (50.9 mmol) and potassium bicarbonate (20.4 g, 202.5 mmol) in THF (128 mL) and water (21 mL) was heated to reflux and then treated with a solution of <b>19</b> (9.55 g, 50.9 mmol) in THF (25 mL). The reaction mixture was stirred at reflux for 24 h before being concentrated in vacuo. The resultant residue was diluted with water and extracted with ethyl acetate. The combined extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), treated with charcoal (15 g), filtered, and concentrated in vacuo to give a solid. The solid was triturated with 10% diethyl ether in pentane then dried in vacuo to give the title compound as a pale-brown solid (8.74 g, 54%). LC-MS: [M + H]<sup>+</sup> = 319/321. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ ppm 9.03 (1 H, s), 7.89 (1 H, s), 7.83 (1 H, s), 7.26 (1 H, s) 6.88 (1 H, s), 4.01 (3 H, s), 1.58 (6 H, d, <i>J</i> = 6.6 Hz).</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> 2-[2-(4-Chloro-6-methoxy-pyridin-3-yl)-4-(2-isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-imidazol-1-yl]-ethanol (<b>12</b>)</h4><div class="NLM_p last">To warmed ethylene carbonate (34 g, 0.39 mol) was added <b>11</b> (8.74 g, 27.4 mmol) and the mixture heated at 130 °C for 3 h. The cooled reaction mixture was diluted with DCM then subjected to flash chromatography (Si-PPC, gradient 0–5% methanol in DCM) to give the title compound as a brown foam (7.52 g, 75%). LC-MS: [M + H]<sup>+</sup> = 363/365. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ ppm 8.27 (1 H, s), 8.02 (1 H, s), 7.85 (1 H, s), 6.93 (1 H, s), 5.98–5.82 (1 H, m), 4.00 (5 H, m), 3.88 (2 H, t, <i>J</i> = 5.1 Hz), 1.51 (6 H, d, <i>J</i> = 6.6 Hz).</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> 2-(2-Isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-8-methoxy-4,5-dihydro-6-oxa-1,3a,9-triaza-benzo[<i>e</i>]azulene (<b>13</b>)</h4><div class="NLM_p last">A solution of <b>12</b> (7.52 g, 20.7 mmol) in DMF (100 mL) was cooled to 0 °C and treated with sodium hydride (804 mg, 20.1 mmol). The resultant mixture was stirred at 0 °C for 10 min then allowed to warm to room temperature and stirred for 72 h. Further sodium hydride (150 mg, 3.75 mmol) was added and stirring continued until no starting material remained (TLC) before the reaction was concentrated in vacuo. The residue was dissolved in ethyl acetate then washed with saturated brine (×3), dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated in vacuo. The resultant residue was triturated in pentane/diethyl ether (5:1) to give the title compound as a brown solid (5.38 g, 79%). LC-MS: [M + H]<sup>+</sup> = 327. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ ppm 9.35 (1 H, s), 7.87 (1 H, s), 7.63 (1 H, s), 6.37 (1 H, s), 6.03–6.02 (1 H, m), 4.54–4.53 (2 H, m), 4.53–4.33 (2 H, m), 3.99 (3 H, s), 1.57 (6 H, d, <i>J</i> = 6.6 Hz).</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 2-(2-Isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3a,9-triaza-benzo[<i>e</i>]azulen-8-ol (<b>14</b>)</h4><div class="NLM_p last">A solution of 2-(2-isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-8-methoxy-4,5-dihydro-6-oxa-1,3a,9-triaza-benzo[<i>e</i>]azulene (1.00 g, 2.97 mmol) in acetic acid (40 mL) was treated with 48% aqueous HBr (37.7 mL) and heated at 80 °C for 5 h. The reaction mixture was concentrated in vacuo then the resultant residue was suspended in water (60 mL) and the pH was adjusted to ∼6 using 5N aqueous NaOH. The precipitate formed was collected by filtration, washed with water, and then dried in vacuo. The resultant solid was triturated in acetone to give the title compound as a beige solid (3.58 g, 69%). LC-MS: [M + H]<sup>+</sup> = 313. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ ppm 8.42 (1 H, s), 7.90 (1 H, s), 7.83 (1 H, s), 5.84 (1 H, s), 5.78 (1 H, m), 4.71–4.30 (4 H, m), 1.45 (6 H, d, <i>J</i> = 6.6 Hz).</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 8-Chloro-2-(2-isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3a,9-triaza-benzo[<i>e</i>]azulene (<b>15</b>)</h4><div class="NLM_p last">A mixture of <b>14</b> (200 mg, 0.64 mmol) and phosphorus(V) oxychloride (15 mL) was heated at 150 °C for 2.25 h using microwave irradiation. The reaction mixture was concentrated in vacuo and the resultant residue taken up into 10% methanol in DCM. The solution was loaded onto a NH<sub>2</sub> cartridge eluting with 10% methanol in DCM. The eluent was concentrated in vacuo to give the title compound as an off-white solid (168 mg, 79%). LC-MS: [M + H]<sup>+</sup> = 331/333. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ ppm 9.29 (1 H, s), 8.01 (1 H, s), 7.93 (1 H, d, <i>J</i> = 0.6 Hz), 7.24 (1H, s), 5.92–5.80 (1 H, m), 4.70–4.63 (2 H, m), 4.63–4.56 (2 H, m), 1.48 (6 H, d, <i>J</i> = 6.6 Hz).</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Trifluoro-methanesulfonic Acid 2-(2-Isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3a,9-triaza-benzo[<i>e</i>]azulen-8-yl Ester (<b>16</b>)</h4><div class="NLM_p last">To a solution of <b>14</b> (400 mg, 1.28 mmol) in <i>N</i>-methyl-2-pyrrolidone (6 mL) was added sodium hydride (57 mg, 1.54 mmol, 65% in mineral oil) and heated at 40 °C for 1 h. The reaction mixture was cooled to room temperature before the addition of <i>N</i>-phenyl-bis(trifluoromethanesulfonimide) (550 mg, 1.54 mmol) and the reaction stirred for 19 h at room temperature. The reaction was quenched with water and the resultant precipitate collected by filtration and dried in vacuo to give the title compound as a pale-brown solid (428 mg, 75%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ ppm 9.50 (1 H, s), 7.88 (1 H, d, <i>J</i> = 0.7 Hz), 7.70 (1 H, s), 6.84 (1 H, s), 5.99–5.87 (1 H, m), 4.68–4.61 (2 H, m), 4.55–4.48 (2 H, m), 1.58 (6 H, d, <i>J</i> = 6.6 Hz).</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 1-Isopropyl-1<i>H</i>-[1,2,4]triazole (<b>18</b>)</h4><div class="NLM_p last">A solution of isopropyl hydrazine hydrochloride <b>(17)</b> (60 g, 0.54 mmol) in formamide (270 mL) was heated at 130 °C for 3 days. The cooled solution was diluted with saturated brine (700 mL) and extracted with ethyl acetate (4 × 1L). The combined organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated in vacuo to give an oil. (The product isopropyl triazole is volatile so vacuum is kept to ∼100 mbar and temperature to ∼35 °C during concentration). The oil was subjected to distillation under reduced pressure (25 mbar, bp 85–90 °C) to give the title compound as a colorless oil (54 g, 90%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ ppm 8.10 (1 H, s), 7.95 (1 H, s), 4.63–4.50 (1 H, m), 1.56 (6 H, d, <i>J</i> = 6.7 Hz). The product is contaminated with a minor amount of formamide. This does not interfere with the lithiation step but can be removed by extraction of the triazole product into cyclohexane.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 2-Chloro-1-(2-isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-ethanone (<b>19</b>)</h4><div class="NLM_p last">To a solution of 1-isopropyl-1<i>H</i>-[1,2,4]triazole (135 mmol, wet with cyclohexane) in THF (220 mL) at −20 °C was added <i>n</i>-butyllithium (54 mL, 2.5M, 135 mmol) dropwise over 10 min and then the mixture stirred and allowed to warm to −5 °C. After 30 min <sup>1</sup>H NMR of a quenched (MeOD) portion showed ∼50% lithiation. Further <i>n</i>-butyllithium (28 mL, 2.5M, 70 mmol) was added and stirring continued for 20 min at −5 to 0 °C. <sup>1</sup>H NMR of a quenched (MeOD) portion showed full lithiation. The reaction mixture (pale yellow suspension) was cooled to −70 °C and treated with 2-chloro-<i>N</i>-methoxy-<i>N</i>-methylacetamide <b>20</b> (27.8 g, 202 mmol, solution in 60 mL THF) dropwise over 45 min and stirring continued for 1.5 h. The cold reaction mixture was added to 1 M HCl (400 mL) with vigorous stirring, the mixture stirred allowed to warm to room temperature. The mixture was extracted twice with ethyl acetate (2 × 500 mL), and the organic extracts dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated in vacuo. The resultant oil was dissolved in pentane, cooled in dry ice, and sonicated intermittently to give a crystalline solid which was filtered to give the title compound as an off-white solid (22g, 87%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ ppm 7.96 (1 H, s), 5.51 (1 H, sept, <i>J</i> = 6.7 Hz), 1.56 (6 H, d, <i>J</i> = 6.7 Hz).</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> General Procedure A</h3><div class="NLM_p">To a suspension of the appropriate pyridone or phenol (1 equiv), the appropriate alcohol (1.3 equiv) and triphenylphosphine (1.5 equiv) in THF or dioxane was added dropwise DIAD (1.5 equiv) and the reaction mixture stirred at room temperature for 16 h. The reaction mixture was diluted with water and extracted with DCM. The combined organic extracts were washed with brine, dried (MgSO<sub>4</sub>), and concentrated in vacuo to give the crude product.</div><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 2-[2-(2-Isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3a,9-triaza-benzo[<i>e</i>]azulen-8-yloxy]-acetamide (<b>24</b>)</h4><div class="NLM_p last">Following general procedure A using <b>14</b> and methylglycolate, then flash chromatography (Si-PPC, gradient 0–5% methanol in DCM) gave a yellow solid (88 mg, 24%). LC-MS: [M + H]<sup>+</sup> = 385. The intermediate ester <b>21</b> (88 mg, 0.23 mmol) was dissolved in a solution of ammonia in methanol (7N, 5 mL) and the reaction mixture heated at 50 °C for 2 h, during which a white precipitate formed. The reaction mixture was concentrated in vacuo and the residue subjected to reverse phase preparative HPLC (C-18, gradient 10–90% MeCN in water, 0.1% formic acid) to give the title compound as a white solid (42 mg, 50%). LC-MS: [M + H]<sup>+</sup> = 370. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>DMSO-<i>d</i><sub>6</sub>) δ ppm 9.07 (1H, s), 7.88 (1H, s), 7.86 (1H, s), 7.41 (1H, s), 7.18 (1H, s), 6.45 (1H, s), 5.87 (1H, sept, <i>J</i> = 6.7 Hz), 4.66 (2H, s), 4.60–4.44 (4H, m), 1.44 (6H, d, <i>J</i> = 6.7 Hz).</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> (<i>S</i>)-2-((2-(1-Isopropyl-1<i>H</i>-1,2,4-triazol-5-yl)-5,6-dihydroimidazo[1,2-<i>d</i>]pyrido[3,4-<i>f</i>][1,4]oxazepin-9-yl)oxy)propanamide (<b>25</b>)</h4><div class="NLM_p last">Following general procedure A using <b>14</b> and ethyl-(<span class="smallcaps smallerCapital">l</span>)-lactate, then flash chromatography (Si-PPC, gradient 0–5% methanol in DCM) to give <b>22</b> as a yellow oil contaminated with triphenylphosphine oxide (70 mg, 29% based on NMR quantification of PPh<sub>3</sub>O). LC-MS: [M + H]<sup>+</sup> = 413. To a solution of the intermediate ester (70 mg, 0.17 mmol) in methanol (5 mL) and water (1 mL) was added lithium hydroxide monohydrate (23 mg, 0.58 mmol) and the reaction mixture stirred at 50 °C for 1 h. The reaction mixture was concentrated in vacuo and the resultant residue azeotroped with acetonitrile (3 × 20 mL). The residue was dissolved in DMF (3 mL), HATU (220 mg, 0.58 mmol), ammonium chloride (46 mg, 0.86 mmol), and triethylamine (120 μL, 0.86 mmol) were added and the reaction mixture stirred at room temperature for 1.5 h. The reaction mixture was quenched with water then extracted with ethyl acetate (3 × 15 mL). The combined organic extracts were washed with brine, dried (MgSO<sub>4</sub>), and concentrated in vacuo. The residue was subjected to reverse phase preparative HPLC (C-18, 10–90% MeCN in water 0.1% formic acid) to give the title compound as a white solid (28 mg, 43%). 63% ee (SFC, retention time = 1.01 min, opposite enantiomer at 0.56 min). LC-MS: [M + H]<sup>+</sup> = 384. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ ppm 9.05 (1H, s), 7.87 (1H, s), 7.86 (1H, s), 7.38 (1H, br s), 7.05 (1H, br s), 6.41 (1H, s), 5.87 (1H, sept, <i>J</i> = 6.6 Hz), 5.17 (1H, q, <i>J</i> = 6.8 Hz), 4.60–4.43 (4H, m), 1.50–1.34 (9H, m).</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 2-[2-(2-Isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3a,9-triaza-benzo[<i>e</i>]azulen-8-yloxy]-2-methyl-propionamide (<b>26</b>)</h4><div class="NLM_p last">Following general procedure A using <b>14</b> and ethyl 2-hydroxyisobutyrate, then flash chromatography (Si-PPC, gradient 0–5% methanol in DCM) gave a <b>23</b> as a yellow oil (103 mg, 40%). LC-MS: [M + H]<sup>+</sup> = 427. To a solution of <b>23</b> (103 mg, 0.24 mmol) in methanol (5 mL) was added water (0.5 mL) and lithium hydroxide monohydrate (19 mg, 0.48 mmol). The reaction mixture was heated at 50 °C for 16 h before the reaction was cooled to room temperature and the pH adjusted with HCl (1N, aq) to give pH ∼ 4. The reaction mixture was concentrated in vacuo to give the crude product as a yellow solid. LC-MS: [M + H]<sup>+</sup> = 399. To the yellow solid (96 mg, 0.24 mmol) in DMF (3 mL) was added HATU (184 mg, 0.48 mmol), ammonium chloride (39 mg, 0.72 mmol), and triethyl amine (100 μL, 0.72 mmol), and then the reaction mixture stirred at room temperature for 2 h. The reaction mixture was concentrated in vacuo and the resultant residue treated with water then extracted with ethyl acetate (3 × 10 mL). The combined organic extracts were washed with brine, dried (MgSO<sub>4</sub>), and concentrated in vacuo. The residue was subjected to reverse phase preparative HPLC (C-18, 10–90% MeCN in water 0.1% formic acid) to give the title compound as a white solid (38 mg, 38%). LC-MS: [M + H]<sup>+</sup> = 398. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ ppm 8.99 (1H, s), 8.11 (1H, s), 7.87 (1H, s), 7.86 (1H, s), 7.16 (1H, s), 6.89 (1H, s), 6.37 (1H, s), 5.89 (1H, sept, <i>J</i> = 6.6 Hz), 4.59–4.42 (4H, m), 1.54 (6H, s), 1.44 (6H, d, <i>J</i> = 6.6 Hz).</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 2-(2-Isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3a,9-triaza-benzo[<i>e</i>]azulen-8-ylamine (<b>27</b>)</h4><div class="NLM_p last">A mixture of <b>16</b> and 3,4-methoxybenzylamine in NMP was heated at 85 °C for 18 h. To the reaction mixture was added water and the resultant precipitate filtered off then dried in vacuo to give a white solid. A solution of the white solid (378 mg, 0.82 mmol) and TFA (15 mL) was heated at 40 °C for 5 h. The reaction mixture was concentrated in vacuo and the residue loaded onto an SCX-2 cartridge, washing with methanol and eluting with 2 M ammonia in methanol. The basic fractions were combined and concentrated in vacuo. The resultant residue was subjected to flash chromatography (Si-PPC, gradient 0 to 10% methanol in DCM) to give the title compound as a white solid (140 mg, 55% total). LC-MS: [M + H]<sup>+</sup> = 312. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ ppm 8.93 (1 H, s), 7.88 (1 H, s), 7.80 (1 H, s), 6.19 (2 H, br, s), 5.98 (1 H, s), 5.90–5.88 (1 H, m), 4.49–4.43 (4 H, m), 1.47 (6 H, d, <i>J</i> = 6.6 Hz).</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 2-{[2-(2-Isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3a,9-triaza-benzo[<i>e</i>]azulen-8-yl]-methylamino}-acetamide (<b>28</b>)</h4><div class="NLM_p last">To a solution of <b>16</b> (100 mg, 0.23 mmol) in NMP (1 mL) was added methylamino-acetic acid methyl ester (51 mg, 0.50 mmol). The resultant solution was stirred for 18 h at 85 °C before a further addition of methylamino-acetic acid methyl ester (51 mg, 0.50 mmol) was made and the reaction stirred for 8 h at 85 °C then at room temperature for 65 h. The reaction was quenched with water and the resultant precipitate collected by filtration. The residue was subjected to flash chromatography (Si-PPC, gradient 0–8% methanol in CH<sub>2</sub>Cl<sub>2</sub>), giving a 2:1 mixture of the title compound and starting material as a white solid (38 mg, 26%). A solution of this mixture (54 mg, 0.14 mmol), THF (2 mL), and 7 N ammonia in methanol (10 mL) was stirred at 40 °C for 19 h then at 50 °C for 18 h. The reaction mixture was cooled then concentrated in vacuo and the resultant residue was subjected to flash chromatography (Si-PPC, gradient 0–10% methanol in CH<sub>2</sub>Cl<sub>2</sub>) to give <b>28</b> as a white solid (16 mg, 30%). LC-MS: [M + H]<sup>+</sup> = 383. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ ppm 9.06 (1 H, s), 7.88 (1 H, d, <i>J</i> = 0.6 Hz), 7.83 (1 H, s), 7.30 (1 H, s), 6.98 (1 H, s), 6.11 (1 H, s), 5.95 (1 H, h, <i>J</i> = 6.6 Hz), 4.54–4.50 (2 H, m), 4.50–4.46 (2 H, m), 4.13 (2 H, s), 3.05 (3 H, s), 1.47 (6 H, d, <i>J</i> = 6.6 Hz).</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> General Procedure B</h3><div class="NLM_p">A suspension of the pyridone <b>14</b> in DMF or NMP was treated with sodium hydride (1.2 equiv) and the reaction mixture stirred at room temperature or 40 °C for 15 min to 1.25 h before the addition of benzenebis(trifluoromethane) sulfonamide (1.2 equiv). Stirring was continued at room temperature until complete consumption of pyridone was seen (TLC or LC-MS) then the appropriate amine added (1–2.5 equiv) and the reaction mixture heated at 70 to 100 °C until no further reaction was seen. The crude products were isolated by removal of solvent in vacuo, precipitation from the reaction mixture by addition of water and extraction with ethyl acetate or CH<sub>2</sub>Cl<sub>2</sub>, or by using an Isolute SCX-2 cartridge.</div><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (<i>S</i>)-1-[2-(2-Isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3a,9-triaza-benzo[<i>e</i>]azulen-8-yl]-pyrrolidine-2-carboxylic Acid Amide (<b>29</b>)</h4><div class="NLM_p last">Following general procedure B using <b>14</b> and <span class="smallcaps smallerCapital">l</span>-prolinamide then flash chromatography (Si-PPC, gradient 0–8% methanol in DCM) followed by recrystallization from methanol gave a white solid (115 mg, 44%); 98% ee (SFC, retention time = 1.48 min, opposite enantiomer at 0.48 min). LC-MS: [M + H]<sup>+</sup> = 409. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ ppm 9.06 (1 H, s), 7.88 (1 H, s), 7.83 (1 H, s), 7.33 (1 H, br), 6.92 (1 H, br), 5.97–5.96 (1 H, m), 5.94 (1 H, s), 4.53–4.45 (4 H, m), 4.30 (1 H, d, <i>J</i> = 8.5 Hz), 3.59 (1 H, s), 3.37 (1 H, d, <i>J</i> = 9.9 Hz), 2.18 (1 H, m), 1.95 (3 H, m), 1.47 (6 H, dd, <i>J</i> = 6.6, 3.4 Hz).</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (<i>R</i>)-1-[2-(2-Isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3a,9-triazabenzo[<i>e</i>]azulen 8-yl]-pyrrolidine-2-carboxylic Acid Amide (<b>30</b>)</h4><div class="NLM_p last">A solution of <b>15</b> (25.0 mg, 0.0756 mmol), <span class="smallcaps smallerCapital">d</span>-prolinamide (57 mg, 0.50 mmol), and triethylamine (0.125 mL, 0.897 mmol) in NMP (1.36 mL, 14.1 mmol) was heated at 150 °C for 2 d. The reaction was filtered through Celite rinsing with EtOAc. The filtrate was washed water followed by brine and the organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>) then concentrated in vacuo to give <b>32</b>; ee >98% (SFC, retention time = 0.48 min, opposite enantiomer at 1.48 min). MS: (ESI+) 409.2. <sup>1</sup>H NMR (500 MHz, DMSO) δ 9.10–9.03 (s, 1H), 7.91–7.86 (s, 1H), 7.86–7.82 (s, 1H), 7.41–7.31 (s, 1H), 6.99–6.91 (s, 1H), 6.03–5.90 (m, 2H), 4.57–4.43 (m, 4H), 4.37–4.24 (d, <i>J</i> = 9.0 Hz, 1H), 3.67–3.54 (t, <i>J</i> = 7.7 Hz, 1H), 3.45–3.37 (m, 1H), 2.25–2.11 (m, 1H), 2.03–1.88 (dddd, <i>J</i> = 13.3, 10.0, 7.0, 3.0 Hz, 3H), 1.52–1.43 (dd, <i>J</i> = 6.6, 4.5 Hz, 6H).</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 2-(2-Isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-8-pyrrolidin-1-yl-4,5-dihydro-6-oxa-1,3a,9-triaza-benzo[<i>e</i>]azulene (<b>31</b>)</h4><div class="NLM_p last"><b>31</b> was prepared similarly to <b>30</b>. LC-MS: (ESI+) = 366.2. <sup>1</sup>H NMR (DMSO) δ ppm 9.08 (1 H, s), 7.88 (1 H, s), 7.82 (1 H, s), 5.94 (1 H, dd, <i>J</i> = 13.6, 6.9 Hz), 4.61–4.32 (4 H, m), 3.40 (4 H, d, <i>J</i> = 6.3 Hz), 1.95 (4 H, t, <i>J</i> = 6.5 Hz), 1.48 (6 H, d, <i>J</i> = 6.6 Hz).</div></div><div id="sec5_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (<i>S</i>)-1-[2-(2-Isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3a,9-triaza-benzo[<i>e</i>]azulen-8-yl]-pyrrolidine-2-carboxylic Acid Methylamide (<b>32</b>)</h4><div class="NLM_p last"><b>32</b> was prepared similarly to <b>31</b>; ee >98% (SFC, retention time = 1.24 min, opposite enantiomer at 1.00 min); <i>m</i>/<i>z</i> 423.2, calcd 422.22. <sup>1</sup>H NMR (DMSO) δ ppm 9.06 (1 H, s), 7.88 (1 H, s), 7.83 (1 H, s), 7.74 (1 H, d, <i>J</i> = 4.3 Hz), 5.95 (2 H, sept, <i>J</i> = 6.7 Hz), 4.58–4.41 (4 H, m), 4.35 (1 H, d, <i>J</i> = 8.5 Hz), 3.67–3.57 (1 H, m), 3.41–3.33 (1 H, m), 2.57 (3 H, d, <i>J</i> = 4.6 Hz), 2.15 (1 H, dd, <i>J</i> = 10.8, 7.7 Hz), 1.94 (3 H, d, <i>J</i> = 6.6 Hz), 1.47 (6 H, dd, <i>J</i> = 6.6, 2.4 Hz).</div></div><div id="sec5_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 8-Bromo-2-(2-isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3a-diaza-benzo[<i>e</i>]azulene (<b>33</b>)</h4><div class="NLM_p last"><b>33</b> was prepared according to the procedures described in ref <a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">21</a>.</div></div><div id="sec5_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (<i>S</i>)-1-[2-(2-Isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3a-diaza-benzo[<i>e</i>]azulen-8-yl]-pyrrolidine-2-carboxylic Acid Amide (<b>34</b>)</h4><div class="NLM_p last">A mixture of <b>33</b> (375 mg, 1.0 mmol), methyl (2<i>S</i>)-pyrrolidine-2-carboxylate (4.0 equiv., 4.0 mmol), cuprous iodide (0.20 equiv, 0.20 mmol), <i>N</i>,<i>N</i>′-dimethylethylenediamine (0.40 equiv, 0.40 mmol), and potassium phosphate tribasic (2.0 equiv, 2.0 mmol) in DMSO (6 mL) was heated at 90 °C for 16 h. The mixture was partitioned between 0.5% aqueous citric acid and ethyl acetate. The organic layer was extracted with 1 M aq sodium carbonate and then discarded. The basic aqueous solution was neutralized by careful addition of 1 M aq HCl and extracted with ethyl acetate. The organic extracts were washed with water, brine, dried over magnesium sulfate, and concentrated in vacuum. The residue was used in the next step without further purification. Yield 140 mg. MS: 409 (M + 1), 407 (M – 1). HATU (1.20 equi., 0.4114 mmol, 100 mas s%) was added to a mixture of (2<i>S</i>)-1-[2-(2-isopropyl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-<i>d</i>][1,4]benzoxazepin-9-yl]pyrrolidine-2-carboxamide (70 mg, 0.17 mmol), ammonium chloride (2.0 equiv, 0.69 mmol) and triethylamine (4.0 equiv, 1.37 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (4 mL, 51.7 mmol). The mixture was stirred for 30 min and then concentrated in vacuo. The residue was partitioned between ethyl acetate and water, and the organic extracts were washed with satd aq sodium bicarbonate, 0.5% aq citric acid, water, brine, and then dried over MgSO<sub>4</sub> and concentrated. The residue was purified by reverse phase chromatography (acetonitrile gradient), yielding 70 mg (50%) of a white powder; > 98% ee (SFC, retention time = 2.69 min, opposite enantiomer at 2.08 min). LC-MS: [M + H]<sup>+</sup> = 408.2. NMR (DMSO-<i>d</i><sub>6</sub>) δ ppm 8.19 (1 H, d, <i>J</i> = 8.9 Hz), 7.87 (1 H, s), 7.77 (1 H, s), 7.40 (1 H, s), 7.04 (1 H, s), 6.36 (1 H, dd, <i>J</i> = 8.9, 2.5 Hz), 6.06 (1 H, d, <i>J</i> = 2.4 Hz), 5.92 (1 H, p, <i>J</i> = 6.6 Hz), 4.51–4.37 (4 H, m), 4.05–3.93 (1 H, m), 3.57 (1 H, t, <i>J</i> = 7.9 Hz), 2.22 (1 H, dd, <i>J</i> = 13.7, 6.3 Hz), 1.97 (3 H, tt, <i>J</i> = 9.4, 5.8 Hz), 1.47 (6 H, dd, <i>J</i> = 6.6, 3.3 Hz).</div></div><div id="sec5_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (<i>S</i>)-1-[2-(2-Isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3a-diaza-benzo[<i>e</i>]azulen-8-yl]piperdine-2-carboxylic Acid Amide (<b>35</b>)</h4><div class="NLM_p last">A mixture of <b>33</b> (1.01 g, 2.7 mmol), methyl piccolinate (3.86 g, 27.0 mmol), copper(I) iodide (0.2 g, 1.08 mmol), 2-(<i>S</i>)-piperidinecarboxylic acid (0.14 g, 1.08 mmol), and potassium phosphate (1.14 g, 5.4 mmol) in DMSO (10 mL) were heated at 80 °C for 24 h. The cooled reaction mixture was loaded onto an Isolute SCX-2 cartridge, washed with methanol, and eluted with 2 M ammonia in methanol. The resultant residue was triturated with diethyl ether to give 1-[2-(2-isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3a-diaza-benzo[<i>e</i>]azulen-8-yl]-piperidine-2-(<i>S</i>)-carboxylic acid (1.04 g, 87% total). LC-MS: [M + H]<sup>+</sup> = 423. A mixture of the intermediate acid (1.15 g, 2.73 mmol), EDCI (0.58 g, 3.0 mmol), HOBt (0.41 g, 3.0 mmol), and DIPEA (2.34 mL, 13.65 mmol) in DMF was stirred at room temperature (2 mL) for 5 min before ammonium chloride (0.44 g, 8.18 mmol) was added and the reaction mixture stirred for 18 h. The reaction mixture was concentrated in vacuo, and the resultant residue triturated with water before being subjected to flash chromatography (Si-PPC, gradient 0–10% methanol in DCM) to give the title compound as a white solid (0.08 g, 6%); ee >98% (SFC, retention time = 1.21 min, opposite enantiomer at 0.86 min). LC-MS: [M + H]<sup>+</sup> = 422. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ ppm 8.18 (1 H, d, <i>J</i> = 9.06 Hz), 7.89 (1 H, d, <i>J</i> = 0.63 Hz), 7.80 (1 H, s), 7.31 (1 H, br, s), 7.01 (1 H, br, s), 6.72 (1 H, dd, <i>J</i> = 9.16, 2.60 Hz), 6.40 (1 H, d, <i>J</i> = 2.54 Hz), 5.92–5.91 (1 H, m), 4.44–4.43 (4 H, m), 4.39 (1 H, m), 3.60 (1 H, d, <i>J</i> = 12.44 Hz), 3.39–3.32 (1 H, m), 2.06 (1 H, d, <i>J</i> = 13.57 Hz), 1.75 (2 H, m), 1.58 (3 H, m), 1.48 (6 H, dd, <i>J</i> = 6.60, 2.59 Hz).</div></div><div id="sec5_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (<i>S</i>)-1-[2-(2-Isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3a-diaza-benzo[<i>e</i>]azulen-8-yl]-azetidine-2-carboxylic Acid Amide (<b>36</b>)</h4><div class="NLM_p last">Following the procedure for <b>35</b> using <b>33</b> and (<span class="smallcaps smallerCapital">l</span>)-azetidine-2-carboxylic acid gave the title compound; ee >98% (SFC, retention time = 1.88 min, opposite enantiomer at 0.77 min). LC-MS: [M + H]<sup>+</sup> = 394. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ ppm 8.22 (1 H, d, <i>J</i> = 8.7 Hz), 7.88 (1 H, d, <i>J</i> = 0.6 Hz), 7.80 (1 H, s), 7.53 (1 H, s), 7.24 (1 H, s), 6.27 (1 H, dd, <i>J</i> = 8.8, 2.4 Hz), 5.99 (1 H, d, <i>J</i> = 2.3 Hz), 5.91–5.90 (1 H, m), 4.47–4.43 (4 H, m), 4.30 (1 H, dd, <i>J</i> = 8.8, 6.9 Hz), 3.93–3.92 (1 H, m), 3.71 (1 H, q, <i>J</i> = 7.8 Hz), 2.54–2.46 (1 H, m), 2.34–2.27 (1 H, m), 1.48 (3 H, d, <i>J</i> = 3.3 Hz), 1.46 (3 H, d, <i>J</i> = 3.3 Hz).</div></div><div id="sec5_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 2-(2-Isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3a-diaza-benzo[<i>e</i>]azulen-8-ol (<b>37</b>)</h4><div class="NLM_p last">A mixture of <b>33</b> (9.5 g, 25.4 mmol), 2-di-<i>tert</i>-butylphosphino-2′,4′,6′-triisopropylbiphenyl (855 mg, 2.0 mmol), tris(dibenzylideneacetone)dipalladium (0) (475 mg, 0.5 mmol), and potassium hydroxide (4.2 g, 76.2 mmol) were suspended in dioxane (29 mL) and water (15 mL). The suspension was degassed with nitrogen and the reaction mixture heated at 90 °C for 1 h. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (20 mL). The aqueous fraction was acidified to pH ∼ 5 by addition of 1 M hydrochloric acid, causing a precipitate to form. The suspension was extracted with ethyl acetate (3 × 15 mL). The combined organic extracts were dried (MgSO<sub>4</sub>) and concentrated in vacuo. The resultant residue was triturated with diethyl ether to give an orange solid (3.6 g, 46%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ ppm 9.90 (1 H, br s), 8.22 (1 H, d, <i>J</i> = 8.9 Hz), 7.88 (1 H, s), 7.82 (1 H, s), 6.61 (1 H, dd, <i>J</i> = 8.9, 2.6 Hz), 6.41 (1 H, d, <i>J</i> = 2.6 Hz), 5.90 (1 H, sept, <i>J</i> = 6.5 Hz), 4.49–4.39 (4 H, m), 1.47 (6 H, d, <i>J</i> = 6.5 Hz).</div></div><div id="sec5_3_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 2-[2-(2-Isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3a-diaza-benzo[<i>e</i>]azulen-8-yloxy]-acetamide (<b>38</b>)</h4><div class="NLM_p last">To a solution of <b>37</b> (80 mg, 0.26 mmol) in DMF (3 mL) was added 2-bromoacetamide (53 mg, 0.39 mmol) and cesium carbonate (109 mg, 0.33 mmol). The reaction mixture stirred at room temperature for 16 h before being diluted with water. The mixture was extracted with ethyl acetate (3 × 10 mL) and the combined organic extracts washed with brine, dried (MgSO<sub>4</sub>), and concentrated in vacuo. The residue was subjected to flash chromatography (Si-PPC, gradient 0–10% methanol in DCM) to give the title compound as a white solid (61 mg, 64%). LC-MS: [M + H]<sup>+</sup> = 369. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ ppm 8.28 (1 H, d, <i>J</i> = 9.8 Hz), 7.85 (1 H, s), 7.82 (1 H, s), 7.51 (1 H, s), 7.35 (1 H, s), 6.76 (1 H, dd, <i>J</i> = 9.8, 2.7 Hz), 6.54 (1 H, d, <i>J</i> = 2.7 Hz), 5.85 (1 H, sept, <i>J</i> = 6.6 Hz), 4.49–4.39 (6 H, m), 1.43 (6 H, d, <i>J</i> = 6.6 Hz).</div></div><div id="sec5_3_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (<i>S</i>)-2-[2-(2-Isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3a-diaza-benzo[<i>e</i>]azulen-8-yloxy]-propionamide (<b>4</b>)</h4><div class="NLM_p last">Following general procedure A using <b>37</b> and (+)-<i>tert</i>-butyl <span class="smallcaps smallerCapital">d</span>-lactate, then flash chromatography (Si-PPC, gradient 0–7% methanol in CH<sub>2</sub>Cl<sub>2</sub>) gave a yellow solid (70 mg, 62%). LC-MS: [M + H]<sup>+</sup> = 440. To a solution of the solid (64 mg, 0.15 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added TFA (0.5 mL) and the reaction mixture stirred at room temperature for 16 h. The reaction mixture was concentrated in vacuo and the residue dissolved in DMF (2 mL). HATU (130 mg, 0.34 mmol), ammonium chloride (27 mg, 0.51 mmol), and triethylamine (71 μL, 0.51 mmol) were added and the reaction mixture stirred at room temperature for 1 h. The reaction mixture was concentrated in vacuo, the residue dissolved in ethyl acetate (10 mL), and the mixture washed with water extracting with ethyl acetate (3 × 10 mL). The combined organic extracts were washed with brine, dried (MgSO<sub>4</sub>), and concentrated in vacuo. The resultant residue was subjected to flash chromatography (Si-PPC gradient 0–10% methanol in ethyl acetate) to give the title compound as a white solid (50 mg, 90%). LC-MS: [M + H]<sup>+</sup> = 383; ee 97% (SFC, retention time = 0.94 min, opposite enantiomer at 0.52 min). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ ppm 8.26 (1 H, d, <i>J</i> = 8.6 Hz), 7.81 (1 H, s), 7.85 (1 H, s), 7.51 (1 H, s), 7.21 (1 H, s), 6.72 (1 H, dd, <i>J</i> = 8.6, 2.6 Hz), 6.49 (1 H, d, <i>J</i> = 2.6 Hz), 5.85 (1 H, sept, <i>J</i> = 6.6 Hz), 4.62 (1 H, q, <i>J</i> = 6.6 Hz), 4.55–4.36 (4 H, m), 1.47–1.36 (9 H, m). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ ppm 173.5, 159.2, 156.9, 150.6, 147.6, 144.6, 131.2, 130.5, 124.0, 111.4, 111.2, 106.0, 74.0, 69.0, 50.7, 50.0, 22.8, 19.1.</div></div><div id="sec5_3_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (<i>S</i>)-2-((2-(1-Isopropyl-1<i>H</i>-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[<i>f</i>]imidazo[1,2-<i>d</i>][1,4]oxazepin-9-yl)oxy)butanamide (<b>39</b>)</h4><div class="NLM_p last">Following the procedure for <b>4</b> above using <b>37</b> and (<i>R</i>)-2-hydroxy-butyric acid <i>tert</i>-butyl ester gave the title compound; ee >98% (SFC, retention time = 0.87 min, opposite enantiomer at 0.46 min). LC-MS: [M + H]<sup>+</sup> = 397. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ ppm 8.26 (1 H, d, <i>J</i> = 8.6 Hz), 7.93 (1 H, s), 7.88 (1 H, s), 7.54 (1 H, s), 7.28 (1 H, s), 6.77 (1 H, dd, <i>J</i> = 8.6, 2.6 Hz), 6.56 (1 H, d, <i>J</i> = 2.6 Hz), 5.88 (1 H, sept, <i>J</i> = 6.6 Hz), 4.48 (5 H, m), 1.83 (2 H, m), 1.48 (6 H, dd, <i>J</i> = 6.60, 2.59 Hz), 0.97 (3 H, t, <i>J</i> = 7.7 Hz).</div></div><div id="sec5_3_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (<i>R</i>)-2-[2-(2-Isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3a-diaza-benzo[<i>e</i>]azulen-8-yloxy]-propionamide (<b>40</b>)</h4><div class="NLM_p last">Following general procedure A <b>37</b> and ethyl-(<span class="smallcaps smallerCapital">l</span>)-lactate, then flash chromatography (Si-PPC, gradient 0–10% methanol in ethyl acetate) gave a yellow solid (315 mg, 66%). LC-MS: [M + H]<sup>+</sup> = 412. To a solution of the yellow solid (315 mg, 0.77 mmol) in methanol (10 mL) was added water (1 mL) and lithium hydroxide monohydrate (46 mg, 1.15 mmol). The reaction mixture was heated at 50 °C for 16 h then HCl (1N, aq) added until pH ∼ 4. The reaction mixture was concentrated in vacuo. The resultant residue was dissolved in DMF (5 mL), and HATU (583 mg, 1.53 mmol), ammonium chloride (122 mg, 2.29 mmol), and triethylamine (320 μL, 2.29 mmol) added. The reaction mixture was stirred at room temperature for 1 h before being concentrated in vacuo. The residue was dissolved in ethyl acetate (10 mL) and the mixture washed with water, extracting with ethyl acetate (3 × 10 mL). The combined organic extracts were washed with brine, dried (MgSO<sub>4</sub>), and concentrated in vacuo. The resultant residue was subjected to flash chromatography (Si-PPC, gradient 0–10% methanol in ethyl acetate), and the product was crystallized from acetonitrile to give the title compound as a white solid (75 mg, 26%). LC-MS: [M + H]<sup>+</sup> = 383; ee 97% (SFC, retention time = 0.52 min, opposite enantiomer at 0.94 min). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ ppm 8.26 (1 H, d, <i>J</i> = 8.6 Hz), 7.85 (1 H, s), 7.81 (1 H, s), 7.50 (1 H, s), 7.21 (1 H, s), 6.71 (1 H, dd, <i>J</i> = 8.6, 2.6 Hz), 6.49 (1 H, d, <i>J</i> = 2.6 Hz), 5.85 (1 H, sept, <i>J</i> = 6.6 Hz), 4.63 (1H, q, <i>J</i> = 6.5 Hz), 4.44 (4 H, s), 1.83 (2 H, m), 1.44–1.40 (9 H, m).</div></div><div id="sec5_3_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 4-Benzyloxy-2-fluoro-benzonitrile (<b>42</b>)</h4><div class="NLM_p last">A solution of 4-hydroxy-2-fluoro-benzonitrile <b>41</b> (80 g, 0.58 mol), potassium carbonate (162 g, 1.17 mol), and benzyl bromide (76.4 mL, 0.64 mol) and potassium iodide (9.6 g, 0.058 mol) in acetone (600 mL) was stirred at room temperature, and a significant exothermic reaction was observed. Stirring continued for 18 h without cooling. The reaction mixture was diluted with water (600 mL) and extracted with EtOAc (500 mL × 2). The combined organic extracts were washed with brine (500 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated in vacuo. The resultant residue was triturated in cyclohexane (300 mL), and the crystalline solid was filtered off and washed to give the title compound (118.2 g, 90%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ ppm 7.51 (1 H, dd, <i>J</i> = 8.70, 7.48 Hz), 7.40 (5 H, m), 6.86–6.76 (2 H, m), 5.11 (2 H, s).</div></div><div id="sec5_3_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 4-Benzyloxy-2-fluoro-benzamidine Hydrochloride (<b>43</b>)</h4><div class="NLM_p last">A solution of <b>42</b> (84 g, 0.37 mol) in THF (450 mL) under an atmosphere of nitrogen, was cooled to −70 °C. The resultant suspension was treated with a solution of 1 M LiHMDS in THF (440 mL, 0.44 mol) over 10 min to reach a maximum temperature of −55 °C. The reaction mixture was allowed to warm to room temperature and stirred for 3 days. The reaction mixture was poured onto ice/1 M HCl mixture, the pH adjusted to ∼1 by addition of 6 M HCl, and washed with EtOAc (500 mL). The organic layer was extracted with 1 M HCl and the combined aqueous extracts washed with EtOAc (500 mL). The acid aqueous extracts were concentrated to low volume in vacuo and the resultant solid filtered off, washed with H<sub>2</sub>O, and dried in vacuo to give the title compound as a pale-cream crystalline solid (74.5 g, 72%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ ppm 9.30 (4 H, d, <i>J</i> = 10.39 Hz), 7.64 (1 H, t, <i>J</i> = 8.59 Hz), 7.49–7.35 (5 H, m), 7.19 (1 H, dd, <i>J</i> = 12.88, 2.41 Hz), 7.06 (1 H, dd, <i>J</i> = 8.77, 2.41 Hz), 5.25 (2 H, s).</div></div><div id="sec5_3_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 5-[2-(4-Benzyloxy-2-fluoro-phenyl)-1<i>H</i>-imidazol-4-yl]-1-isopropyl-1<i>H</i>-[1,2,4]triazole (<b>44</b>)</h4><div class="NLM_p last">A solution of <b>43</b> (74.5 g, 0.265 mol) in THF (705 mL) was treated with potassium hydrogen carbonate (106 g, 1.06 mol) and water (150 mL). The resultant mixture was heated to reflux to give a white suspension. While maintaining gentle reflux, a solution of <b>19</b> (50 g, 0.265 mol) was added dropwise over 40 min. The resultant suspension gradually dissolved, giving a dark-red mixture that was refluxed for 18 h. The mixture was cooled to room temperature, diluted with saturated aqueous NaCl solution (500 mL), and extracted with EtOAc (500 mL). The organic extract was washed with saturated aqueous NaCl solution, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated in vacuo to give a pink solid. The solid was triturated in a mixture of MTBE/pentane (1:1 by volume, 300 mL), collected by filtration, washed with a MTBE/pentane mixture, and dried in vacuo to give the title compound as a pale-pink solid (84 g, 84%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ ppm 7.95–7.93 (2 H, m), 7.76 (1 H, s), 7.44–7.42 (5 H, m), 7.12 (1 H, dd, <i>J</i> = 13.1, 2.5 Hz), 7.03 (1 H, dd, <i>J</i> = 8.7, 2.47 Hz), 5.90 (1 H, m), 5.21 (2 H, s), 1.46 (6 H, d, <i>J</i> = 6.6 Hz).</div></div><div id="sec5_3_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 2-[2-(4-Benzyloxy-2-fluoro-phenyl)-4-(2-isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-imidazol-1-yl]-ethanol (<b>45</b>)</h4><div class="NLM_p last">A suspension of <b>44</b> (48 g, 0.55 mol) and 1,3-dioxolan-2-one (30 mL) in toluene (100 mL) was heated at 130 °C for 7.5 h, allowing some solvent to evaporate until reaction was initiated. The cooled reaction mixture was concentrated in vacuo and the residue treated with acetonitrile (50 mL), stirred, sonicated, and cooled in an ice bath. The resultant solid was collected by filtration, washed with cold acetonitrile then diethyl ether, and dried in vacuo at 60 °C to give the title compound (65.2 g, 70%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ ppm 8.04 (1 H, s), 7.80 (1 H, d, <i>J</i> = 0.7 Hz), 7.43–7.41 (6 H, m), 6.89 (1 H, dd, <i>J</i> = 8.6, 2.5 Hz), 6.79 (1 H, dd, <i>J</i> = 11.7, 2.5 Hz), 5.93–5.92 (1 H, m), 5.11 (2 H, s), 4.02 (2 H, t, <i>J</i> = 4.9 Hz), 3.89 (2 H, t, <i>J</i> = 5.0 Hz), 1.49 (6 H, d, <i>J</i> = 6.6 Hz). LC-MS: [M + H]<sup>+</sup> = 422.</div></div><div id="sec5_3_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 8-Benzyloxy-2-(2-isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3a-diaza-benzo[<i>e</i>]azulene (<b>46</b>)</h4><div class="NLM_p last">A solution of <b>45</b> (25.0 g, 59.3 mmol) in DMF (890 mL) was treated with sodium hydride (3.51 g, 94.89 mmol) portionwise. The resultant mixture was stirred for 23 h at room temperature and then quenched with ice and water. The precipitate was collected by filtration, washed with water, and dried in vacuo at 60 °C to give the title compound as an off-white solid (13.9 g, 58%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ ppm 8.43 (1 H, d, <i>J</i> = 9.0 Hz), 7.87 (1 H, s), 7.63 (1 H, s), 7.41–7.39 (5 H, m), 6.82 (1 H, dd, <i>J</i> = 9.0, 2.6 Hz), 6.64 (1 H, d, <i>J</i> = 2.6 Hz), 6.00 (1 H, m), 5.10 (2 H, s), 4.50–4.48 (2 H, m), 4.42–4.41 (2 H, m), 1.59 (6 H, d, <i>J</i> = 6.6 Hz). LC-MS: [M + H]<sup>+</sup> = 402.</div></div><div id="sec5_3_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 2-(2-Isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3a-diaza-benzo[<i>e</i>]azulen-8-ol (<b>37</b>)</h4><div class="NLM_p last">A solution of <b>46</b> in a mixture of EtOAc (350 mL) and IMS (150 mL), under argon atmosphere, was treated with Pd/C. The atmosphere was exchanged with hydrogen, and the resultant reaction mixture was stirred at room temperature for 20 h. The hydrogen atmosphere was exchanged with argon, the reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (∼60 mL), filtered through a pad of Celite, and washed with a mixture of DCM/IMS (9:1 by volume). The resultant solution was concentrated in vacuo to give the title compound as an off-white solid (9.42 g, 51%). More material was recovered by thorough washing of the Celite residue to provide the title compound in 83% total yield. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ ppm 8.22 (1 H, d, <i>J</i> = 8.8 Hz), 7.89 (1 H, s), 7.82 (1 H, s), 6.61 (1 H, dd, <i>J</i> = 8.8, 2.4 Hz), 6.41 (1 H, d, <i>J</i> = 2.4 Hz), 5.95–5.86 (1 H, m), 4.45 (4 H, m), 1.47 (6 H, d, <i>J</i> = 6.6 Hz). LC-MS: [M + H]<sup>+</sup> = 312.</div></div><div id="sec5_3_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (<i>S</i>)-2-[2-(2-Isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3a-diaza-benzo[<i>e</i>]azulen-8-yloxy]-propionic Acid Methyl Ester (<b>47</b>)</h4><div class="NLM_p last">A suspension of <b>37</b> (6.3 g, 20.23 mmol), (<i>R</i>)-2-hydroxy-propionic acid methyl ester (2.51 mL, 26.3 mmol), and triphenylphosphine (7.96 g, 30.35 mmol) in dioxane (190 mL) was cooled with a water bath and then treated with diisopropylazodicarboxylate (5.98 mL, 30.35 mmol) dropwise and then stirred at room temperature for 2 h. The resultant mixture was concentrated in vacuo, the residue was dry loaded onto silica (∼120 g) and subjected to flash chromatography (Si-PPC, gradient 0–10% MeOH in MTBE) to give the title compound as an off-white foam (7.0 g, 87%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ ppm 8.31 (1 H, d, <i>J</i> = 9.0 Hz), 7.89 (2 H, m), 6.75 (1 H, dd, <i>J</i> = 9.0, 2.6 Hz), 6.51 (1 H, d, <i>J</i> = 2.6 Hz), 5.92–5.85 (1 H, m), 5.07 (1 H, m), 4.49 (4 H, m), 3.70 (3 H, s), 1.52 (3 H, d, <i>J</i> = 6.7 Hz), 1.47 (6 H, d, <i>J</i> = 6.6 Hz). LC-MS: [M + H]<sup>+</sup> = 398.</div></div><div id="sec5_3_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> (<i>S</i>)-2-[2-(2-Isopropyl-2<i>H</i>-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3a-diaza-benzo[<i>e</i>]azulen-8-yloxy]-propionamide (<b>4</b>)</h4><div class="NLM_p last">A solution of <b>47</b> (8.84 g, 22.24 mmol) in 7 N NH<sub>3</sub> in MeOH (150 mL) was stirred at room temperature for 7 h. The resultant white suspension was concentrated in vacuo and the residue triturated in diethyl ether. The solid was collected by filtration and dried in vacuo to give the title compound as an off-white solid (8.37 g, 98%).</div></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Characterization of Biochemical and Cellular Activity in Vitro</h3><div class="NLM_p">Enzymatic activity of the class I PI3K isoforms was measured using a fluorescence polarization assay that monitors formation of the product 3,4,5-inositoltriphosphate molecule (PIP3) as it competes with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in phosphatidyl inositide-3-phosphate product results in a decrease in fluorescence polarization signal as the labeled fluorophore is displaced from the GRP-1 protein binding site. Class I PI3K isoforms were purchased from PerkinElmer or were expressed and purified as heterodimeric recombinant proteins. Tetramethylrhodamine-labeled PIP3 (TAMRA-PIP3), di-C8-PIP2, and PIP3 detection reagents were purchased from Echelon Biosciences. PI3K isoforms were assayed under initial rate conditions in the presence of 10 mM Tris (pH 7.5), 25 μM ATP, 9.75 μM PIP2, 5% glycerol, 4 mM MgCl<sub>2</sub>, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, and 2% (v/v) DMSO at the following concentrations for each isoform: PI3Kα,β at 60 ng/mL, PI3Kγ at 8 ng/mL, PI3Kδ at 45 ng/mL. After assay for 30 min at 25 °C, reactions were terminated with a final concentration of 9 mM EDTA, 4.5 nM TAMRA-PIP3, and 4.2 μg/mL GRP-1 detector protein before reading fluorescence polarization on an Envision plate reader. Apparent <i>K</i><sub>i</sub> values were determined at a fixed concentration of ATP near the measured <i>K</i><sub>m</sub> for ATP for each isoenzym\, and were calculated by fitting of the dose–response curves to an equation for tight-binding competitive inhibition. All apparent <i>K</i><sub>i</sub> values represent geometric means of minimum of three determinations. These assays generally produced results within 2-fold of the reported mean.</div><div class="NLM_p last">Antiproliferative cellular assays were conducted using PC3, KPL-4, and MCF7-neo/HER2 human tumor cell lines. PC3 and KPL-4 cells were provided by ATCC, and MCF7-neo/HER2 cells were provided by Genentech Research laboratories. MCF7-neo/HER2 is an in vivo selected line developed at Genentech and originally derived from the parental human MCF7 breast cancer cell line (ATCC, Manassas, VA). Cell lines were cultured in RPMI supplemented with 10% fetal bovine serum, 100 units/mL penicillin, and 100 μg/mL streptomycin, 10 mM HEPES, and 2 mM glutamine at 37 °C under 5% CO<sub>2</sub>. MCF7-neo/HER2 and KPL-4 cells were seeded in 384-well plates in media at 1000 cells/well, while PC3 cells were seeded in 384-well plates in media at 3000 cells/well and incubated overnight prior to the addition of compounds to a final DMSO concentration of 0.5% v/v. MCF7-neo/HER2 cells were incubated for 3 days and KPL-4 and PC3 cells were incubated for 4 days prior to the addition of CellTiter-Glo reagent (Promega) and reading of luminescence using an Analyst plate reader. For antiproliferative assays, a cytostatic agent such as aphidicolin and a cytotoxic agent such as staurosporine were included as controls. Dose–response curves were fit to a four-parameter equation, and relative EC<sub>50</sub>s were calculated using Assay Explorer software. All cellular EC<sub>50</sub> values represent geometric means of a minimum of two determinations and these assays generally produced results within 3-fold of the reported mean.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> Plasma Protein Binding</h3><div class="NLM_p last">The extent of protein binding was determined in vitro, in CD-1 mouse, Sprague–Dawley rat, cynomolgus monkey, beagle dog, and human plasma (Bioreclamation, Inc., Hicksville, NY) by equilibrium dialysis using the RED Device (Thermo Fisher Scientific, Rockford, IL). Compounds were added to pooled plasma (<i>n</i> ≥ 3) at a total concentration of 5 μM. Plasma samples were equilibrated with phosphate-buffered saline (pH 7.4) at 37 °C in 90% humidity and 5% CO<sub>2</sub> for 4 h. Following dialysis, compound concentration in plasma and buffer was measured by LC-MS/MS. The percent unbound compound in plasma was determined by dividing the concentration measured in the postdialysis buffer by that measured in the postdialysis plasma and multiplying by 100.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Metabolic Stability in Liver Microsomes</h3><div class="NLM_p last">The oxidative metabolism of compounds was evaluated in pooled liver microsomes (Corning, Tewksbury, MA) from CD-1 mice, Sprague–Dawley rats, cynomolgus monkeys, beagle dogs, and humans. The incubation mixture was prepared for each species in 0.1 M-potassium phosphate buffer (pH 7.4) containing 0.5 mg/mL microsomal protein, 1 mM NADPH, and 1 μM of compound. Reactions were initiated with the addition of NADPH. Samples were incubated at 37 °C and aliquots were sampled at 0, 20, 40, and 60 min. Reactions were quenched with acetonitrile containing 0.1% formic acid and internal standard at each time point. Samples were centrifuged at 3000<i>g</i> for 10 min. The supernatant was diluted with water (1:2 ratio), and the percentage of compound remaining was determined by LC–MS/MS using the <i>t</i> = 0 peak area ratio values as 100%.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The in vitro Cl<sub>int</sub> and scaled hepatic Cl were determined as described by Obach.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i56"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01483">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42625" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42625" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b01483" class="ext-link">10.1021/acs.jmedchem.5b01483</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">A kinase selectivity panel for <b>4</b>, a figure explaining the Link and Grow strategies used to design PI3Kα specific inhibitors, crystal structure metrics as well as a depiction of a crystal structure of a benzoxepin bound to PI3Kγ (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3R7R">3R7R</a>) where residues are labeled to highlight differences between PI3Kα and the other isoforms within the active site (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01483/suppl_file/jm5b01483_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01483/suppl_file/jm5b01483_si_001.pdf">jm5b01483_si_001.pdf (556.85 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The coordinates of <b>5</b> in PI3Kα have been deposited with PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DXH">5DXH</a>. The coordinates of <b>4</b> in PI3Kα and PI3Kδ have been deposited with PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DXT">5DXT</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DXU">5DXU</a>, respectively.</p><div class="testing" data-doi="10.1021/acs.jmedchem.5b01483" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14864" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14864" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy P. Heffron</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a8dcc0cdcecedac7c6e8cfcdc6cd86cbc7c5"><span class="__cf_email__" data-cfemail="14607c717272667b7a5473717a713a777b79">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert A. Heald</span> - <span class="hlFld-Affiliation affiliation">Argenta, Early Discovery
Charles River, 7-9
Spire Green Centre, Flex Meadow, Harlow, EssexCM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chudi Ndubaku</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">BinQing Wei</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin Augistin</span> - <span class="hlFld-Affiliation affiliation">Proteros
Biostructures GmbH, Bunsenstr.
7aD, 82152 Martinsried, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven Do</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kyle Edgar</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Charles Eigenbrot</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lori Friedman</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emanuela Gancia</span> - <span class="hlFld-Affiliation affiliation">Argenta, Early Discovery
Charles River, 7-9
Spire Green Centre, Flex Meadow, Harlow, EssexCM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philip S. Jackson</span> - <span class="hlFld-Affiliation affiliation">Argenta, Early Discovery
Charles River, 7-9
Spire Green Centre, Flex Meadow, Harlow, EssexCM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Graham Jones</span> - <span class="hlFld-Affiliation affiliation">Argenta, Early Discovery
Charles River, 7-9
Spire Green Centre, Flex Meadow, Harlow, EssexCM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aleksander Kolesnikov</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Leslie B. Lee</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John D. Lesnick</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cristina Lewis</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Neville McLean</span> - <span class="hlFld-Affiliation affiliation">Argenta, Early Discovery
Charles River, 7-9
Spire Green Centre, Flex Meadow, Harlow, EssexCM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mario Mörtl</span> - <span class="hlFld-Affiliation affiliation">Proteros
Biostructures GmbH, Bunsenstr.
7aD, 82152 Martinsried, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jim Nonomiya</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jodie Pang</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steve Price</span> - <span class="hlFld-Affiliation affiliation">Argenta, Early Discovery
Charles River, 7-9
Spire Green Centre, Flex Meadow, Harlow, EssexCM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Wei Prior</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Laurent Salphati</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steve Sideris</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven T. Staben</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefan Steinbacher</span> - <span class="hlFld-Affiliation affiliation">Proteros
Biostructures GmbH, Bunsenstr.
7aD, 82152 Martinsried, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vickie Tsui</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey Wallin</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Deepak Sampath</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alan G. Olivero</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d104e4111-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i58">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32847" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32847" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank our analytical chemistry group for compound purification and determination of purity and ee by HPLC/SFC, mass spectroscopy, and <sup>1</sup>H NMR. We thank Krista K. Bowman, Alberto Estevez, Kyle Mortara, and Jiansheng Wu for technical assistance of protein expression and purification. We acknowledge the Paul Scherrer Institut, Villigen, Switzerland, for provision of synchrotron radiation beamtime at beamline X06SA of the SLS and would like to thank Meitian Wang and Tomizaki Takashi.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i59" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i59"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i60" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i60"> Abbreviations Used</h2><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphoinositide 3-kinase</p></td></tr><tr><td class="NLM_term">PTEN</td><td class="NLM_def"><p class="first last">phosphatase and tensin homologue</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyl-<i>O</i>-(7-azabenzotiazol-1-yl)uronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">NIS</td><td class="NLM_def"><p class="first last"><i>N</i>-iodosuccinimide</p></td></tr><tr><td class="NLM_term">DIAD</td><td class="NLM_def"><p class="first last">diisopropylazodicarboxylate</p></td></tr><tr><td class="NLM_term">Si-PPC prepacked silica cartridge</td><td class="NLM_def"></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">PR</td><td class="NLM_def"><p class="first last">partial regression</p></td></tr><tr><td class="NLM_term">CR</td><td class="NLM_def"><p class="first last">complete regression</p></td></tr><tr><td class="NLM_term">IMS</td><td class="NLM_def"><p class="first last">industrial methylated spirits</p></td></tr><tr><td class="NLM_term">ABT</td><td class="NLM_def"><p class="first last">1-aminobenzotrizole</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i61">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68052" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68052" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 35 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Vivanco, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">The Phosphatidylinositol 3-Kinase-AKT Pathway in Human Cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">489</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span><span class="refDoi"> DOI: 10.1038/nrc839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1038%2Fnrc839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=12094235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=489-501&author=I.+Vivancoauthor=C.+L.+Sawyers&title=The+Phosphatidylinositol+3-Kinase-AKT+Pathway+in+Human+Cancer&doi=10.1038%2Fnrc839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphatidylinositol 3-Kinase-AKT pathway in human cancer</span></div><div class="casAuthors">Vivanco, Igor; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">489-501</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  One signal that is overactivated in a wide range of tumor types is the prodn. of a phospholipid, phosphatidylinositol (3,4,5) trisphosphate, by phosphatidylinositol 3-kinase (PI3K).  This lipid and the protein kinase that is activated by it, AKT, trigger a cascade of responses, from cell growth and proliferation to survival and motility, that drive tumor progression.  Small-mol. therapeutics that block PI3K signaling might deal a severe blow to cancer cells by blocking many aspects of the tumor-cell phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzAQ-0qeD7pLVg90H21EOLACvtfcHk0lgFSPWs8YCDyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKltLs%253D&md5=c6762d32f9f1281632f4ccdbcd29268c</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1038%2Fnrc839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc839%26sid%3Dliteratum%253Aachs%26aulast%3DVivanco%26aufirst%3DI.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DThe%2520Phosphatidylinositol%25203-Kinase-AKT%2520Pathway%2520in%2520Human%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26spage%3D489%26epage%3D501%26doi%3D10.1038%2Fnrc839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Cantley, L. C.</span><span> </span><span class="NLM_article-title">The Phosphoinositide 3-Kinase Pathway</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">296</span><span class="NLM_x">, </span> <span class="NLM_fpage">1655</span><span class="NLM_x">–</span> <span class="NLM_lpage">1657</span><span class="refDoi"> DOI: 10.1126/science.296.5573.1655</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1126%2Fscience.296.5573.1655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=12040186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlChu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2002&pages=1655-1657&author=L.+C.+Cantley&title=The+Phosphoinositide+3-Kinase+Pathway&doi=10.1126%2Fscience.296.5573.1655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphoinositide 3-kinase pathway</span></div><div class="casAuthors">Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">5573</span>),
    <span class="NLM_cas:pages">1655-1657</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review with 8 refs.  Phosphorylated lipids are produced at cellular membranes during signaling events and contribute to the recruitment and activation of various signaling components.  The role of phosphoinositide 3-kinase (PI3K), which catalyzes the prodn. of phosphatidylinositol 3,4,5-trisphosphate, in cell survival pathways; the regulation of gene expression and cell metab.; and cytoskeletal rearrangements are highlighted.  The PI3K pathway is implicated in human diseases including diabetes and cancer, and understanding the intricacies of this pathway may provide new avenues for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9pxSplxmS1rVg90H21EOLACvtfcHk0lgFSPWs8YCDyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlChu7s%253D&md5=110c8a351448aed6ab938b9ccf90a655</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1126%2Fscience.296.5573.1655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.296.5573.1655%26sid%3Dliteratum%253Aachs%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DThe%2520Phosphoinositide%25203-Kinase%2520Pathway%26jtitle%3DScience%26date%3D2002%26volume%3D296%26spage%3D1655%26epage%3D1657%26doi%3D10.1126%2Fscience.296.5573.1655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Guertin, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabatini, D. M.</span><span> </span><span class="NLM_article-title">Defining the Role of mTOR in Cancer</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span><span class="refDoi"> DOI: 10.1016/j.ccr.2007.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.ccr.2007.05.008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=9-22&author=D.+A.+Guertinauthor=D.+M.+Sabatini&title=Defining+the+Role+of+mTOR+in+Cancer&doi=10.1016%2Fj.ccr.2007.05.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2007.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2007.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DGuertin%26aufirst%3DD.%2BA.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DDefining%2520the%2520Role%2520of%2520mTOR%2520in%2520Cancer%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D12%26spage%3D9%26epage%3D22%26doi%3D10.1016%2Fj.ccr.2007.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Fasolo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sessa, C.</span><span> </span><span class="NLM_article-title">mTOR Inhibitors in the Treatment of Cancer</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1717</span><span class="NLM_x">–</span> <span class="NLM_lpage">1734</span><span class="refDoi"> DOI: 10.1517/13543784.17.11.1717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1517%2F13543784.17.11.1717" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2008&pages=1717-1734&author=A.+Fasoloauthor=C.+Sessa&title=mTOR+Inhibitors+in+the+Treatment+of+Cancer&doi=10.1517%2F13543784.17.11.1717"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1d&amp;dbid=16384&amp;doi=10.1517%2F13543784.17.11.1717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.17.11.1717%26sid%3Dliteratum%253Aachs%26aulast%3DFasolo%26aufirst%3DA.%26aulast%3DSessa%26aufirst%3DC.%26atitle%3DmTOR%2520Inhibitors%2520in%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2008%26volume%3D17%26spage%3D1717%26epage%3D1734%26doi%3D10.1517%2F13543784.17.11.1717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Bellacosa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Cristofano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testa, J. R.</span><span> </span><span class="NLM_article-title">Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting</span> <span class="citation_source-journal">Adv. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">86</span><span class="refDoi"> DOI: 10.1016/S0065-230X(05)94002-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2FS0065-230X%2805%2994002-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=16095999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD28Xot1elur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2005&pages=29-86&author=A.+Bellacosaauthor=C.+C.+Kumarauthor=A.+Di+Cristofanoauthor=J.+R.+Testa&title=Activation+of+AKT+Kinases+in+Cancer%3A+Implications+for+Therapeutic+Targeting&doi=10.1016%2FS0065-230X%2805%2994002-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1eR"><div class="casContent"><span class="casTitleNuber">1e</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of AKT kinases in cancer: implications for therapeutic targeting</span></div><div class="casAuthors">Bellacosa, Alfonso; Kumar, C. Chandra; Di Cristofano, Antonio; Testa, Joseph Robert</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29-86</span>CODEN:
                <span class="NLM_cas:coden">ACRSAJ</span>;
        ISSN:<span class="NLM_cas:issn">0065-230X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The AKT1, AKT2, and AKT3 kinases have emerged as crit. mediators of signal transduction pathways downstream of activated tyrosine kinases and phosphatidylinositol 3-kinase.  An ever-increasing list of AKT substrates has precisely defined the multiple functions of this kinase family in normal physiol. and disease states.  Cellular processes regulated by AKT include cell proliferation and survival, cell size and response to nutrient availability, intermediary metab., angiogenesis, and tissue invasion.  All these processes represent hallmarks of cancer, and a burgeoning literature has defined the importance of AKT alterations in human cancer and exptl. models of tumorigenesis, continuing the legacy represented by the original identification of v-Akt as the transforming oncogene of a murine retrovirus.  Many oncoproteins and tumor suppressors intersect in the AKT pathway, finely regulating cellular functions at the interface of signal transduction and classical metabolic regulation.  This careful balance is altered in human cancer by a variety of activating and inactivating mechanisms that target both AKT and interrelated proteins.  Reprogramming of this altered circuitry by pharmacol. modulation of the AKT pathway represents a powerful strategy for rational cancer therapy.  In this review, we summarize a large body of data, from many types of cancer, indicating that AKT activation is one of the most common mol. alterations in human malignancy.  We also review mechanisms of activation of AKT kinases, examples of therapeutic modulation of the AKT pathway in animal models, and the current status of efforts to target mol. components of the AKT pathway for cancer therapy and, possibly, cancer prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbtUdzglK927Vg90H21EOLACvtfcHk0liH0WT29MS_oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xot1elur4%253D&md5=556e3c5787e0179786db3cb2e2f1dcf6</span></div><a href="/servlet/linkout?suffix=cit1e&amp;dbid=16384&amp;doi=10.1016%2FS0065-230X%2805%2994002-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-230X%252805%252994002-5%26sid%3Dliteratum%253Aachs%26aulast%3DBellacosa%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DC.%2BC.%26aulast%3DDi%2BCristofano%26aufirst%3DA.%26aulast%3DTesta%26aufirst%3DJ.%2BR.%26atitle%3DActivation%2520of%2520AKT%2520Kinases%2520in%2520Cancer%253A%2520Implications%2520for%2520Therapeutic%2520Targeting%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D2005%26volume%3D94%26spage%3D29%26epage%3D86%26doi%3D10.1016%2FS0065-230X%2805%2994002-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Ihle, N. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powis, G.</span><span> </span><span class="NLM_article-title">Take Your PIK: Phosphatidylinositol 3-Kinase Inhibitors Race Through the Clinic Toward Cancer Therapy</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-08-0801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1158%2F1535-7163.MCT-08-0801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=19139107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjvFSntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=1-9&author=N.+T.+Ihleauthor=G.+Powis&title=Take+Your+PIK%3A+Phosphatidylinositol+3-Kinase+Inhibitors+Race+Through+the+Clinic+Toward+Cancer+Therapy&doi=10.1158%2F1535-7163.MCT-08-0801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1fR"><div class="casContent"><span class="casTitleNuber">1f</span><div class="casTitle"><span class="NLM_cas:atitle">Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy</span></div><div class="casAuthors">Ihle, Nathan T.; Powis, Garth</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-9</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway is currently one of the most exciting drug targets in oncol.  However, only a short time ago, the paradigm existed that drugs targeted to the four PI3K class I isoforms would be too toxic for use in cancer therapy due to effects on physiol. signaling.  Since that time, studies have delineated the roles of these four isoforms in nonpathol. signaling as well as their roles in cancer.  An extensive effort has gone into developing agents that inhibit one or more PI3K isoforms, as well as closely related proteins implicated in cancer.  These agents have proved to be tolerable and therapeutically beneficial in animal studies, and a no. are in clin. testing.  The agents, their properties, and their mol. targets are discussed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtwozBC-h437Vg90H21EOLACvtfcHk0liH0WT29MS_oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjvFSntA%253D%253D&md5=4bc339da7fdd1dc74e13eadf76ae53ce</span></div><a href="/servlet/linkout?suffix=cit1f&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0801%26sid%3Dliteratum%253Aachs%26aulast%3DIhle%26aufirst%3DN.%2BT.%26aulast%3DPowis%26aufirst%3DG.%26atitle%3DTake%2520Your%2520PIK%253A%2520Phosphatidylinositol%25203-Kinase%2520Inhibitors%2520Race%2520Through%2520the%2520Clinic%2520Toward%2520Cancer%2520Therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D1%26epage%3D9%26doi%3D10.1158%2F1535-7163.MCT-08-0801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J. J.</span><span> </span><span class="NLM_article-title">Targeting the Phosphoinositide 3-Kinase Pathway in Cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">627</span><span class="NLM_x">–</span> <span class="NLM_lpage">644</span><span class="refDoi"> DOI: 10.1038/nrd2926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1038%2Fnrd2926" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=19644473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=627-644&author=P.+Liuauthor=H.+Chengauthor=T.+M.+Robertsauthor=J.+J.+Zhao&title=Targeting+the+Phosphoinositide+3-Kinase+Pathway+in+Cancer&doi=10.1038%2Fnrd2926"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1gR"><div class="casContent"><span class="casTitleNuber">1g</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the phosphoinositide 3-kinase pathway in cancer</span></div><div class="casAuthors">Liu, Pixu; Cheng, Hailing; Roberts, Thomas M.; Zhao, Jean J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">627-644</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The phosphoinositide 3-kinase (PI3K) pathway is a key signal transduction system that links oncogenes and multiple receptor classes to many essential cellular functions, and is perhaps the most commonly activated signalling pathway in human cancer.  This pathway therefore presents both an opportunity and a challenge for cancer therapy.  Even as inhibitors that target PI3K isoforms and other major nodes in the pathway, including AKT and mammalian target of rapamycin (mTOR), reach clin. trials, major issues remain.  Here, we highlight recent progress that has been made in our understanding of the PI3K pathway and discuss the potential of and challenges for the development of therapeutic agents that target this pathway in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUk9T-ZoNDtLVg90H21EOLACvtfcHk0lhYr05w3BKmOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D&md5=fdc94abd15178a9dbe7c56dafbfb7787</span></div><a href="/servlet/linkout?suffix=cit1g&amp;dbid=16384&amp;doi=10.1038%2Fnrd2926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2926%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26atitle%3DTargeting%2520the%2520Phosphoinositide%25203-Kinase%2520Pathway%2520in%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D627%26epage%3D644%26doi%3D10.1038%2Fnrd2926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Jackson, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoenwaelder, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goncalves, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nesbitt, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenche, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dopheide, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sturgeon, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prabaharan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniele, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulkarni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbott, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saylik, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughan, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angus, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salem, H. H.</span><span> </span><span class="NLM_article-title">PI 3-kinase p110β: a new target for antithrombotic therapy</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">507</span><span class="NLM_x">–</span> <span class="NLM_lpage">514</span><span class="refDoi"> DOI: 10.1038/nm1232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1038%2Fnm1232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=15834429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVOlsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=507-514&author=S.+P.+Jacksonauthor=S.+M.+Schoenwaelderauthor=I.+Goncalvesauthor=W.+S.+Nesbittauthor=C.+L.+Yapauthor=C.+E.+Wrightauthor=V.+Kencheauthor=K.+E.+Andersonauthor=S.+M.+Dopheideauthor=Y.+Yuanauthor=S.+A.+Sturgeonauthor=H.+Prabaharanauthor=P.+E.+Thompsonauthor=G.+D.+Smithauthor=P.+R.+Shepherdauthor=N.+Danieleauthor=S.+Kulkarniauthor=B.+Abbottauthor=D.+Saylikauthor=C.+Jonesauthor=L.+Luauthor=S.+Giulianoauthor=S.+C.+Hughanauthor=J.+A.+Angusauthor=A.+D.+Robertsonauthor=H.+H.+Salem&title=PI+3-kinase+p110%CE%B2%3A+a+new+target+for+antithrombotic+therapy&doi=10.1038%2Fnm1232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">PI 3-kinase p110β: a new target for antithrombotic therapy</span></div><div class="casAuthors">Jackson, Shaun P.; Schoenwaelder, Simone M.; Goncalves, Isaac; Nesbitt, Warwick S.; Yap, Cindy L.; Wright, Christine E.; Kenche, Vijaya; Anderson, Karen E.; Dopheide, Sacha M.; Yuan, Yuping; Sturgeon, Sharelle A.; Prabaharan, Hishani; Thompson, Philip E.; Smith, Gregg D.; Shepherd, Peter R.; Daniele, Nathalie; Kulkarni, Suhasini; Abbott, Belinda; Saylik, Dilek; Jones, Catherine; Lu, Lucy; Giuliano, Simon; Hughan, Sascha C.; Angus, James A.; Robertson, Alan D.; Salem, Hatem H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">507-514</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Platelet activation at sites of vascular injury is essential for the arrest of bleeding; however, excessive platelet accumulation at regions of atherosclerotic plaque rupture can result in the development of arterial thrombi, pptg. diseases such as acute myocardial infarction and ischemic stroke.  Rheol. disturbances (high shear stress) have an important role in promoting arterial thrombosis by enhancing the adhesive and signaling function of platelet integrin αIIbβ3 (GPIIb-IIIa).  In this study we have defined a key role for the Type Ia phosphoinositide 3-kinase (PI3K) p110β isoform in regulating the formation and stability of integrin αIIbβ3 adhesion bonds, necessary for shear activation of platelets.  Isoform-selective PI3K p110β inhibitors have been developed which prevent formation of stable integrin αIIbβ3 adhesion contacts, leading to defective platelet thrombus formation.  In vivo, these inhibitors eliminate occlusive thrombus formation but do not prolong bleeding time.  These studies define PI3K p110β as an important new target for antithrombotic therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYYnYolzsDrrVg90H21EOLACvtfcHk0lhYr05w3BKmOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVOlsrk%253D&md5=c8dc7ba1955e86104ae913d39f22674b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnm1232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1232%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DS.%2BP.%26aulast%3DSchoenwaelder%26aufirst%3DS.%2BM.%26aulast%3DGoncalves%26aufirst%3DI.%26aulast%3DNesbitt%26aufirst%3DW.%2BS.%26aulast%3DYap%26aufirst%3DC.%2BL.%26aulast%3DWright%26aufirst%3DC.%2BE.%26aulast%3DKenche%26aufirst%3DV.%26aulast%3DAnderson%26aufirst%3DK.%2BE.%26aulast%3DDopheide%26aufirst%3DS.%2BM.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DSturgeon%26aufirst%3DS.%2BA.%26aulast%3DPrabaharan%26aufirst%3DH.%26aulast%3DThompson%26aufirst%3DP.%2BE.%26aulast%3DSmith%26aufirst%3DG.%2BD.%26aulast%3DShepherd%26aufirst%3DP.%2BR.%26aulast%3DDaniele%26aufirst%3DN.%26aulast%3DKulkarni%26aufirst%3DS.%26aulast%3DAbbott%26aufirst%3DB.%26aulast%3DSaylik%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DGiuliano%26aufirst%3DS.%26aulast%3DHughan%26aufirst%3DS.%2BC.%26aulast%3DAngus%26aufirst%3DJ.%2BA.%26aulast%3DRobertson%26aufirst%3DA.%2BD.%26aulast%3DSalem%26aufirst%3DH.%2BH.%26atitle%3DPI%25203-kinase%2520p110%25CE%25B2%253A%2520a%2520new%2520target%2520for%2520antithrombotic%2520therapy%26jtitle%3DNat.%2520Med.%26date%3D2005%26volume%3D11%26spage%3D507%26epage%3D514%26doi%3D10.1038%2Fnm1232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Wee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiederschain, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maira, S.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">deBeaumont, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stegmeier, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lengauer, C.</span><span> </span><span class="NLM_article-title">PTEN-Deficient Cancers Depend on PIK3CB</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">13057</span><span class="NLM_x">–</span> <span class="NLM_lpage">13062</span><span class="refDoi"> DOI: 10.1073/pnas.0802655105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1073%2Fpnas.0802655105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=18755892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFSitbrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=13057-13062&author=S.+Weeauthor=D.+Wiederschainauthor=S.-M.+Mairaauthor=A.+Looauthor=C.+Millerauthor=R.+deBeaumontauthor=F.+Stegmeierauthor=Y.-M.+Yaoauthor=C.+Lengauer&title=PTEN-Deficient+Cancers+Depend+on+PIK3CB&doi=10.1073%2Fpnas.0802655105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">PTEN-deficient cancers depend on PIK3CB</span></div><div class="casAuthors">Wee, Susan; Wiederschain, Dmitri; Maira, Sauveur-Michel; Loo, Alice; Miller, Christine; de Beaumont, Rosalie; Stegmeier, Frank; Yao, Yung-Mae; Lengauer, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">13057-13062</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Deregulation of the PI3K signaling pathway is obsd. in many human cancers and occurs most frequently through loss of PTEN phosphatase tumor suppressor function or through somatic activating mutations in the Class IA PI3K, PIK3CA.  Tumors harboring activated p110α, the protein product of PIK3CA, require p110α activity for growth and survival and hence are expected to be responsive to inhibitors of its lipid kinase activity.  Whether PTEN-deficient cancers similarly depend on p110α activity to sustain activation of the PI3K pathway has been unclear.  In this study, we used a single-vector lentiviral inducible shRNA system to selectively inactivate the three Class IA PI3Ks, PIK3CA, PIK3CB, and PIK3CD, to det. which PI3K isoforms are responsible for driving the abnormal proliferation of PTEN-deficient cancers.  Down-regulation of PIK3CA in colorectal cancer cells harboring mutations in PIK3CA inhibited downstream PI3K signaling and cell growth.  Surprisingly, PIK3CA depletion affected neither PI3K signaling nor cell growth in 3 PTEN-deficient cancer cell lines.  In contrast, down-regulation of the PIK3CB isoform, which encodes p110β, resulted in pathway inactivation and subsequent inhibition of growth in both cell-based and in vivo settings.  This essential function of PIK3CB in PTEN-deficient cancer cells required its lipid kinase activity.  Our findings demonstrate that although p110α activation is required to sustain the proliferation of established PIK3CA-mutant tumors, PTEN-deficient tumors are dependent instead on p110β signaling.  This unexpected finding demonstrates the need to tailor therapeutic approaches to the genetic basis of PI3K pathway activation to achieve optimal treatment response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5ybGsv3DVCrVg90H21EOLACvtfcHk0lh3xLbrQyjP_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFSitbrO&md5=b7c690d3631ac6cbee9d7d7414dae1da</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0802655105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0802655105%26sid%3Dliteratum%253Aachs%26aulast%3DWee%26aufirst%3DS.%26aulast%3DWiederschain%26aufirst%3DD.%26aulast%3DMaira%26aufirst%3DS.-M.%26aulast%3DLoo%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DC.%26aulast%3DdeBeaumont%26aufirst%3DR.%26aulast%3DStegmeier%26aufirst%3DF.%26aulast%3DYao%26aufirst%3DY.-M.%26aulast%3DLengauer%26aufirst%3DC.%26atitle%3DPTEN-Deficient%2520Cancers%2520Depend%2520on%2520PIK3CB%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D13057%26epage%3D13062%26doi%3D10.1073%2Fpnas.0802655105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hancox, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosulich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trigwell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenaghan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellston, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dry, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crafter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlaam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Cruz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castriotta, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedge, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrington, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cumberbatch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, S. T.</span><span> </span><span class="NLM_article-title">Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">48</span><span class="NLM_x">–</span> <span class="NLM_lpage">58</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0406</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1158%2F1535-7163.MCT-14-0406" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=25398829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslWksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=48-58&author=U.+Hancoxauthor=S.+Cosulichauthor=L.+Hansonauthor=C.+Trigwellauthor=C.+Lenaghanauthor=R.+Ellstonauthor=H.+Dryauthor=C.+Crafterauthor=B.+Barlaamauthor=M.+Fitzekauthor=P.+D.+Smithauthor=D.+Ogilvieauthor=C.+D%E2%80%99Cruzauthor=L.+Castriottaauthor=S.+R.+Wedgeauthor=L.+Wardauthor=S.+Powellauthor=M.+Lawsonauthor=B.+R.+Daviesauthor=E.+A.+Harringtonauthor=E.+Fosterauthor=M.+Cumberbatchauthor=S.+Greenauthor=S.+T.+Barry&title=Inhibition+of+PI3K%CE%B2+signaling+with+AZD8186+inhibits+growth+of+PTEN-deficient+breast+and+prostate+tumors+alone+and+in+combination+with+docetaxel&doi=10.1158%2F1535-7163.MCT-14-0406"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel</span></div><div class="casAuthors">Hancox, Urs; Cosulich, Sabina; Hanson, Lyndsey; Trigwell, Cath; Lenaghan, Carol; Ellston, Rebecca; Dry, Hannah; Crafter, Claire; Barlaam, Bernard; Fitzek, Martina; Smith, Paul D.; Ogilvie, Donald; D'Cruz, Celina; Castriotta, Lillian; Wedge, Stephen R.; Ward, Lara; Powell, Steve; Lawson, Mandy; Davies, Barry R.; Harrington, Elizabeth A.; Foster, Emily; Cumberbatch, Marie; Green, Stephen; Barry, Simon T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-58</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Loss of PTEN protein results in upregulation of the PI3K/AKT pathway, which appears dependent on the PI3Kβ isoform.  Inhibitors of PI3Kβ have potential to reduce growth of tumors in which loss of PTEN drives tumor progression.  We have developed a small-mol. inhibitor of PI3Kβ and PI3Kδ (AZD8186) and assessed its antitumor activity across a panel of cell lines.  We have then explored the antitumor effects as single agent and in combination with docetaxel in triple-neg. breast (TNBC) and prostate cancer models.  In vitro, AZD8186 inhibited growth of a range of cell lines.  Sensitivity was assocd. with inhibition of the AKT pathway.  Cells sensitive to AZD8186 (GI50 < 1 μmol/L) are enriched for, but not exclusively assocd. with, PTEN deficiency.  In vivo, AZD8186 inhibits PI3K pathway biomarkers in prostate and TNBC tumors.  Scheduling treatment with AZD8186 shows antitumor activity required only intermittent exposure, and that increased tumor control is achieved when AZD8186 is used in combination with docetaxel.  AZD8186 is a potent inhibitor of PI3Kβ with activity against PI3Kδ signaling, and has potential to reduce growth of tumors dependent on dysregulated PTEN for growth.  Moreover, AZD8186 can be combined with docetaxel, a chemotherapy commonly used to treat advanced TBNC and prostate tumors.  The ability to schedule AZD8186 and maintain efficacy offers opportunity to combine AZD8186 more effectively with other drugs.  Mol Cancer Ther; 14(1); 48-58. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2CTPle3Nb1bVg90H21EOLACvtfcHk0lgDfUuTOOJO2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslWksQ%253D%253D&md5=0519e40a6a4e9458ad73336bd5764e2c</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0406&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0406%26sid%3Dliteratum%253Aachs%26aulast%3DHancox%26aufirst%3DU.%26aulast%3DCosulich%26aufirst%3DS.%26aulast%3DHanson%26aufirst%3DL.%26aulast%3DTrigwell%26aufirst%3DC.%26aulast%3DLenaghan%26aufirst%3DC.%26aulast%3DEllston%26aufirst%3DR.%26aulast%3DDry%26aufirst%3DH.%26aulast%3DCrafter%26aufirst%3DC.%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DFitzek%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26aulast%3DOgilvie%26aufirst%3DD.%26aulast%3DD%25E2%2580%2599Cruz%26aufirst%3DC.%26aulast%3DCastriotta%26aufirst%3DL.%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DWard%26aufirst%3DL.%26aulast%3DPowell%26aufirst%3DS.%26aulast%3DLawson%26aufirst%3DM.%26aulast%3DDavies%26aufirst%3DB.%2BR.%26aulast%3DHarrington%26aufirst%3DE.%2BA.%26aulast%3DFoster%26aufirst%3DE.%26aulast%3DCumberbatch%26aufirst%3DM.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DBarry%26aufirst%3DS.%2BT.%26atitle%3DInhibition%2520of%2520PI3K%25CE%25B2%2520signaling%2520with%2520AZD8186%2520inhibits%2520growth%2520of%2520PTEN-deficient%2520breast%2520and%2520prostate%2520tumors%2520alone%2520and%2520in%2520combination%2520with%2520docetaxel%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D48%26epage%3D58%26doi%3D10.1158%2F1535-7163.MCT-14-0406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Barlaam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosulich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degorce, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancox, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert-van der Brempt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohmann, J.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maudet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgentin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquet, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Péru, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plé, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saleh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vautier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warin, N.</span><span> </span><span class="NLM_article-title">Discovery of (R)-8-(1-(3,5-Difluorophenylamino)ethyl)-N,N-dimethyl-2-mopholino-4-oxo-4<i>H</i>-chromene-6-carboxamide (AZD8186): A Potent and Selective Inhibitor of PI3Kβ and PI3Kδ for the Treatment of PTEN-Deficient Cancers</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">943</span><span class="NLM_x">–</span> <span class="NLM_lpage">962</span><span class="refDoi"> DOI: 10.1021/jm501629p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501629p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=943-962&author=B.+Barlaamauthor=S.+Cosulichauthor=S.+Degorceauthor=M.+Fitzekauthor=S.+Greenauthor=U.+Hancoxauthor=C.+Lambert-van+der+Bremptauthor=J.-J.+Lohmannauthor=M.+Maudetauthor=R.+Morgentinauthor=M.-J.+Pasquetauthor=A.+P%C3%A9ruauthor=P.+Pl%C3%A9author=T.+Salehauthor=M.+Vautierauthor=M.+Walkerauthor=L.+Wardauthor=N.+Warin&title=Discovery+of+%28R%29-8-%281-%283%2C5-Difluorophenylamino%29ethyl%29-N%2CN-dimethyl-2-mopholino-4-oxo-4H-chromene-6-carboxamide+%28AZD8186%29%3A+A+Potent+and+Selective+Inhibitor+of+PI3K%CE%B2+and+PI3K%CE%B4+for+the+Treatment+of+PTEN-Deficient+Cancers&doi=10.1021%2Fjm501629p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1021%2Fjm501629p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501629p%26sid%3Dliteratum%253Aachs%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DCosulich%26aufirst%3DS.%26aulast%3DDegorce%26aufirst%3DS.%26aulast%3DFitzek%26aufirst%3DM.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DHancox%26aufirst%3DU.%26aulast%3DLambert-van%2Bder%2BBrempt%26aufirst%3DC.%26aulast%3DLohmann%26aufirst%3DJ.-J.%26aulast%3DMaudet%26aufirst%3DM.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DPasquet%26aufirst%3DM.-J.%26aulast%3DP%25C3%25A9ru%26aufirst%3DA.%26aulast%3DPl%25C3%25A9%26aufirst%3DP.%26aulast%3DSaleh%26aufirst%3DT.%26aulast%3DVautier%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DM.%26aulast%3DWard%26aufirst%3DL.%26aulast%3DWarin%26aufirst%3DN.%26atitle%3DDiscovery%2520of%2520%2528R%2529-8-%25281-%25283%252C5-Difluorophenylamino%2529ethyl%2529-N%252CN-dimethyl-2-mopholino-4-oxo-4H-chromene-6-carboxamide%2520%2528AZD8186%2529%253A%2520A%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520PI3K%25CE%25B2%2520and%2520PI3K%25CE%25B4%2520for%2520the%2520Treatment%2520of%2520PTEN-Deficient%2520Cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D943%26epage%3D962%26doi%3D10.1021%2Fjm501629p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Bedard, P. L.; Davies, M. A.; Kopetz, S.; Flaherty, K. T.; Shapiro, G.; Luke, J. J.; Spreafico, A.; Wu, B.; Gomez, C.; Cartot-Cotton, S.; Mazuir, F.; Micallef, S.; Demers, B.; Juric, D.</span><span> </span><span class="NLM_article-title">First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737)</span>.  <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span>, <span class="NLM_issue">suppl</span>; abstract  <span class="NLM_fpage">2564</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=2564&issue=suppl&author=P.+L.+Bedard&author=M.+A.+Davies&author=S.+Kopetz&author=K.+T.+Flaherty&author=G.+Shapiro&author=J.+J.+Luke&author=A.+Spreafico&author=B.+Wu&author=C.+Gomez&author=S.+Cartot-Cotton&author=F.+Mazuir&author=S.+Micallef&author=B.+Demers&author=D.+Juric&title=First-in-human+trial+of+the+PI3K%CE%B2-selective+inhibitor+SAR260301+in+patients+with+advanced+solid+tumors+%28NCT01673737%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBedard%26aufirst%3DP.%2BL.%26atitle%3DFirst-in-human%2520trial%2520of%2520the%2520PI3K%25CE%25B2-selective%2520inhibitor%2520SAR260301%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%2520%2528NCT01673737%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26issue%3Dsuppl%26spage%3D2564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Arkenau, H.-T.; Mateo, J.; Lemech, C. R.; Infante, J. R.; Burris, H. A.; Bang, Y.-J.; Eder, J. P.; Herbst, R. S.; Sharma, S.; Motwani, M.; Kumar, R.; De Bono, J. S.</span><span> </span><span class="NLM_article-title">A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors</span>.  <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span>, <span class="NLM_issue">suppl</span>; abstract  <span class="NLM_fpage">2514</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=25002718" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=2514&issue=suppl&author=H.-T.+Arkenau&author=J.+Mateo&author=C.+R.+Lemech&author=J.+R.+Infante&author=H.+A.+Burris&author=Y.-J.+Bang&author=J.+P.+Eder&author=R.+S.+Herbst&author=S.+Sharma&author=M.+Motwani&author=R.+Kumar&author=J.+S.+De+Bono&title=A+phase+I%2FII%2C+first-in-human+dose-escalation+study+of+GSK2636771+in+patients+%28pts%29+with+PTEN-deficient+advanced+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DArkenau%26aufirst%3DH.-T.%26atitle%3DA%2520phase%2520I%252FII%252C%2520first-in-human%2520dose-escalation%2520study%2520of%2520GSK2636771%2520in%2520patients%2520%2528pts%2529%2520with%2520PTEN-deficient%2520advanced%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26issue%3Dsuppl%26spage%3D2514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sadhu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dick, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tino, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staunton, D. E.</span><span> </span><span class="NLM_article-title">Selective Role of PI3Kδ in Neutrophil Inflammatory Responses</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">308</span><span class="NLM_x">, </span> <span class="NLM_fpage">764</span><span class="NLM_x">–</span> <span class="NLM_lpage">769</span><span class="refDoi"> DOI: 10.1016/S0006-291X(03)01480-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2FS0006-291X%2803%2901480-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2003&pages=764-769&author=C.+Sadhuauthor=K.+Dickauthor=W.+T.+Tinoauthor=D.+E.+Staunton&title=Selective+Role+of+PI3K%CE%B4+in+Neutrophil+Inflammatory+Responses&doi=10.1016%2FS0006-291X%2803%2901480-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1016%2FS0006-291X%2803%2901480-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-291X%252803%252901480-3%26sid%3Dliteratum%253Aachs%26aulast%3DSadhu%26aufirst%3DC.%26aulast%3DDick%26aufirst%3DK.%26aulast%3DTino%26aufirst%3DW.%2BT.%26aulast%3DStaunton%26aufirst%3DD.%2BE.%26atitle%3DSelective%2520Role%2520of%2520PI3K%25CE%25B4%2520in%2520Neutrophil%2520Inflammatory%2520Responses%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2003%26volume%3D308%26spage%3D764%26epage%3D769%26doi%3D10.1016%2FS0006-291X%2803%2901480-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sadhu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masinovsky, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dick, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sowell, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staunton, D. E.</span><span> </span><span class="NLM_article-title">Essential Role of Phosphoinositide 3-Kinase δ in Neutrophil Directional Movement</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">170</span><span class="NLM_x">, </span> <span class="NLM_fpage">2647</span><span class="NLM_x">–</span> <span class="NLM_lpage">2654</span><span class="refDoi"> DOI: 10.4049/jimmunol.170.5.2647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.4049%2Fjimmunol.170.5.2647" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2003&pages=2647-2654&author=C.+Sadhuauthor=B.+Masinovskyauthor=K.+Dickauthor=C.+G.+Sowellauthor=D.+E.+Staunton&title=Essential+Role+of+Phosphoinositide+3-Kinase+%CE%B4+in+Neutrophil+Directional+Movement&doi=10.4049%2Fjimmunol.170.5.2647"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.170.5.2647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.170.5.2647%26sid%3Dliteratum%253Aachs%26aulast%3DSadhu%26aufirst%3DC.%26aulast%3DMasinovsky%26aufirst%3DB.%26aulast%3DDick%26aufirst%3DK.%26aulast%3DSowell%26aufirst%3DC.%2BG.%26aulast%3DStaunton%26aufirst%3DD.%2BE.%26atitle%3DEssential%2520Role%2520of%2520Phosphoinositide%25203-Kinase%2520%25CE%25B4%2520in%2520Neutrophil%2520Directional%2520Movement%26jtitle%3DJ.%2520Immunol.%26date%3D2003%26volume%3D170%26spage%3D2647%26epage%3D2654%26doi%3D10.4049%2Fjimmunol.170.5.2647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Fruman, D. A.</span><span> </span><span class="NLM_article-title">Phosphoinositide 3-Kinase and its Targets in B-cell and T-cell Signaling</span> <span class="citation_source-journal">Curr. Opin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">–</span> <span class="NLM_lpage">320</span><span class="refDoi"> DOI: 10.1016/j.coi.2004.03.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.coi.2004.03.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=15134780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvVamtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2004&pages=314-320&author=D.+A.+Fruman&title=Phosphoinositide+3-Kinase+and+its+Targets+in+B-cell+and+T-cell+Signaling&doi=10.1016%2Fj.coi.2004.03.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5cR"><div class="casContent"><span class="casTitleNuber">5c</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide 3-kinase and its targets in B-cell and T-cell signaling</span></div><div class="casAuthors">Fruman, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">314-320</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Phosphoinositide 3-kinase (PI3K) activation is essential for lymphocyte proliferation driven by receptors for antigen, costimulatory ligands and cytokines.  The lipid products of PI3K contribute to the assembly of membrane-assocd. signaling complexes by promoting recruitment of selected proteins from the cytoplasm.  Many proteins possess domains that are able to bind selectively to PI3K products.  Different 'PI3K effector' proteins are coupled to distinct biol. responses, depending on cell type and on the receptor that is engaged.  In B cells and T cells, Tec-family tyrosine kinases and Akt serine/threonine kinases are emerging as crucial mediators of proliferation and survival signals downstream of PI3K.  Of particular interest is recent evidence that PI3K signaling controls increases in lymphocyte size and metabolic activity that accompany cell cycle progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnOMRHTLdWzbVg90H21EOLACvtfcHk0lhQxmQ_NvSeZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvVamtr4%253D&md5=18b4b46533f2d49312f123a4c72915b8</span></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1016%2Fj.coi.2004.03.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coi.2004.03.014%26sid%3Dliteratum%253Aachs%26aulast%3DFruman%26aufirst%3DD.%2BA.%26atitle%3DPhosphoinositide%25203-Kinase%2520and%2520its%2520Targets%2520in%2520B-cell%2520and%2520T-cell%2520Signaling%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D2004%26volume%3D16%26spage%3D314%26epage%3D320%26doi%3D10.1016%2Fj.coi.2004.03.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Okkenhaug, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanhaesebroeck, B.</span><span> </span><span class="NLM_article-title">PI3K in Lymphocyte Development, Differentiation, and Activation</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">317</span><span class="NLM_x">–</span> <span class="NLM_lpage">330</span><span class="refDoi"> DOI: 10.1038/nri1056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1038%2Fnri1056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=12669022" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisFWku70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=317-330&author=K.+Okkenhaugauthor=B.+Vanhaesebroeck&title=PI3K+in+Lymphocyte+Development%2C+Differentiation%2C+and+Activation&doi=10.1038%2Fnri1056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5dR"><div class="casContent"><span class="casTitleNuber">5d</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K in lymphocyte development, differentiation and activation</span></div><div class="casAuthors">Okkenhaug, Klaus; Vanhaesebroeck, Bart</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">317-330</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Phosphoinositide 3-kinases (PI3K) regulate numerous biol. processes, including cell growth, differentiation, survival, proliferation, migration, and metab.  In the immune system, impaired PI3K signaling leads to immunodeficiency, whereas unrestrained PI3K signaling contributes to autoimmunity and leukemia.  New insights into the role of PI3K in lymphocyte biol. have been derived from gene-targeting studies, which have identified the PI3K subunits that are involved in B-cell and T-cell signaling.  In particular, the catalytic subunit p110δ seems to be adapted to transmit antigen receptor signaling in B and T cells.  Addnl. recent work has provided new insights into the mol. interactions that lead to PI3K activation and the signaling pathways that are regulated by PI3K.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqMNzLr_tCL7Vg90H21EOLACvtfcHk0lgVvY7OcwMveg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisFWku70%253D&md5=97161849a1a965ce48f2641ec19c7941</span></div><a href="/servlet/linkout?suffix=cit5d&amp;dbid=16384&amp;doi=10.1038%2Fnri1056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1056%26sid%3Dliteratum%253Aachs%26aulast%3DOkkenhaug%26aufirst%3DK.%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26atitle%3DPI3K%2520in%2520Lymphocyte%2520Development%252C%2520Differentiation%252C%2520and%2520Activation%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2003%26volume%3D3%26spage%3D317%26epage%3D330%26doi%3D10.1038%2Fnri1056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Rommel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camps, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span> </span><span class="NLM_article-title">PI3Kδ and PI3Kγ: Partners in Crime in Inflammation in Rheumatoid Arthritis and Beyond?</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">201</span><span class="refDoi"> DOI: 10.1038/nri2036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1038%2Fnri2036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=17290298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=191-201&author=C.+Rommelauthor=M.+Campsauthor=H.+Ji&title=PI3K%CE%B4+and+PI3K%CE%B3%3A+Partners+in+Crime+in+Inflammation+in+Rheumatoid+Arthritis+and+Beyond%3F&doi=10.1038%2Fnri2036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5eR"><div class="casContent"><span class="casTitleNuber">5e</span><div class="casTitle"><span class="NLM_cas:atitle">PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond?</span></div><div class="casAuthors">Rommel, Christian; Camps, Montserrat; Ji, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">191-201</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Dysregulated signal transduction in innate and adaptive immune cells is known to be assocd. with the development of various autoimmune and inflammatory diseases.  Consequently, targeting intracellular signaling of the pro-inflammatory cytokine network heralds hope for the next generation of anti-inflammatory drugs.  Phosphoinositide 3-kinases (PI3Ks) generate lipid-based second messengers that control an array of intracellular signaling pathways that are known to have important roles in leukocytes.  In light of the recent progress in the development of selective PI3K inhibitors, and the beneficial effects of these inhibitors in models of acute and chronic inflammatory disorders, the authors discuss the therapeutic potential of blocking PI3K isoforms for the treatment of rheumatoid arthritis and other immune-mediated diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKSAduhwUrPrVg90H21EOLACvtfcHk0lgVvY7OcwMveg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrtbk%253D&md5=2fdb3507d06ddf7d5485185f4573790f</span></div><a href="/servlet/linkout?suffix=cit5e&amp;dbid=16384&amp;doi=10.1038%2Fnri2036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2036%26sid%3Dliteratum%253Aachs%26aulast%3DRommel%26aufirst%3DC.%26aulast%3DCamps%26aufirst%3DM.%26aulast%3DJi%26aufirst%3DH.%26atitle%3DPI3K%25CE%25B4%2520and%2520PI3K%25CE%25B3%253A%2520Partners%2520in%2520Crime%2520in%2520Inflammation%2520in%2520Rheumatoid%2520Arthritis%2520and%2520Beyond%253F%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2007%26volume%3D7%26spage%3D191%26epage%3D201%26doi%3D10.1038%2Fnri2036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Ameriks, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venable, J. D.</span><span> </span><span class="NLM_article-title">Small Molecule Inhibitors of Phosphoinositide 3-Kinase (PI3K) δ and γ</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">738</span><span class="NLM_x">–</span> <span class="NLM_lpage">753</span><span class="refDoi"> DOI: 10.2174/156802609789044434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.2174%2F156802609789044434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=19689378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFehsLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=738-753&author=M.+K.+Ameriksauthor=J.+D.+Venable&title=Small+Molecule+Inhibitors+of+Phosphoinositide+3-Kinase+%28PI3K%29+%CE%B4+and+%CE%B3&doi=10.2174%2F156802609789044434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5fR"><div class="casContent"><span class="casTitleNuber">5f</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule inhibitors of phosphoinositide 3-kinase (PI3K) δ and γ</span></div><div class="casAuthors">Ameriks, Michael K.; Venable, Jennifer D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">738-753</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  In recent years, pharmaceutical companies have increasingly focused on phosphoinositide 3-kinases delta (PI3Kδ) and gamma (PI3Kγ) as therapeutic targets for the treatment of inflammatory and autoimmune diseases.  All class 1 PI3-kinases (α/β/γ/δ) generate phospholipid second messengers that help govern cellular processes such as migration, proliferation, and apoptosis.  PI3K δ/γ lipid kinases are mainly restricted to the hematopoetic system whereas PI3Kα/β are ubiquitously expressed, thus raising potential toxicity concerns for chronic indications such as asthma and rheumatoid arthritis.  Therefore, the challenge in developing a small mol. inhibitor of PI3K is to define and attain the appropriate isoform selectivity profile.  Significant advances in the design of such compds. have been achieved by utilizing x-ray crystal structures of various inhibitors bound to PI3Kγ in conjunction with pharmacophore modeling and high-throughput screening.  Herein, we review the history and challenges involved with the discovery of small mol. isoform-specific PI3K inhibitors.  Recent progress in the design of selective PI3Kδ, PI3Kγ, and PI3Kδ/γ dual inhibitors will be presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeoiBWisF3T7Vg90H21EOLACvtfcHk0lgVo9ElkKC-8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFehsLnP&md5=1cae29b32c03158fe8b933fabe8b7a2b</span></div><a href="/servlet/linkout?suffix=cit5f&amp;dbid=16384&amp;doi=10.2174%2F156802609789044434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802609789044434%26sid%3Dliteratum%253Aachs%26aulast%3DAmeriks%26aufirst%3DM.%2BK.%26aulast%3DVenable%26aufirst%3DJ.%2BD.%26atitle%3DSmall%2520Molecule%2520Inhibitors%2520of%2520Phosphoinositide%25203-Kinase%2520%2528PI3K%2529%2520%25CE%25B4%2520and%2520%25CE%25B3%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D738%26epage%3D753%26doi%3D10.2174%2F156802609789044434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ruckle, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rommel, C.</span><span> </span><span class="NLM_article-title">PI3Kγ Inhibition: Towards an Aspirin for the 21st Century?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">903</span><span class="NLM_x">–</span> <span class="NLM_lpage">918</span><span class="refDoi"> DOI: 10.1038/nrd2145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1038%2Fnrd2145" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=903-918&author=T.+Ruckleauthor=M.+K.+Schwarzauthor=C.+Rommel&title=PI3K%CE%B3+Inhibition%3A+Towards+an+Aspirin+for+the+21st+Century%3F&doi=10.1038%2Fnrd2145"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1038%2Fnrd2145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2145%26sid%3Dliteratum%253Aachs%26aulast%3DRuckle%26aufirst%3DT.%26aulast%3DSchwarz%26aufirst%3DM.%2BK.%26aulast%3DRommel%26aufirst%3DC.%26atitle%3DPI3K%25CE%25B3%2520Inhibition%253A%2520Towards%2520an%2520Aspirin%2520for%2520the%252021st%2520Century%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D903%26epage%3D918%26doi%3D10.1038%2Fnrd2145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Barber, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartolome, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redondo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez-Arias, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camps, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruckle, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez-A, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balomenos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rommel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrera, A. C.</span><span> </span><span class="NLM_article-title">PI3Kγ Inhibition Blocks Glomerulonephritis and Extends Lifespan in a Mouse Model of Systemic Lupus</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">933</span><span class="NLM_x">–</span> <span class="NLM_lpage">935</span><span class="refDoi"> DOI: 10.1038/nm1291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1038%2Fnm1291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=16127435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpslelurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=933-935&author=D.+F.+Barberauthor=A.+Bartolomeauthor=C.+Hernandezauthor=J.+M.+Floresauthor=C.+Redondoauthor=C.+Fernandez-Ariasauthor=M.+Campsauthor=T.+Ruckleauthor=M.+K.+Schwarzauthor=S.+Rodriguezauthor=C.+Martinez-Aauthor=D.+Balomenosauthor=C.+Rommelauthor=A.+C.+Carrera&title=PI3K%CE%B3+Inhibition+Blocks+Glomerulonephritis+and+Extends+Lifespan+in+a+Mouse+Model+of+Systemic+Lupus&doi=10.1038%2Fnm1291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">PI3Kγ inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus</span></div><div class="casAuthors">Barber, Domingo F.; Bartolome, Almira; Hernandez, Carmen; Flores, Juana M.; Redondo, Clara; Fernandez-Arias, Cristina; Camps, Montserrat; Rueckle, Thomas; Schwarz, Matthias K.; Rodriguez, Santiago; Martinez-A, Carlos; Balomenos, Dimitrios; Rommel, Christian; Carrera, Ana C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">933-935</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Systemic lupus erythematosus (SLE) is a chronic inflammatory disease generated by deregulation of T cell-mediated B-cell activation, which results in glomerulonephritis and renal failure.  Disease is treated with immunosuppressants and cytostatic agents that have numerous side effects.  Here the authors examine the use of inhibitors of phosphoinositide 3-kinase (PI3K) γ, a lipid kinase that regulates inflammation, in the MRL-lpr mouse model of SLE.  Treatment reduced glomerulonephritis and prolonged lifespan, suggesting that P13Kγ may be a useful target in the treatment of chronic inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd9Xak5Gdl_rVg90H21EOLACvtfcHk0lgVo9ElkKC-8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpslelurk%253D&md5=95434bc2c945d81c940c1b959599d89b</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1038%2Fnm1291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1291%26sid%3Dliteratum%253Aachs%26aulast%3DBarber%26aufirst%3DD.%2BF.%26aulast%3DBartolome%26aufirst%3DA.%26aulast%3DHernandez%26aufirst%3DC.%26aulast%3DFlores%26aufirst%3DJ.%2BM.%26aulast%3DRedondo%26aufirst%3DC.%26aulast%3DFernandez-Arias%26aufirst%3DC.%26aulast%3DCamps%26aufirst%3DM.%26aulast%3DRuckle%26aufirst%3DT.%26aulast%3DSchwarz%26aufirst%3DM.%2BK.%26aulast%3DRodriguez%26aufirst%3DS.%26aulast%3DMartinez-A%26aufirst%3DC.%26aulast%3DBalomenos%26aufirst%3DD.%26aulast%3DRommel%26aufirst%3DC.%26aulast%3DCarrera%26aufirst%3DA.%2BC.%26atitle%3DPI3K%25CE%25B3%2520Inhibition%2520Blocks%2520Glomerulonephritis%2520and%2520Extends%2520Lifespan%2520in%2520a%2520Mouse%2520Model%2520of%2520Systemic%2520Lupus%26jtitle%3DNat.%2520Med.%26date%3D2005%26volume%3D11%26spage%3D933%26epage%3D935%26doi%3D10.1038%2Fnm1291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Wymann, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjorklof, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomast, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trifilieff, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altruda, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laffargue, M.</span><span> </span><span class="NLM_article-title">Phosphoinositide 3-Kinase γ: A Key Modulator in Inflammation and Allergy</span> <span class="citation_source-journal">Biochem. Soc. Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">275</span><span class="NLM_x">–</span> <span class="NLM_lpage">280</span><span class="refDoi"> DOI: 10.1042/bst0310275</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1042%2Fbst0310275" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=12546701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptF2qtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2003&pages=275-280&author=M.+P.+Wymannauthor=K.+Bjorklofauthor=R.+Calvezauthor=P.+Finanauthor=M.+Thomastauthor=A.+Trifilieffauthor=M.+Barbierauthor=F.+Altrudaauthor=E.+Hirschauthor=M.+Laffargue&title=Phosphoinositide+3-Kinase+%CE%B3%3A+A+Key+Modulator+in+Inflammation+and+Allergy&doi=10.1042%2Fbst0310275"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6cR"><div class="casContent"><span class="casTitleNuber">6c</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide 3-kinase γ: a key modulator in inflammation and allergy</span></div><div class="casAuthors">Wymann, M. P.; Bjoerkloef, K.; Calvez, R.; Finan, P.; Thomast, M.; Trifilieff, A.; Barbier, M.; Altruda, F.; Hirsch, E.; Laffargue, M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">275-280</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Chronic inflammation and allergy involve the activation of tissue-resident cells and, later on, the invasion of effector cells.  We have previously shown that the loss of phosphoinositide 3-kinase (PI3K) γ impairs chemokine-dependent migration of neutrophils and macrophages both in vitro and in vivo .  On the other hand, PI3Kγ is not required either during phagocytic processes or in the activation of bactericidal activities like granule secretion and particle-mediated respiratory burst in neutrophils.  Tissue mast cells are key regulators in allergy and inflammation and release histamine upon clustering of their IgE receptors.  We have demonstrated that murine mast cell responses are exacerbated in vitro and in vivo by autocrine signals, and require functional PI3Kγ.  Adenosine, acting through the A3 adenosine receptor, as well as other agonists of Gαi-coupled receptors, transiently increased PtdIns(3,4,5) P 3 exclusively via PI3Kγ.  PI3Kγ-derived PtdIns(3,4,5) P 3 was instrumental for initiation of a sustained influx of external Ca2+ and degranulation.  Mice that lacked PI3Kγ did not form edema when challenged by passive systemic anaphylaxis.  PI3Kγ thus relays inflammatory signals through various GPCRs, and is thus central to mast cell function.  Taken together, this suggests that pharmaceutical targeting of PI3Kγ might alleviate inflammation at both early and late stages of the allergic response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSxvbIu0vVf7Vg90H21EOLACvtfcHk0lgp5toC8f2TbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptF2qtw%253D%253D&md5=5163ba45e24d7304db751f5beb16556f</span></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1042%2Fbst0310275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbst0310275%26sid%3Dliteratum%253Aachs%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DBjorklof%26aufirst%3DK.%26aulast%3DCalvez%26aufirst%3DR.%26aulast%3DFinan%26aufirst%3DP.%26aulast%3DThomast%26aufirst%3DM.%26aulast%3DTrifilieff%26aufirst%3DA.%26aulast%3DBarbier%26aufirst%3DM.%26aulast%3DAltruda%26aufirst%3DF.%26aulast%3DHirsch%26aufirst%3DE.%26aulast%3DLaffargue%26aufirst%3DM.%26atitle%3DPhosphoinositide%25203-Kinase%2520%25CE%25B3%253A%2520A%2520Key%2520Modulator%2520in%2520Inflammation%2520and%2520Allergy%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2003%26volume%3D31%26spage%3D275%26epage%3D280%26doi%3D10.1042%2Fbst0310275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Hirsch, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katanaev, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garlanda, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azzolino, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirola, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silengo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sozzani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantovani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altruda, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wymann, M. P.</span><span> </span><span class="NLM_article-title">Central role for G protein-coupled phosphoinositide 3-kinase γ in inflammation</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">287</span><span class="NLM_x">, </span> <span class="NLM_fpage">1049</span><span class="NLM_x">–</span> <span class="NLM_lpage">1053</span><span class="refDoi"> DOI: 10.1126/science.287.5455.1049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1126%2Fscience.287.5455.1049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10669418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtFyqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2000&pages=1049-1053&author=E.+Hirschauthor=V.+L.+Katanaevauthor=C.+Garlandaauthor=O.+Azzolinoauthor=L.+Pirolaauthor=L.+Silengoauthor=S.+Sozzaniauthor=A.+Mantovaniauthor=F.+Altrudaauthor=M.+P.+Wymann&title=Central+role+for+G+protein-coupled+phosphoinositide+3-kinase+%CE%B3+in+inflammation&doi=10.1126%2Fscience.287.5455.1049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6dR"><div class="casContent"><span class="casTitleNuber">6d</span><div class="casTitle"><span class="NLM_cas:atitle">Central role for G protein-coupled phosphoinositide 3-kinase γ in inflammation</span></div><div class="casAuthors">Hirsch, Emilio; Katanaev, Vladimir L.; Garlanda, Cecilia; Azzolino, Ornella; Pirola, Luciano; Silengo, Lorenzo; Sozzani, Silvano; Mantovani, Alberto; Altruda, Fiorella; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">5455</span>),
    <span class="NLM_cas:pages">1049-1053</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinase (PI3K) activity is crucial for leukocyte function, but the roles of the 4 receptor-activated isoforms are unclear.  Mice lacking heterotrimeric guanine nucleotide-binding protein (G protein)-coupled PI3Kγ were viable and had fully differentiated neutrophils and macrophages.  Chemoattractant-stimulated PI3Kγ-/- neutrophils did not produce phosphatidylinositol 3,4,5-trisphosphate, did not activate protein kinase B, and displayed impaired respiratory burst and motility.  Peritoneal PI3Kγ-null macrophages showed a reduced migration toward a wide range of chemotactic stimuli and a severely defective accumulation in a septic peritonitis model.  Thus, PI3Kγ is a crucial signaling mol. required for macrophage accumulation in inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovE06YS7tEErVg90H21EOLACvtfcHk0lgp5toC8f2TbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtFyqtbs%253D&md5=8594ff672743c7873560576b00cd96db</span></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=10.1126%2Fscience.287.5455.1049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.287.5455.1049%26sid%3Dliteratum%253Aachs%26aulast%3DHirsch%26aufirst%3DE.%26aulast%3DKatanaev%26aufirst%3DV.%2BL.%26aulast%3DGarlanda%26aufirst%3DC.%26aulast%3DAzzolino%26aufirst%3DO.%26aulast%3DPirola%26aufirst%3DL.%26aulast%3DSilengo%26aufirst%3DL.%26aulast%3DSozzani%26aufirst%3DS.%26aulast%3DMantovani%26aufirst%3DA.%26aulast%3DAltruda%26aufirst%3DF.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DCentral%2520role%2520for%2520G%2520protein-coupled%2520phosphoinositide%25203-kinase%2520%25CE%25B3%2520in%2520inflammation%26jtitle%3DScience%26date%3D2000%26volume%3D287%26spage%3D1049%26epage%3D1053%26doi%3D10.1126%2Fscience.287.5455.1049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Camps, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rückle, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardissone, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rintelen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrandi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillieron, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gretener, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leroy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitte, P.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wymann, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirillo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rommel, C.</span><span> </span><span class="NLM_article-title">Blockade of PI3Kγ Suppresses Joint Inflammation and Damage in Mouse Models of Rheumatoid Arthritis</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">936</span><span class="NLM_x">–</span> <span class="NLM_lpage">943</span><span class="refDoi"> DOI: 10.1038/nm1284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1038%2Fnm1284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=16127437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpslelur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=936-943&author=M.+Campsauthor=T.+R%C3%BCckleauthor=H.+Jiauthor=V.+Ardissoneauthor=F.+Rintelenauthor=J.+Shawauthor=C.+Ferrandiauthor=C.+Chabertauthor=C.+Gillieronauthor=B.+Franconauthor=T.+Martinauthor=D.+Gretenerauthor=D.+Perrinauthor=D.+Leroyauthor=P.-A.+Vitteauthor=E.+Hirschauthor=M.+P.+Wymannauthor=R.+Cirilloauthor=M.+K.+Schwarzauthor=C.+Rommel&title=Blockade+of+PI3K%CE%B3+Suppresses+Joint+Inflammation+and+Damage+in+Mouse+Models+of+Rheumatoid+Arthritis&doi=10.1038%2Fnm1284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6eR"><div class="casContent"><span class="casTitleNuber">6e</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis</span></div><div class="casAuthors">Camps, Montserrat; Rueckle, Thomas; Ji, Hong; Ardissone, Vittoria; Rintelen, Felix; Shaw, Jeffrey; Ferrandi, Chiara; Chabert, Christian; Gillieron, Corine; Francon, Bernard; Martin, Thierry; Gretener, Denise; Perrin, Dominique; Leroy, Didier; Vitte, Pierre-Alain; Hirsch, Emilio; Wymann, Matthias P.; Cirillo, Rocco; Schwarz, Matthias K.; Rommel, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">936-943</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinases (PI3K) have long been considered promising drug targets for the treatment of inflammatory and autoimmune disorders as well as cancer and cardiovascular diseases.  But the lack of specificity, isoform selectivity and poor biopharmaceutical profile of PI3K inhibitors have so far hampered rigorous disease-relevant target validation.  Here we describe the identification and development of specific, selective and orally active small-mol. inhibitors of PI3Kγ (encoded by Pik3cg).  We show that Pik3cg-/- mice are largely protected in mouse models of rheumatoid arthritis; this protection correlates with defective neutrophil migration, further validating PI3Kγ as a therapeutic target.  We also describe that oral treatment with a PI3Kγ inhibitor suppresses the progression of joint inflammation and damage in two distinct mouse models of rheumatoid arthritis, reproducing the protective effects shown by Pik3cg-/- mice.  Our results identify selective PI3Kγ inhibitors as potential therapeutic mols. for the treatment of chronic inflammatory disorders such as rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEyzzdnR3FXLVg90H21EOLACvtfcHk0lg2xwmucIiW8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpslelur8%253D&md5=1fed7126427b519a4a457a8bf31ade7d</span></div><a href="/servlet/linkout?suffix=cit6e&amp;dbid=16384&amp;doi=10.1038%2Fnm1284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1284%26sid%3Dliteratum%253Aachs%26aulast%3DCamps%26aufirst%3DM.%26aulast%3DR%25C3%25BCckle%26aufirst%3DT.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DArdissone%26aufirst%3DV.%26aulast%3DRintelen%26aufirst%3DF.%26aulast%3DShaw%26aufirst%3DJ.%26aulast%3DFerrandi%26aufirst%3DC.%26aulast%3DChabert%26aufirst%3DC.%26aulast%3DGillieron%26aufirst%3DC.%26aulast%3DFrancon%26aufirst%3DB.%26aulast%3DMartin%26aufirst%3DT.%26aulast%3DGretener%26aufirst%3DD.%26aulast%3DPerrin%26aufirst%3DD.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DVitte%26aufirst%3DP.-A.%26aulast%3DHirsch%26aufirst%3DE.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DCirillo%26aufirst%3DR.%26aulast%3DSchwarz%26aufirst%3DM.%2BK.%26aulast%3DRommel%26aufirst%3DC.%26atitle%3DBlockade%2520of%2520PI3K%25CE%25B3%2520Suppresses%2520Joint%2520Inflammation%2520and%2520Damage%2520in%2520Mouse%2520Models%2520of%2520Rheumatoid%2520Arthritis%26jtitle%3DNat.%2520Med.%26date%3D2005%26volume%3D11%26spage%3D936%26epage%3D943%26doi%3D10.1038%2Fnm1284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Pomel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klicic, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covini, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Church, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roulin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgat-Charvillon, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valognes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camps, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillieron, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leroy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gretener, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitte, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carboni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rommel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rückle, T.</span><span> </span><span class="NLM_article-title">Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase γ</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">3857</span><span class="NLM_x">–</span> <span class="NLM_lpage">3871</span><span class="refDoi"> DOI: 10.1021/jm0601598</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0601598" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=3857-3871&author=V.+Pomelauthor=J.+Klicicauthor=D.+Coviniauthor=D.+D.+Churchauthor=J.+P.+Shawauthor=K.+Roulinauthor=F.+Burgat-Charvillonauthor=D.+Valognesauthor=M.+Campsauthor=C.+Chabertauthor=C.+Gillieronauthor=B.+Franconauthor=D.+Perrinauthor=D.+Leroyauthor=D.+Gretenerauthor=A.+Nicholsauthor=P.+A.+Vitteauthor=S.+Carboniauthor=C.+Rommelauthor=M.+K.+Schwarzauthor=T.+R%C3%BCckle&title=Furan-2-ylmethylene+thiazolidinediones+as+novel%2C+potent%2C+and+selective+inhibitors+of+phosphoinositide+3-kinase+%CE%B3&doi=10.1021%2Fjm0601598"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6f&amp;dbid=16384&amp;doi=10.1021%2Fjm0601598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0601598%26sid%3Dliteratum%253Aachs%26aulast%3DPomel%26aufirst%3DV.%26aulast%3DKlicic%26aufirst%3DJ.%26aulast%3DCovini%26aufirst%3DD.%26aulast%3DChurch%26aufirst%3DD.%2BD.%26aulast%3DShaw%26aufirst%3DJ.%2BP.%26aulast%3DRoulin%26aufirst%3DK.%26aulast%3DBurgat-Charvillon%26aufirst%3DF.%26aulast%3DValognes%26aufirst%3DD.%26aulast%3DCamps%26aufirst%3DM.%26aulast%3DChabert%26aufirst%3DC.%26aulast%3DGillieron%26aufirst%3DC.%26aulast%3DFrancon%26aufirst%3DB.%26aulast%3DPerrin%26aufirst%3DD.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DGretener%26aufirst%3DD.%26aulast%3DNichols%26aufirst%3DA.%26aulast%3DVitte%26aufirst%3DP.%2BA.%26aulast%3DCarboni%26aufirst%3DS.%26aulast%3DRommel%26aufirst%3DC.%26aulast%3DSchwarz%26aufirst%3DM.%2BK.%26aulast%3DR%25C3%25BCckle%26aufirst%3DT.%26atitle%3DFuran-2-ylmethylene%2520thiazolidinediones%2520as%2520novel%252C%2520potent%252C%2520and%2520selective%2520inhibitors%2520of%2520phosphoinositide%25203-kinase%2520%25CE%25B3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D3857%26epage%3D3871%26doi%3D10.1021%2Fjm0601598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Pereira, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strangman, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marion, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldberg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roll, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersen, R. J.</span><span> </span><span class="NLM_article-title">Synthesis of Phosphatidylinositol 3-Kinase (PI3K) Inhibitory Analogues of the Sponge Meroterpenoid Liphagal</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8523</span><span class="NLM_x">–</span> <span class="NLM_lpage">8533</span><span class="refDoi"> DOI: 10.1021/jm100531u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100531u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFShtb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8523-8533&author=A.+R.+Pereiraauthor=W.+K.+Strangmanauthor=F.+Marionauthor=L.+Feldbergauthor=D.+Rollauthor=R.+Mallonauthor=I.+Hollanderauthor=R.+J.+Andersen&title=Synthesis+of+Phosphatidylinositol+3-Kinase+%28PI3K%29+Inhibitory+Analogues+of+the+Sponge+Meroterpenoid+Liphagal&doi=10.1021%2Fjm100531u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6gR"><div class="casContent"><span class="casTitleNuber">6g</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Phosphatidylinositol 3-Kinase (PI3K) Inhibitory Analogues of the Sponge Meroterpenoid Liphagal</span></div><div class="casAuthors">Pereira, Alban R.; Strangman, Wendy K.; Marion, Frederic; Feldberg, Larry; Roll, Deborah; Mallon, Robert; Hollander, Irwin; Andersen, Raymond J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8523-8533</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The sponge meroterpenoid liphagal (+)-I and racemic and nonracemic analogs such as (±)-II were prepd. and their inhibition of phosphatidylinositol-3-kinases α and γ (PI3Kα and PI3Kγ, resp.) was detd.  II inhibited PI3Kα and PI3Kγ with IC50 values of 66 nM and 1840 nM, resp., showing a 27-fold preference for PI3Kα; in addn., II exhibited enhanced chem. stability and modestly enhanced potency and selectivity compared with those of I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-dJ0WNMQ0nrVg90H21EOLACvtfcHk0lgL1lH--aMRsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFShtb7F&md5=fe31011bbe5e502c62daf12167cea734</span></div><a href="/servlet/linkout?suffix=cit6g&amp;dbid=16384&amp;doi=10.1021%2Fjm100531u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100531u%26sid%3Dliteratum%253Aachs%26aulast%3DPereira%26aufirst%3DA.%2BR.%26aulast%3DStrangman%26aufirst%3DW.%2BK.%26aulast%3DMarion%26aufirst%3DF.%26aulast%3DFeldberg%26aufirst%3DL.%26aulast%3DRoll%26aufirst%3DD.%26aulast%3DMallon%26aufirst%3DR.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DAndersen%26aufirst%3DR.%2BJ.%26atitle%3DSynthesis%2520of%2520Phosphatidylinositol%25203-Kinase%2520%2528PI3K%2529%2520Inhibitory%2520Analogues%2520of%2520the%2520Sponge%2520Meroterpenoid%2520Liphagal%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8523%26epage%3D8533%26doi%3D10.1021%2Fjm100531u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Leahy, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhr, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baik, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cannoy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forsyth, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeong, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuss, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heald, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holst, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaeger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lougheed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plonowski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stout, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakes, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raeber, O.</span><span> </span><span class="NLM_article-title">Discovery of a Novel Series of Potent and Orally Bioavailable Phosphoinositide 3-Kinase γ Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">5467</span><span class="NLM_x">–</span> <span class="NLM_lpage">5482</span><span class="refDoi"> DOI: 10.1021/jm300403a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300403a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1OqtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5467-5482&author=J.+W.+Leahyauthor=C.+A.+Buhrauthor=H.+W.+Johnsonauthor=B.+G.+Kimauthor=T.+Baikauthor=J.+Cannoyauthor=T.+P.+Forsythauthor=J.+W.+Jeongauthor=M.+S.+Leeauthor=S.+Maauthor=K.+Nosonauthor=L.+Wangauthor=M.+Williamsauthor=J.+M.+Nussauthor=E.+Brooksauthor=P.+Fosterauthor=L.+Goonauthor=N.+Healdauthor=C.+Holstauthor=C.+Jaegerauthor=S.+Lamauthor=J.+Lougheedauthor=L.+Nguyenauthor=A.+Plonowskiauthor=J.+Songauthor=T.+Stoutauthor=X.+Wuauthor=M.+F.+Yakesauthor=P.+Yuauthor=W.+Zhangauthor=P.+Lambauthor=O.+Raeber&title=Discovery+of+a+Novel+Series+of+Potent+and+Orally+Bioavailable+Phosphoinositide+3-Kinase+%CE%B3+Inhibitors&doi=10.1021%2Fjm300403a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6hR"><div class="casContent"><span class="casTitleNuber">6h</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel Series of Potent and Orally Bioavailable Phosphoinositide 3-Kinase γ Inhibitors</span></div><div class="casAuthors">Leahy, James W.; Buhr, Chris A.; Johnson, Henry W. B.; Kim, Byung Gyu; Baik, TaeGon; Cannoy, Jonah; Forsyth, Timothy P.; Jeong, Joon Won; Lee, Matthew S.; Ma, Sunghoon; Noson, Kevin; Wang, Longcheng; Williams, Matthew; Nuss, John M.; Brooks, Eric; Foster, Paul; Goon, Leanne; Heald, Nathan; Holst, Charles; Jaeger, Christopher; Lam, Scott; Lougheed, Julie; Nguyen, Lam; Plonowski, Arthur; Song, Joanne; Stout, Thomas; Wu, Xiang; Yakes, Michael F.; Yu, Peiwen; Zhang, Wentao; Lamb, Peter; Raeber, Olivia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5467-5482</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The phosphoinositide 3-kinases (PI3Ks) have been linked to an extraordinarily diversified group of cellular functions making these enzymes compelling targets for the treatment of disease.  A large body of evidence has linked PI3Kγ to the modulation of autoimmune and inflammatory processes making it an intriguing target for drug discovery.  A high-throughput screening (HTS) campaign revealed two hits that were nominated for further optimization studies.  The in vitro activity of the first HTS hit, I, designated as the sulfonylpiperazine scaffold, was optimized utilizing structure-based design.  However, nonoptimal pharmacokinetic properties precluded this series from further studies.  An overlay of the x-ray structures of the sulfonylpiperazine scaffold and the second HTS hit, II, within their complexes with PI3Kγ revealed a high degree of overlap.  This feature was utilized to design a series of hybrid analogs including advanced leads such as III with desirable potency, selectivity, and oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxapmg3cIbmLVg90H21EOLACvtfcHk0ljK6hBX9kR3kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1OqtrY%253D&md5=c9986a8e80b1188c52a9d36d3f1d24f3</span></div><a href="/servlet/linkout?suffix=cit6h&amp;dbid=16384&amp;doi=10.1021%2Fjm300403a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300403a%26sid%3Dliteratum%253Aachs%26aulast%3DLeahy%26aufirst%3DJ.%2BW.%26aulast%3DBuhr%26aufirst%3DC.%2BA.%26aulast%3DJohnson%26aufirst%3DH.%2BW.%26aulast%3DKim%26aufirst%3DB.%2BG.%26aulast%3DBaik%26aufirst%3DT.%26aulast%3DCannoy%26aufirst%3DJ.%26aulast%3DForsyth%26aufirst%3DT.%2BP.%26aulast%3DJeong%26aufirst%3DJ.%2BW.%26aulast%3DLee%26aufirst%3DM.%2BS.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DNoson%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DNuss%26aufirst%3DJ.%2BM.%26aulast%3DBrooks%26aufirst%3DE.%26aulast%3DFoster%26aufirst%3DP.%26aulast%3DGoon%26aufirst%3DL.%26aulast%3DHeald%26aufirst%3DN.%26aulast%3DHolst%26aufirst%3DC.%26aulast%3DJaeger%26aufirst%3DC.%26aulast%3DLam%26aufirst%3DS.%26aulast%3DLougheed%26aufirst%3DJ.%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DPlonowski%26aufirst%3DA.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DStout%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DYakes%26aufirst%3DM.%2BF.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DLamb%26aufirst%3DP.%26aulast%3DRaeber%26aufirst%3DO.%26atitle%3DDiscovery%2520of%2520a%2520Novel%2520Series%2520of%2520Potent%2520and%2520Orally%2520Bioavailable%2520Phosphoinositide%25203-Kinase%2520%25CE%25B3%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5467%26epage%3D5482%26doi%3D10.1021%2Fjm300403a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group">Collier, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez-Botella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornebise, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cottrell, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doran, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahajan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maltais, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moody, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huck, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aronov, A. M.</span><span> </span><span class="NLM_article-title">Structural Basis for Isoform Selectivity in a Class of Benzothiazole Inhibitors of Phosphoinositide 3-Kinase γ</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">517</span><span class="NLM_x">–</span> <span class="NLM_lpage">521</span><span class="refDoi"> DOI: 10.1021/jm500362j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500362j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6i&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsFWnsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=517-521&author=P.+N.+Collierauthor=G.+Martinez-Botellaauthor=M.+Cornebiseauthor=K.+M.+Cottrellauthor=J.+D.+Doranauthor=J.+P.+Griffithauthor=S.+Mahajanauthor=F.+Maltaisauthor=C.+S.+Moodyauthor=E.+P.+Huckauthor=T.+Wangauthor=A.+M.+Aronov&title=Structural+Basis+for+Isoform+Selectivity+in+a+Class+of+Benzothiazole+Inhibitors+of+Phosphoinositide+3-Kinase+%CE%B3&doi=10.1021%2Fjm500362j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6iR"><div class="casContent"><span class="casTitleNuber">6i</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for Isoform Selectivity in a Class of Benzothiazole Inhibitors of Phosphoinositide 3-Kinase γ</span></div><div class="casAuthors">Collier, Philip N.; Martinez-Botella, Gabriel; Cornebise, Mark; Cottrell, Kevin M.; Doran, John D.; Griffith, James P.; Mahajan, Sudipta; Maltais, Francois; Moody, Cameron S.; Huck, Emilie Porter; Wang, Tiansheng; Aronov, Alex M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">517-521</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinase γ (PI3Kγ) is an attractive target to potentially treat a range of disease states.  Herein, we describe the evolution of a reported phenylthiazole pan-PI3K inhibitor into a family of potent and selective benzothiazole inhibitors.  Using x-ray crystallog., we discovered that compd. I occupies a previously unreported hydrophobic binding cleft adjacent to the ATP binding site of PI3Kγ, and achieves its selectivity by exploiting natural sequence differences among PI3K isoforms in this region.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDVpUaz7njz7Vg90H21EOLACvtfcHk0ljK6hBX9kR3kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsFWnsrk%253D&md5=dd5ce3f9e524747d10d094c9f9b9127c</span></div><a href="/servlet/linkout?suffix=cit6i&amp;dbid=16384&amp;doi=10.1021%2Fjm500362j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500362j%26sid%3Dliteratum%253Aachs%26aulast%3DCollier%26aufirst%3DP.%2BN.%26aulast%3DMartinez-Botella%26aufirst%3DG.%26aulast%3DCornebise%26aufirst%3DM.%26aulast%3DCottrell%26aufirst%3DK.%2BM.%26aulast%3DDoran%26aufirst%3DJ.%2BD.%26aulast%3DGriffith%26aufirst%3DJ.%2BP.%26aulast%3DMahajan%26aufirst%3DS.%26aulast%3DMaltais%26aufirst%3DF.%26aulast%3DMoody%26aufirst%3DC.%2BS.%26aulast%3DHuck%26aufirst%3DE.%2BP.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DAronov%26aufirst%3DA.%2BM.%26atitle%3DStructural%2520Basis%2520for%2520Isoform%2520Selectivity%2520in%2520a%2520Class%2520of%2520Benzothiazole%2520Inhibitors%2520of%2520Phosphoinositide%25203-Kinase%2520%25CE%25B3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D517%26epage%3D521%26doi%3D10.1021%2Fjm500362j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6j"><span><span class="NLM_label">(j) </span><span class="NLM_contrib-group">Oka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yabuuchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakahara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sekiguchi, Y.</span><span> </span><span class="NLM_article-title">Discovery and optimization of a series of 2-aminothiazole-oxazoles as potent phosphoinositide 3-kinase γ inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">7534</span><span class="NLM_x">–</span> <span class="NLM_lpage">7538</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.10.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6j&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.bmcl.2012.10.028" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=7534-7538&author=Y.+Okaauthor=T.+Yabuuchiauthor=Y.+Fujiiauthor=H.+Ohtakeauthor=S.+Wakaharaauthor=K.+Matsumotoauthor=M.+Endoauthor=Y.+Tamuraauthor=Y.+Sekiguchi&title=Discovery+and+optimization+of+a+series+of+2-aminothiazole-oxazoles+as+potent+phosphoinositide+3-kinase+%CE%B3+inhibitors&doi=10.1016%2Fj.bmcl.2012.10.028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6j&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.10.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.10.028%26sid%3Dliteratum%253Aachs%26aulast%3DOka%26aufirst%3DY.%26aulast%3DYabuuchi%26aufirst%3DT.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DOhtake%26aufirst%3DH.%26aulast%3DWakahara%26aufirst%3DS.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DEndo%26aufirst%3DM.%26aulast%3DTamura%26aufirst%3DY.%26aulast%3DSekiguchi%26aufirst%3DY.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520a%2520series%2520of%25202-aminothiazole-oxazoles%2520as%2520potent%2520phosphoinositide%25203-kinase%2520%25CE%25B3%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D7534%26epage%3D7538%26doi%3D10.1016%2Fj.bmcl.2012.10.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fruman, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rommel, C.</span><span> </span><span class="NLM_article-title">ΠI3Kδ Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">562</span><span class="NLM_x">–</span> <span class="NLM_lpage">572</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-11-0249</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1158%2F2159-8290.CD-11-0249" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=562-572&author=D.+A.+Frumanauthor=C.+Rommel&title=%CE%A0I3K%CE%B4+Inhibitors+in+Cancer%3A+Rationale+and+Serendipity+Merge+in+the+Clinic&doi=10.1158%2F2159-8290.CD-11-0249"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-11-0249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-11-0249%26sid%3Dliteratum%253Aachs%26aulast%3DFruman%26aufirst%3DD.%2BA.%26aulast%3DRommel%26aufirst%3DC.%26atitle%3D%25CE%25A0I3K%25CE%25B4%2520Inhibitors%2520in%2520Cancer%253A%2520Rationale%2520and%2520Serendipity%2520Merge%2520in%2520the%2520Clinic%26jtitle%3DCancer%2520Discovery%26date%3D2011%26volume%3D1%26spage%3D562%26epage%3D572%26doi%3D10.1158%2F2159-8290.CD-11-0249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lannutti, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meadows, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, S. E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashishian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrd, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loriaux, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puri, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulrich, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giese, N. A.</span><span> </span><span class="NLM_article-title">CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">594</span><span class="refDoi"> DOI: 10.1182/blood-2010-03-275305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1182%2Fblood-2010-03-275305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=20959606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1aqtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=591-594&author=B.+J.+Lannuttiauthor=S.+A.+Meadowsauthor=S.+E.+M.+Hermanauthor=A.+Kashishianauthor=B.+Steinerauthor=A.+J.+Johnsonauthor=J.+C.+Byrdauthor=J.+W.+Tynerauthor=M.+M.+Loriauxauthor=M.+Deiningerauthor=B.+J.+Drukerauthor=K.+J.+Puriauthor=R.+G.+Ulrichauthor=N.+A.+Giese&title=CAL-101%2C+a+p110delta+selective+phosphatidylinositol-3-kinase+inhibitor+for+the+treatment+of+B-cell+malignancies%2C+inhibits+PI3K+signaling+and+cellular+viability&doi=10.1182%2Fblood-2010-03-275305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability</span></div><div class="casAuthors">Lannutti, Brian J.; Meadows, Sarah A.; Herman, Sarah E. M.; Kashishian, Adam; Steiner, Bart; Johnson, Amy J.; Byrd, John C.; Tyner, Jeffrey W.; Loriaux, Marc M.; Deininger, Mike; Druker, Brian J.; Puri, Kamal D.; Ulrich, Roger G.; Giese, Neill A.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">591-594</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-kinase p110δ serves as a central integration point for signaling from cell surface receptors known to promote malignant B-cell proliferation and survival.  This provides a rationale for the development of small mol. inhibitors that selectively target p110δ as a treatment approach for patients with B-cell malignancies.  We thus identified 5-fluoro-3-phenyl-2-[(S)-1-(9H-purin-6-ylamino)-propyl]-3H-quinazolin-4-one (CAL-101), a highly selective and potent p110δ small mol. inhibitor (half-maximal effective concn. [EC50] = 8nM).  Using tumor cell lines and primary patient samples representing multiple B-cell malignancies, we have demonstrated that constitutive phosphatidylinositol-3-kinase pathway activation is p110δ-dependent.  CAL-101 blocked constitutive phosphatidylinositol-3-kinase signaling, resulting in decreased phosphorylation of Akt and other downstream effectors, an increase in poly(ADP-ribose) polymerase and caspase cleavage and an induction of apoptosis.  These effects have been obsd. across a broad range of immature and mature B-cell malignancies, thereby providing a rationale for the ongoing clin. evaluation of CAL-101.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrID8zgXRVmvbVg90H21EOLACvtfcHk0liDhL8Q3I6pMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1aqtro%253D&md5=423bf1fbea274424db3b818fdc6733b0</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-03-275305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-03-275305%26sid%3Dliteratum%253Aachs%26aulast%3DLannutti%26aufirst%3DB.%2BJ.%26aulast%3DMeadows%26aufirst%3DS.%2BA.%26aulast%3DHerman%26aufirst%3DS.%2BE.%2BM.%26aulast%3DKashishian%26aufirst%3DA.%26aulast%3DSteiner%26aufirst%3DB.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DDeininger%26aufirst%3DM.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DPuri%26aufirst%3DK.%2BJ.%26aulast%3DUlrich%26aufirst%3DR.%2BG.%26aulast%3DGiese%26aufirst%3DN.%2BA.%26atitle%3DCAL-101%252C%2520a%2520p110delta%2520selective%2520phosphatidylinositol-3-kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520B-cell%2520malignancies%252C%2520inhibits%2520PI3K%2520signaling%2520and%2520cellular%2520viability%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26spage%3D591%26epage%3D594%26doi%3D10.1182%2Fblood-2010-03-275305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Subramaniam, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whye, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Efimenko, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tosello, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Keersmaecker, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashishian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castillo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordon-Cardo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davé, U. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrando, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lannutti, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diacovo, T. G.</span><span> </span><span class="NLM_article-title">Targeting Nonclassical Oncogenes for Therapy in T-ALL</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">459</span><span class="NLM_x">–</span> <span class="NLM_lpage">472</span><span class="refDoi"> DOI: 10.1016/j.ccr.2012.02.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.ccr.2012.02.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=22516257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvVSnsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=459-472&author=P.+S.+Subramaniamauthor=D.+W.+Whyeauthor=E.+Efimenkoauthor=J.+Chenauthor=V.+Toselloauthor=K.+De+Keersmaeckerauthor=A.+Kashishianauthor=M.+A.+Thompsonauthor=M.+Castilloauthor=C.+Cordon-Cardoauthor=U.+P.+Dav%C3%A9author=A.+Ferrandoauthor=B.+J.+Lannuttiauthor=T.+G.+Diacovo&title=Targeting+Nonclassical+Oncogenes+for+Therapy+in+T-ALL&doi=10.1016%2Fj.ccr.2012.02.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Nonclassical Oncogenes for Therapy in T-ALL</span></div><div class="casAuthors">Subramaniam, Prem S.; Whye, Dosh W.; Efimenko, Evgeni; Chen, Jianchung; Tosello, Valeria; De Keersmaecker, Kim; Kashishian, Adam; Thompson, Mary Ann; Castillo, Mireia; Cordon-Cardo, Carlos; Dave, Utpal P.; Ferrando, Adolfo; Lannutti, Brian J.; Diacovo, Thomas G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">459-472</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Constitutive phosphoinositide 3-kinase (PI3K)/Akt activation is common in T cell acute lymphoblastic leukemia (T-ALL).  Although four distinct class I PI3K isoforms (α, β, γ, δ) could participate in T-ALL pathogenesis, none has been implicated in this process.  We report that in the absence of PTEN phosphatase tumor suppressor function, PI3Kγ or PI3Kδ alone can support leukemogenesis, whereas inactivation of both isoforms suppressed tumor formation.  The reliance of PTEN null T-ALL on the combined activities of PI3Kγ/δ was further demonstrated by the ability of a dual inhibitor to reduce disease burden and prolong survival in mice as well as prevent proliferation and promote activation of proapoptotic pathways in human tumors.  These results support combined inhibition of PI3Kγ/δ as therapy for T-ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosNmXI2hkyJLVg90H21EOLACvtfcHk0ljmHxHvj-VL7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvVSnsr8%253D&md5=398af95a5213dd668b882bf33b222a8c</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2012.02.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2012.02.029%26sid%3Dliteratum%253Aachs%26aulast%3DSubramaniam%26aufirst%3DP.%2BS.%26aulast%3DWhye%26aufirst%3DD.%2BW.%26aulast%3DEfimenko%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTosello%26aufirst%3DV.%26aulast%3DDe%2BKeersmaecker%26aufirst%3DK.%26aulast%3DKashishian%26aufirst%3DA.%26aulast%3DThompson%26aufirst%3DM.%2BA.%26aulast%3DCastillo%26aufirst%3DM.%26aulast%3DCordon-Cardo%26aufirst%3DC.%26aulast%3DDav%25C3%25A9%26aufirst%3DU.%2BP.%26aulast%3DFerrando%26aufirst%3DA.%26aulast%3DLannutti%26aufirst%3DB.%2BJ.%26aulast%3DDiacovo%26aufirst%3DT.%2BG.%26atitle%3DTargeting%2520Nonclassical%2520Oncogenes%2520for%2520Therapy%2520in%2520T-ALL%26jtitle%3DCancer%2520Cell%26date%3D2012%26volume%3D21%26spage%3D459%26epage%3D472%26doi%3D10.1016%2Fj.ccr.2012.02.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Schmid, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avraamides, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dippold, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foubert, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellies, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acevedo, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manglicmot, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrasidlo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginsberg, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheresh, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Field, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varner, J. A.</span><span> </span><span class="NLM_article-title">Receptor Tyrosine Kinases and TLR/IL1Rs Unexpectedly Activate Myeloid Cell PI3Kγ, A Single Convergent Point Promoting Tumor Inflammation and Progression</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">715</span><span class="NLM_x">–</span> <span class="NLM_lpage">727</span><span class="refDoi"> DOI: 10.1016/j.ccr.2011.04.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.ccr.2011.04.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=715-727&author=M.+C.+Schmidauthor=C.+J.+Avraamidesauthor=H.+C.+Dippoldauthor=I.+Francoauthor=P.+Foubertauthor=L.+G.+Elliesauthor=L.+M.+Acevedoauthor=J.+R.+Manglicmotauthor=X.+Songauthor=W.+Wrasidloauthor=S.+L.+Blairauthor=M.+H.+Ginsbergauthor=D.+A.+Chereshauthor=E.+Hirschauthor=S.+J.+Fieldauthor=J.+A.+Varner&title=Receptor+Tyrosine+Kinases+and+TLR%2FIL1Rs+Unexpectedly+Activate+Myeloid+Cell+PI3K%CE%B3%2C+A+Single+Convergent+Point+Promoting+Tumor+Inflammation+and+Progression&doi=10.1016%2Fj.ccr.2011.04.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2011.04.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2011.04.016%26sid%3Dliteratum%253Aachs%26aulast%3DSchmid%26aufirst%3DM.%2BC.%26aulast%3DAvraamides%26aufirst%3DC.%2BJ.%26aulast%3DDippold%26aufirst%3DH.%2BC.%26aulast%3DFranco%26aufirst%3DI.%26aulast%3DFoubert%26aufirst%3DP.%26aulast%3DEllies%26aufirst%3DL.%2BG.%26aulast%3DAcevedo%26aufirst%3DL.%2BM.%26aulast%3DManglicmot%26aufirst%3DJ.%2BR.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DWrasidlo%26aufirst%3DW.%26aulast%3DBlair%26aufirst%3DS.%2BL.%26aulast%3DGinsberg%26aufirst%3DM.%2BH.%26aulast%3DCheresh%26aufirst%3DD.%2BA.%26aulast%3DHirsch%26aufirst%3DE.%26aulast%3DField%26aufirst%3DS.%2BJ.%26aulast%3DVarner%26aufirst%3DJ.%2BA.%26atitle%3DReceptor%2520Tyrosine%2520Kinases%2520and%2520TLR%252FIL1Rs%2520Unexpectedly%2520Activate%2520Myeloid%2520Cell%2520PI3K%25CE%25B3%252C%2520A%2520Single%2520Convergent%2520Point%2520Promoting%2520Tumor%2520Inflammation%2520and%2520Progression%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26spage%3D715%26epage%3D727%26doi%3D10.1016%2Fj.ccr.2011.04.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm406387.htm" class="extLink">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm406387.htm</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm406387.htm."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="note"><p class="first last">Reviews of class I PI3K inhibitors under clinical evaluation:</p></div><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Carnero, A.</span><span> </span><span class="NLM_article-title">Novel Inhibitors of the PI3K Family</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1265</span><span class="NLM_x">–</span> <span class="NLM_lpage">1277</span><span class="refDoi"> DOI: 10.1517/13543780903066798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1517%2F13543780903066798" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=1265-1277&author=A.+Carnero&title=Novel+Inhibitors+of+the+PI3K+Family&doi=10.1517%2F13543780903066798"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1517%2F13543780903066798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543780903066798%26sid%3Dliteratum%253Aachs%26aulast%3DCarnero%26aufirst%3DA.%26atitle%3DNovel%2520Inhibitors%2520of%2520the%2520PI3K%2520Family%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2009%26volume%3D18%26spage%3D1265%26epage%3D1277%26doi%3D10.1517%2F13543780903066798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Courtney, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corcoran, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">The PI3K Pathway as a Drug Target in Human Cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1075</span><span class="refDoi"> DOI: 10.1200/JCO.2009.25.3641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1200%2FJCO.2009.25.3641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=20085938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktF2lt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=1075&author=K.+D.+Courtneyauthor=R.+B.+Corcoranauthor=J.+A.+Engelman&title=The+PI3K+Pathway+as+a+Drug+Target+in+Human+Cancer&doi=10.1200%2FJCO.2009.25.3641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">The PI3K pathway as drug target in human cancer</span></div><div class="casAuthors">Courtney, Kevin D.; Corcoran, Ryan B.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1075-1083</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The phosphatidylinositol 3-kinase (PI3K) signaling axis impacts on cancer cell growth, survival, motility, and metab.  This pathway is activated by several different mechanisms in cancers, including somatic mutation and amplification of genes encoding key components.  In addn., PI3K signaling may serve integral functions for noncancerous cells in the tumor microenvironment.  Consequently, therapeutics targeting the PI3K pathway are being developed at a rapid pace, and preclin. and early clin. studies are beginning to suggest specific strategies to effectively use them.  However, the central role of PI3K signaling in a large array of diverse biol. processes raises concerns about its use in therapeutics and increases the need to develop sophisticated strategies for its use.  In this review, we will discuss how PI3K signaling affects the growth and survival of tumor cells.  From this vantage, we will consider how inhibitors of the PI3K signaling cascade, either alone or in combination with other therapeutics, can most effectively be used for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpPqtk2bVl0rVg90H21EOLACvtfcHk0lgP3eVs4N-8AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktF2lt7w%253D&md5=b88b394919647e2eb47e7735355fde2a</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.25.3641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.25.3641%26sid%3Dliteratum%253Aachs%26aulast%3DCourtney%26aufirst%3DK.%2BD.%26aulast%3DCorcoran%26aufirst%3DR.%2BB.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520PI3K%2520Pathway%2520as%2520a%2520Drug%2520Target%2520in%2520Human%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D1075%26doi%3D10.1200%2FJCO.2009.25.3641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hixon, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paccagnella, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millham, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Olle, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gualberto, A.</span><span> </span><span class="NLM_article-title">Development of Inhibitors of the IGF-1R/PI3K/Akt/mTOR Pathway</span> <span class="citation_source-journal">Rev. Recent Clin. Trials</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">189</span><span class="NLM_x">–</span> <span class="NLM_lpage">208</span><span class="refDoi"> DOI: 10.2174/157488710792007329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.2174%2F157488710792007329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=20533896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFKqsrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=189-208&author=M.+L.+Hixonauthor=L.+Paccagnellaauthor=R.+Millhamauthor=R.+Perez-Olleauthor=A.+Gualberto&title=Development+of+Inhibitors+of+the+IGF-1R%2FPI3K%2FAkt%2FmTOR+Pathway&doi=10.2174%2F157488710792007329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10c</span><div class="casTitle"><span class="NLM_cas:atitle">Development of inhibitors of the IGF-IR/PI3K/Akt/mTOR pathway</span></div><div class="casAuthors">Hixon, Mary L.; Paccagnella, Luisa; Millham, Robert; Perez-Olle, Raul; Gualberto, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Reviews on Recent Clinical Trials</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">189-208</span>CODEN:
                <span class="NLM_cas:coden">RRCTB2</span>;
        ISSN:<span class="NLM_cas:issn">1574-8871</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Progress has been made towards the development of agents targeting tyrosine kinase receptors and other mols. involved in signalling pathways important for cell proliferation, motility, and apoptosis.  Inhibitor mols. designed to be highly specific with the aim of decreasing toxicity have proven to be generally well tolerated.  However, the efficacy of targeted agents may be impacted by cross-talk between pathways and downregulation of neg. feed-back loops.  That is the case of the IGF-IR/PI3K/Akt/mTOR pathway.  This issue raises the question of how these targeted agents could be combined to prevent or delay resistance without significantly increasing toxicity.  Several mTOR inhibitors have been approved for cancer therapy, and late-stage clin. trials of IGF-IR inhibitors are underway.  The outcome of ongoing clin. studies of IGF-IR, PI3K, Akt and mTOR inhibitors as well as further testing of the combination of these agents will be key for the development of therapeutic options in a wide range of oncol. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGootsaAecGArrVg90H21EOLACvtfcHk0lgP3eVs4N-8AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFKqsrfJ&md5=b2c1643995fec5371c54112057c9d920</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=10.2174%2F157488710792007329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157488710792007329%26sid%3Dliteratum%253Aachs%26aulast%3DHixon%26aufirst%3DM.%2BL.%26aulast%3DPaccagnella%26aufirst%3DL.%26aulast%3DMillham%26aufirst%3DR.%26aulast%3DPerez-Olle%26aufirst%3DR.%26aulast%3DGualberto%26aufirst%3DA.%26atitle%3DDevelopment%2520of%2520Inhibitors%2520of%2520the%2520IGF-1R%252FPI3K%252FAkt%252FmTOR%2520Pathway%26jtitle%3DRev.%2520Recent%2520Clin.%2520Trials%26date%3D2010%26volume%3D5%26spage%3D189%26epage%3D208%26doi%3D10.2174%2F157488710792007329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Shuttleworth, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cecil, A. R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomassi, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2686</span><span class="NLM_x">–</span> <span class="NLM_lpage">2714</span><span class="refDoi"> DOI: 10.2174/092986711796011229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.2174%2F092986711796011229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=21649578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Cit73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=2686-2714&author=S.+J.+Shuttleworthauthor=F.+A.+Silvaauthor=A.+R.+L.+Cecilauthor=C.+D.+Tomassiauthor=T.+J.+Hillauthor=F.+I.+Raynaudauthor=P.+A.+Clarkeauthor=P.+Workman&title=Progress+in+the+preclinical+discovery+and+clinical+development+of+class+I+and+dual+class+I%2FIV+phosphoinositide+3-kinase+%28PI3K%29+inhibitors&doi=10.2174%2F092986711796011229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10dR"><div class="casContent"><span class="casTitleNuber">10d</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors</span></div><div class="casAuthors">Shuttleworth, S. J.; Silva, F. A.; Cecil, A. R. L.; Tomassi, C. D.; Hill, T. J.; Raynaud, F. I.; Clarke, P. A.; Workman, P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2686-2714</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The phosphoinositide 3-kinases (PI3Ks) constitute an important family of lipid kinase enzymes that control a range of cellular processes through their regulation of a network of signal transduction pathways, and have emerged as important therapeutic targets in the context of cancer, inflammation and cardiovascular diseases.  Since the mid-late 1990s, considerable progress was made in the discovery and development of small mol. ATP-competitive PI3K inhibitors, a no. of which have entered early phase human trials over recent years from which key clin. results are now being disclosed.  This review summarizes progress made to date, primarily on the discovery and characterization of class I and dual class I/IV subtype inhibitors, together with advances that were made in translational and clin. research, notably in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpibTyG_ua2WLVg90H21EOLACvtfcHk0lgP3eVs4N-8AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Cit73M&md5=baf93d773ce18eb70ebc5549c14f422c</span></div><a href="/servlet/linkout?suffix=cit10d&amp;dbid=16384&amp;doi=10.2174%2F092986711796011229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711796011229%26sid%3Dliteratum%253Aachs%26aulast%3DShuttleworth%26aufirst%3DS.%2BJ.%26aulast%3DSilva%26aufirst%3DF.%2BA.%26aulast%3DCecil%26aufirst%3DA.%2BR.%2BL.%26aulast%3DTomassi%26aufirst%3DC.%2BD.%26aulast%3DHill%26aufirst%3DT.%2BJ.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DProgress%2520in%2520the%2520preclinical%2520discovery%2520and%2520clinical%2520development%2520of%2520class%2520I%2520and%2520dual%2520class%2520I%252FIV%2520phosphoinositide%25203-kinase%2520%2528PI3K%2529%2520inhibitors%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D2686%26epage%3D2714%26doi%3D10.2174%2F092986711796011229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Phosphoinositide 3-kinase α inhibitors: a patent review</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">789</span><span class="NLM_x">–</span> <span class="NLM_lpage">799</span><span class="refDoi"> DOI: 10.1517/13543776.2013.779673</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1517%2F13543776.2013.779673" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=23488930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslCks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=789-799&author=W.+A.+Denny&title=Phosphoinositide+3-kinase+%CE%B1+inhibitors%3A+a+patent+review&doi=10.1517%2F13543776.2013.779673"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10eR"><div class="casContent"><span class="casTitleNuber">10e</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide 3-kinase α inhibitors: a patent review</span></div><div class="casAuthors">Denny, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">789-799</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The alpha isoform of the class 1A family of phosphatidylinositol 3-kinases (PI3Kα) has been extensively studied and exploited as a target for cancer drugs.  A large no. of compds., from a wide variety of structural scaffolds, are in development.  There is an ongoing debate about the desirability for selectivity between PI3Kα and the other isoforms.  Areas covered: The article briefly outlines the nature and role of the class 1A PI3K in cell signalling and provides a table of representative inhibitors of these enzymes that have proceeded to clin. trial, with literature data on their isoform selectivity.  It covers the published patent literature from 2011 to 2012 (search completed in Dec. 2012), with a particular focus on compds. with a level of selective inhibition of PI3Kα.  In most cases, representative examples of claimed compds. and data on their inhibitory effects are provided.  Expert opinion: Features of the development of PI3K inhibitors to date have been the plasticity of the enzymes, which possess binding sites for a bewildering no. of small mol. scaffolds, and the need to det. the optimal patterns of selectivity between both the PI3K isoforms and the related downstream serine/threonine kinase mammalian target of rapamycin (mTOR) for therapeutic effect.  Both themes are apparent in the recent patents reviewed here, with a wide variety of drug types, including variations on existing scaffolds and completely new ones, being evident.  While many of these are dual PI3K/mTOR inhibitors, the PI3Kα-selective pyrido[2,3-b]pyrazine heterocycles reported by Intellikine and the (thiazolyl)pyrrolidinecarboxamides of Novartis are of particular interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0mWqyfPDxVbVg90H21EOLACvtfcHk0ljS2_acvj8noQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslCks7Y%253D&md5=4e0f5604400d18d1b31d1134d8697fff</span></div><a href="/servlet/linkout?suffix=cit10e&amp;dbid=16384&amp;doi=10.1517%2F13543776.2013.779673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2013.779673%26sid%3Dliteratum%253Aachs%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DPhosphoinositide%25203-kinase%2520%25CE%25B1%2520inhibitors%253A%2520a%2520patent%2520review%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2013%26volume%3D23%26spage%3D789%26epage%3D799%26doi%3D10.1517%2F13543776.2013.779673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Yap, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjerke, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Drugging PI3K in cancer: refining targets and therapeutic strategies</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">98</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span><span class="refDoi"> DOI: 10.1016/j.coph.2015.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.coph.2015.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=26117819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWrt7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=98-107&author=T.+A.+Yapauthor=L.+Bjerkeauthor=P.+A.+Clarkeauthor=P.+Workman&title=Drugging+PI3K+in+cancer%3A+refining+targets+and+therapeutic+strategies&doi=10.1016%2Fj.coph.2015.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10fR"><div class="casContent"><span class="casTitleNuber">10f</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging PI3K in cancer: refining targets and therapeutic strategies</span></div><div class="casAuthors">Yap, Timothy A.; Bjerke, Lynn; Clarke, Paul A.; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">98-107</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The phosphatidylinositol-3 kinase (PI3K) pathway is one of the most frequently activated pathogenic signalling routes in human cancers, making it a rational and important target for innovative anticancer drug development and precision medicine.  The three main classes of PI3K inhibitors currently in clin. testing comprise dual pan-Class I PI3K/mTOR inhibitors, pan-Class I PI3K inhibitors lacking significant mTOR activity and isoform-selective PI3K inhibitors.  A major step forward in recent years is the progression of over 30 small mol. PI3K inhibitors into clin. trials and the first regulatory approval of the PI3Kδ inhibitor idelalisib for multiple B-cell malignancies.  This review article focuses on the progress made in the discovery and development of novel PI3K inhibitors, with an emphasis on antitumor activity and tolerability profiles for agents that have entered clin. trials.  We also discuss the key issues of drug resistance, patient selection approaches and rational targeted combinations.  Finally, we envision the future development and use of PI3K inhibitors for the treatment of patients with a range of malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDxyCAEREi_7Vg90H21EOLACvtfcHk0ljS2_acvj8noQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWrt7bJ&md5=9a0238f97d8ecdc54e0c5b9b6ce4fc76</span></div><a href="/servlet/linkout?suffix=cit10f&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2015.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2015.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DBjerke%26aufirst%3DL.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DDrugging%2520PI3K%2520in%2520cancer%253A%2520refining%2520targets%2520and%2520therapeutic%2520strategies%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2015%26volume%3D23%26spage%3D98%26epage%3D107%26doi%3D10.1016%2Fj.coph.2015.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="note"><p class="first last">For PI3Kα isoform selective inhibitors in clinical trials, see:</p></div><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fritsch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatenay-Rivauday, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guthy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erdmann, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Pover, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferretti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trappe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brachmann, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maira, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chene, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cozens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlegel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caravatti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span> </span><span class="NLM_article-title">Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1117</span><span class="NLM_x">–</span> <span class="NLM_lpage">1129</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0865</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1158%2F1535-7163.MCT-13-0865" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=24608574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsFWjsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1117-1129&author=C.+Fritschauthor=A.+Huangauthor=C.+Chatenay-Rivaudayauthor=C.+Schnellauthor=A.+Reddyauthor=M.+Liuauthor=A.+Kauffmannauthor=D.+Guthyauthor=D.+Erdmannauthor=A.+De+Poverauthor=P.+Furetauthor=H.+Gaoauthor=S.+Ferrettiauthor=Y.+Wangauthor=J.+Trappeauthor=S.+M.+Brachmannauthor=S.+M.+Mairaauthor=C.+Wilsonauthor=M.+Boehmauthor=C.+Garcia-Echeverriaauthor=P.+Cheneauthor=M.+Wiesmannauthor=R.+Cozensauthor=J.+Leharauthor=R.+Schlegelauthor=G.+Caravattiauthor=F.+Hofmannauthor=W.+R.+Sellers&title=Characterization+of+the+novel+and+specific+PI3K%CE%B1+inhibitor+NVP-BYL719+and+development+of+the+patient+stratification+strategy+for+clinical+trials&doi=10.1158%2F1535-7163.MCT-13-0865"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials</span></div><div class="casAuthors">Fritsch, Christine; Huang, Alan; Chatenay-Rivauday, Christian; Schnell, Christian; Reddy, Anupama; Liu, Manway; Kauffmann, Audrey; Guthy, Daniel; Erdmann, Dirk; De Pover, Alain; Furet, Pascal; Gao, Hui; Ferretti, Stephane; Wang, Youzhen; Trappe, Joerg; Brachmann, Saskia M.; Maira, Sauveur-Michel; Wilson, Christopher; Boehm, Markus; Garcia-Echeverria, Carlos; Chene, Patrick; Wiesmann, Marion; Cozens, Robert; Lehar, Joseph; Schlegel, Robert; Caravatti, Giorgio; Hofmann, Francesco; Sellers, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1117-1129</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Somatic PIK3CA mutations are frequently found in solid tumors, raising the hypothesis that selective inhibition of PI3Kα may have robust efficacy in PIK3CA-mutant cancers while sparing patients the side-effects assocd. with broader inhibition of the class I phosphoinositide 3-kinase (PI3K) family.  Here, we report the biol. properties of the 2-aminothiazole deriv. NVP-BYL719, a selective inhibitor of PI3Kα and its most common oncogenic mutant forms.  The compd. selectivity combined with excellent drug-like properties translates to dose- and time-dependent inhibition of PI3Kα signaling in vivo, resulting in robust therapeutic efficacy and tolerability in PIK3CA-dependent tumors.  Novel targeted therapeutics such as NVP-BYL719, designed to modulate aberrant functions elicited by cancer-specific genetic alterations upon which the disease depends, require well-defined patient stratification strategies in order to maximize their therapeutic impact and benefit for the patients.  Here, we also describe the application of the Cancer Cell Line Encyclopedia as a preclin. platform to refine the patient stratification strategy for NVP-BYL719 and found that PIK3CA mutation was the foremost pos. predictor of sensitivity while revealing addnl. pos. and neg. assocns. such as PIK3CA amplification and PTEN mutation, resp.  These patient selection determinants are being assayed in the ongoing NVP-BYL719 clin. trials.  Mol Cancer Ther; 13(5); 1117-29. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzBW6u023PF7Vg90H21EOLACvtfcHk0liZzKOoVCDOMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsFWjsb4%253D&md5=58d9132052dd9d430361021b0f877475</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0865&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0865%26sid%3Dliteratum%253Aachs%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DChatenay-Rivauday%26aufirst%3DC.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DReddy%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DKauffmann%26aufirst%3DA.%26aulast%3DGuthy%26aufirst%3DD.%26aulast%3DErdmann%26aufirst%3DD.%26aulast%3DDe%2BPover%26aufirst%3DA.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DFerretti%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DTrappe%26aufirst%3DJ.%26aulast%3DBrachmann%26aufirst%3DS.%2BM.%26aulast%3DMaira%26aufirst%3DS.%2BM.%26aulast%3DWilson%26aufirst%3DC.%26aulast%3DBoehm%26aufirst%3DM.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DChene%26aufirst%3DP.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DLehar%26aufirst%3DJ.%26aulast%3DSchlegel%26aufirst%3DR.%26aulast%3DCaravatti%26aufirst%3DG.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26atitle%3DCharacterization%2520of%2520the%2520novel%2520and%2520specific%2520PI3K%25CE%25B1%2520inhibitor%2520NVP-BYL719%2520and%2520development%2520of%2520the%2520patient%2520stratification%2520strategy%2520for%2520clinical%2520trials%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D1117%26epage%3D1129%26doi%3D10.1158%2F1535-7163.MCT-13-0865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Barlaam, B.; Cosulich, S.; Delouvrie, B.; Fitzek, M.; Germain, H.; Green, S.; Harris, C. S.; Hudson, K.; Lambert-van der Brempt, C.; Lamorlette, M.; Antoine, L. G.; Morgentin, R.; Ouvry, G.; Page, K.; Pasquet, G.; Ruston, L.; Saleh, T.; Vautier, M.; Ward, L.</span><span> </span><span class="NLM_article-title">Discovery of AZD8835, a potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of PIK3CA-dependent cancers</span>.  <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span>, <span class="NLM_issue">suppl</span>, abstract  <span class="NLM_fpage">2830</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2015-2830</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1158%2F1538-7445.AM2015-2830" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=2830&issue=suppl&author=B.+Barlaam&author=S.+Cosulich&author=B.+Delouvrie&author=M.+Fitzek&author=H.+Germain&author=S.+Green&author=C.+S.+Harris&author=K.+Hudson&author=C.+Lambert-van+der+Brempt&author=M.+Lamorlette&author=L.+G.+Antoine&author=R.+Morgentin&author=G.+Ouvry&author=K.+Page&author=G.+Pasquet&author=L.+Ruston&author=T.+Saleh&author=M.+Vautier&author=L.+Ward&title=Discovery+of+AZD8835%2C+a+potent+and+selective+inhibitor+of+PI3K%CE%B1+and+PI3K%CE%B4+for+the+treatment+of+PIK3CA-dependent+cancers&doi=10.1158%2F1538-7445.AM2015-2830"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2015-2830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2015-2830%26sid%3Dliteratum%253Aachs%26aulast%3DBarlaam%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520AZD8835%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520PI3K%25CE%25B1%2520and%2520PI3K%25CE%25B4%2520for%2520the%2520treatment%2520of%2520PIK3CA-dependent%2520cancers%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26issue%3Dsuppl%26spage%3D2830%26doi%3D10.1158%2F1538-7445.AM2015-2830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="note"><p class="first last">For recent reviews of isoform selective PI3K inhibitors, see:</p></div><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Marone, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cmiljanovic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giese, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wymann, M. P.</span><span> </span><span class="NLM_article-title">Targeting Phosphoinositide 3-Kinase—Moving Towards Therapy</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Proteins Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">1784</span><span class="NLM_x">, </span> <span class="NLM_fpage">159</span><span class="NLM_x">–</span> <span class="NLM_lpage">185</span><span class="refDoi"> DOI: 10.1016/j.bbapap.2007.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.bbapap.2007.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=17997386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlerug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1784&publication_year=2008&pages=159-185&author=R.+Maroneauthor=V.+Cmiljanovicauthor=B.+Gieseauthor=M.+P.+Wymann&title=Targeting+Phosphoinositide+3-Kinase%E2%80%94Moving+Towards+Therapy&doi=10.1016%2Fj.bbapap.2007.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting phosphoinositide 3-kinase-Moving towards therapy</span></div><div class="casAuthors">Marone, Romina; Cmiljanovic, Vladimir; Giese, Bernd; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1784</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">159-185</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Phosphoinositide 3-kinases (PI3K) orchestrate cell responses including mitogenic signaling, cell survival and growth, metabolic control, vesicular trafficking, degranulation, cytoskeletal rearrangement and migration.  Deregulation of the PI3K pathway occurs by activating mutations in growth factor receptors or the PIK3CA locus coding for PI3Kα, by loss of function of the lipid phosphatase and tensin homolog deleted in chromosome ten (PTEN/MMAC/TEP1), by the up-regulation of protein kinase B (PKB/Akt), or the impairment of the tuberous sclerosis complex (TSC1/2).  All these events are linked to growth and proliferation, and have thus prompted a significant interest in the pharmaceutical targeting of the PI3K pathway in cancer.  Genetic targeting of PI3Kγ (p110γ) and PI3Kδ (p110δ) in mice has underlined a central role of these PI3K isoforms in inflammation and allergy, as they modulate chemotaxis of leukocytes and degranulation in mast cells.  Proof-of-concept mols. selective for PI3Kγ have already successfully alleviated disease progress in murine models of rheumatoid arthritis and lupus erythematosus.  As targeting PI3K moves forward to therapy of chronic, non-fatal disease, safety concerns for PI3K inhibitors increase.  Many of the present inhibitor series interfere with target of rapamycin (TOR), DNA-dependent protein kinase (DNA-PKcs) and activity of the ataxia telangiectasia mutated gene product (ATM).  Here we review the current disease-relevant knowledge for isoform-specific PI3K function in the above mentioned diseases, and review the progress of > 400 recent patents covering pharmaceutical targeting of PI3K.  Currently, several drugs targeting the PI3K pathway have entered clin. trials (phase I) for solid tumors and suppression of tissue damage after myocardial infarction (phases I,II).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwrI_aSA632bVg90H21EOLACvtfcHk0lgC11MxdirSyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlerug%253D%253D&md5=bf9f259b3da61067631823656658e0f7</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2007.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2007.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DMarone%26aufirst%3DR.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DGiese%26aufirst%3DB.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DTargeting%2520Phosphoinositide%25203-Kinase%25E2%2580%2594Moving%2520Towards%2520Therapy%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2008%26volume%3D1784%26spage%3D159%26epage%3D185%26doi%3D10.1016%2Fj.bbapap.2007.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Chemically Targetting the PI3K Family</span> <span class="citation_source-journal">Biochem. Soc. Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">–</span> <span class="NLM_lpage">249</span><span class="refDoi"> DOI: 10.1042/BST0350245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1042%2FBST0350245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=17371250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt1Wrsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=245-249&author=Z.+A.+Knightauthor=K.+M.+Shokat&title=Chemically+Targetting+the+PI3K+Family&doi=10.1042%2FBST0350245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically targeting the PI3K family</span></div><div class="casAuthors">Knight, Z. A.; Shokat, K. M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">245-249</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  PI3K (phosphoinositide 3-kinase) is a key regulator of cell growth, metab., and survival.  The frequent activation of the PI3K pathway in cancer has stimulated widespread interest in identifying potent and selective inhibitors of PI3K isoforms.  The present paper highlights recent progress in identifying such mols. and the challenges that remain for efforts to pharmacol. target the PI3K family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtmivxnuTfQ7Vg90H21EOLACvtfcHk0lgC11MxdirSyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt1Wrsb4%253D&md5=b7243ad076ba15f65214acc8a3b09d65</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1042%2FBST0350245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST0350245%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DChemically%2520Targetting%2520the%2520PI3K%2520Family%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2007%26volume%3D35%26spage%3D245%26epage%3D249%26doi%3D10.1042%2FBST0350245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ward, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finan, P.</span><span> </span><span class="NLM_article-title">Isoform-specific Phosphoinositide 3-Kinase Inhibitors as Therapeutic Agents</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">426</span><span class="NLM_x">–</span> <span class="NLM_lpage">434</span><span class="refDoi"> DOI: 10.1016/S1471-4892(03)00078-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2FS1471-4892%2803%2900078-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=12901953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlvFGju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=426-434&author=S.+G.+Wardauthor=P.+Finan&title=Isoform-specific+Phosphoinositide+3-Kinase+Inhibitors+as+Therapeutic+Agents&doi=10.1016%2FS1471-4892%2803%2900078-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12cR"><div class="casContent"><span class="casTitleNuber">12c</span><div class="casTitle"><span class="NLM_cas:atitle">Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents</span></div><div class="casAuthors">Ward, Stephen G.; Finan, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">426-434</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The phosphoinositide 3-kinase (PI3K) family of enzymes consists of several closely related isoforms that are thought to have distinct biol. roles.  Until now, researchers have been frustrated by poor selectivity of the available pharmacol. inhibitors, which are unable to distinguish adequately the activities of different PI3K isoforms.  Recently published patent specifications describe new PI3K inhibitors, including several that are selective for the PI3Kδ isoform.  There is now cautious optimism that isoform-selective PI3K inhibitors will provide new avenues for therapeutic applications in a range of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoooGyT_yJeLLVg90H21EOLACvtfcHk0lgC11MxdirSyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlvFGju7c%253D&md5=301655ddf3635b506ddb01a95d608f1d</span></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1016%2FS1471-4892%2803%2900078-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1471-4892%252803%252900078-X%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DS.%2BG.%26aulast%3DFinan%26aufirst%3DP.%26atitle%3DIsoform-specific%2520Phosphoinositide%25203-Kinase%2520Inhibitors%2520as%2520Therapeutic%2520Agents%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2003%26volume%3D3%26spage%3D426%26epage%3D434%26doi%3D10.1016%2FS1471-4892%2803%2900078-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Sundstrom, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, D. L.</span><span> </span><span class="NLM_article-title">Inhibitors of Phosphoinositide-3-Kinase: A Structure-Based Approach to Understanding Potency and Selectivity</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">840</span><span class="NLM_x">–</span> <span class="NLM_lpage">850</span><span class="refDoi"> DOI: 10.1039/b819067b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1039%2Fb819067b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=19225663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvFGru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=840-850&author=T.+J.+Sundstromauthor=A.+C.+Andersonauthor=D.+L.+Wright&title=Inhibitors+of+Phosphoinositide-3-Kinase%3A+A+Structure-Based+Approach+to+Understanding+Potency+and+Selectivity&doi=10.1039%2Fb819067b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12dR"><div class="casContent"><span class="casTitleNuber">12d</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of phosphoinositide-3-kinase: a structure-based approach to understanding potency and selectivity</span></div><div class="casAuthors">Sundstrom, Teather J.; Anderson, Amy C.; Wright, Dennis L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">840-850</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Phosphoinositide-3-kinase is a pivotal protein involved in a wide variety of signaling cascades and there has been a great deal of interest in the development of potent and selective inhibitors of this enzyme.  In this review, the potency and selectivity of the known inhibitors is presented along with key structural information that helps rationalize the obsd. trends.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1X1C0qBQxy7Vg90H21EOLACvtfcHk0lgZRAw6GfpxCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvFGru70%253D&md5=77356f92a07e4314aa2bd90e2382c7c0</span></div><a href="/servlet/linkout?suffix=cit12d&amp;dbid=16384&amp;doi=10.1039%2Fb819067b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb819067b%26sid%3Dliteratum%253Aachs%26aulast%3DSundstrom%26aufirst%3DT.%2BJ.%26aulast%3DAnderson%26aufirst%3DA.%2BC.%26aulast%3DWright%26aufirst%3DD.%2BL.%26atitle%3DInhibitors%2520of%2520Phosphoinositide-3-Kinase%253A%2520A%2520Structure-Based%2520Approach%2520to%2520Understanding%2520Potency%2520and%2520Selectivity%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2009%26volume%3D7%26spage%3D840%26epage%3D850%26doi%3D10.1039%2Fb819067b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hayakawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaizawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koizumi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohishi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterfield, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of imidazo[1,2-<i>a</i>]pyridine derivatives as novel PI3 kinase p110α inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">403</span><span class="NLM_x">–</span> <span class="NLM_lpage">412</span><span class="refDoi"> DOI: 10.1016/j.bmc.2006.09.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.bmc.2006.09.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=17049248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Cmt77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=403-412&author=M.+Hayakawaauthor=H.+Kaizawaauthor=K.+Kawaguchiauthor=N.+Ishikawaauthor=T.+Koizumiauthor=T.+Ohishiauthor=M.+Yamanoauthor=M.+Okadaauthor=M.+Ohtaauthor=S.+Tsukamotoauthor=F.+I.+Raynaudauthor=M.+D.+Waterfieldauthor=P.+Parkerauthor=P.+Workman&title=Synthesis+and+biological+evaluation+of+imidazo%5B1%2C2-a%5Dpyridine+derivatives+as+novel+PI3+kinase+p110%CE%B1+inhibitors&doi=10.1016%2Fj.bmc.2006.09.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110α inhibitors</span></div><div class="casAuthors">Hayakawa, Masahiko; Kaizawa, Hiroyuki; Kawaguchi, Ken-ichi; Ishikawa, Noriko; Koizumi, Tomonobu; Ohishi, Takahide; Yamano, Mayumi; Okada, Minoru; Ohta, Mitsuaki; Tsukamoto, Shin-ichi; Raynaud, Florence I.; Waterfield, Michael D.; Parker, Peter; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">403-412</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">3-{1-[(4-Fluorophenyl)sulfonyl]-1H-pyrazol-3-yl}-2-methylimidazo[1,2-a]pyridine, 2a, was discovered in our chem. library as a novel p110α inhibitor with an IC50 of 0.67 μM, through screening in a scintillation proximity assay.  Optimization of the substituents of 2a increased the p110α inhibitory activity by more than 300-fold (2g: IC50 = 0.0018 μM).  Further structural modification of 2g afforded thiazole deriv. 12 (I), which has potent p110α inhibitory activity (IC50 of 0.0028 μM) and is highly selective for p110α over other PI3K isoforms.  Compd. 12 also inhibited serum-induced cell proliferation of A375 and HeLa cells in vitro with IC50 values of 0.14 μM and 0.21 μM, resp., and suppressed tumor growth by 37% in a mouse HeLa xenograft model when dosed i.p. at 25 mg/kg.  These results suggest that selective p110α inhibitors may have potential as cancer therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtD0faWirHM7Vg90H21EOLACvtfcHk0lgZRAw6GfpxCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Cmt77L&md5=775c2f4e69fd565d13df597610ec44dd</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.09.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.09.047%26sid%3Dliteratum%253Aachs%26aulast%3DHayakawa%26aufirst%3DM.%26aulast%3DKaizawa%26aufirst%3DH.%26aulast%3DKawaguchi%26aufirst%3DK.%26aulast%3DIshikawa%26aufirst%3DN.%26aulast%3DKoizumi%26aufirst%3DT.%26aulast%3DOhishi%26aufirst%3DT.%26aulast%3DYamano%26aufirst%3DM.%26aulast%3DOkada%26aufirst%3DM.%26aulast%3DOhta%26aufirst%3DM.%26aulast%3DTsukamoto%26aufirst%3DS.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DWaterfield%26aufirst%3DM.%2BD.%26aulast%3DParker%26aufirst%3DP.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520imidazo%255B1%252C2-a%255Dpyridine%2520derivatives%2520as%2520novel%2520PI3%2520kinase%2520p110%25CE%25B1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D403%26epage%3D412%26doi%3D10.1016%2Fj.bmc.2006.09.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pereira, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strangman, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marion, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldberg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roll, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersen, R.</span><span> </span><span class="NLM_article-title">Synthesis of Phosphatidylinositol 3-Kinase (PI3K) Inhibitory Analogues of the Sponge Meroterpenoid Liphagal. J</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8523</span><span class="NLM_x">–</span> <span class="NLM_lpage">8533</span><span class="refDoi"> DOI: 10.1021/jm100531u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100531u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8523-8533&author=A.+R.+Pereiraauthor=W.+K.+Strangmanauthor=F.+Marionauthor=L.+Feldbergauthor=D.+Rollauthor=R.+Mallonauthor=I.+Hollanderauthor=R.+Andersen&title=Synthesis+of+Phosphatidylinositol+3-Kinase+%28PI3K%29+Inhibitory+Analogues+of+the+Sponge+Meroterpenoid+Liphagal.+J&doi=10.1021%2Fjm100531u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1021%2Fjm100531u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100531u%26sid%3Dliteratum%253Aachs%26aulast%3DPereira%26aufirst%3DA.%2BR.%26aulast%3DStrangman%26aufirst%3DW.%2BK.%26aulast%3DMarion%26aufirst%3DF.%26aulast%3DFeldberg%26aufirst%3DL.%26aulast%3DRoll%26aufirst%3DD.%26aulast%3DMallon%26aufirst%3DR.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DAndersen%26aufirst%3DR.%26atitle%3DSynthesis%2520of%2520Phosphatidylinositol%25203-Kinase%2520%2528PI3K%2529%2520Inhibitory%2520Analogues%2520of%2520the%2520Sponge%2520Meroterpenoid%2520Liphagal.%2520J%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8523%26epage%3D8533%26doi%3D10.1021%2Fjm100531u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Gilbert, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bursavich, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehnhardt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delos Santos, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldberg, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatesan, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallon, R.</span><span> </span><span class="NLM_article-title">Novel Purine and Pyrazolo[3,4-d]pyrimidine Inhibitors of PI3 Kinase-a: Hit to Lead Studies</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">636</span><span class="NLM_x">–</span> <span class="NLM_lpage">639</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.11.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.bmcl.2009.11.051" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=636-639&author=A.+M.+Gilbertauthor=P.+Nowakauthor=N.+Brooijmansauthor=M.+G.+Bursavichauthor=C.+Dehnhardtauthor=E.+Delos+Santosauthor=L.+R.+Feldbergauthor=I.+Hollanderauthor=S.+Kimauthor=S.+Lombardiauthor=K.+Parkauthor=A.+M.+Venkatesanauthor=R.+Mallon&title=Novel+Purine+and+Pyrazolo%5B3%2C4-d%5Dpyrimidine+Inhibitors+of+PI3+Kinase-a%3A+Hit+to+Lead+Studies&doi=10.1016%2Fj.bmcl.2009.11.051"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.11.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.11.051%26sid%3Dliteratum%253Aachs%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DNowak%26aufirst%3DP.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DBursavich%26aufirst%3DM.%2BG.%26aulast%3DDehnhardt%26aufirst%3DC.%26aulast%3DDelos%2BSantos%26aufirst%3DE.%26aulast%3DFeldberg%26aufirst%3DL.%2BR.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLombardi%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DVenkatesan%26aufirst%3DA.%2BM.%26aulast%3DMallon%26aufirst%3DR.%26atitle%3DNovel%2520Purine%2520and%2520Pyrazolo%255B3%252C4-d%255Dpyrimidine%2520Inhibitors%2520of%2520PI3%2520Kinase-a%253A%2520Hit%2520to%2520Lead%2520Studies%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D636%26epage%3D639%26doi%3D10.1016%2Fj.bmcl.2009.11.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Kendall, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederick, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mawson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baguley, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaussade, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, P. R.</span><span> </span><span class="NLM_article-title">Synthesis, biological evaluation and molecular modeling of sulfonohydrazides as selective PI3K p110α inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">7677</span><span class="NLM_x">–</span> <span class="NLM_lpage">7687</span><span class="refDoi"> DOI: 10.1016/j.bmc.2007.08.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.bmc.2007.08.062" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=7677-7687&author=J.+D.+Kendallauthor=G.+W.+Rewcastleauthor=R.+Frederickauthor=C.+Mawsonauthor=W.+A.+Dennyauthor=E.+S.+Marshallauthor=B.+C.+Baguleyauthor=C.+Chaussadeauthor=S.+P.+Jacksonauthor=P.+R.+Shepherd&title=Synthesis%2C+biological+evaluation+and+molecular+modeling+of+sulfonohydrazides+as+selective+PI3K+p110%CE%B1+inhibitors&doi=10.1016%2Fj.bmc.2007.08.062"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13d&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2007.08.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2007.08.062%26sid%3Dliteratum%253Aachs%26aulast%3DKendall%26aufirst%3DJ.%2BD.%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DFrederick%26aufirst%3DR.%26aulast%3DMawson%26aufirst%3DC.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DMarshall%26aufirst%3DE.%2BS.%26aulast%3DBaguley%26aufirst%3DB.%2BC.%26aulast%3DChaussade%26aufirst%3DC.%26aulast%3DJackson%26aufirst%3DS.%2BP.%26aulast%3DShepherd%26aufirst%3DP.%2BR.%26atitle%3DSynthesis%252C%2520biological%2520evaluation%2520and%2520molecular%2520modeling%2520of%2520sulfonohydrazides%2520as%2520selective%2520PI3K%2520p110%25CE%25B1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D7677%26epage%3D7687%26doi%3D10.1016%2Fj.bmc.2007.08.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zunder, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loewith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokoe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toth, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balla, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">733</span><span class="NLM_x">–</span> <span class="NLM_lpage">747</span><span class="refDoi"> DOI: 10.1016/j.cell.2006.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.cell.2006.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=16647110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD28XltlSkt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2006&pages=733-747&author=Z.+A.+Knightauthor=B.+Gonzalezauthor=M.+E.+Feldmanauthor=E.+R.+Zunderauthor=D.+D.+Goldenbergauthor=O.+Williamsauthor=R.+Loewithauthor=D.+Stokoeauthor=A.+Ballaauthor=B.+Tothauthor=T.+Ballaauthor=W.+A.+Weissauthor=R.+L.+Williamsauthor=K.+M.+Shokat&title=A+Pharmacological+Map+of+the+PI3-K+Family+Defines+a+Role+for+p110%CE%B1+in+Insulin+Signaling&doi=10.1016%2Fj.cell.2006.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13eR"><div class="casContent"><span class="casTitleNuber">13e</span><div class="casTitle"><span class="NLM_cas:atitle">A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling</span></div><div class="casAuthors">Knight, Zachary A.; Gonzalez, Beatriz; Feldman, Morri E.; Zunder, Eli R.; Goldenberg, David D.; Williams, Olusegun; Loewith, Robbie; Stokoe, David; Balla, Andras; Toth, Balazs; Balla, Tamas; Weiss, William A.; Williams, Roger L.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">733-747</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinases (PI3-Ks) are an important emerging class of drug targets, but the unique roles of PI3-K isoforms remain poorly defined.  We describe here an approach to pharmacol. interrogate the PI3-K family.  A chem. diverse panel of PI3-K inhibitors was synthesized, and their target selectivity was biochem. enumerated, revealing cryptic homologies across targets and chemotypes.  Crystal structures of three inhibitors bound to p110γ identify a conformationally mobile region that is uniquely exploited by selective compds.  This chem. array was then used to define the PI3-K isoforms required for insulin signaling.  We find that p110α is the primary insulin-responsive PI3-K in cultured cells, whereas p110β is dispensable but sets a phenotypic threshold for p110α activity.  Compds. targeting p110α block the acute effects of insulin treatment in vivo, whereas a p110β inhibitor has no effect.  These results illustrate systematic target validation using a matrix of inhibitors that span a protein family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrozjvOeMXP3bVg90H21EOLACvtfcHk0lg5T__H7ZwIAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltlSkt7o%253D&md5=b95a8cb433927ff9a75b33fc4ac2c8a0</span></div><a href="/servlet/linkout?suffix=cit13e&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DGonzalez%26aufirst%3DB.%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DZunder%26aufirst%3DE.%2BR.%26aulast%3DGoldenberg%26aufirst%3DD.%2BD.%26aulast%3DWilliams%26aufirst%3DO.%26aulast%3DLoewith%26aufirst%3DR.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DBalla%26aufirst%3DA.%26aulast%3DToth%26aufirst%3DB.%26aulast%3DBalla%26aufirst%3DT.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DA%2520Pharmacological%2520Map%2520of%2520the%2520PI3-K%2520Family%2520Defines%2520a%2520Role%2520for%2520p110%25CE%25B1%2520in%2520Insulin%2520Signaling%26jtitle%3DCell%26date%3D2006%26volume%3D125%26spage%3D733%26epage%3D747%26doi%3D10.1016%2Fj.cell.2006.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Jamieson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, J. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolekar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchanan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baguley, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, P. R.</span><span> </span><span class="NLM_article-title">A drug targeting only p110α can block phosphoinositide 3-kinase signaling and tumour growth in certain cell types</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">438</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span><span class="refDoi"> DOI: 10.1042/BJ20110502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1042%2FBJ20110502" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=438&publication_year=2011&pages=53-62&author=S.+Jamiesonauthor=J.+U.+Flanaganauthor=S.+Kolekarauthor=S.+Buchananauthor=J.+D.+Kendallauthor=W.-J.+Leeauthor=G.+W.+Rewcastleauthor=W.+A.+Dennyauthor=R.+Singhauthor=J.+Dicksonauthor=B.+C.+Baguleyauthor=P.+R.+Shepherd&title=A+drug+targeting+only+p110%CE%B1+can+block+phosphoinositide+3-kinase+signaling+and+tumour+growth+in+certain+cell+types&doi=10.1042%2FBJ20110502"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1042%2FBJ20110502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20110502%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DS.%26aulast%3DFlanagan%26aufirst%3DJ.%2BU.%26aulast%3DKolekar%26aufirst%3DS.%26aulast%3DBuchanan%26aufirst%3DS.%26aulast%3DKendall%26aufirst%3DJ.%2BD.%26aulast%3DLee%26aufirst%3DW.-J.%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DDickson%26aufirst%3DJ.%26aulast%3DBaguley%26aufirst%3DB.%2BC.%26aulast%3DShepherd%26aufirst%3DP.%2BR.%26atitle%3DA%2520drug%2520targeting%2520only%2520p110%25CE%25B1%2520can%2520block%2520phosphoinositide%25203-kinase%2520signaling%2520and%2520tumour%2520growth%2520in%2520certain%2520cell%2520types%26jtitle%3DBiochem.%2520J.%26date%3D2011%26volume%3D438%26spage%3D53%26epage%3D62%26doi%3D10.1042%2FBJ20110502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guagnano, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairhurst, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imbach-Weese, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruce, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritsch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blasco, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aichholz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caravatti, G.</span><span> </span><span class="NLM_article-title">Discovery of NVP-BYL719 a Potent and Selective Phosphatidylinositol-3 Kinase Alpha Inhibitor Selected for Clinical Evaluation</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3741</span><span class="NLM_x">–</span> <span class="NLM_lpage">3748</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.bmcl.2013.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=23726034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosFaisrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3741-3748&author=P.+Furetauthor=V.+Guagnanoauthor=R.+A.+Fairhurstauthor=P.+Imbach-Weeseauthor=I.+Bruceauthor=M.+Knappauthor=C.+Fritschauthor=F.+Blascoauthor=J.+Blanzauthor=R.+Aichholzauthor=J.+Hamonauthor=D.+Fabbroauthor=G.+Caravatti&title=Discovery+of+NVP-BYL719+a+Potent+and+Selective+Phosphatidylinositol-3+Kinase+Alpha+Inhibitor+Selected+for+Clinical+Evaluation&doi=10.1016%2Fj.bmcl.2013.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation</span></div><div class="casAuthors">Furet, Pascal; Guagnano, Vito; Fairhurst, Robin A.; Imbach-Weese, Patricia; Bruce, Ian; Knapp, Mark; Fritsch, Christine; Blasco, Francesca; Blanz, Joachim; Aichholz, Reiner; Hamon, Jacques; Fabbro, Doriano; Caravatti, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3741-3748</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-kinase α (PI3Kα) is a therapeutic target of high interest in anticancer drug research.  On the basis of a binding model rationalizing the high selectivity and potency of a particular series of 2-aminothiazole compds. in inhibiting PI3Kα, a medicinal chem. program has led to the discovery of the clin. candidate NVP-BYL719 I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraN93Vwrfb4bVg90H21EOLACvtfcHk0lg5T__H7ZwIAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosFaisrY%253D&md5=a0d2d69e01e7a82a5fed04114105925e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DImbach-Weese%26aufirst%3DP.%26aulast%3DBruce%26aufirst%3DI.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DBlasco%26aufirst%3DF.%26aulast%3DBlanz%26aufirst%3DJ.%26aulast%3DAichholz%26aufirst%3DR.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DCaravatti%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520NVP-BYL719%2520a%2520Potent%2520and%2520Selective%2520Phosphatidylinositol-3%2520Kinase%2520Alpha%2520Inhibitor%2520Selected%2520for%2520Clinical%2520Evaluation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3741%26epage%3D3748%26doi%3D10.1016%2Fj.bmcl.2013.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Bruce, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akhlaq, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloomfield, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Budd, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuenoud, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gedeck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayler, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Head, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leblanc, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Grand, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oza, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilgrim, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Press, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sviridenko, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitehead, L.</span><span> </span><span class="NLM_article-title">Development of Isoform Selective PI3-Kinase Inhibitors as Pharmacological Tools for Elucidating the PI3K Pathway</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">5445</span><span class="NLM_x">–</span> <span class="NLM_lpage">5450</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.07.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.bmcl.2012.07.042" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=5445-5450&author=I.+Bruceauthor=M.+Akhlaqauthor=G.+C.+Bloomfieldauthor=E.+Buddauthor=B.+Coxauthor=B.+Cuenoudauthor=P.+Finanauthor=P.+Gedeckauthor=J.+Hattoauthor=J.+F.+Haylerauthor=D.+Headauthor=T.+Kellerauthor=L.+Kirmanauthor=C.+Leblancauthor=D.+Le+Grandauthor=C.+McCarthyauthor=D.+O%E2%80%99Connorauthor=C.+Owenauthor=M.+S.+Ozaauthor=G.+Pilgrimauthor=N.+E.+Pressauthor=L.+Sviridenkoauthor=L.+Whitehead&title=Development+of+Isoform+Selective+PI3-Kinase+Inhibitors+as+Pharmacological+Tools+for+Elucidating+the+PI3K+Pathway&doi=10.1016%2Fj.bmcl.2012.07.042"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.07.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.07.042%26sid%3Dliteratum%253Aachs%26aulast%3DBruce%26aufirst%3DI.%26aulast%3DAkhlaq%26aufirst%3DM.%26aulast%3DBloomfield%26aufirst%3DG.%2BC.%26aulast%3DBudd%26aufirst%3DE.%26aulast%3DCox%26aufirst%3DB.%26aulast%3DCuenoud%26aufirst%3DB.%26aulast%3DFinan%26aufirst%3DP.%26aulast%3DGedeck%26aufirst%3DP.%26aulast%3DHatto%26aufirst%3DJ.%26aulast%3DHayler%26aufirst%3DJ.%2BF.%26aulast%3DHead%26aufirst%3DD.%26aulast%3DKeller%26aufirst%3DT.%26aulast%3DKirman%26aufirst%3DL.%26aulast%3DLeblanc%26aufirst%3DC.%26aulast%3DLe%2BGrand%26aufirst%3DD.%26aulast%3DMcCarthy%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DD.%26aulast%3DOwen%26aufirst%3DC.%26aulast%3DOza%26aufirst%3DM.%2BS.%26aulast%3DPilgrim%26aufirst%3DG.%26aulast%3DPress%26aufirst%3DN.%2BE.%26aulast%3DSviridenko%26aufirst%3DL.%26aulast%3DWhitehead%26aufirst%3DL.%26atitle%3DDevelopment%2520of%2520Isoform%2520Selective%2520PI3-Kinase%2520Inhibitors%2520as%2520Pharmacological%2520Tools%2520for%2520Elucidating%2520the%2520PI3K%2520Pathway%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D5445%26epage%3D5450%26doi%3D10.1016%2Fj.bmcl.2012.07.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staben, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B.-Y.</span><span> </span><span class="NLM_article-title">The Rational Design of PI3 Kinase Inhibitors Exhibiting Selectivity Over the PI3K-β Isoform</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7815</span><span class="NLM_x">–</span> <span class="NLM_lpage">7833</span><span class="refDoi"> DOI: 10.1021/jm2007084</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007084" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7815-7833&author=T.+P.+Heffronauthor=B.+Weiauthor=A.+Oliveroauthor=S.+T.+Stabenauthor=V.+Tsuiauthor=S.+Doauthor=J.+Dotsonauthor=A.+Folkesauthor=P.+Goldsmithauthor=P.+Goldsmithauthor=J.+Gunznerauthor=J.+Lesnickauthor=C.+Lewisauthor=S.+Mathieuauthor=J.+Nonomiyaauthor=S.+Shuttleworthauthor=D.+P.+Sutherlinauthor=N.+C.+Wanauthor=S.+Wangauthor=C.+Wiesmannauthor=B.-Y.+Zhu&title=The+Rational+Design+of+PI3+Kinase+Inhibitors+Exhibiting+Selectivity+Over+the+PI3K-%CE%B2+Isoform&doi=10.1021%2Fjm2007084"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm2007084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007084%26sid%3Dliteratum%253Aachs%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DOlivero%26aufirst%3DA.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DFolkes%26aufirst%3DA.%26aulast%3DGoldsmith%26aufirst%3DP.%26aulast%3DGoldsmith%26aufirst%3DP.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DShuttleworth%26aufirst%3DS.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DB.-Y.%26atitle%3DThe%2520Rational%2520Design%2520of%2520PI3%2520Kinase%2520Inhibitors%2520Exhibiting%2520Selectivity%2520Over%2520the%2520PI3K-%25CE%25B2%2520Isoform%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7815%26epage%3D7833%26doi%3D10.1021%2Fjm2007084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Staben, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ndubaku, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaquiere, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bull, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edgar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heald, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolesnikov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLean, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ord, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouge, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weismann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P.</span><span> </span><span class="NLM_article-title">Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase β isoform</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">2606</span><span class="NLM_x">–</span> <span class="NLM_lpage">2613</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.02.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.bmcl.2013.02.102" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=2606-2613&author=S.+T.+Stabenauthor=C.+Ndubakuauthor=N.+Blaquiereauthor=M.+Belvinauthor=R.+J.+Bullauthor=D.+Dudleyauthor=K.+Edgarauthor=D.+Grayauthor=R.+Healdauthor=T.+P.+Heffronauthor=G.+E.+Jonesauthor=M.+Jonesauthor=A.+Kolesnikovauthor=L.+Leeauthor=J.+Lesnickauthor=C.+Lewisauthor=J.+Murrayauthor=N.+J.+McLeanauthor=J.+Nonomiyaauthor=A.+G.+Oliveroauthor=R.+Ordauthor=J.+Pangauthor=S.+Priceauthor=W.+W.+Priorauthor=L.+Rougeauthor=L.+Salphatiauthor=D.+Sampathauthor=J.+Wallinauthor=L.+Wangauthor=B.+Weiauthor=C.+Weismannauthor=P.+Wu&title=Discovery+of+thiazolobenzoxepin+PI3-kinase+inhibitors+that+spare+the+PI3-kinase+%CE%B2+isoform&doi=10.1016%2Fj.bmcl.2013.02.102"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.02.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.02.102%26sid%3Dliteratum%253Aachs%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DNdubaku%26aufirst%3DC.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DBull%26aufirst%3DR.%2BJ.%26aulast%3DDudley%26aufirst%3DD.%26aulast%3DEdgar%26aufirst%3DK.%26aulast%3DGray%26aufirst%3DD.%26aulast%3DHeald%26aufirst%3DR.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DJones%26aufirst%3DG.%2BE.%26aulast%3DJones%26aufirst%3DM.%26aulast%3DKolesnikov%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DMcLean%26aufirst%3DN.%2BJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DOrd%26aufirst%3DR.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DRouge%26aufirst%3DL.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DWallin%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWeismann%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520thiazolobenzoxepin%2520PI3-kinase%2520inhibitors%2520that%2520spare%2520the%2520PI3-kinase%2520%25CE%25B2%2520isoform%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D2606%26epage%3D2613%26doi%3D10.1016%2Fj.bmcl.2013.02.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Folkes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmadi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alderton, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alix, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuckowree, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depledge, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancox, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kugendradas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lensun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pergl-Wilson, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saghir, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallweber, H. J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhyvoloup, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvelebil, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S. J.</span><span> </span><span class="NLM_article-title">The Identification of 2-(1<i>H</i>-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5522</span><span class="NLM_x">–</span> <span class="NLM_lpage">5532</span><span class="refDoi"> DOI: 10.1021/jm800295d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800295d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVCmsr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5522-5532&author=A.+J.+Folkesauthor=K.+Ahmadiauthor=W.+K.+Aldertonauthor=S.+Alixauthor=S.+J.+Bakerauthor=G.+Boxauthor=I.+S.+Chuckowreeauthor=P.+A.+Clarkeauthor=P.+Depledgeauthor=S.+A.+Ecclesauthor=L.+S.+Friedmanauthor=A.+Hayesauthor=T.+C.+Hancoxauthor=A.+Kugendradasauthor=L.+Lensunauthor=P.+Mooreauthor=A.+G.+Oliveroauthor=J.+Pangauthor=S.+Patelauthor=G.+H.+Pergl-Wilsonauthor=F.+I.+Raynaudauthor=A.+Robsonauthor=N.+Saghirauthor=L.+Salphatiauthor=S.+Sohalauthor=M.+H.+Ultschauthor=M.+Valentiauthor=H.+J.+A.+Wallweberauthor=N.+C.+Wanauthor=C.+Wiesmannauthor=P.+Workmanauthor=P.+Zhyvoloupauthor=M.+J.+Zvelebilauthor=S.+J.+Shuttleworth&title=The+Identification+of+2-%281H-Indazol-4-yl%29-6-%284-methanesulfonyl-piperazin-1-ylmethyl%29-4-morpholin-4-yl-thieno%5B3%2C2-d%5Dpyrimidine+%28GDC-0941%29+as+a+Potent%2C+Selective%2C+Orally+Bioavailable+Inhibitor+of+Class+I+PI3+Kinase+for+the+Treatment+of+Cancer&doi=10.1021%2Fjm800295d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer</span></div><div class="casAuthors">Folkes, Adrian J.; Ahmadi, Khatereh; Alderton, Wendy K.; Alix, Sonia; Baker, Stewart J.; Box, Gary; Chuckowree, Irina S.; Clarke, Paul A.; Depledge, Paul; Eccles, Suzanne A.; Friedman, Lori S.; Hayes, Angela; Hancox, Timothy C.; Kugendradas, Arumugam; Lensun, Letitia; Moore, Pauline; Olivero, Alan G.; Pang, Jodie; Patel, Sonal; Pergl-Wilson, Giles H.; Raynaud, Florence I.; Robson, Anthony; Saghir, Nahid; Salphati, Laurent; Sohal, Sukhjit; Ultsch, Mark H.; Valenti, Melanie; Wallweber, Heidi J. A.; Wan, Nan Chi; Wiesmann, Christian; Workman, Paul; Zhyvoloup, Alexander; Zvelebil, Marketa J.; Shuttleworth, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5522-5532</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-kinase (PI3K) is an important target in cancer due to the deregulation of the PI3K/Akt signaling pathway in a wide variety of tumors.  A series of thieno[3,2-d]pyrimidine derivs. were prepd. and evaluated as inhibitors of PI3 kinase p110α.  The synthesis, biol. activity, and further profiling of these compds. are described.  This work resulted in the discovery of GDC-0941 (I) which is a potent, selective, orally bioavailable inhibitor of PI3K and is currently being evaluated in human clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojkFv29FXqO7Vg90H21EOLACvtfcHk0lg6U1d7g_5fDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVCmsr7E&md5=742084954685353ceaf18660ab3a0703</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm800295d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800295d%26sid%3Dliteratum%253Aachs%26aulast%3DFolkes%26aufirst%3DA.%2BJ.%26aulast%3DAhmadi%26aufirst%3DK.%26aulast%3DAlderton%26aufirst%3DW.%2BK.%26aulast%3DAlix%26aufirst%3DS.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%2BS.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DDepledge%26aufirst%3DP.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHancox%26aufirst%3DT.%2BC.%26aulast%3DKugendradas%26aufirst%3DA.%26aulast%3DLensun%26aufirst%3DL.%26aulast%3DMoore%26aufirst%3DP.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DPergl-Wilson%26aufirst%3DG.%2BH.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DRobson%26aufirst%3DA.%26aulast%3DSaghir%26aufirst%3DN.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSohal%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%2BH.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%2BA.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DZhyvoloup%26aufirst%3DP.%26aulast%3DZvelebil%26aufirst%3DM.%2BJ.%26aulast%3DShuttleworth%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520Identification%2520of%25202-%25281H-Indazol-4-yl%2529-6-%25284-methanesulfonyl-piperazin-1-ylmethyl%2529-4-morpholin-4-yl-thieno%255B3%252C2-d%255Dpyrimidine%2520%2528GDC-0941%2529%2520as%2520a%2520Potent%252C%2520Selective%252C%2520Orally%2520Bioavailable%2520Inhibitor%2520of%2520Class%2520I%2520PI3%2520Kinase%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5522%26epage%3D5532%26doi%3D10.1021%2Fjm800295d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castanedo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuckowree, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folks, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pegg, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouge, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A.</span><span> </span><span class="NLM_article-title">Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7579</span><span class="NLM_x">–</span> <span class="NLM_lpage">7587</span><span class="refDoi"> DOI: 10.1021/jm2009327</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2009327" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Ort7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7579-7587&author=D.+P.+Sutherlinauthor=L.+Baoauthor=M.+Berryauthor=G.+Castanedoauthor=I.+Chuckowreeauthor=J.+Dotsonauthor=A.+Folksauthor=L.+Friedmanauthor=R.+Goldsmithauthor=J.+Gunznerauthor=T.+Heffronauthor=J.+Lesnickauthor=C.+Lewisauthor=S.+Mathieuauthor=J.+Murrayauthor=J.+Nonomiyaauthor=J.+Pangauthor=N.+Peggauthor=W.+W.+Priorauthor=L.+Rougeauthor=L.+Salphatiauthor=D.+Sampathauthor=Q.+Tianauthor=V.+Tsuiauthor=N.+C.+Wanauthor=S.+Wangauthor=B.+Q.+Weiauthor=C.+Wiesmannauthor=P.+Wuauthor=B.-Y.+Zhuauthor=A.+Olivero&title=Discovery+of+a+Potent%2C+Selective%2C+and+Orally+Available+Class+I+Phosphatidylinositol+3-Kinase+%28PI3K%29%2FMammalian+Target+of+Rapamycin+%28mTOR%29+Kinase+Inhibitor+%28GDC-0980%29+for+the+Treatment+of+Cancer&doi=10.1021%2Fjm2009327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer</span></div><div class="casAuthors">Sutherlin, Daniel P.; Bao, Linda; Berry, Megan; Castanedo, Georgette; Chuckowree, Irina; Dotson, Jenna; Folks, Adrian; Friedman, Lori; Goldsmith, Richard; Gunzner, Janet; Heffron, Timothy; Lesnick, John; Lewis, Cristina; Mathieu, Simon; Murray, Jeremy; Nonomiya, Jim; Pang, Jodie; Pegg, Niel; Prior, Wei Wei; Rouge, Lionel; Salphati, Laurent; Sampath, Deepak; Tian, Qingping; Tsui, Vickie; Wan, Nan Chi; Wang, Shumei; Wei, Bin Qing; Wiesmann, Christian; Wu, Ping; Zhu, Bing-Yan; Olivero, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7579-7587</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of 2 (GDC-0980, I), a class I PI3K and mTOR kinase inhibitor for oncol. indications, is described. mTOR inhibition was added to the class I PI3K inhibitor 1 (GDC-0941) scaffold primarily through the substitution of the indazole in 1 for a 2-aminopyrimidine.  This substitution also increased the microsomal stability and the free fraction of compds. as evidenced through a pairwise comparison of mols. that were otherwise identical.  Highlighted in detail are analogs of an advanced compd. 4 that were designed to improve soly., resulting in 2.  This compd., is potent across PI3K class I isoforms with IC50s of 5, 27, 7, and 14 nM for PI3Kα, β, δ, and γ, resp., inhibits mTOR with a Ki of 17 nM yet is highly selective vs. a large panel of kinases including others in the PIKK family.  On the basis of the cell potency, low clearance in mouse, and high free fraction, 2 demonstrated significant efficacy in mouse xenografts when dosed as low as 1 mg/kg orally and is currently in phase I clin. trials for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-3-5KDI509bVg90H21EOLACvtfcHk0lhmHJO68C6KMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Ort7%252FJ&md5=ba7ede710885b51fffa63977fc64d3f5</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm2009327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2009327%26sid%3Dliteratum%253Aachs%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DBao%26aufirst%3DL.%26aulast%3DBerry%26aufirst%3DM.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DFolks%26aufirst%3DA.%26aulast%3DFriedman%26aufirst%3DL.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DHeffron%26aufirst%3DT.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPegg%26aufirst%3DN.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DRouge%26aufirst%3DL.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DTian%26aufirst%3DQ.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DB.%2BQ.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DB.-Y.%26aulast%3DOlivero%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Available%2520Class%2520I%2520Phosphatidylinositol%25203-Kinase%2520%2528PI3K%2529%252FMammalian%2520Target%2520of%2520Rapamycin%2520%2528mTOR%2529%2520Kinase%2520Inhibitor%2520%2528GDC-0980%2529%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7579%26epage%3D7587%26doi%3D10.1021%2Fjm2009327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Ndubaku, C. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staben, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgardner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaquiere, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bull, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edgar, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heald, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolesnikov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nannini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span> </span><span class="NLM_article-title">Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1<i>H</i>-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-<i>d</i>][1,4]oxazepin-9-yl]-1<i>H</i>-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">4597</span><span class="NLM_x">–</span> <span class="NLM_lpage">4610</span><span class="refDoi"> DOI: 10.1021/jm4003632</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4003632" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVWjur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4597-4610&author=C.+O.+Ndubakuauthor=T.+P.+Heffronauthor=S.+T.+Stabenauthor=M.+Baumgardnerauthor=N.+Blaquiereauthor=E.+Bradleyauthor=R.+Bullauthor=S.+Doauthor=J.+Dotsonauthor=D.+Dudleyauthor=K.+A.+Edgarauthor=L.+S.+Friedmanauthor=R.+Goldsmithauthor=R.+A.+Healdauthor=A.+Kolesnikovauthor=L.+Leeauthor=C.+Lewisauthor=M.+Nanniniauthor=J.+Nonomiyaauthor=J.+Pangauthor=S.+Priceauthor=W.+W.+Priorauthor=L.+Salphatiauthor=S.+Siderisauthor=J.+J.+Wallinauthor=L.+Wangauthor=B.+Weiauthor=D.+Sampathauthor=A.+G.+Olivero&title=Discovery+of+2-%7B3-%5B2-%281-Isopropyl-3-methyl-1H-1%2C2%E2%80%934-triazol-5-yl%29-5%2C6-dihydrobenzo%5Bf%5Dimidazo%5B1%2C2-d%5D%5B1%2C4%5Doxazepin-9-yl%5D-1H-pyrazol-1-yl%7D-2-methylpropanamide+%28GDC-0032%29%3A+A+%CE%B2-Sparing+Phosphoinositide+3-Kinase+Inhibitor+with+High+Unbound+Exposure+and+Robust+in+Vivo+Antitumor+Activity&doi=10.1021%2Fjm4003632"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity</span></div><div class="casAuthors">Ndubaku, Chudi O.; Heffron, Timothy P.; Staben, Steven T.; Baumgardner, Matthew; Blaquiere, Nicole; Bradley, Erin; Bull, Richard; Do, Steven; Dotson, Jennafer; Dudley, Danette; Edgar, Kyle A.; Friedman, Lori S.; Goldsmith, Richard; Heald, Robert A.; Kolesnikov, Aleksandr; Lee, Leslie; Lewis, Cristina; Nannini, Michelle; Nonomiya, Jim; Pang, Jodie; Price, Steve; Prior, Wei Wei; Salphati, Laurent; Sideris, Steve; Wallin, Jeffery J.; Wang, Lan; Wei, BinQing; Sampath, Deepak; Olivero, Alan G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4597-4610</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dysfunctional signaling through the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway leads to uncontrolled tumor proliferation.  In the course of the discovery of novel benzoxepin PI3K inhibitors, we obsd. a strong dependency of in vivo antitumor activity on the free-drug exposure.  By lowering the intrinsic clearance, we derived a set of imidazobenzoxazepin compds. that showed improved unbound drug exposure and effectively suppressed growth of tumors in a mouse xenograft model at low drug dose levels.  One of these compds., GDC-0032 (I), was progressed to clin. trials and is currently under phase I evaluation as a potential treatment for human malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvaWg9tu7Zv7Vg90H21EOLACvtfcHk0lho3q2lgHeKDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVWjur8%253D&md5=f9c169c99757708a9d327ad0b022fde9</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm4003632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4003632%26sid%3Dliteratum%253Aachs%26aulast%3DNdubaku%26aufirst%3DC.%2BO.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DBaumgardner%26aufirst%3DM.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DBradley%26aufirst%3DE.%26aulast%3DBull%26aufirst%3DR.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DDudley%26aufirst%3DD.%26aulast%3DEdgar%26aufirst%3DK.%2BA.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DHeald%26aufirst%3DR.%2BA.%26aulast%3DKolesnikov%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DWallin%26aufirst%3DJ.%2BJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26atitle%3DDiscovery%2520of%25202-%257B3-%255B2-%25281-Isopropyl-3-methyl-1H-1%252C2%25E2%2580%25934-triazol-5-yl%2529-5%252C6-dihydrobenzo%255Bf%255Dimidazo%255B1%252C2-d%255D%255B1%252C4%255Doxazepin-9-yl%255D-1H-pyrazol-1-yl%257D-2-methylpropanamide%2520%2528GDC-0032%2529%253A%2520A%2520%25CE%25B2-Sparing%2520Phosphoinositide%25203-Kinase%2520Inhibitor%2520with%2520High%2520Unbound%2520Exposure%2520and%2520Robust%2520in%2520Vivo%2520Antitumor%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4597%26epage%3D4610%26doi%3D10.1021%2Fjm4003632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="note"><p class="first last">A depiction of a crystal structure of a benzoxepin bound to PI3Kγ (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3R7R">3R7R</a>) where residues are labeled to highlight differences between PI3Kα and the other isoforms within the active site can be found as <a href="/doi/suppl/10.1021/acs.jmedchem.5b01483/suppl_file/jm5b01483_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Staben, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdick, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouge, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P.</span><span> </span><span class="NLM_article-title">Structure-based design of thienobenzoxepin inhibitors of PI3-kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4054</span><span class="NLM_x">–</span> <span class="NLM_lpage">4058</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.04.124</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.bmcl.2011.04.124" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=4054-4058&author=S.+T.+Stabenauthor=M.+Siuauthor=R.+Goldsmithauthor=A.+G.+Oliveroauthor=S.+Doauthor=D.+J.+Burdickauthor=T.+P.+Heffronauthor=J.+Dotsonauthor=D.+P.+Sutherlinauthor=B.-Y.+Zhuauthor=V.+Tsuiauthor=H.+Leauthor=L.+Leeauthor=J.+Lesnickauthor=C.+Lewisauthor=J.+M.+Murrayauthor=J.+Nonomiyaauthor=J.+Pangauthor=W.+W.+Priorauthor=L.+Salphatiauthor=L.+Rougeauthor=D.+Sampathauthor=S.+Siderisauthor=C.+Wiesmannauthor=P.+Wu&title=Structure-based+design+of+thienobenzoxepin+inhibitors+of+PI3-kinase&doi=10.1016%2Fj.bmcl.2011.04.124"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.04.124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.04.124%26sid%3Dliteratum%253Aachs%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DSiu%26aufirst%3DM.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DBurdick%26aufirst%3DD.%2BJ.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DZhu%26aufirst%3DB.-Y.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DLe%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DRouge%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DP.%26atitle%3DStructure-based%2520design%2520of%2520thienobenzoxepin%2520inhibitors%2520of%2520PI3-kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D4054%26epage%3D4058%26doi%3D10.1016%2Fj.bmcl.2011.04.124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Huang, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandelker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt-Kittler, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuels, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velculescu, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinzler, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogelstein, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabelli, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amzel, L. M.</span><span> </span><span class="NLM_article-title">The Structure of Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">318</span><span class="NLM_x">, </span> <span class="NLM_fpage">1744</span><span class="NLM_x">–</span> <span class="NLM_lpage">1748</span><span class="refDoi"> DOI: 10.1126/science.1150799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1126%2Fscience.1150799" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2007&pages=1744-1748&author=C.-H.+Huangauthor=D.+Mandelkerauthor=O.+Schmidt-Kittlerauthor=Y.+Samuelsauthor=V.+E.+Velculescuauthor=K.+W.+Kinzlerauthor=B.+Vogelsteinauthor=S.+B.+Gabelliauthor=L.+M.+Amzel&title=The+Structure+of+Human+p110%CE%B1%2Fp85%CE%B1+Complex+Elucidates+the+Effects+of+Oncogenic+PI3K%CE%B1+Mutations&doi=10.1126%2Fscience.1150799"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1126%2Fscience.1150799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1150799%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DC.-H.%26aulast%3DMandelker%26aufirst%3DD.%26aulast%3DSchmidt-Kittler%26aufirst%3DO.%26aulast%3DSamuels%26aufirst%3DY.%26aulast%3DVelculescu%26aufirst%3DV.%2BE.%26aulast%3DKinzler%26aufirst%3DK.%2BW.%26aulast%3DVogelstein%26aufirst%3DB.%26aulast%3DGabelli%26aufirst%3DS.%2BB.%26aulast%3DAmzel%26aufirst%3DL.%2BM.%26atitle%3DThe%2520Structure%2520of%2520Human%2520p110%25CE%25B1%252Fp85%25CE%25B1%2520Complex%2520Elucidates%2520the%2520Effects%2520of%2520Oncogenic%2520PI3K%25CE%25B1%2520Mutations%26jtitle%3DScience%26date%3D2007%26volume%3D318%26spage%3D1744%26epage%3D1748%26doi%3D10.1126%2Fscience.1150799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="note"><p class="first last">After the conclusion of our research efforts, a report suggesting the importance of hydrogen bonding with Gln859 to achieve PI3Kα specificity in a different series of molecules. See refs <a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">15, 16</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="note"><p class="first last">A figure depicting the computational Link/Grow strategy is included as <a href="/doi/suppl/10.1021/acs.jmedchem.5b01483/suppl_file/jm5b01483_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Li, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, C. K.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hank, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murry, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobiassen, H.</span><span> </span><span class="NLM_article-title">An Optimized Process for Formation of 2,4-Disubstituted Imidazoles from Condensation of Amidines and α-Haloketones</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">682</span><span class="NLM_x">–</span> <span class="NLM_lpage">683</span><span class="refDoi"> DOI: 10.1021/op025552b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op025552b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2002&pages=682-683&author=B.+Liauthor=C.+K.-F.+Chiuauthor=R.+F.+Hankauthor=J.+Murryauthor=J.+Rothauthor=H.+Tobiassen&title=An+Optimized+Process+for+Formation+of+2%2C4-Disubstituted+Imidazoles+from+Condensation+of+Amidines+and+%CE%B1-Haloketones&doi=10.1021%2Fop025552b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fop025552b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop025552b%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DB.%26aulast%3DChiu%26aufirst%3DC.%2BK.-F.%26aulast%3DHank%26aufirst%3DR.%2BF.%26aulast%3DMurry%26aufirst%3DJ.%26aulast%3DRoth%26aufirst%3DJ.%26aulast%3DTobiassen%26aufirst%3DH.%26atitle%3DAn%2520Optimized%2520Process%2520for%2520Formation%2520of%25202%252C4-Disubstituted%2520Imidazoles%2520from%2520Condensation%2520of%2520Amidines%2520and%2520%25CE%25B1-Haloketones%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2002%26volume%3D6%26spage%3D682%26epage%3D683%26doi%3D10.1021%2Fop025552b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><div class="note"><p class="first last">There are multiple reported values for liver blood flow of a rat. One estimate is 55.2 mL/min/kg:</p></div><span class="NLM_contrib-group">Tschida, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vance-Bryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaske, D. E.</span><span> </span><span class="NLM_article-title">Anti-infective agents and hepatic disease</span> <span class="citation_source-journal">Med. Clin. North Am.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">895</span><span class="NLM_x">–</span> <span class="NLM_lpage">917</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=7791429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADyaK2MXntVagtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=1995&pages=895-917&author=S.+J.+Tschidaauthor=K.+Vance-Bryanauthor=D.+E.+Zaske&title=Anti-infective+agents+and+hepatic+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-infective agents and hepatic disease</span></div><div class="casAuthors">Tschida, Suzanne J.; Vance-Bryan, Kyle; Zaske, Darwin E.</div><div class="citationInfo"><span class="NLM_cas:title">Medical Clinics of North America</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">895-917</span>CODEN:
                <span class="NLM_cas:coden">MCNAA9</span>;
        ISSN:<span class="NLM_cas:issn">0025-7125</span>.
    </div><div class="casAbstract">A review with 72 refs. on the pharmacokinetic principles related to antibacterial drug disposition in patient with hepatic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquHFfsK-S1ubVg90H21EOLACvtfcHk0lgzq8glP4GmHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXntVagtrY%253D&md5=e6dbb44eae3a3e7fc682ea35674242cf</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTschida%26aufirst%3DS.%2BJ.%26aulast%3DVance-Bryan%26aufirst%3DK.%26aulast%3DZaske%26aufirst%3DD.%2BE.%26atitle%3DAnti-infective%2520agents%2520and%2520hepatic%2520disease%26jtitle%3DMed.%2520Clin.%2520North%2520Am.%26date%3D1995%26volume%3D79%26spage%3D895%26epage%3D917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liston, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silber, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacIntyre, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rance, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wastall, P.</span><span> </span><span class="NLM_article-title">The prediction of humanpharmacokinetic parameters from preclinical and in vitro metabolism data</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">46</span><span class="NLM_x">–</span> <span class="NLM_lpage">58</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=9336307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADyaK2sXmslCltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1997&pages=46-58&author=R.+S.+Obachauthor=J.+G.+Baxterauthor=T.+E.+Listonauthor=B.+M.+Silberauthor=B.+C.+Jonesauthor=F.+MacIntyreauthor=D.+J.+Ranceauthor=P.+Wastall&title=The+prediction+of+humanpharmacokinetic+parameters+from+preclinical+and+in+vitro+metabolism+data"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data</span></div><div class="casAuthors">Obach, R. Scott; Baxter, James G.; Liston, Theodore E.; Silber, B. Michael; Jones, Barry C.; Macintyre, Flona; Rance, David J.; Wastall, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-58</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">A review with 35 refs.  We describe a comprehensive retrospective anal. in which the abilities of several methods by which human pharmacokinetic parameters are predicted from preclin. pharmacokinetic data and/or in vitro metab. data were assessed.  The prediction methods examd. included both methods from the scientific literature as well as some described in this report for the first time.  Four methods were examd. for their ability to predict human vol. of distribution.  Three were highly predictive, yielding, on av., predictions that were within 60% to 90% of actual values.  Twelve methods were assessed for their utility in predicting clearance.  The most successful allometric scaling method yielded clearance predictions that were, on av., within 80% of actual values.  The best methods in which in vitro metab. data from human liver microsomes were scaled to in vivo clearance values yielded predicted clearance values that were, on av., within 70% to 80% of actual values.  Human t1/2 was predicted by combining predictions of human vol. of distribution and clearance.  The best t1/2 prediction methods successfully assigned compds. to appropriate dosing regimen categories (e.g., once daily, twice daily and so forth) 70% to 80% of the time.  In addn., correlations between human t1/2 and t1/2 values from preclin. species were also generally successful (72-87%) when used to predict human dosing regimens.  In summary, this retrospective anal. has identified several approaches by which human pharmacokinetic data can be predicted from preclin. data.  Such approaches should find utility in the drug discovery and development processes in the identification and selection of compds. that will possess appropriate pharmacokinetic characteristics in humans for progression to clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppAngniZ4izLVg90H21EOLACvtfcHk0lgzq8glP4GmHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmslCltr0%253D&md5=68d1910d925e26ec4a8ef23043ffb1ed</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DBaxter%26aufirst%3DJ.%2BG.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DSilber%26aufirst%3DB.%2BM.%26aulast%3DJones%26aufirst%3DB.%2BC.%26aulast%3DMacIntyre%26aufirst%3DF.%26aulast%3DRance%26aufirst%3DD.%2BJ.%26aulast%3DWastall%26aufirst%3DP.%26atitle%3DThe%2520prediction%2520of%2520humanpharmacokinetic%2520parameters%2520from%2520preclinical%2520and%2520in%2520vitro%2520metabolism%2520data%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D283%26spage%3D46%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Pryde, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T.-D.</span><span> </span><span class="NLM_article-title">Aldehyde Oxidase: An Enzyme of Emerging Importance in Drug Discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8441</span><span class="NLM_x">–</span> <span class="NLM_lpage">8460</span><span class="refDoi"> DOI: 10.1021/jm100888d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100888d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFygt73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8441-8460&author=D.+C.+Prydeauthor=D.+Dalvieauthor=Q.+Huauthor=P.+Jonesauthor=R.+S.+Obachauthor=T.-D.+Tran&title=Aldehyde+Oxidase%3A+An+Enzyme+of+Emerging+Importance+in+Drug+Discovery&doi=10.1021%2Fjm100888d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Aldehyde Oxidase: An Enzyme of Emerging Importance in Drug Discovery</span></div><div class="casAuthors">Pryde, David C.; Dalvie, Deepak; Hu, Qiyue; Jones, Peter; Obach, R. Scott; Tran, Thien-Duc</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8441-8460</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Aldehyde oxidase has for many years been recognized as a metabolizing enzyme contained within the cytosolic compartment of many tissues and in many species.  The first literature ref. to AO dates from the 1930s, but literature citations to this enzyme have been steadily growing ever since, esp. in the past decade.  It has been increasingly recognized in this past decade that AO, through its unique structure, distribution, and substrate recognition, has an important role to play in the metab. of drugs.  In this timely Perspective, we present the current knowledge of the enzyme's expression, its structure, and its distribution across species.  We offer an anal. of substrates recognized by AO and highlight clin. examples where metab. by this enzyme has had significant clin. impact or led to the termination of a drug development program.  Finally, through anal. of the structure of known substrates, we present data to suggest the significant impact AO could play on future drug discovery programs along with strategies that could be employed to mitigate this.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqALwFS70G6tLVg90H21EOLACvtfcHk0lgzq8glP4GmHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFygt73N&md5=972eb9862a7dc7bff024b530ab40de7f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm100888d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100888d%26sid%3Dliteratum%253Aachs%26aulast%3DPryde%26aufirst%3DD.%2BC.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DTran%26aufirst%3DT.-D.%26atitle%3DAldehyde%2520Oxidase%253A%2520An%2520Enzyme%2520of%2520Emerging%2520Importance%2520in%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8441%26epage%3D8460%26doi%3D10.1021%2Fjm100888d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Edgar, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span> </span><span class="NLM_article-title">Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">1164</span><span class="NLM_x">–</span> <span class="NLM_lpage">1172</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-2525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1158%2F0008-5472.CAN-09-2525" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=1164-1172&author=K.+A.+Edgarauthor=J.+J.+Wallinauthor=M.+Berryauthor=L.+B.+Leeauthor=W.+W.+Priorauthor=D.+Sampathauthor=L.+S.+Friedmanauthor=M.+Belvin&title=Isoform-Specific+Phosphoinositide+3-Kinase+Inhibitors+Exert+Distinct+Effects+in+Solid+Tumors&doi=10.1158%2F0008-5472.CAN-09-2525"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-2525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-2525%26sid%3Dliteratum%253Aachs%26aulast%3DEdgar%26aufirst%3DK.%2BA.%26aulast%3DWallin%26aufirst%3DJ.%2BJ.%26aulast%3DBerry%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DL.%2BB.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DBelvin%26aufirst%3DM.%26atitle%3DIsoform-Specific%2520Phosphoinositide%25203-Kinase%2520Inhibitors%2520Exert%2520Distinct%2520Effects%2520in%2520Solid%2520Tumors%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D1164%26epage%3D1172%26doi%3D10.1158%2F0008-5472.CAN-09-2525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="note"><p class="first last">Enzymatic IC<sub>50</sub> values were determined by Invitrogen for <b>4</b> against the following kinases, PI3KC2b (IC<sub>50</sub> = 261 nM), PI3KC2a (IC<sub>50</sub> > 10 μM), hVPS34 (IC<sub>50</sub> = 2.84 μM). <i>K</i><sub>i,app</sub> for mTOR was determined to be 4.3 μM. A complete list of kinases tested at Invitrogen is included as <a href="/doi/suppl/10.1021/acs.jmedchem.5b01483/suppl_file/jm5b01483_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="note"><p class="first last">The in vitro EC<sub>50</sub> values for inhibition of pAKT in MCF7-neo/HER2 cells are 4 and 10 nM for <b>3</b> and <b>4</b>, respectively.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="note"><p class="first last">Hepatic CL was predicted to be 5 mL/min/kg by microsomal incubations. Allometric scaling projected a plasma CL of 3 mL/min/kg (based on the rule of exponents).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Halladay, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaffer, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinhababu, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khojasteh-Bakht, S. C.</span><span> </span><span class="NLM_article-title">Metabolic Stability Screen for Drug Discovery Using Cassette Analysis and Column Switching</span> <span class="citation_source-journal">Drug Metab. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">67</span><span class="NLM_x">–</span> <span class="NLM_lpage">72</span><span class="refDoi"> DOI: 10.2174/187231207779814364</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.2174%2F187231207779814364" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=19356021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtleru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2007&pages=67-72&author=J.+S.+Halladayauthor=S.+Wongauthor=S.+M.+Jafferauthor=A.+K.+Sinhababuauthor=S.+C.+Khojasteh-Bakht&title=Metabolic+Stability+Screen+for+Drug+Discovery+Using+Cassette+Analysis+and+Column+Switching&doi=10.2174%2F187231207779814364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic stability screen for drug discovery using cassette analysis and column switching</span></div><div class="casAuthors">Halladay, Jason S.; Wong, Susan; Jaffer, Sharmin M.; Sinhababu, Achintya K.; Khojasteh-Bakht, S. Cyrus</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-72</span>CODEN:
                <span class="NLM_cas:coden">DMLRBM</span>;
        ISSN:<span class="NLM_cas:issn">1872-3128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">In vitro metabolic stability assays are used to screen compds. for stability in the presence of various drug metabolizing enzymes, usually cytochrome P 450 in liver prepns. (e.g., liver microsomes).  High-throughput metabolic stability assays using pooling methods have been developed to keep pace with screening requirements at the lead ADME optimization stage.  In our lab., we have improved the metabolic stability assay using the cassette anal. method, column switching, and incorporated time saving techniques in method development to yield a robust method which reduces data turnaround time, increases compd. throughput, and maximizes mass spectrometer usage.  This method can det. metabolic stability using microsomes or hepatocytes from any species.  We describe our findings following incubation of 40 different compds. with human liver microsomes and anal. by the cassette and discrete anal. methods.  Similar metabolic stability results were obtained using the cassette anal. and discrete anal. method.  An overall 70% time savings was achieved by pooling four new compds. into one sample for method development/MS optimization, cassetting four samples into one sample to minimize the no. of injections on LC/MS/MS anal., and using a column switching system to analyze the samples, which results in a two-fold decrease in the LC/MS/MS anal. time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKzVSm6sBe1bVg90H21EOLACvtfcHk0lgf8QSOHOM6iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtleru74%253D&md5=e00c66b3ca6a1eaee107c4eb81e07bf5</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.2174%2F187231207779814364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187231207779814364%26sid%3Dliteratum%253Aachs%26aulast%3DHalladay%26aufirst%3DJ.%2BS.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DJaffer%26aufirst%3DS.%2BM.%26aulast%3DSinhababu%26aufirst%3DA.%2BK.%26aulast%3DKhojasteh-Bakht%26aufirst%3DS.%2BC.%26atitle%3DMetabolic%2520Stability%2520Screen%2520for%2520Drug%2520Discovery%2520Using%2520Cassette%2520Analysis%2520and%2520Column%2520Switching%26jtitle%3DDrug%2520Metab.%2520Lett.%26date%3D2007%26volume%3D1%26spage%3D67%26epage%3D72%26doi%3D10.2174%2F187231207779814364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b','cit1c','cit1d','cit1e','cit1f','cit1g'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4a','cit4b','cit4c','cit4d'],'ref5':['cit5a','cit5b','cit5c','cit5d','cit5e','cit5f'],'ref6':['cit6a','cit6b','cit6c','cit6d','cit6e','cit6f','cit6g','cit6h','cit6i','cit6j'],'ref7':['cit7a','cit7b','cit7c'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10a','cit10b','cit10c','cit10d','cit10e','cit10f'],'ref11':['cit11a','cit11b'],'ref12':['cit12a','cit12b','cit12c','cit12d'],'ref13':['cit13a','cit13b','cit13c','cit13d','cit13e'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':[],'ref23':['cit23'],'ref24':['cit24'],'ref25':[],'ref26':[],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':[],'ref33':[],'ref34':[],'ref35':['cit35']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 51 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Lindsey G. DeRatt, Edward C. Lawson, Kiran Kumar, Soyon S. Hwang, Renee L. DesJarlais, <span class="NLM_string-name hlFld-ContribAuthor">Scott D. Kuduk</span>. </span><span class="cited-content_cbyCitation_article-title">Tandem Suzuki Coupling/Intramolecular Oxetane Ring Opening to Form Polycyclic Ring Systems. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (15)
                                     , 5828-5832. <a href="https://doi.org/10.1021/acs.orglett.0c01899" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c01899</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c01899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c01899%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DTandem%252BSuzuki%252BCoupling%25252FIntramolecular%252BOxetane%252BRing%252BOpening%252Bto%252BForm%252BPolycyclic%252BRing%252BSystems%26aulast%3DDeRatt%26aufirst%3DLindsey%2BG.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D05062020%26date%3D23072020%26volume%3D22%26issue%3D15%26spage%3D5828%26epage%3D5832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Aimie
E. Garces, <span class="NLM_string-name hlFld-ContribAuthor">Michael J. Stocks</span>. </span><span class="cited-content_cbyCitation_article-title">Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (10)
                                     , 4815-4850. <a href="https://doi.org/10.1021/acs.jmedchem.8b01492" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01492</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01492%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DClass%252B1%252BPI3K%252BClinical%252BCandidates%252Band%252BRecent%252BInhibitor%252BDesign%252BStrategies%25253A%252BA%252BMedicinal%252BChemistry%252BPerspective%26aulast%3DGarces%26aufirst%3DAimie%2BE.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D25092018%26date%3D24122018%26volume%3D62%26issue%3D10%26spage%3D4815%26epage%3D4850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Pirama
Nayagam Arunachalam, Prakasam Kuppusamy, Sivakumar Ganesan, Suresh Krishnamoorthy, Roshan Y. Nimje, Lokesh Babu Jarugu, Nanjundaswamy Kanikahalli Chikkananjaiah, China Anki Reddy, Prakash Anjanappa, Murali Botlagunta, Sridhar Vanteru, Nageswararao Maddala, Muniyappa Shankar, Satheesh Nair, John Hynes, Jr., Joseph B. Santella, III, Percy H. Carter, Richard Rampulla, Muthalagu Vetrichelvan, Anuradha Gupta, Arun Kumar Gupta, <span class="NLM_string-name hlFld-ContribAuthor">Arvind Mathur</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a Scalable Synthesis for the Potent Kinase Inhibitor BMS-986236; 1-(5-(4-(3-Hydroxy-3-methylbutyl)-1H-1,2,3-triazol-1-yl)-4-(isopropylamino)pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine-5-carbonitrile. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2019,</strong> <em>23 </em>
                                    (5)
                                     , 912-918. <a href="https://doi.org/10.1021/acs.oprd.9b00023" title="DOI URL">https://doi.org/10.1021/acs.oprd.9b00023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.9b00023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.9b00023%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DDevelopment%252Bof%252Ba%252BScalable%252BSynthesis%252Bfor%252Bthe%252BPotent%252BKinase%252BInhibitor%252BBMS-986236%25253B%252B1-%2525285-%2525284-%2525283-Hydroxy-3-methylbutyl%252529-1H-1%25252C2%25252C3-triazol-1-yl%252529-4-%252528isopropylamino%252529pyridin-2-yl%252529-1H-pyrazolo%25255B3%25252C4-b%25255Dpyridine-5-carbonitrile%26aulast%3DArunachalam%26aufirst%3DPirama%2BNayagam%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D16012019%26date%3D09042019%26date%3D27032019%26volume%3D23%26issue%3D5%26spage%3D912%26epage%3D918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Vunnam Srinivasulu, Ihsan Shehadeh, Monther A. Khanfar, Omar G. Malik, Hamadeh Tarazi, Imad A. Abu-Yousef, Anusha Sebastian, Nabil Baniowda, Matthew John O’Connor, <span class="NLM_string-name hlFld-ContribAuthor">Taleb H. Al-Tel</span>. </span><span class="cited-content_cbyCitation_article-title">One-Pot Synthesis of Diverse Collections of Benzoxazepine and Indolopyrazine Fused to Heterocyclic Systems. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>84 </em>
                                    (2)
                                     , 934-948. <a href="https://doi.org/10.1021/acs.joc.8b02878" title="DOI URL">https://doi.org/10.1021/acs.joc.8b02878</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b02878&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b02878%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DOne-Pot%252BSynthesis%252Bof%252BDiverse%252BCollections%252Bof%252BBenzoxazepine%252Band%252BIndolopyrazine%252BFused%252Bto%252BHeterocyclic%252BSystems%26aulast%3DSrinivasulu%26aufirst%3DVunnam%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D10112018%26date%3D04012019%26date%3D24122018%26volume%3D84%26issue%3D2%26spage%3D934%26epage%3D948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dean G. Brown, <span class="NLM_string-name hlFld-ContribAuthor">Jonas Boström</span>. </span><span class="cited-content_cbyCitation_article-title">Where Do Recent Small Molecule Clinical Development Candidates Come From?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (21)
                                     , 9442-9468. <a href="https://doi.org/10.1021/acs.jmedchem.8b00675" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhere%252BDo%252BRecent%252BSmall%252BMolecule%252BClinical%252BDevelopment%252BCandidates%252BCome%252BFrom%25253F%26aulast%3DBrown%26aufirst%3DDean%2BG.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D27042018%26date%3D09072018%26date%3D19062018%26volume%3D61%26issue%3D21%26spage%3D9442%26epage%3D9468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Prakash
D. Jadhav, Xin Lu, <span class="NLM_string-name hlFld-ContribAuthor">Rai-Shung Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Gold-Catalyzed [5+2]- and [5+1]-Annulations between Ynamides and 1,2-Benzisoxazoles with Ligand-Controlled Chemoselectivity. </span><span class="cited-content_cbyCitation_journal-name">ACS Catalysis</span><span> <strong>2018,</strong> <em>8 </em>
                                    (10)
                                     , 9697-9701. <a href="https://doi.org/10.1021/acscatal.8b03011" title="DOI URL">https://doi.org/10.1021/acscatal.8b03011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscatal.8b03011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscatal.8b03011%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Catalysis%26atitle%3DGold-Catalyzed%252B%25255B5%25252B2%25255D-%252Band%252B%25255B5%25252B1%25255D-Annulations%252Bbetween%252BYnamides%252Band%252B1%25252C2-Benzisoxazoles%252Bwith%252BLigand-Controlled%252BChemoselectivity%26aulast%3DJadhav%26aufirst%3DPrakash%2BD.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D02082018%26date%3D17092018%26date%3D25092018%26date%3D20092018%26volume%3D8%26issue%3D10%26spage%3D9697%26epage%3D9701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian S.  Safina</span>, <span class="hlFld-ContribAuthor ">Richard L.  Elliott</span>, <span class="hlFld-ContribAuthor ">Andrew K.  Forrest</span>, <span class="hlFld-ContribAuthor ">Robert A.  Heald</span>, <span class="hlFld-ContribAuthor ">Jeremy M.  Murray</span>, <span class="hlFld-ContribAuthor ">Jim  Nonomiya</span>, <span class="hlFld-ContribAuthor ">Jodie  Pang</span>, <span class="hlFld-ContribAuthor ">Laurent  Salphati</span>, <span class="hlFld-ContribAuthor ">Eileen M.  Seward</span>, <span class="hlFld-ContribAuthor ">Steven T.  Staben</span>, <span class="hlFld-ContribAuthor ">Mark  Ultsch</span>, <span class="hlFld-ContribAuthor ">Binqing  Wei</span>, <span class="hlFld-ContribAuthor ">Wenqian  Yang</span>, and <span class="hlFld-ContribAuthor ">Daniel P.  Sutherlin</span>  . </span><span class="cited-content_cbyCitation_article-title">Design of Selective Benzoxazepin PI3Kδ Inhibitors Through Control of Dihedral Angles. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>8 </em>
                                    (9)
                                     , 936-940. <a href="https://doi.org/10.1021/acsmedchemlett.7b00170" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.7b00170</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.7b00170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.7b00170%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%252Bof%252BSelective%252BBenzoxazepin%252BPI3K%2525CE%2525B4%252BInhibitors%252BThrough%252BControl%252Bof%252BDihedral%252BAngles%26aulast%3DSafina%26aufirst%3DBrian%2BS.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D18042017%26date%3D25082017%26date%3D29082017%26date%3D14092017%26date%3D25082017%26volume%3D8%26issue%3D9%26spage%3D936%26epage%3D940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthew R.  Hassett</span>, <span class="hlFld-ContribAuthor ">Anna R.  Sternberg</span>, and <span class="hlFld-ContribAuthor ">Paul D.  Roepe</span>  . </span><span class="cited-content_cbyCitation_article-title">Inhibition of Human Class I vs Class III Phosphatidylinositol 3′-Kinases. </span><span class="cited-content_cbyCitation_journal-name">Biochemistry</span><span> <strong>2017,</strong> <em>56 </em>
                                    (33)
                                     , 4326-4334. <a href="https://doi.org/10.1021/acs.biochem.7b00413" title="DOI URL">https://doi.org/10.1021/acs.biochem.7b00413</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.biochem.7b00413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.biochem.7b00413%26sid%3Dliteratum%253Aachs%26date%3D2011%26jtitle%3DJ.%2520Med.%2520Chem.%26volume%3D54%26spage%3D1473%26epage%3D1480%26jtitle%3DBiochemistry%26atitle%3DInhibition%252Bof%252BHuman%252BClass%252BI%252Bvs%252BClass%252BIII%252BPhosphatidylinositol%252B3%2525E2%252580%2525B2-Kinases%26aulast%3DHassett%26aufirst%3DMatthew%2BR.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D02052017%26date%3D11072017%26date%3D08082017%26date%3D22082017%26date%3D18072017%26volume%3D56%26issue%3D33%26spage%3D4326%26epage%3D4334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carolin  Schwehm</span>, <span class="hlFld-ContribAuthor ">Barrie  Kellam</span>, <span class="hlFld-ContribAuthor ">Aimie E.  Garces</span>, <span class="hlFld-ContribAuthor ">Stephen J.  Hill</span>, <span class="hlFld-ContribAuthor ">Nicholas D.  Kindon</span>, <span class="hlFld-ContribAuthor ">Tracey D.  Bradshaw</span>, <span class="hlFld-ContribAuthor ">Jin  Li</span>, <span class="hlFld-ContribAuthor ">Simon J. F.  Macdonald</span>, <span class="hlFld-ContribAuthor ">James E.  Rowedder</span>, <span class="hlFld-ContribAuthor ">Leigh A.  Stoddart</span>, and <span class="hlFld-ContribAuthor ">Michael J.  Stocks</span>  . </span><span class="cited-content_cbyCitation_article-title">Design and Elaboration of a Tractable Tricyclic Scaffold To Synthesize Druglike Inhibitors of Dipeptidyl Peptidase-4 (DPP-4), Antagonists of the C–C Chemokine Receptor Type 5 (CCR5), and Highly Potent and Selective Phosphoinositol-3 Kinase δ (PI3Kδ) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (4)
                                     , 1534-1554. <a href="https://doi.org/10.1021/acs.jmedchem.6b01801" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01801</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01801%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BElaboration%252Bof%252Ba%252BTractable%252BTricyclic%252BScaffold%252BTo%252BSynthesize%252BDruglike%252BInhibitors%252Bof%252BDipeptidyl%252BPeptidase-4%252B%252528DPP-4%252529%25252C%252BAntagonists%252Bof%252Bthe%252BC%2525E2%252580%252593C%252BChemokine%252BReceptor%252BType%252B5%252B%252528CCR5%252529%25252C%252Band%252BHighly%252BPotent%252Band%252BSelective%252BPhosphoinositol-3%252BKinase%252B%2525CE%2525B4%252B%252528PI3K%2525CE%2525B4%252529%252BInhibitors%26aulast%3DSchwehm%26aufirst%3DCarolin%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D12122016%26date%3D10022017%26date%3D23022017%26date%3D27012017%26volume%3D60%26issue%3D4%26spage%3D1534%26epage%3D1554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor "> Timothy P.    Heffron </span><span class="hlFld-ContribAuthor "> Andrew    McClory </span><span class="hlFld-ContribAuthor "> Andreas    Stumpf </span>. </span><span class="cited-content_cbyCitation_article-title">The Discovery and Process Chemistry Development of GDC-0084, a Brain Penetrating Inhibitor of PI3K and mTOR. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 147-173. <a href="https://doi.org/10.1021/bk-2016-1239.ch006" title="DOI URL">https://doi.org/10.1021/bk-2016-1239.ch006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bk-2016-1239.ch006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbk-2016-1239.ch006%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BDiscovery%252Band%252BProcess%252BChemistry%252BDevelopment%252Bof%252BGDC-0084%25252C%252Ba%252BBrain%252BPenetrating%252BInhibitor%252Bof%252BPI3K%252Band%252BmTOR%26aulast%3DHeffron%26aufirst%3DTimothy%2BP.%26date%3D2016%26date%3D2016%26spage%3D147%26epage%3D173%26atitle%3DComprehensive%252BAccounts%252Bof%252BPharmaceutical%252BResearch%252Band%252BDevelopment%25253A%252BFrom%252BDiscovery%252Bto%252BLate-Stage%252BProcess%252BDevelopment%252BVolume%252B1%26aulast%3DAbdel-Magid%26aufirst%3DAhmed%2BF.%26date%3D2016%26date%3D2016%26volume%3D1239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jia-Jun  Liu</span>, <span class="hlFld-ContribAuthor ">Chin-Sheng  Yu</span>, <span class="hlFld-ContribAuthor ">Hsiao-Wei  Wu</span>, <span class="hlFld-ContribAuthor ">Yu-Jen  Chang</span>, <span class="hlFld-ContribAuthor ">Chih-Peng  Lin</span>, <span class="hlFld-ContribAuthor ">Chih-Hao  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">The structure-based cancer-related single amino acid variation prediction. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-021-92793-w" title="DOI URL">https://doi.org/10.1038/s41598-021-92793-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-021-92793-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-021-92793-w%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DThe%252Bstructure-based%252Bcancer-related%252Bsingle%252Bamino%252Bacid%252Bvariation%252Bprediction%26aulast%3DLiu%26aufirst%3DJia-Jun%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Le  Yu</span>, <span class="hlFld-ContribAuthor ">Jessica  Wei</span>, <span class="hlFld-ContribAuthor ">Pengda  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Cancer Biology</span><span> <strong>2021,</strong> <em>5 </em><a href="https://doi.org/10.1016/j.semcancer.2021.06.019" title="DOI URL">https://doi.org/10.1016/j.semcancer.2021.06.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.semcancer.2021.06.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.semcancer.2021.06.019%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Cancer%2520Biology%26atitle%3DAttacking%252Bthe%252BPI3K%25252FAkt%25252FmTOR%252Bsignaling%252Bpathway%252Bfor%252Btargeted%252Btherapeutic%252Btreatment%252Bin%252Bhuman%252Bcancer%26aulast%3DYu%26aufirst%3DLe%26date%3D2021%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dima A.  Sabbah</span>, <span class="hlFld-ContribAuthor ">Rima  Hajjo</span>, <span class="hlFld-ContribAuthor ">Sanaa K.  Bardaweel</span>, <span class="hlFld-ContribAuthor ">Haizhen A.  Zhong</span>. </span><span class="cited-content_cbyCitation_article-title">Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016–2020). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2021,</strong> <em>8 </em>, 1-16. <a href="https://doi.org/10.1080/13543776.2021.1924150" title="DOI URL">https://doi.org/10.1080/13543776.2021.1924150</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2021.1924150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2021.1924150%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DPhosphatidylinositol%252B3-kinase%252B%252528PI3K%252529%252Binhibitors%25253A%252Ba%252Brecent%252Bupdate%252Bon%252Binhibitor%252Bdesign%252Band%252Bclinical%252Btrials%252B%2525282016%2525E2%252580%2525932020%252529%26aulast%3DSabbah%26aufirst%3DDima%2BA.%26date%3D2021%26date%3D2021%26volume%3D8%26spage%3D1%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Manoj K  Rathinaswamy</span>, <span class="hlFld-ContribAuthor ">Zied  Gaieb</span>, <span class="hlFld-ContribAuthor ">Kaelin D  Fleming</span>, <span class="hlFld-ContribAuthor ">Chiara  Borsari</span>, <span class="hlFld-ContribAuthor ">Noah J  Harris</span>, <span class="hlFld-ContribAuthor ">Brandon E  Moeller</span>, <span class="hlFld-ContribAuthor ">Matthias P  Wymann</span>, <span class="hlFld-ContribAuthor ">Rommie E  Amaro</span>, <span class="hlFld-ContribAuthor ">John E  Burke</span>. </span><span class="cited-content_cbyCitation_article-title">Disease-related mutations in PI3Kγ disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors. </span><span class="cited-content_cbyCitation_journal-name">eLife</span><span> <strong>2021,</strong> <em>10 </em><a href="https://doi.org/10.7554/eLife.64691" title="DOI URL">https://doi.org/10.7554/eLife.64691</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.7554/eLife.64691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.7554%2FeLife.64691%26sid%3Dliteratum%253Aachs%26jtitle%3DeLife%26atitle%3DDisease-related%252Bmutations%252Bin%252BPI3K%2525CE%2525B3%252Bdisrupt%252Bregulatory%252BC-terminal%252Bdynamics%252Band%252Breveal%252Ba%252Bpath%252Bto%252Bselective%252Binhibitors%26aulast%3DRathinaswamy%26aufirst%3DManoj%2BK%26date%3D2021%26date%3D2021%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dongyan  Gu</span>, <span class="hlFld-ContribAuthor ">Gang  Cheng</span>, <span class="hlFld-ContribAuthor ">Mengmeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Yu-Bo  Zhou</span>, <span class="hlFld-ContribAuthor ">Jia  Li</span>, <span class="hlFld-ContribAuthor ">Rong  Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2-(5-(quinolin-6-yl)-1,3,4-oxadiazol-2-yl)acetamide derivatives as novel PI3Kα inhibitors via docking-based virtual screening. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>29 </em>, 115863. <a href="https://doi.org/10.1016/j.bmc.2020.115863" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115863</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115863%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2-%2525285-%252528quinolin-6-yl%252529-1%25252C3%25252C4-oxadiazol-2-yl%252529acetamide%252Bderivatives%252Bas%252Bnovel%252BPI3K%2525CE%2525B1%252Binhibitors%252Bvia%252Bdocking-based%252Bvirtual%252Bscreening%26aulast%3DGu%26aufirst%3DDongyan%26date%3D2021%26volume%3D29%26spage%3D115863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao-Yue  Xiang</span>, <span class="hlFld-ContribAuthor ">Xiang  Wang</span>, <span class="hlFld-ContribAuthor ">Yan-Hong  Chen</span>, <span class="hlFld-ContribAuthor ">Xi  Zhang</span>, <span class="hlFld-ContribAuthor ">Cun  Tan</span>, <span class="hlFld-ContribAuthor ">Yi  Wang</span>, <span class="hlFld-ContribAuthor ">Yi  Su</span>, <span class="hlFld-ContribAuthor ">Zhi-Wei  Gao</span>, <span class="hlFld-ContribAuthor ">Xiao-Yan  Chen</span>, <span class="hlFld-ContribAuthor ">Bing  Xiong</span>, <span class="hlFld-ContribAuthor ">Zhao-Bing  Gao</span>, <span class="hlFld-ContribAuthor ">Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Ling-Hua  Meng</span>, <span class="hlFld-ContribAuthor ">Chun-Hao  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) as an orally bioavailable, highly potent, PI3K alpha inhibitor for the treatment of advanced solid tumors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112913. <a href="https://doi.org/10.1016/j.ejmech.2020.112913" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112913</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112913%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Bmethyl%252B%2525285-%2525286-%252528%2525284-%252528methylsulfonyl%252529piperazin-1-yl%252529methyl%252529-4-morpholinopyrrolo%25255B2%25252C1-f%25255D%25255B1%25252C2%25252C4%25255Dtriazin-2-yl%252529-4-%252528trifluoromethyl%252529pyridin-2-yl%252529carbamate%252B%252528CYH33%252529%252Bas%252Ban%252Borally%252Bbioavailable%25252C%252Bhighly%252Bpotent%25252C%252BPI3K%252Balpha%252Binhibitor%252Bfor%252Bthe%252Btreatment%252Bof%252Badvanced%252Bsolid%252Btumors%26aulast%3DXiang%26aufirst%3DHao-Yue%26date%3D2021%26volume%3D209%26spage%3D112913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefan G.  Koenig</span>, <span class="hlFld-ContribAuthor ">Keena L.  Green</span>, <span class="hlFld-ContribAuthor ">Barbara  Müller</span>, <span class="hlFld-ContribAuthor ">C. Gregory  Sowell</span>, <span class="hlFld-ContribAuthor ">David  Askin</span>, <span class="hlFld-ContribAuthor ">Francis  Gosselin</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a practical synthesis to PI3K α-selective inhibitor GDC-0326. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2021,</strong> <em>79 </em>, 131840. <a href="https://doi.org/10.1016/j.tet.2020.131840" title="DOI URL">https://doi.org/10.1016/j.tet.2020.131840</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2020.131840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2020.131840%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DDevelopment%252Bof%252Ba%252Bpractical%252Bsynthesis%252Bto%252BPI3K%252B%2525CE%2525B1-selective%252Binhibitor%252BGDC-0326%26aulast%3DKoenig%26aufirst%3DStefan%2BG.%26date%3D2021%26volume%3D79%26spage%3D131840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nash D.  Rochman</span>, <span class="hlFld-ContribAuthor ">Yuri I.  Wolf</span>, <span class="hlFld-ContribAuthor ">Eugene V.  Koonin</span>. </span><span class="cited-content_cbyCitation_article-title">Deep phylogeny of cancer drivers and compensatory mutations. </span><span class="cited-content_cbyCitation_journal-name">Communications Biology</span><span> <strong>2020,</strong> <em>3 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s42003-020-01276-7" title="DOI URL">https://doi.org/10.1038/s42003-020-01276-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s42003-020-01276-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs42003-020-01276-7%26sid%3Dliteratum%253Aachs%26jtitle%3DCommunications%2520Biology%26atitle%3DDeep%252Bphylogeny%252Bof%252Bcancer%252Bdrivers%252Band%252Bcompensatory%252Bmutations%26aulast%3DRochman%26aufirst%3DNash%2BD.%26date%3D2020%26date%3D2020%26volume%3D3%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rammohan R.Y.  Bheemanaboina</span>. </span><span class="cited-content_cbyCitation_article-title">Isoform-Selective PI3K Inhibitors for Various Diseases. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2020,</strong> <em>20 </em>
                                    (12)
                                     , 1074-1092. <a href="https://doi.org/10.2174/1568026620666200106141717" title="DOI URL">https://doi.org/10.2174/1568026620666200106141717</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026620666200106141717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026620666200106141717%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DIsoform-Selective%252BPI3K%252BInhibitors%252Bfor%252BVarious%252BDiseases%26aulast%3DBheemanaboina%26aufirst%3DRammohan%2BR.Y.%26date%3D2020%26volume%3D20%26issue%3D12%26spage%3D1074%26epage%3D1092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kuanglei  Wang</span>, <span class="hlFld-ContribAuthor ">Hongxi  Zhu</span>, <span class="hlFld-ContribAuthor ">Hongqian  Zhao</span>, <span class="hlFld-ContribAuthor ">Kun  Zhang</span>, <span class="hlFld-ContribAuthor ">Yongshou  Tian</span>. </span><span class="cited-content_cbyCitation_article-title">Application of carbamyl in structural optimization. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>98 </em>, 103757. <a href="https://doi.org/10.1016/j.bioorg.2020.103757" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103757</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103757%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DApplication%252Bof%252Bcarbamyl%252Bin%252Bstructural%252Boptimization%26aulast%3DWang%26aufirst%3DKuanglei%26date%3D2020%26volume%3D98%26spage%3D103757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xingrong  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaorong  Liang</span>, <span class="hlFld-ContribAuthor ">Jenninfer  LeCouter</span>, <span class="hlFld-ContribAuthor ">Savita  Ubhayakar</span>, <span class="hlFld-ContribAuthor ">Jacob  Chen</span>, <span class="hlFld-ContribAuthor ">Jay  Cheng</span>, <span class="hlFld-ContribAuthor ">Tom  Lee</span>, <span class="hlFld-ContribAuthor ">Joe  Lubach</span>, <span class="hlFld-ContribAuthor ">Jim  Nonomiya</span>, <span class="hlFld-ContribAuthor ">Sheerin  Shahidi-Latham</span>, <span class="hlFld-ContribAuthor ">Cristine  Quiason</span>, <span class="hlFld-ContribAuthor ">Eric  Solon</span>, <span class="hlFld-ContribAuthor ">Matthew  Wright</span>, <span class="hlFld-ContribAuthor ">Cornelis E.C.A.  Hop</span>, <span class="hlFld-ContribAuthor ">Timothy P.  Heffron</span>. </span><span class="cited-content_cbyCitation_article-title">Characterization of Antineovascularization Activity and Ocular Pharmacokinetics of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GNE-947. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2020,</strong> <em>48 </em>
                                    (5)
                                     , 408-419. <a href="https://doi.org/10.1124/dmd.119.089763" title="DOI URL">https://doi.org/10.1124/dmd.119.089763</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.119.089763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.119.089763%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DCharacterization%252Bof%252BAntineovascularization%252BActivity%252Band%252BOcular%252BPharmacokinetics%252Bof%252BPhosphoinositide%252B3-Kinase%25252FMammalian%252BTarget%252Bof%252BRapamycin%252BInhibitor%252BGNE-947%26aulast%3DLiu%26aufirst%3DXingrong%26date%3D2020%26date%3D2020%26volume%3D48%26issue%3D5%26spage%3D408%26epage%3D419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vikra Ardiansyah  Zaini</span>, <span class="hlFld-ContribAuthor ">Purwantiningsih  Sugita</span>, <span class="hlFld-ContribAuthor ">Luthfan  Irfana</span>, <span class="hlFld-ContribAuthor ">Suminar Setiati  Achmadi</span>. </span><span class="cited-content_cbyCitation_article-title">In Silico Screening Anticancer of Six Triterpenoids toward miR-494 and TNF-α Targets. </span><span class="cited-content_cbyCitation_journal-name">Jurnal Kimia Sains dan Aplikasi</span><span> <strong>2020,</strong> <em>23 </em>
                                    (4)
                                     , 117-123. <a href="https://doi.org/10.14710/jksa.23.4.117-123" title="DOI URL">https://doi.org/10.14710/jksa.23.4.117-123</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.14710/jksa.23.4.117-123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.14710%2Fjksa.23.4.117-123%26sid%3Dliteratum%253Aachs%26jtitle%3DJurnal%2520Kimia%2520Sains%2520dan%2520Aplikasi%26atitle%3DIn%252BSilico%252BScreening%252BAnticancer%252Bof%252BSix%252BTriterpenoids%252Btoward%252BmiR-494%252Band%252BTNF-%2525CE%2525B1%252BTargets%26aulast%3DZaini%26aufirst%3DVikra%2BArdiansyah%26date%3D2020%26date%3D2020%26volume%3D23%26issue%3D4%26spage%3D117%26epage%3D123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mikhail M.  Degtyarik</span>, <span class="hlFld-ContribAuthor ">Andrey N.  Bogatikov</span>, <span class="hlFld-ContribAuthor ">Sergei V.  Voitekhovich</span>, <span class="hlFld-ContribAuthor ">Alexander S.  Lyakhov</span>, <span class="hlFld-ContribAuthor ">Ludmila S.  Ivashkevich</span>, <span class="hlFld-ContribAuthor ">Yuri V.  Grigoriev</span>, <span class="hlFld-ContribAuthor ">Oleg A.  Ivashkevich</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and structure of copper(II) complexes with 1-iso-propyl-1Н-1,2,4-triazole. </span><span class="cited-content_cbyCitation_journal-name">Journal of the Belarusian State University. Chemistry</span><span> <strong>2020,</strong> <em> </em>
                                    (1)
                                     , 64-73. <a href="https://doi.org/10.33581/2520-257X-2020-1-64-73" title="DOI URL">https://doi.org/10.33581/2520-257X-2020-1-64-73</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.33581/2520-257X-2020-1-64-73&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.33581%2F2520-257X-2020-1-64-73%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520Belarusian%2520State%2520University.%2520Chemistry%26atitle%3DSynthesis%252Band%252Bstructure%252Bof%252Bcopper%252528II%252529%252Bcomplexes%252Bwith%252B1-iso-propyl-1%2525D0%25259D-1%25252C2%25252C4-triazole%26aulast%3DDegtyarik%26aufirst%3DMikhail%2BM.%26date%3D2020%26date%3D2020%26issue%3D1%26spage%3D64%26epage%3D73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jacob A.  McPhail</span>, <span class="hlFld-ContribAuthor ">John E.  Burke</span>. </span><span class="cited-content_cbyCitation_article-title">Drugging the Phosphoinositide 3-Kinase (PI3K) and Phosphatidylinositol 4-Kinase (PI4K) Family of Enzymes for Treatment of Cancer, Immune Disorders, and Viral/Parasitic Infections. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 203-222. <a href="https://doi.org/10.1007/978-3-030-50621-6_9" title="DOI URL">https://doi.org/10.1007/978-3-030-50621-6_9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-50621-6_9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-50621-6_9%26sid%3Dliteratum%253Aachs%26atitle%3DDrugging%252Bthe%252BPhosphoinositide%252B3-Kinase%252B%252528PI3K%252529%252Band%252BPhosphatidylinositol%252B4-Kinase%252B%252528PI4K%252529%252BFamily%252Bof%252BEnzymes%252Bfor%252BTreatment%252Bof%252BCancer%25252C%252BImmune%252BDisorders%25252C%252Band%252BViral%25252FParasitic%252BInfections%26aulast%3DMcPhail%26aufirst%3DJacob%2BA.%26date%3D2020%26date%3D2020%26spage%3D203%26epage%3D222%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DDruggable%252BLipid%252BSignaling%252BPathways%26aulast%3DKihara%26aufirst%3DYasuyuki%26date%3D2020%26volume%3D1274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Georgi K.  Kanev</span>, <span class="hlFld-ContribAuthor ">Chris  de Graaf</span>, <span class="hlFld-ContribAuthor ">Iwan J.P.  de Esch</span>, <span class="hlFld-ContribAuthor ">Rob  Leurs</span>, <span class="hlFld-ContribAuthor ">Thomas  Würdinger</span>, <span class="hlFld-ContribAuthor ">Bart A.  Westerman</span>, <span class="hlFld-ContribAuthor ">Albert J.  Kooistra</span>. </span><span class="cited-content_cbyCitation_article-title">The Landscape of Atypical and Eukaryotic Protein Kinases. </span><span class="cited-content_cbyCitation_journal-name">Trends in Pharmacological Sciences</span><span> <strong>2019,</strong> <em>40 </em>
                                    (11)
                                     , 818-832. <a href="https://doi.org/10.1016/j.tips.2019.09.002" title="DOI URL">https://doi.org/10.1016/j.tips.2019.09.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tips.2019.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tips.2019.09.002%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Pharmacological%2520Sciences%26atitle%3DThe%252BLandscape%252Bof%252BAtypical%252Band%252BEukaryotic%252BProtein%252BKinases%26aulast%3DKanev%26aufirst%3DGeorgi%2BK.%26date%3D2019%26volume%3D40%26issue%3D11%26spage%3D818%26epage%3D832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Valentina  Romeo</span>, <span class="hlFld-ContribAuthor ">Sarah  Gierke</span>, <span class="hlFld-ContribAuthor ">Kyle A.  Edgar</span>, <span class="hlFld-ContribAuthor ">Scot D.  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Effects of PI3K Inhibition on Afucosylated Antibody–Driven FcγRIIIa Events and Phospho-S6 Activity in NK Cells. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Immunology</span><span> <strong>2019,</strong> <em>203 </em>
                                    (1)
                                     , 137-147. <a href="https://doi.org/10.4049/jimmunol.1801418" title="DOI URL">https://doi.org/10.4049/jimmunol.1801418</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4049/jimmunol.1801418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4049%2Fjimmunol.1801418%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Immunology%26atitle%3DEffects%252Bof%252BPI3K%252BInhibition%252Bon%252BAfucosylated%252BAntibody%2525E2%252580%252593Driven%252BFc%2525CE%2525B3RIIIa%252BEvents%252Band%252BPhospho-S6%252BActivity%252Bin%252BNK%252BCells%26aulast%3DRomeo%26aufirst%3DValentina%26date%3D2019%26date%3D2019%26volume%3D203%26issue%3D1%26spage%3D137%26epage%3D147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shubham  Srivastava</span>, <span class="hlFld-ContribAuthor ">Bhanwar  Singh Choudhary</span>, <span class="hlFld-ContribAuthor ">Pakhuri  Mehta</span>, <span class="hlFld-ContribAuthor ">Sukanya</span>, <span class="hlFld-ContribAuthor ">Manish  Sharma</span>, <span class="hlFld-ContribAuthor ">Ruchi  Malik</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular dynamics insights for PI3K-δ inhibition & structure guided identification of novel PI3K-δ inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2019,</strong> <em>37 </em>
                                    (9)
                                     , 2404-2414. <a href="https://doi.org/10.1080/07391102.2018.1489304" title="DOI URL">https://doi.org/10.1080/07391102.2018.1489304</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2018.1489304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2018.1489304%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DMolecular%252Bdynamics%252Binsights%252Bfor%252BPI3K-%2525CE%2525B4%252Binhibition%252B%252526%252Bstructure%252Bguided%252Bidentification%252Bof%252Bnovel%252BPI3K-%2525CE%2525B4%252Binhibitors%26aulast%3DSrivastava%26aufirst%3DShubham%26date%3D2019%26date%3D2018%26volume%3D37%26issue%3D9%26spage%3D2404%26epage%3D2414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samane  Poursan</span>, <span class="hlFld-ContribAuthor ">Somayeh  Ahadi</span>, <span class="hlFld-ContribAuthor ">Saeed  Balalaie</span>, <span class="hlFld-ContribAuthor ">Frank  Rominger</span>, <span class="hlFld-ContribAuthor ">Hamid Reza  Bijanzadeh</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Novel Functionalized Fused Oxazepine and Diazepine Analogues Containing Coumarin Backbone through Domino Reaction. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2019,</strong> <em>4 </em>
                                    (20)
                                     , 6403-6407. <a href="https://doi.org/10.1002/slct.201900918" title="DOI URL">https://doi.org/10.1002/slct.201900918</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.201900918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.201900918%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BNovel%252BFunctionalized%252BFused%252BOxazepine%252Band%252BDiazepine%252BAnalogues%252BContaining%252BCoumarin%252BBackbone%252Bthrough%252BDomino%252BReaction%26aulast%3DPoursan%26aufirst%3DSamane%26date%3D2019%26date%3D2019%26volume%3D4%26issue%3D20%26spage%3D6403%26epage%3D6407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Jun  Wei</span>, <span class="hlFld-ContribAuthor ">Chang  Wang</span>, <span class="hlFld-ContribAuthor ">Dongyan  Gu</span>, <span class="hlFld-ContribAuthor ">Yongzhou  Hu</span>, <span class="hlFld-ContribAuthor ">Rong  Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3Kδ-selective inhibitors for treating B-cell-mediated malignancies. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>170 </em>, 112-125. <a href="https://doi.org/10.1016/j.ejmech.2019.03.005" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.03.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.03.005%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bbenzothiadiazine%252Bderivatives%252Bas%252Bpotent%252BPI3K%2525CE%2525B4-selective%252Binhibitors%252Bfor%252Btreating%252BB-cell-mediated%252Bmalignancies%26aulast%3DMa%26aufirst%3DXiaodong%26date%3D2019%26volume%3D170%26spage%3D112%26epage%3D125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Li  Shen</span>, <span class="hlFld-ContribAuthor ">Jiankang  Zhang</span>, <span class="hlFld-ContribAuthor ">Guoqiang  Liu</span>, <span class="hlFld-ContribAuthor ">Shuyu  Zhan</span>, <span class="hlFld-ContribAuthor ">Baoyue  Ding</span>, <span class="hlFld-ContribAuthor ">Xiaoqing  Lv</span>. </span><span class="cited-content_cbyCitation_article-title">Novel 4-Acrylamido-Quinoline Derivatives as Potent PI3K/mTOR Dual Inhibitors: The Design, Synthesis, and in vitro and in vivo Biological Evaluation. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2019,</strong> <em>7 </em><a href="https://doi.org/10.3389/fchem.2019.00236" title="DOI URL">https://doi.org/10.3389/fchem.2019.00236</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2019.00236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2019.00236%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DNovel%252B4-Acrylamido-Quinoline%252BDerivatives%252Bas%252BPotent%252BPI3K%25252FmTOR%252BDual%252BInhibitors%25253A%252BThe%252BDesign%25252C%252BSynthesis%25252C%252Band%252Bin%252Bvitro%252Band%252Bin%252Bvivo%252BBiological%252BEvaluation%26aulast%3DMa%26aufirst%3DXiaodong%26date%3D2019%26date%3D2019%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna C.  Giddens</span>, <span class="hlFld-ContribAuthor ">Swarna A.  Gamage</span>, <span class="hlFld-ContribAuthor ">Jackie D.  Kendall</span>, <span class="hlFld-ContribAuthor ">Woo-Jeong  Lee</span>, <span class="hlFld-ContribAuthor ">Bruce C.  Baguley</span>, <span class="hlFld-ContribAuthor ">Christina M.  Buchanan</span>, <span class="hlFld-ContribAuthor ">Stephen M.F.  Jamieson</span>, <span class="hlFld-ContribAuthor ">James M.J.  Dickson</span>, <span class="hlFld-ContribAuthor ">Peter R.  Shepherd</span>, <span class="hlFld-ContribAuthor ">William A.  Denny</span>, <span class="hlFld-ContribAuthor ">Gordon W.  Rewcastle</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of solubilized sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (8)
                                     , 1529-1545. <a href="https://doi.org/10.1016/j.bmc.2019.02.050" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.02.050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.02.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.02.050%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bsolubilized%252Bsulfonamide%252Banalogues%252Bof%252Bthe%252Bphosphatidylinositol%252B3-kinase%252Binhibitor%252BZSTK474%26aulast%3DGiddens%26aufirst%3DAnna%2BC.%26date%3D2019%26volume%3D27%26issue%3D8%26spage%3D1529%26epage%3D1545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michelle  Miller</span>, <span class="hlFld-ContribAuthor ">Philip  Thompson</span>, <span class="hlFld-ContribAuthor ">Sandra  Gabelli</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Determinants of Isoform Selectivity in PI3K Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2019,</strong> <em>9 </em>
                                    (3)
                                     , 82. <a href="https://doi.org/10.3390/biom9030082" title="DOI URL">https://doi.org/10.3390/biom9030082</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom9030082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom9030082%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DStructural%252BDeterminants%252Bof%252BIsoform%252BSelectivity%252Bin%252BPI3K%252BInhibitors%26aulast%3DMiller%26aufirst%3DMichelle%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D3%26spage%3D82" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jun-Fang  Guo</span>, <span class="hlFld-ContribAuthor ">Zhong-Qi  Ning</span>, <span class="hlFld-ContribAuthor ">Xia  Wu</span>, <span class="hlFld-ContribAuthor ">Yan-Jiang  Qiao</span>, <span class="hlFld-ContribAuthor ">Xing  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a natural PI3Kδ inhibitor through virtual screening and biological assay study. </span><span class="cited-content_cbyCitation_journal-name">Biochemical and Biophysical Research Communications</span><span> <strong>2019,</strong> <em>508 </em>
                                    (3)
                                     , 709-714. <a href="https://doi.org/10.1016/j.bbrc.2018.12.009" title="DOI URL">https://doi.org/10.1016/j.bbrc.2018.12.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbrc.2018.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbrc.2018.12.009%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520and%2520Biophysical%2520Research%2520Communications%26atitle%3DDiscovery%252Bof%252Ba%252Bnatural%252BPI3K%2525CE%2525B4%252Binhibitor%252Bthrough%252Bvirtual%252Bscreening%252Band%252Bbiological%252Bassay%252Bstudy%26aulast%3DGuo%26aufirst%3DJun-Fang%26date%3D2019%26volume%3D508%26issue%3D3%26spage%3D709%26epage%3D714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ana  Angulo-Urarte</span>, <span class="hlFld-ContribAuthor ">Pedro  Casado</span>, <span class="hlFld-ContribAuthor ">Sandra D.  Castillo</span>, <span class="hlFld-ContribAuthor ">Piotr  Kobialka</span>, <span class="hlFld-ContribAuthor ">Maria Paraskevi  Kotini</span>, <span class="hlFld-ContribAuthor ">Ana M.  Figueiredo</span>, <span class="hlFld-ContribAuthor ">Pau  Castel</span>, <span class="hlFld-ContribAuthor ">Vinothini  Rajeeve</span>, <span class="hlFld-ContribAuthor ">Maria  Milà-Guasch</span>, <span class="hlFld-ContribAuthor ">Jaime  Millan</span>, <span class="hlFld-ContribAuthor ">Cora  Wiesner</span>, <span class="hlFld-ContribAuthor ">Helena  Serra</span>, <span class="hlFld-ContribAuthor ">Laia  Muixi</span>, <span class="hlFld-ContribAuthor ">Oriol  Casanovas</span>, <span class="hlFld-ContribAuthor ">Francesc  Viñals</span>, <span class="hlFld-ContribAuthor ">Markus  Affolter</span>, <span class="hlFld-ContribAuthor ">Holger  Gerhardt</span>, <span class="hlFld-ContribAuthor ">Stephan  Huveneers</span>, <span class="hlFld-ContribAuthor ">Heinz-Georg  Belting</span>, <span class="hlFld-ContribAuthor ">Pedro R.  Cutillas</span>, <span class="hlFld-ContribAuthor ">Mariona  Graupera</span>. </span><span class="cited-content_cbyCitation_article-title">Endothelial cell rearrangements during vascular patterning require PI3-kinase-mediated inhibition of actomyosin contractility. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2018,</strong> <em>9 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41467-018-07172-3" title="DOI URL">https://doi.org/10.1038/s41467-018-07172-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41467-018-07172-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41467-018-07172-3%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DEndothelial%252Bcell%252Brearrangements%252Bduring%252Bvascular%252Bpatterning%252Brequire%252BPI3-kinase-mediated%252Binhibition%252Bof%252Bactomyosin%252Bcontractility%26aulast%3DAngulo-Urarte%26aufirst%3DAna%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fazeela Mahaboob Begum  S.M.</span>, <span class="hlFld-ContribAuthor ">Kalai  Chitra</span>, <span class="hlFld-ContribAuthor ">Benin  Joseph</span>, <span class="hlFld-ContribAuthor ">Raji  Sundararajan</span>, <span class="hlFld-ContribAuthor ">Hemalatha  S.</span>. </span><span class="cited-content_cbyCitation_article-title">Gelidiella acerosa inhibits lung cancer proliferation. </span><span class="cited-content_cbyCitation_journal-name">BMC Complementary and Alternative Medicine</span><span> <strong>2018,</strong> <em>18 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12906-018-2165-1" title="DOI URL">https://doi.org/10.1186/s12906-018-2165-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12906-018-2165-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12906-018-2165-1%26sid%3Dliteratum%253Aachs%26jtitle%3DBMC%2520Complementary%2520and%2520Alternative%2520Medicine%26atitle%3DGelidiella%252Bacerosa%252Binhibits%252Blung%252Bcancer%252Bproliferation%26aulast%3DS.M.%26aufirst%3DFazeela%2BMahaboob%2BBegum%26date%3D2018%26date%3D2018%26volume%3D18%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jia  Wang</span>, <span class="hlFld-ContribAuthor ">Grace Qun  Gong</span>, <span class="hlFld-ContribAuthor ">Yan  Zhou</span>, <span class="hlFld-ContribAuthor ">Woo-Jeong  Lee</span>, <span class="hlFld-ContribAuthor ">Christina Maree  Buchanan</span>, <span class="hlFld-ContribAuthor ">William Alexander  Denny</span>, <span class="hlFld-ContribAuthor ">Gordon William  Rewcastle</span>, <span class="hlFld-ContribAuthor ">Jackie Diane  Kendall</span>, <span class="hlFld-ContribAuthor ">James Michael Jeremy  Dickson</span>, <span class="hlFld-ContribAuthor ">Jack Urquhart  Flanagan</span>, <span class="hlFld-ContribAuthor ">Peter Robin  Shepherd</span>, <span class="hlFld-ContribAuthor ">De-Hua  Yang</span>, <span class="hlFld-ContribAuthor ">Ming-Wei  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">High-throughput screening campaigns against a PI3Kα isoform bearing the H1047R mutation identified potential inhibitors with novel scaffolds. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmacologica Sinica</span><span> <strong>2018,</strong> <em>39 </em>
                                    (11)
                                     , 1816-1822. <a href="https://doi.org/10.1038/s41401-018-0057-z" title="DOI URL">https://doi.org/10.1038/s41401-018-0057-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41401-018-0057-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41401-018-0057-z%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmacologica%2520Sinica%26atitle%3DHigh-throughput%252Bscreening%252Bcampaigns%252Bagainst%252Ba%252BPI3K%2525CE%2525B1%252Bisoform%252Bbearing%252Bthe%252BH1047R%252Bmutation%252Bidentified%252Bpotential%252Binhibitors%252Bwith%252Bnovel%252Bscaffolds%26aulast%3DWang%26aufirst%3DJia%26date%3D2018%26date%3D2018%26volume%3D39%26issue%3D11%26spage%3D1816%26epage%3D1822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gillian L.  Dornan</span>, <span class="hlFld-ContribAuthor ">John E.  Burke</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Immunology</span><span> <strong>2018,</strong> <em>9 </em><a href="https://doi.org/10.3389/fimmu.2018.00575" title="DOI URL">https://doi.org/10.3389/fimmu.2018.00575</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fimmu.2018.00575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffimmu.2018.00575%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Immunology%26atitle%3DMolecular%252BMechanisms%252Bof%252BHuman%252BDisease%252BMediated%252Bby%252BOncogenic%252Band%252BPrimary%252BImmunodeficiency%252BMutations%252Bin%252BClass%252BIA%252BPhosphoinositide%252B3-Kinases%26aulast%3DDornan%26aufirst%3DGillian%2BL.%26date%3D2018%26date%3D2018%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Milan  Jovanović</span>, <span class="hlFld-ContribAuthor ">Katarina  Nikolić</span>, <span class="hlFld-ContribAuthor ">Žarko  Gagić</span>, <span class="hlFld-ContribAuthor ">Danica  Agbaba</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular modeling and analysis of the 3D pharmacophore structure of the selective PI3K-α inhibitors as antitumor agents. </span><span class="cited-content_cbyCitation_journal-name">Arhiv za farmaciju</span><span> <strong>2018,</strong> <em>68 </em>
                                    (4)
                                     , 860-873. <a href="https://doi.org/10.5937/ArhFarm1804860J" title="DOI URL">https://doi.org/10.5937/ArhFarm1804860J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5937/ArhFarm1804860J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5937%2FArhFarm1804860J%26sid%3Dliteratum%253Aachs%26jtitle%3DArhiv%2520za%2520farmaciju%26atitle%3DMolecular%252Bmodeling%252Band%252Banalysis%252Bof%252Bthe%252B3D%252Bpharmacophore%252Bstructure%252Bof%252Bthe%252Bselective%252BPI3K-%2525CE%2525B1%252Binhibitors%252Bas%252Bantitumor%252Bagents%26aulast%3DJovanovi%25C4%2587%26aufirst%3DMilan%26date%3D2018%26volume%3D68%26issue%3D4%26spage%3D860%26epage%3D873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiuyan  Yang</span>, <span class="hlFld-ContribAuthor ">Xi  Zhang</span>, <span class="hlFld-ContribAuthor ">Min  Huang</span>, <span class="hlFld-ContribAuthor ">Kun  Song</span>, <span class="hlFld-ContribAuthor ">Xuefen  Li</span>, <span class="hlFld-ContribAuthor ">Meilang  Huang</span>, <span class="hlFld-ContribAuthor ">Linghua  Meng</span>, <span class="hlFld-ContribAuthor ">Jian  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">New Insights into PI3K Inhibitor Design using X-ray Structures of PI3Kα Complexed with a Potent Lead Compound. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2017,</strong> <em>7 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-017-15260-5" title="DOI URL">https://doi.org/10.1038/s41598-017-15260-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-017-15260-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-017-15260-5%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DNew%252BInsights%252Binto%252BPI3K%252BInhibitor%252BDesign%252Busing%252BX-ray%252BStructures%252Bof%252BPI3K%2525CE%2525B1%252BComplexed%252Bwith%252Ba%252BPotent%252BLead%252BCompound%26aulast%3DYang%26aufirst%3DXiuyan%26date%3D2017%26date%3D2017%26volume%3D7%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xavier  Rossello</span>, <span class="hlFld-ContribAuthor ">Jaime A.  Riquelme</span>, <span class="hlFld-ContribAuthor ">Zhenhe  He</span>, <span class="hlFld-ContribAuthor ">Stasa  Taferner</span>, <span class="hlFld-ContribAuthor ">Bart  Vanhaesebroeck</span>, <span class="hlFld-ContribAuthor ">Sean M.  Davidson</span>, <span class="hlFld-ContribAuthor ">Derek M.  Yellon</span>. </span><span class="cited-content_cbyCitation_article-title">The role of PI3Kα isoform in cardioprotection. </span><span class="cited-content_cbyCitation_journal-name">Basic Research in Cardiology</span><span> <strong>2017,</strong> <em>112 </em>
                                    (6)
                                     <a href="https://doi.org/10.1007/s00395-017-0657-7" title="DOI URL">https://doi.org/10.1007/s00395-017-0657-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00395-017-0657-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00395-017-0657-7%26sid%3Dliteratum%253Aachs%26jtitle%3DBasic%2520Research%2520in%2520Cardiology%26atitle%3DThe%252Brole%252Bof%252BPI3K%2525CE%2525B1%252Bisoform%252Bin%252Bcardioprotection%26aulast%3DRossello%26aufirst%3DXavier%26date%3D2017%26date%3D2017%26volume%3D112%26issue%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Swarna A.  Gamage</span>, <span class="hlFld-ContribAuthor ">Anna C.  Giddens</span>, <span class="hlFld-ContribAuthor ">Kit Y.  Tsang</span>, <span class="hlFld-ContribAuthor ">Jack U.  Flanagan</span>, <span class="hlFld-ContribAuthor ">Jackie D.  Kendall</span>, <span class="hlFld-ContribAuthor ">Woo-Jeong  Lee</span>, <span class="hlFld-ContribAuthor ">Bruce C.  Baguley</span>, <span class="hlFld-ContribAuthor ">Christina M.  Buchanan</span>, <span class="hlFld-ContribAuthor ">Stephen M.F.  Jamieson</span>, <span class="hlFld-ContribAuthor ">Peter R.  Shepherd</span>, <span class="hlFld-ContribAuthor ">William A.  Denny</span>, <span class="hlFld-ContribAuthor ">Gordon W.  Rewcastle</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2017,</strong> <em>25 </em>
                                    (20)
                                     , 5859-5874. <a href="https://doi.org/10.1016/j.bmc.2017.09.025" title="DOI URL">https://doi.org/10.1016/j.bmc.2017.09.025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2017.09.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2017.09.025%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bsulfonamide%252Banalogues%252Bof%252Bthe%252Bphosphatidylinositol%252B3-kinase%252Binhibitor%252BZSTK474%26aulast%3DGamage%26aufirst%3DSwarna%2BA.%26date%3D2017%26volume%3D25%26issue%3D20%26spage%3D5859%26epage%3D5874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew J.  Takeda</span>, <span class="hlFld-ContribAuthor ">Yu  Zhang</span>, <span class="hlFld-ContribAuthor ">Gillian L.  Dornan</span>, <span class="hlFld-ContribAuthor ">Braden D.  Siempelkamp</span>, <span class="hlFld-ContribAuthor ">Meredith L.  Jenkins</span>, <span class="hlFld-ContribAuthor ">Helen F.  Matthews</span>, <span class="hlFld-ContribAuthor ">Joshua J.  McElwee</span>, <span class="hlFld-ContribAuthor ">Weimin  Bi</span>, <span class="hlFld-ContribAuthor ">Filiz O.  Seeborg</span>, <span class="hlFld-ContribAuthor ">Helen C.  Su</span>, <span class="hlFld-ContribAuthor ">John E.  Burke</span>, <span class="hlFld-ContribAuthor ">Carrie L.  Lucas</span>. </span><span class="cited-content_cbyCitation_article-title">Novel  PIK3CD  mutations affecting N-terminal residues of p110δ cause activated PI3Kδ syndrome (APDS) in humans. </span><span class="cited-content_cbyCitation_journal-name">Journal of Allergy and Clinical Immunology</span><span> <strong>2017,</strong> <em>140 </em>
                                    (4)
                                     , 1152-1156.e10. <a href="https://doi.org/10.1016/j.jaci.2017.03.026" title="DOI URL">https://doi.org/10.1016/j.jaci.2017.03.026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jaci.2017.03.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jaci.2017.03.026%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Allergy%2520and%2520Clinical%2520Immunology%26atitle%3DNovel%252BPIK3CD%252Bmutations%252Baffecting%252BN-terminal%252Bresidues%252Bof%252Bp110%2525CE%2525B4%252Bcause%252Bactivated%252BPI3K%2525CE%2525B4%252Bsyndrome%252B%252528APDS%252529%252Bin%252Bhumans%26aulast%3DTakeda%26aufirst%3DAndrew%2BJ.%26date%3D2017%26volume%3D140%26issue%3D4%26spage%3D1152%26epage%3D1156.e10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Grace Q.  Gong</span>, <span class="hlFld-ContribAuthor ">Jackie D.  Kendall</span>, <span class="hlFld-ContribAuthor ">James M.J.  Dickson</span>, <span class="hlFld-ContribAuthor ">Gordon W.  Rewcastle</span>, <span class="hlFld-ContribAuthor ">Christina M.  Buchanan</span>, <span class="hlFld-ContribAuthor ">William A.  Denny</span>, <span class="hlFld-ContribAuthor ">Peter R.  Shepherd</span>, <span class="hlFld-ContribAuthor ">Jack U.  Flanagan</span>. </span><span class="cited-content_cbyCitation_article-title">Combining properties of different classes of PI3Kα inhibitors to understand the molecular features that confer selectivity. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Journal</span><span> <strong>2017,</strong> <em>474 </em>
                                    (13)
                                     , 2261-2276. <a href="https://doi.org/10.1042/BCJ20161098" title="DOI URL">https://doi.org/10.1042/BCJ20161098</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1042/BCJ20161098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1042%2FBCJ20161098%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Journal%26atitle%3DCombining%252Bproperties%252Bof%252Bdifferent%252Bclasses%252Bof%252BPI3K%2525CE%2525B1%252Binhibitors%252Bto%252Bunderstand%252Bthe%252Bmolecular%252Bfeatures%252Bthat%252Bconfer%252Bselectivity%26aulast%3DGong%26aufirst%3DGrace%2BQ.%26date%3D2017%26date%3D2017%26volume%3D474%26issue%3D13%26spage%3D2261%26epage%3D2276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Glenn R.  Masson</span>, <span class="hlFld-ContribAuthor ">Sarah L.  Maslen</span>, <span class="hlFld-ContribAuthor ">Roger L.  Williams</span>. </span><span class="cited-content_cbyCitation_article-title">Analysis of phosphoinositide 3-kinase inhibitors by bottom-up electron-transfer dissociation hydrogen/deuterium exchange mass spectrometry. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Journal</span><span> <strong>2017,</strong> <em>474 </em>
                                    (11)
                                     , 1867-1877. <a href="https://doi.org/10.1042/BCJ20170127" title="DOI URL">https://doi.org/10.1042/BCJ20170127</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1042/BCJ20170127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1042%2FBCJ20170127%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Journal%26atitle%3DAnalysis%252Bof%252Bphosphoinositide%252B3-kinase%252Binhibitors%252Bby%252Bbottom-up%252Belectron-transfer%252Bdissociation%252Bhydrogen%25252Fdeuterium%252Bexchange%252Bmass%252Bspectrometry%26aulast%3DMasson%26aufirst%3DGlenn%2BR.%26date%3D2017%26date%3D2017%26volume%3D474%26issue%3D11%26spage%3D1867%26epage%3D1877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gillian L.  Dornan</span>, <span class="hlFld-ContribAuthor ">Braden D.  Siempelkamp</span>, <span class="hlFld-ContribAuthor ">Meredith L.  Jenkins</span>, <span class="hlFld-ContribAuthor ">Oscar  Vadas</span>, <span class="hlFld-ContribAuthor ">Carrie L.  Lucas</span>, <span class="hlFld-ContribAuthor ">John E.  Burke</span>. </span><span class="cited-content_cbyCitation_article-title">Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in
              PIK3CD
              and
              PIK3R1. </span><span class="cited-content_cbyCitation_journal-name">Proceedings of the National Academy of Sciences</span><span> <strong>2017,</strong> <em>114 </em>
                                    (8)
                                     , 1982-1987. <a href="https://doi.org/10.1073/pnas.1617244114" title="DOI URL">https://doi.org/10.1073/pnas.1617244114</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1073/pnas.1617244114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1073%2Fpnas.1617244114%26sid%3Dliteratum%253Aachs%26jtitle%3DProceedings%2520of%2520the%2520National%2520Academy%2520of%2520Sciences%26atitle%3DConformational%252Bdisruption%252Bof%252BPI3K%2525CE%2525B4%252Bregulation%252Bby%252Bimmunodeficiency%252Bmutations%252Bin%252BPIK3CD%252Band%252BPIK3R1%26aulast%3DDornan%26aufirst%3DGillian%2BL.%26date%3D2017%26date%3D2017%26volume%3D114%26issue%3D8%26spage%3D1982%26epage%3D1987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Liu</span>, <span class="hlFld-ContribAuthor ">Wen-zhu  Wan</span>, <span class="hlFld-ContribAuthor ">Yan  Li</span>, <span class="hlFld-ContribAuthor ">Guan-lian  Zhou</span>, <span class="hlFld-ContribAuthor ">Xin-guang  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2017,</strong> <em>8 </em>
                                    (4)
                                     , 7181-7200. <a href="https://doi.org/10.18632/oncotarget.12742" title="DOI URL">https://doi.org/10.18632/oncotarget.12742</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.12742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.12742%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DRecent%252Bdevelopment%252Bof%252BATP-competitive%252Bsmall%252Bmolecule%252Bphosphatidylinostitol-3-kinase%252Binhibitors%252Bas%252Banticancer%252Bagents%26aulast%3DLiu%26aufirst%3DYu%26date%3D2017%26date%3D2016%26volume%3D8%26issue%3D4%26spage%3D7181%26epage%3D7200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sam G.  Moss</span>, <span class="hlFld-ContribAuthor ">Ian A.  Pocock</span>, <span class="hlFld-ContribAuthor ">Joseph B.  Sweeney</span>. </span><span class="cited-content_cbyCitation_article-title">Tandem Aryne-Capture/Sigmatropic Rearrangement as a Metal-Free Entry to Functionalized
              N
              -Aryl Pyrrolidines. </span><span class="cited-content_cbyCitation_journal-name">Chemistry - A European Journal</span><span> <strong>2017,</strong> <em>23 </em>
                                    (1)
                                     , 101-104. <a href="https://doi.org/10.1002/chem.201605290" title="DOI URL">https://doi.org/10.1002/chem.201605290</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.201605290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.201605290%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520-%2520A%2520European%2520Journal%26atitle%3DTandem%252BAryne-Capture%25252FSigmatropic%252BRearrangement%252Bas%252Ba%252BMetal-Free%252BEntry%252Bto%252BFunctionalized%252BN%252B-Aryl%252BPyrrolidines%26aulast%3DMoss%26aufirst%3DSam%2BG.%26date%3D2017%26date%3D2016%26volume%3D23%26issue%3D1%26spage%3D101%26epage%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Steven T.  Staben</span>. </span><span class="cited-content_cbyCitation_article-title">Isoform Selective PI3K Inhibitors for Treating Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 333-333. <a href="https://doi.org/10.1007/7355_2016_27" title="DOI URL">https://doi.org/10.1007/7355_2016_27</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2016_27&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2016_27%26sid%3Dliteratum%253Aachs%26atitle%3DIsoform%252BSelective%252BPI3K%252BInhibitors%252Bfor%252BTreating%252BCancer%26aulast%3DStaben%26aufirst%3DSteven%2BT.%26date%3D2017%26spage%3D333%26epage%3D333%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DCancer%252BII%26aulast%3DWaring%26aufirst%3DMichael%2BJ.%26date%3D2018%26volume%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adam G.  Meyer</span>, <span class="hlFld-ContribAuthor ">Alex C.  Bissember</span>, <span class="hlFld-ContribAuthor ">Christopher  Hyland</span>, <span class="hlFld-ContribAuthor ">Jason A.  Smith</span>, <span class="hlFld-ContribAuthor ">Charlotte C.  Williams</span>, <span class="hlFld-ContribAuthor ">Farzad  Zamani</span>, <span class="hlFld-ContribAuthor ">Steven-Alan G.  Abel</span>. </span><span class="cited-content_cbyCitation_article-title">Seven-Membered Rings. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 579-633. <a href="https://doi.org/10.1016/B978-0-08-102310-5.00016-3" title="DOI URL">https://doi.org/10.1016/B978-0-08-102310-5.00016-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-102310-5.00016-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-102310-5.00016-3%26sid%3Dliteratum%253Aachs%26atitle%3DSeven-Membered%252BRings%26aulast%3DMeyer%26aufirst%3DAdam%2BG.%26date%3D2017%26spage%3D579%26epage%3D633%26pub%3DElsevier%26date%3D2017%26volume%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adriana  Soler</span>, <span class="hlFld-ContribAuthor ">Ana M.  Figueiredo</span>, <span class="hlFld-ContribAuthor ">Pau  Castel</span>, <span class="hlFld-ContribAuthor ">Laura  Martin</span>, <span class="hlFld-ContribAuthor ">Erika  Monelli</span>, <span class="hlFld-ContribAuthor ">Ana  Angulo-Urarte</span>, <span class="hlFld-ContribAuthor ">Maria  Milà-Guasch</span>, <span class="hlFld-ContribAuthor ">Francesc  Viñals</span>, <span class="hlFld-ContribAuthor ">Jose  Baselga</span>, <span class="hlFld-ContribAuthor ">Oriol  Casanovas</span>, <span class="hlFld-ContribAuthor ">Mariona  Graupera</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2016,</strong> <em>22 </em>
                                    (23)
                                     , 5805-5817. <a href="https://doi.org/10.1158/1078-0432.CCR-15-3051" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-15-3051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-15-3051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-15-3051%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DTherapeutic%252BBenefit%252Bof%252BSelective%252BInhibition%252Bof%252Bp110%2525CE%2525B1%252BPI3-Kinase%252Bin%252BPancreatic%252BNeuroendocrine%252BTumors%26aulast%3DSoler%26aufirst%3DAdriana%26date%3D2016%26date%3D2016%26volume%3D22%26issue%3D23%26spage%3D5805%26epage%3D5817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Di  Shang</span>, <span class="hlFld-ContribAuthor ">Juechen  Ni</span>, <span class="hlFld-ContribAuthor ">Xinyu  Gao</span>, <span class="hlFld-ContribAuthor ">Chengren  Li</span>, <span class="hlFld-ContribAuthor ">Xiaomeng  Lin</span>, <span class="hlFld-ContribAuthor ">Zhinan  Wang</span>, <span class="hlFld-ContribAuthor ">Ning  Du</span>, <span class="hlFld-ContribAuthor ">Shuang  Li</span>, <span class="hlFld-ContribAuthor ">Yongheng  Xing</span>. </span><span class="cited-content_cbyCitation_article-title">Various structures of complexes fabricated using transition metals and triazole ligands and their inhibition effects on xanthine luminescence. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2016,</strong> <em>40 </em>
                                    (9)
                                     , 8100-8109. <a href="https://doi.org/10.1039/C6NJ01503D" title="DOI URL">https://doi.org/10.1039/C6NJ01503D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6NJ01503D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6NJ01503D%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DVarious%252Bstructures%252Bof%252Bcomplexes%252Bfabricated%252Busing%252Btransition%252Bmetals%252Band%252Btriazole%252Bligands%252Band%252Btheir%252Binhibition%252Beffects%252Bon%252Bxanthine%252Bluminescence%26aulast%3DShang%26aufirst%3DDi%26date%3D2016%26date%3D2016%26volume%3D40%26issue%3D9%26spage%3D8100%26epage%3D8109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01483&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of clinical candidate inhibitors of class I PI3Ks, <b>1</b>; class I PI3Ks and mTOR kinase, <b>2</b>; class I PI3Ks with selectivity for PI3Kα relative to PI3Kβ, <b>3</b>; PI3Kα isoform selective, <b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01483&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Crystal structure of <b>5</b> in PI3Kα (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DXH">5DXH</a>). Probable hydrogen bond between Gln859 and backbone NH of Thr856 is labeled in red. Also indicated are the corresponding residues in the other Class I PI3K isoforms. (B) Overlay of A with the public crystal structure of PI3Kα (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RD0">2RD0</a>). (C) Structure, PI3Kα <i>K</i><sub>i,app</sub> and isoform selectivity of <b>5</b>, the PI3K inhibitor contained within crystal structure A.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01483&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01483&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) NIS, DMF; (b) <i>t</i>-BuONO<sub>2</sub>, TFA, MeOH; (c) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF; (d) LiHMDS, THF, −78 °C; (e) <b>19</b>, KHCO<sub>3</sub>, THF, H<sub>2</sub>O, reflux; (f) toluene, 130 °C; (g) NaH, DMF; (h) HBr, AcOH, 80 °C; (i) POCl<sub>3</sub>; (j) NaH, PhNTf<sub>2</sub>, NMP; (k) formamide 130 °C; (l) (i) <i>n</i>-BuLi, THF −15 °C, (ii) <b>20</b>, −70 °C.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01483&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Alcohol, PPh<sub>3</sub>, DIAD, THF or dioxane; (b) 7 N NH<sub>3</sub>, MeOH, 50 °C; (c) (i) LiOH·H<sub>2</sub>O, MeOH, H<sub>2</sub>O, 50 °C, (ii) NH<sub>4</sub>Cl, HATU, DMF, Et<sub>3</sub>N; (d) (i) NaH, DMF, PhNTf<sub>2</sub>, (ii) <span class="smallcaps smallerCapital">l</span>-prolinamide, 70–100 °C; (e) amine, Et<sub>3</sub>N, NMP, 150 °C; (f) (i) 3,4-methoxybenzylamine, NMP, 85 °C, (ii) TFA 40 °C; (g) (i) CH<sub>3</sub>HNCH<sub>2</sub>CO<sub>2</sub>CH<sub>3</sub>, NMP, 85 °C, (ii) 7 N NH<sub>3</sub>, MeOH, 50 °C.</p></p></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Docking model of <b>29</b> in PI3Kα. Compound <b>29</b> is predicted to form three concerted hydrogen bonds with the protein. A two-dimensional depiction of structure <b>29</b> is shown next to the docking model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01483&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0011.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01483&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) (i) amino acid, CuI, K<sub>3</sub>PO<sub>4</sub>, DMSO, 80–90 °C, (ii) NH<sub>4</sub>Cl, EDCI, HOBt, DIPEA, DMF, or NH<sub>4</sub>Cl, HATU, DMF, Et<sub>3</sub>N; (b) KOH, dioxane, water, Pd<sub>2</sub>dba<sub>3</sub>, 2-ditertbutylphosphino-2′,4′,6′-triisopropylbiphenyl, 90 °C; (c) (i) <i>t</i>-Bu-(<span class="smallcaps smallerCapital">d</span>)-lactate or <i>t</i>-Bu-(<i>R</i>)-2-hydroxybutyrate, PPh<sub>3</sub>, DIAD, THF, (ii) TFA, CH<sub>2</sub>Cl<sub>2</sub>, (iii) NH<sub>4</sub>Cl, HATU, DMF, Et<sub>3</sub>N; (d) 2-bromoacetamide, Cs<sub>2</sub>CO<sub>3</sub>, DMF; (e) (i) ethyl-(<span class="smallcaps smallerCapital">l</span>)-lactate, PPh<sub>3</sub>, DIAD, THF, (ii) LiOH·H<sub>2</sub>O, MeOH, H<sub>2</sub>O, 50 °C, (iii) NH<sub>4</sub>Cl, HATU, DMF, Et<sub>3</sub>N.</p></p></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Distributions of the observed torsion angles in the CSD database where −CH<sub>2</sub>– separates an amide and an aryl ether (A) or −CHMe– separates an amide and an aryl ether (B). Query structures of Mogul searches (setting: exact structures) are shown in inset with the torsional bond colored in red. The preferred angles are labeled by the red arrows. (C) Docking model <b>4</b> in PI3Kα. <b>4</b> is predicted to form three concerted hydrogen bonds with the protein. A two-dimensional depiction of <b>4</b> is shown next to the docking model. The dihedral angle along the C–O (colored in red) bond is 79°.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01483&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Crystal structures of <b>4</b> bound to PI3Kα (A; PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DXT">5DXT</a>) and PI3Kδ (B; PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DXU">5DXU</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01483&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Dose–response curves of fitted tumor volumes in response to <b>3</b> and <b>4</b> at the doses shown against MCF7-neo/HER2 (A) and KPL-4 (B) breast cancer xenografts in mice relative to vehicle (MCT; 0.5% methycellulose/0.2% Tween-80) after daily (QD) oral (PO) dosing for 21 days. Rx = treatment period.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01483&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0008.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Quantification of pAkt<sup>Ser473</sup> levels in MCF7-neo-HER2 tumor xenografts 1 h after a single dose of MCT vehicle (0.5% methycellulose/0.2% Tween-80), <b>3</b> at 25 mg/kg or <b>4</b> at 0.39, 0.78, 1.56, 3.25, 6.25, or 12.5 mg/kg. Phosphorylated Akt (pAkt<sup>Ser473</sup>) and total Akt (tAkt) levels were measured by Mesoscale Discovery assay, and values are expressed as ratio of pAkt/tAkt. Error bars represent SEM for tumor xenograft samples from four different animals. Corresponding unbound plasma drug concentrations (closed diamonds) for each dose of <b>3</b> or <b>4</b> are plotted on the right <i>y</i>-axis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01483&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/medium/jm-2015-01483r_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0012.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01483/20160205/images/large/jm-2015-01483r_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01483&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) K<sub>2</sub>CO<sub>3</sub>, BnBr, KI, acetone; (b) LiHMDS, THF, −78 °C; (c) <b>19</b>, KHCO<sub>3</sub>, THF, H<sub>2</sub>O; (d) 1,3-dioxolan-2-one, toluene, 100 °C; (e) NaH, DMF; (f) H<sub>2</sub>, Pd/C, EtOAc, IMS; (g) (<i>R</i>)-2-hydroxy-propionic acid methyl ester, PPh<sub>3</sub>, DIAD, dioxane; (h) 7 N NH<sub>3</sub>, MeOH.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i61">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78255" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78255" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 35 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Vivanco, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">The Phosphatidylinositol 3-Kinase-AKT Pathway in Human Cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">489</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span><span class="refDoi"> DOI: 10.1038/nrc839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1038%2Fnrc839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=12094235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=489-501&author=I.+Vivancoauthor=C.+L.+Sawyers&title=The+Phosphatidylinositol+3-Kinase-AKT+Pathway+in+Human+Cancer&doi=10.1038%2Fnrc839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphatidylinositol 3-Kinase-AKT pathway in human cancer</span></div><div class="casAuthors">Vivanco, Igor; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">489-501</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  One signal that is overactivated in a wide range of tumor types is the prodn. of a phospholipid, phosphatidylinositol (3,4,5) trisphosphate, by phosphatidylinositol 3-kinase (PI3K).  This lipid and the protein kinase that is activated by it, AKT, trigger a cascade of responses, from cell growth and proliferation to survival and motility, that drive tumor progression.  Small-mol. therapeutics that block PI3K signaling might deal a severe blow to cancer cells by blocking many aspects of the tumor-cell phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzAQ-0qeD7pLVg90H21EOLACvtfcHk0lgsDZacVVfz8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKltLs%253D&md5=c6762d32f9f1281632f4ccdbcd29268c</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1038%2Fnrc839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc839%26sid%3Dliteratum%253Aachs%26aulast%3DVivanco%26aufirst%3DI.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DThe%2520Phosphatidylinositol%25203-Kinase-AKT%2520Pathway%2520in%2520Human%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26spage%3D489%26epage%3D501%26doi%3D10.1038%2Fnrc839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Cantley, L. C.</span><span> </span><span class="NLM_article-title">The Phosphoinositide 3-Kinase Pathway</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">296</span><span class="NLM_x">, </span> <span class="NLM_fpage">1655</span><span class="NLM_x">–</span> <span class="NLM_lpage">1657</span><span class="refDoi"> DOI: 10.1126/science.296.5573.1655</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1126%2Fscience.296.5573.1655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=12040186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlChu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2002&pages=1655-1657&author=L.+C.+Cantley&title=The+Phosphoinositide+3-Kinase+Pathway&doi=10.1126%2Fscience.296.5573.1655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphoinositide 3-kinase pathway</span></div><div class="casAuthors">Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">5573</span>),
    <span class="NLM_cas:pages">1655-1657</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review with 8 refs.  Phosphorylated lipids are produced at cellular membranes during signaling events and contribute to the recruitment and activation of various signaling components.  The role of phosphoinositide 3-kinase (PI3K), which catalyzes the prodn. of phosphatidylinositol 3,4,5-trisphosphate, in cell survival pathways; the regulation of gene expression and cell metab.; and cytoskeletal rearrangements are highlighted.  The PI3K pathway is implicated in human diseases including diabetes and cancer, and understanding the intricacies of this pathway may provide new avenues for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9pxSplxmS1rVg90H21EOLACvtfcHk0lgsDZacVVfz8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlChu7s%253D&md5=110c8a351448aed6ab938b9ccf90a655</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1126%2Fscience.296.5573.1655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.296.5573.1655%26sid%3Dliteratum%253Aachs%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DThe%2520Phosphoinositide%25203-Kinase%2520Pathway%26jtitle%3DScience%26date%3D2002%26volume%3D296%26spage%3D1655%26epage%3D1657%26doi%3D10.1126%2Fscience.296.5573.1655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Guertin, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabatini, D. M.</span><span> </span><span class="NLM_article-title">Defining the Role of mTOR in Cancer</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span><span class="refDoi"> DOI: 10.1016/j.ccr.2007.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.ccr.2007.05.008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=9-22&author=D.+A.+Guertinauthor=D.+M.+Sabatini&title=Defining+the+Role+of+mTOR+in+Cancer&doi=10.1016%2Fj.ccr.2007.05.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2007.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2007.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DGuertin%26aufirst%3DD.%2BA.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DDefining%2520the%2520Role%2520of%2520mTOR%2520in%2520Cancer%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D12%26spage%3D9%26epage%3D22%26doi%3D10.1016%2Fj.ccr.2007.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Fasolo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sessa, C.</span><span> </span><span class="NLM_article-title">mTOR Inhibitors in the Treatment of Cancer</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1717</span><span class="NLM_x">–</span> <span class="NLM_lpage">1734</span><span class="refDoi"> DOI: 10.1517/13543784.17.11.1717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1517%2F13543784.17.11.1717" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2008&pages=1717-1734&author=A.+Fasoloauthor=C.+Sessa&title=mTOR+Inhibitors+in+the+Treatment+of+Cancer&doi=10.1517%2F13543784.17.11.1717"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1d&amp;dbid=16384&amp;doi=10.1517%2F13543784.17.11.1717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.17.11.1717%26sid%3Dliteratum%253Aachs%26aulast%3DFasolo%26aufirst%3DA.%26aulast%3DSessa%26aufirst%3DC.%26atitle%3DmTOR%2520Inhibitors%2520in%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2008%26volume%3D17%26spage%3D1717%26epage%3D1734%26doi%3D10.1517%2F13543784.17.11.1717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Bellacosa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Cristofano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testa, J. R.</span><span> </span><span class="NLM_article-title">Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting</span> <span class="citation_source-journal">Adv. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">86</span><span class="refDoi"> DOI: 10.1016/S0065-230X(05)94002-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2FS0065-230X%2805%2994002-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=16095999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD28Xot1elur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2005&pages=29-86&author=A.+Bellacosaauthor=C.+C.+Kumarauthor=A.+Di+Cristofanoauthor=J.+R.+Testa&title=Activation+of+AKT+Kinases+in+Cancer%3A+Implications+for+Therapeutic+Targeting&doi=10.1016%2FS0065-230X%2805%2994002-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1eR"><div class="casContent"><span class="casTitleNuber">1e</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of AKT kinases in cancer: implications for therapeutic targeting</span></div><div class="casAuthors">Bellacosa, Alfonso; Kumar, C. Chandra; Di Cristofano, Antonio; Testa, Joseph Robert</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29-86</span>CODEN:
                <span class="NLM_cas:coden">ACRSAJ</span>;
        ISSN:<span class="NLM_cas:issn">0065-230X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The AKT1, AKT2, and AKT3 kinases have emerged as crit. mediators of signal transduction pathways downstream of activated tyrosine kinases and phosphatidylinositol 3-kinase.  An ever-increasing list of AKT substrates has precisely defined the multiple functions of this kinase family in normal physiol. and disease states.  Cellular processes regulated by AKT include cell proliferation and survival, cell size and response to nutrient availability, intermediary metab., angiogenesis, and tissue invasion.  All these processes represent hallmarks of cancer, and a burgeoning literature has defined the importance of AKT alterations in human cancer and exptl. models of tumorigenesis, continuing the legacy represented by the original identification of v-Akt as the transforming oncogene of a murine retrovirus.  Many oncoproteins and tumor suppressors intersect in the AKT pathway, finely regulating cellular functions at the interface of signal transduction and classical metabolic regulation.  This careful balance is altered in human cancer by a variety of activating and inactivating mechanisms that target both AKT and interrelated proteins.  Reprogramming of this altered circuitry by pharmacol. modulation of the AKT pathway represents a powerful strategy for rational cancer therapy.  In this review, we summarize a large body of data, from many types of cancer, indicating that AKT activation is one of the most common mol. alterations in human malignancy.  We also review mechanisms of activation of AKT kinases, examples of therapeutic modulation of the AKT pathway in animal models, and the current status of efforts to target mol. components of the AKT pathway for cancer therapy and, possibly, cancer prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbtUdzglK927Vg90H21EOLACvtfcHk0lhST0ZbCHy7jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xot1elur4%253D&md5=556e3c5787e0179786db3cb2e2f1dcf6</span></div><a href="/servlet/linkout?suffix=cit1e&amp;dbid=16384&amp;doi=10.1016%2FS0065-230X%2805%2994002-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-230X%252805%252994002-5%26sid%3Dliteratum%253Aachs%26aulast%3DBellacosa%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DC.%2BC.%26aulast%3DDi%2BCristofano%26aufirst%3DA.%26aulast%3DTesta%26aufirst%3DJ.%2BR.%26atitle%3DActivation%2520of%2520AKT%2520Kinases%2520in%2520Cancer%253A%2520Implications%2520for%2520Therapeutic%2520Targeting%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D2005%26volume%3D94%26spage%3D29%26epage%3D86%26doi%3D10.1016%2FS0065-230X%2805%2994002-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Ihle, N. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powis, G.</span><span> </span><span class="NLM_article-title">Take Your PIK: Phosphatidylinositol 3-Kinase Inhibitors Race Through the Clinic Toward Cancer Therapy</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-08-0801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1158%2F1535-7163.MCT-08-0801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=19139107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjvFSntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=1-9&author=N.+T.+Ihleauthor=G.+Powis&title=Take+Your+PIK%3A+Phosphatidylinositol+3-Kinase+Inhibitors+Race+Through+the+Clinic+Toward+Cancer+Therapy&doi=10.1158%2F1535-7163.MCT-08-0801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1fR"><div class="casContent"><span class="casTitleNuber">1f</span><div class="casTitle"><span class="NLM_cas:atitle">Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy</span></div><div class="casAuthors">Ihle, Nathan T.; Powis, Garth</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-9</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway is currently one of the most exciting drug targets in oncol.  However, only a short time ago, the paradigm existed that drugs targeted to the four PI3K class I isoforms would be too toxic for use in cancer therapy due to effects on physiol. signaling.  Since that time, studies have delineated the roles of these four isoforms in nonpathol. signaling as well as their roles in cancer.  An extensive effort has gone into developing agents that inhibit one or more PI3K isoforms, as well as closely related proteins implicated in cancer.  These agents have proved to be tolerable and therapeutically beneficial in animal studies, and a no. are in clin. testing.  The agents, their properties, and their mol. targets are discussed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtwozBC-h437Vg90H21EOLACvtfcHk0lhST0ZbCHy7jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjvFSntA%253D%253D&md5=4bc339da7fdd1dc74e13eadf76ae53ce</span></div><a href="/servlet/linkout?suffix=cit1f&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0801%26sid%3Dliteratum%253Aachs%26aulast%3DIhle%26aufirst%3DN.%2BT.%26aulast%3DPowis%26aufirst%3DG.%26atitle%3DTake%2520Your%2520PIK%253A%2520Phosphatidylinositol%25203-Kinase%2520Inhibitors%2520Race%2520Through%2520the%2520Clinic%2520Toward%2520Cancer%2520Therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D1%26epage%3D9%26doi%3D10.1158%2F1535-7163.MCT-08-0801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J. J.</span><span> </span><span class="NLM_article-title">Targeting the Phosphoinositide 3-Kinase Pathway in Cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">627</span><span class="NLM_x">–</span> <span class="NLM_lpage">644</span><span class="refDoi"> DOI: 10.1038/nrd2926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1038%2Fnrd2926" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=19644473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=627-644&author=P.+Liuauthor=H.+Chengauthor=T.+M.+Robertsauthor=J.+J.+Zhao&title=Targeting+the+Phosphoinositide+3-Kinase+Pathway+in+Cancer&doi=10.1038%2Fnrd2926"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1gR"><div class="casContent"><span class="casTitleNuber">1g</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the phosphoinositide 3-kinase pathway in cancer</span></div><div class="casAuthors">Liu, Pixu; Cheng, Hailing; Roberts, Thomas M.; Zhao, Jean J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">627-644</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The phosphoinositide 3-kinase (PI3K) pathway is a key signal transduction system that links oncogenes and multiple receptor classes to many essential cellular functions, and is perhaps the most commonly activated signalling pathway in human cancer.  This pathway therefore presents both an opportunity and a challenge for cancer therapy.  Even as inhibitors that target PI3K isoforms and other major nodes in the pathway, including AKT and mammalian target of rapamycin (mTOR), reach clin. trials, major issues remain.  Here, we highlight recent progress that has been made in our understanding of the PI3K pathway and discuss the potential of and challenges for the development of therapeutic agents that target this pathway in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUk9T-ZoNDtLVg90H21EOLACvtfcHk0lhST0ZbCHy7jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D&md5=fdc94abd15178a9dbe7c56dafbfb7787</span></div><a href="/servlet/linkout?suffix=cit1g&amp;dbid=16384&amp;doi=10.1038%2Fnrd2926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2926%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26atitle%3DTargeting%2520the%2520Phosphoinositide%25203-Kinase%2520Pathway%2520in%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D627%26epage%3D644%26doi%3D10.1038%2Fnrd2926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Jackson, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoenwaelder, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goncalves, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nesbitt, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenche, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dopheide, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sturgeon, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prabaharan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniele, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulkarni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbott, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saylik, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughan, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angus, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salem, H. H.</span><span> </span><span class="NLM_article-title">PI 3-kinase p110β: a new target for antithrombotic therapy</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">507</span><span class="NLM_x">–</span> <span class="NLM_lpage">514</span><span class="refDoi"> DOI: 10.1038/nm1232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1038%2Fnm1232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=15834429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVOlsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=507-514&author=S.+P.+Jacksonauthor=S.+M.+Schoenwaelderauthor=I.+Goncalvesauthor=W.+S.+Nesbittauthor=C.+L.+Yapauthor=C.+E.+Wrightauthor=V.+Kencheauthor=K.+E.+Andersonauthor=S.+M.+Dopheideauthor=Y.+Yuanauthor=S.+A.+Sturgeonauthor=H.+Prabaharanauthor=P.+E.+Thompsonauthor=G.+D.+Smithauthor=P.+R.+Shepherdauthor=N.+Danieleauthor=S.+Kulkarniauthor=B.+Abbottauthor=D.+Saylikauthor=C.+Jonesauthor=L.+Luauthor=S.+Giulianoauthor=S.+C.+Hughanauthor=J.+A.+Angusauthor=A.+D.+Robertsonauthor=H.+H.+Salem&title=PI+3-kinase+p110%CE%B2%3A+a+new+target+for+antithrombotic+therapy&doi=10.1038%2Fnm1232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">PI 3-kinase p110β: a new target for antithrombotic therapy</span></div><div class="casAuthors">Jackson, Shaun P.; Schoenwaelder, Simone M.; Goncalves, Isaac; Nesbitt, Warwick S.; Yap, Cindy L.; Wright, Christine E.; Kenche, Vijaya; Anderson, Karen E.; Dopheide, Sacha M.; Yuan, Yuping; Sturgeon, Sharelle A.; Prabaharan, Hishani; Thompson, Philip E.; Smith, Gregg D.; Shepherd, Peter R.; Daniele, Nathalie; Kulkarni, Suhasini; Abbott, Belinda; Saylik, Dilek; Jones, Catherine; Lu, Lucy; Giuliano, Simon; Hughan, Sascha C.; Angus, James A.; Robertson, Alan D.; Salem, Hatem H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">507-514</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Platelet activation at sites of vascular injury is essential for the arrest of bleeding; however, excessive platelet accumulation at regions of atherosclerotic plaque rupture can result in the development of arterial thrombi, pptg. diseases such as acute myocardial infarction and ischemic stroke.  Rheol. disturbances (high shear stress) have an important role in promoting arterial thrombosis by enhancing the adhesive and signaling function of platelet integrin αIIbβ3 (GPIIb-IIIa).  In this study we have defined a key role for the Type Ia phosphoinositide 3-kinase (PI3K) p110β isoform in regulating the formation and stability of integrin αIIbβ3 adhesion bonds, necessary for shear activation of platelets.  Isoform-selective PI3K p110β inhibitors have been developed which prevent formation of stable integrin αIIbβ3 adhesion contacts, leading to defective platelet thrombus formation.  In vivo, these inhibitors eliminate occlusive thrombus formation but do not prolong bleeding time.  These studies define PI3K p110β as an important new target for antithrombotic therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYYnYolzsDrrVg90H21EOLACvtfcHk0lir1WqxhV0DSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVOlsrk%253D&md5=c8dc7ba1955e86104ae913d39f22674b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnm1232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1232%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DS.%2BP.%26aulast%3DSchoenwaelder%26aufirst%3DS.%2BM.%26aulast%3DGoncalves%26aufirst%3DI.%26aulast%3DNesbitt%26aufirst%3DW.%2BS.%26aulast%3DYap%26aufirst%3DC.%2BL.%26aulast%3DWright%26aufirst%3DC.%2BE.%26aulast%3DKenche%26aufirst%3DV.%26aulast%3DAnderson%26aufirst%3DK.%2BE.%26aulast%3DDopheide%26aufirst%3DS.%2BM.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DSturgeon%26aufirst%3DS.%2BA.%26aulast%3DPrabaharan%26aufirst%3DH.%26aulast%3DThompson%26aufirst%3DP.%2BE.%26aulast%3DSmith%26aufirst%3DG.%2BD.%26aulast%3DShepherd%26aufirst%3DP.%2BR.%26aulast%3DDaniele%26aufirst%3DN.%26aulast%3DKulkarni%26aufirst%3DS.%26aulast%3DAbbott%26aufirst%3DB.%26aulast%3DSaylik%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DGiuliano%26aufirst%3DS.%26aulast%3DHughan%26aufirst%3DS.%2BC.%26aulast%3DAngus%26aufirst%3DJ.%2BA.%26aulast%3DRobertson%26aufirst%3DA.%2BD.%26aulast%3DSalem%26aufirst%3DH.%2BH.%26atitle%3DPI%25203-kinase%2520p110%25CE%25B2%253A%2520a%2520new%2520target%2520for%2520antithrombotic%2520therapy%26jtitle%3DNat.%2520Med.%26date%3D2005%26volume%3D11%26spage%3D507%26epage%3D514%26doi%3D10.1038%2Fnm1232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Wee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiederschain, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maira, S.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">deBeaumont, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stegmeier, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lengauer, C.</span><span> </span><span class="NLM_article-title">PTEN-Deficient Cancers Depend on PIK3CB</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">13057</span><span class="NLM_x">–</span> <span class="NLM_lpage">13062</span><span class="refDoi"> DOI: 10.1073/pnas.0802655105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1073%2Fpnas.0802655105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=18755892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFSitbrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=13057-13062&author=S.+Weeauthor=D.+Wiederschainauthor=S.-M.+Mairaauthor=A.+Looauthor=C.+Millerauthor=R.+deBeaumontauthor=F.+Stegmeierauthor=Y.-M.+Yaoauthor=C.+Lengauer&title=PTEN-Deficient+Cancers+Depend+on+PIK3CB&doi=10.1073%2Fpnas.0802655105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">PTEN-deficient cancers depend on PIK3CB</span></div><div class="casAuthors">Wee, Susan; Wiederschain, Dmitri; Maira, Sauveur-Michel; Loo, Alice; Miller, Christine; de Beaumont, Rosalie; Stegmeier, Frank; Yao, Yung-Mae; Lengauer, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">13057-13062</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Deregulation of the PI3K signaling pathway is obsd. in many human cancers and occurs most frequently through loss of PTEN phosphatase tumor suppressor function or through somatic activating mutations in the Class IA PI3K, PIK3CA.  Tumors harboring activated p110α, the protein product of PIK3CA, require p110α activity for growth and survival and hence are expected to be responsive to inhibitors of its lipid kinase activity.  Whether PTEN-deficient cancers similarly depend on p110α activity to sustain activation of the PI3K pathway has been unclear.  In this study, we used a single-vector lentiviral inducible shRNA system to selectively inactivate the three Class IA PI3Ks, PIK3CA, PIK3CB, and PIK3CD, to det. which PI3K isoforms are responsible for driving the abnormal proliferation of PTEN-deficient cancers.  Down-regulation of PIK3CA in colorectal cancer cells harboring mutations in PIK3CA inhibited downstream PI3K signaling and cell growth.  Surprisingly, PIK3CA depletion affected neither PI3K signaling nor cell growth in 3 PTEN-deficient cancer cell lines.  In contrast, down-regulation of the PIK3CB isoform, which encodes p110β, resulted in pathway inactivation and subsequent inhibition of growth in both cell-based and in vivo settings.  This essential function of PIK3CB in PTEN-deficient cancer cells required its lipid kinase activity.  Our findings demonstrate that although p110α activation is required to sustain the proliferation of established PIK3CA-mutant tumors, PTEN-deficient tumors are dependent instead on p110β signaling.  This unexpected finding demonstrates the need to tailor therapeutic approaches to the genetic basis of PI3K pathway activation to achieve optimal treatment response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5ybGsv3DVCrVg90H21EOLACvtfcHk0lir1WqxhV0DSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFSitbrO&md5=b7c690d3631ac6cbee9d7d7414dae1da</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0802655105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0802655105%26sid%3Dliteratum%253Aachs%26aulast%3DWee%26aufirst%3DS.%26aulast%3DWiederschain%26aufirst%3DD.%26aulast%3DMaira%26aufirst%3DS.-M.%26aulast%3DLoo%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DC.%26aulast%3DdeBeaumont%26aufirst%3DR.%26aulast%3DStegmeier%26aufirst%3DF.%26aulast%3DYao%26aufirst%3DY.-M.%26aulast%3DLengauer%26aufirst%3DC.%26atitle%3DPTEN-Deficient%2520Cancers%2520Depend%2520on%2520PIK3CB%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D13057%26epage%3D13062%26doi%3D10.1073%2Fpnas.0802655105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hancox, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosulich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trigwell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenaghan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellston, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dry, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crafter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlaam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Cruz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castriotta, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedge, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrington, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cumberbatch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, S. T.</span><span> </span><span class="NLM_article-title">Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">48</span><span class="NLM_x">–</span> <span class="NLM_lpage">58</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0406</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1158%2F1535-7163.MCT-14-0406" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=25398829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslWksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=48-58&author=U.+Hancoxauthor=S.+Cosulichauthor=L.+Hansonauthor=C.+Trigwellauthor=C.+Lenaghanauthor=R.+Ellstonauthor=H.+Dryauthor=C.+Crafterauthor=B.+Barlaamauthor=M.+Fitzekauthor=P.+D.+Smithauthor=D.+Ogilvieauthor=C.+D%E2%80%99Cruzauthor=L.+Castriottaauthor=S.+R.+Wedgeauthor=L.+Wardauthor=S.+Powellauthor=M.+Lawsonauthor=B.+R.+Daviesauthor=E.+A.+Harringtonauthor=E.+Fosterauthor=M.+Cumberbatchauthor=S.+Greenauthor=S.+T.+Barry&title=Inhibition+of+PI3K%CE%B2+signaling+with+AZD8186+inhibits+growth+of+PTEN-deficient+breast+and+prostate+tumors+alone+and+in+combination+with+docetaxel&doi=10.1158%2F1535-7163.MCT-14-0406"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel</span></div><div class="casAuthors">Hancox, Urs; Cosulich, Sabina; Hanson, Lyndsey; Trigwell, Cath; Lenaghan, Carol; Ellston, Rebecca; Dry, Hannah; Crafter, Claire; Barlaam, Bernard; Fitzek, Martina; Smith, Paul D.; Ogilvie, Donald; D'Cruz, Celina; Castriotta, Lillian; Wedge, Stephen R.; Ward, Lara; Powell, Steve; Lawson, Mandy; Davies, Barry R.; Harrington, Elizabeth A.; Foster, Emily; Cumberbatch, Marie; Green, Stephen; Barry, Simon T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-58</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Loss of PTEN protein results in upregulation of the PI3K/AKT pathway, which appears dependent on the PI3Kβ isoform.  Inhibitors of PI3Kβ have potential to reduce growth of tumors in which loss of PTEN drives tumor progression.  We have developed a small-mol. inhibitor of PI3Kβ and PI3Kδ (AZD8186) and assessed its antitumor activity across a panel of cell lines.  We have then explored the antitumor effects as single agent and in combination with docetaxel in triple-neg. breast (TNBC) and prostate cancer models.  In vitro, AZD8186 inhibited growth of a range of cell lines.  Sensitivity was assocd. with inhibition of the AKT pathway.  Cells sensitive to AZD8186 (GI50 < 1 μmol/L) are enriched for, but not exclusively assocd. with, PTEN deficiency.  In vivo, AZD8186 inhibits PI3K pathway biomarkers in prostate and TNBC tumors.  Scheduling treatment with AZD8186 shows antitumor activity required only intermittent exposure, and that increased tumor control is achieved when AZD8186 is used in combination with docetaxel.  AZD8186 is a potent inhibitor of PI3Kβ with activity against PI3Kδ signaling, and has potential to reduce growth of tumors dependent on dysregulated PTEN for growth.  Moreover, AZD8186 can be combined with docetaxel, a chemotherapy commonly used to treat advanced TBNC and prostate tumors.  The ability to schedule AZD8186 and maintain efficacy offers opportunity to combine AZD8186 more effectively with other drugs.  Mol Cancer Ther; 14(1); 48-58. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2CTPle3Nb1bVg90H21EOLACvtfcHk0lir1WqxhV0DSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslWksQ%253D%253D&md5=0519e40a6a4e9458ad73336bd5764e2c</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0406&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0406%26sid%3Dliteratum%253Aachs%26aulast%3DHancox%26aufirst%3DU.%26aulast%3DCosulich%26aufirst%3DS.%26aulast%3DHanson%26aufirst%3DL.%26aulast%3DTrigwell%26aufirst%3DC.%26aulast%3DLenaghan%26aufirst%3DC.%26aulast%3DEllston%26aufirst%3DR.%26aulast%3DDry%26aufirst%3DH.%26aulast%3DCrafter%26aufirst%3DC.%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DFitzek%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26aulast%3DOgilvie%26aufirst%3DD.%26aulast%3DD%25E2%2580%2599Cruz%26aufirst%3DC.%26aulast%3DCastriotta%26aufirst%3DL.%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DWard%26aufirst%3DL.%26aulast%3DPowell%26aufirst%3DS.%26aulast%3DLawson%26aufirst%3DM.%26aulast%3DDavies%26aufirst%3DB.%2BR.%26aulast%3DHarrington%26aufirst%3DE.%2BA.%26aulast%3DFoster%26aufirst%3DE.%26aulast%3DCumberbatch%26aufirst%3DM.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DBarry%26aufirst%3DS.%2BT.%26atitle%3DInhibition%2520of%2520PI3K%25CE%25B2%2520signaling%2520with%2520AZD8186%2520inhibits%2520growth%2520of%2520PTEN-deficient%2520breast%2520and%2520prostate%2520tumors%2520alone%2520and%2520in%2520combination%2520with%2520docetaxel%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D48%26epage%3D58%26doi%3D10.1158%2F1535-7163.MCT-14-0406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Barlaam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosulich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degorce, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancox, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert-van der Brempt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohmann, J.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maudet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgentin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquet, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Péru, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plé, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saleh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vautier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warin, N.</span><span> </span><span class="NLM_article-title">Discovery of (R)-8-(1-(3,5-Difluorophenylamino)ethyl)-N,N-dimethyl-2-mopholino-4-oxo-4<i>H</i>-chromene-6-carboxamide (AZD8186): A Potent and Selective Inhibitor of PI3Kβ and PI3Kδ for the Treatment of PTEN-Deficient Cancers</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">943</span><span class="NLM_x">–</span> <span class="NLM_lpage">962</span><span class="refDoi"> DOI: 10.1021/jm501629p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501629p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=943-962&author=B.+Barlaamauthor=S.+Cosulichauthor=S.+Degorceauthor=M.+Fitzekauthor=S.+Greenauthor=U.+Hancoxauthor=C.+Lambert-van+der+Bremptauthor=J.-J.+Lohmannauthor=M.+Maudetauthor=R.+Morgentinauthor=M.-J.+Pasquetauthor=A.+P%C3%A9ruauthor=P.+Pl%C3%A9author=T.+Salehauthor=M.+Vautierauthor=M.+Walkerauthor=L.+Wardauthor=N.+Warin&title=Discovery+of+%28R%29-8-%281-%283%2C5-Difluorophenylamino%29ethyl%29-N%2CN-dimethyl-2-mopholino-4-oxo-4H-chromene-6-carboxamide+%28AZD8186%29%3A+A+Potent+and+Selective+Inhibitor+of+PI3K%CE%B2+and+PI3K%CE%B4+for+the+Treatment+of+PTEN-Deficient+Cancers&doi=10.1021%2Fjm501629p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1021%2Fjm501629p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501629p%26sid%3Dliteratum%253Aachs%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DCosulich%26aufirst%3DS.%26aulast%3DDegorce%26aufirst%3DS.%26aulast%3DFitzek%26aufirst%3DM.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DHancox%26aufirst%3DU.%26aulast%3DLambert-van%2Bder%2BBrempt%26aufirst%3DC.%26aulast%3DLohmann%26aufirst%3DJ.-J.%26aulast%3DMaudet%26aufirst%3DM.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DPasquet%26aufirst%3DM.-J.%26aulast%3DP%25C3%25A9ru%26aufirst%3DA.%26aulast%3DPl%25C3%25A9%26aufirst%3DP.%26aulast%3DSaleh%26aufirst%3DT.%26aulast%3DVautier%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DM.%26aulast%3DWard%26aufirst%3DL.%26aulast%3DWarin%26aufirst%3DN.%26atitle%3DDiscovery%2520of%2520%2528R%2529-8-%25281-%25283%252C5-Difluorophenylamino%2529ethyl%2529-N%252CN-dimethyl-2-mopholino-4-oxo-4H-chromene-6-carboxamide%2520%2528AZD8186%2529%253A%2520A%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520PI3K%25CE%25B2%2520and%2520PI3K%25CE%25B4%2520for%2520the%2520Treatment%2520of%2520PTEN-Deficient%2520Cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D943%26epage%3D962%26doi%3D10.1021%2Fjm501629p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Bedard, P. L.; Davies, M. A.; Kopetz, S.; Flaherty, K. T.; Shapiro, G.; Luke, J. J.; Spreafico, A.; Wu, B.; Gomez, C.; Cartot-Cotton, S.; Mazuir, F.; Micallef, S.; Demers, B.; Juric, D.</span><span> </span><span class="NLM_article-title">First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737)</span>.  <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span>, <span class="NLM_issue">suppl</span>; abstract  <span class="NLM_fpage">2564</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=2564&issue=suppl&author=P.+L.+Bedard&author=M.+A.+Davies&author=S.+Kopetz&author=K.+T.+Flaherty&author=G.+Shapiro&author=J.+J.+Luke&author=A.+Spreafico&author=B.+Wu&author=C.+Gomez&author=S.+Cartot-Cotton&author=F.+Mazuir&author=S.+Micallef&author=B.+Demers&author=D.+Juric&title=First-in-human+trial+of+the+PI3K%CE%B2-selective+inhibitor+SAR260301+in+patients+with+advanced+solid+tumors+%28NCT01673737%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBedard%26aufirst%3DP.%2BL.%26atitle%3DFirst-in-human%2520trial%2520of%2520the%2520PI3K%25CE%25B2-selective%2520inhibitor%2520SAR260301%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%2520%2528NCT01673737%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26issue%3Dsuppl%26spage%3D2564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Arkenau, H.-T.; Mateo, J.; Lemech, C. R.; Infante, J. R.; Burris, H. A.; Bang, Y.-J.; Eder, J. P.; Herbst, R. S.; Sharma, S.; Motwani, M.; Kumar, R.; De Bono, J. S.</span><span> </span><span class="NLM_article-title">A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors</span>.  <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span>, <span class="NLM_issue">suppl</span>; abstract  <span class="NLM_fpage">2514</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=25002718" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=2514&issue=suppl&author=H.-T.+Arkenau&author=J.+Mateo&author=C.+R.+Lemech&author=J.+R.+Infante&author=H.+A.+Burris&author=Y.-J.+Bang&author=J.+P.+Eder&author=R.+S.+Herbst&author=S.+Sharma&author=M.+Motwani&author=R.+Kumar&author=J.+S.+De+Bono&title=A+phase+I%2FII%2C+first-in-human+dose-escalation+study+of+GSK2636771+in+patients+%28pts%29+with+PTEN-deficient+advanced+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DArkenau%26aufirst%3DH.-T.%26atitle%3DA%2520phase%2520I%252FII%252C%2520first-in-human%2520dose-escalation%2520study%2520of%2520GSK2636771%2520in%2520patients%2520%2528pts%2529%2520with%2520PTEN-deficient%2520advanced%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26issue%3Dsuppl%26spage%3D2514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sadhu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dick, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tino, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staunton, D. E.</span><span> </span><span class="NLM_article-title">Selective Role of PI3Kδ in Neutrophil Inflammatory Responses</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">308</span><span class="NLM_x">, </span> <span class="NLM_fpage">764</span><span class="NLM_x">–</span> <span class="NLM_lpage">769</span><span class="refDoi"> DOI: 10.1016/S0006-291X(03)01480-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2FS0006-291X%2803%2901480-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2003&pages=764-769&author=C.+Sadhuauthor=K.+Dickauthor=W.+T.+Tinoauthor=D.+E.+Staunton&title=Selective+Role+of+PI3K%CE%B4+in+Neutrophil+Inflammatory+Responses&doi=10.1016%2FS0006-291X%2803%2901480-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1016%2FS0006-291X%2803%2901480-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-291X%252803%252901480-3%26sid%3Dliteratum%253Aachs%26aulast%3DSadhu%26aufirst%3DC.%26aulast%3DDick%26aufirst%3DK.%26aulast%3DTino%26aufirst%3DW.%2BT.%26aulast%3DStaunton%26aufirst%3DD.%2BE.%26atitle%3DSelective%2520Role%2520of%2520PI3K%25CE%25B4%2520in%2520Neutrophil%2520Inflammatory%2520Responses%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2003%26volume%3D308%26spage%3D764%26epage%3D769%26doi%3D10.1016%2FS0006-291X%2803%2901480-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sadhu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masinovsky, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dick, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sowell, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staunton, D. E.</span><span> </span><span class="NLM_article-title">Essential Role of Phosphoinositide 3-Kinase δ in Neutrophil Directional Movement</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">170</span><span class="NLM_x">, </span> <span class="NLM_fpage">2647</span><span class="NLM_x">–</span> <span class="NLM_lpage">2654</span><span class="refDoi"> DOI: 10.4049/jimmunol.170.5.2647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.4049%2Fjimmunol.170.5.2647" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2003&pages=2647-2654&author=C.+Sadhuauthor=B.+Masinovskyauthor=K.+Dickauthor=C.+G.+Sowellauthor=D.+E.+Staunton&title=Essential+Role+of+Phosphoinositide+3-Kinase+%CE%B4+in+Neutrophil+Directional+Movement&doi=10.4049%2Fjimmunol.170.5.2647"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.170.5.2647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.170.5.2647%26sid%3Dliteratum%253Aachs%26aulast%3DSadhu%26aufirst%3DC.%26aulast%3DMasinovsky%26aufirst%3DB.%26aulast%3DDick%26aufirst%3DK.%26aulast%3DSowell%26aufirst%3DC.%2BG.%26aulast%3DStaunton%26aufirst%3DD.%2BE.%26atitle%3DEssential%2520Role%2520of%2520Phosphoinositide%25203-Kinase%2520%25CE%25B4%2520in%2520Neutrophil%2520Directional%2520Movement%26jtitle%3DJ.%2520Immunol.%26date%3D2003%26volume%3D170%26spage%3D2647%26epage%3D2654%26doi%3D10.4049%2Fjimmunol.170.5.2647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Fruman, D. A.</span><span> </span><span class="NLM_article-title">Phosphoinositide 3-Kinase and its Targets in B-cell and T-cell Signaling</span> <span class="citation_source-journal">Curr. Opin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">–</span> <span class="NLM_lpage">320</span><span class="refDoi"> DOI: 10.1016/j.coi.2004.03.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.coi.2004.03.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=15134780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvVamtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2004&pages=314-320&author=D.+A.+Fruman&title=Phosphoinositide+3-Kinase+and+its+Targets+in+B-cell+and+T-cell+Signaling&doi=10.1016%2Fj.coi.2004.03.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5cR"><div class="casContent"><span class="casTitleNuber">5c</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide 3-kinase and its targets in B-cell and T-cell signaling</span></div><div class="casAuthors">Fruman, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">314-320</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Phosphoinositide 3-kinase (PI3K) activation is essential for lymphocyte proliferation driven by receptors for antigen, costimulatory ligands and cytokines.  The lipid products of PI3K contribute to the assembly of membrane-assocd. signaling complexes by promoting recruitment of selected proteins from the cytoplasm.  Many proteins possess domains that are able to bind selectively to PI3K products.  Different 'PI3K effector' proteins are coupled to distinct biol. responses, depending on cell type and on the receptor that is engaged.  In B cells and T cells, Tec-family tyrosine kinases and Akt serine/threonine kinases are emerging as crucial mediators of proliferation and survival signals downstream of PI3K.  Of particular interest is recent evidence that PI3K signaling controls increases in lymphocyte size and metabolic activity that accompany cell cycle progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnOMRHTLdWzbVg90H21EOLACvtfcHk0lggHtDVJTsPHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvVamtr4%253D&md5=18b4b46533f2d49312f123a4c72915b8</span></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1016%2Fj.coi.2004.03.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coi.2004.03.014%26sid%3Dliteratum%253Aachs%26aulast%3DFruman%26aufirst%3DD.%2BA.%26atitle%3DPhosphoinositide%25203-Kinase%2520and%2520its%2520Targets%2520in%2520B-cell%2520and%2520T-cell%2520Signaling%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D2004%26volume%3D16%26spage%3D314%26epage%3D320%26doi%3D10.1016%2Fj.coi.2004.03.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Okkenhaug, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanhaesebroeck, B.</span><span> </span><span class="NLM_article-title">PI3K in Lymphocyte Development, Differentiation, and Activation</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">317</span><span class="NLM_x">–</span> <span class="NLM_lpage">330</span><span class="refDoi"> DOI: 10.1038/nri1056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1038%2Fnri1056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=12669022" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisFWku70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=317-330&author=K.+Okkenhaugauthor=B.+Vanhaesebroeck&title=PI3K+in+Lymphocyte+Development%2C+Differentiation%2C+and+Activation&doi=10.1038%2Fnri1056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5dR"><div class="casContent"><span class="casTitleNuber">5d</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K in lymphocyte development, differentiation and activation</span></div><div class="casAuthors">Okkenhaug, Klaus; Vanhaesebroeck, Bart</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">317-330</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Phosphoinositide 3-kinases (PI3K) regulate numerous biol. processes, including cell growth, differentiation, survival, proliferation, migration, and metab.  In the immune system, impaired PI3K signaling leads to immunodeficiency, whereas unrestrained PI3K signaling contributes to autoimmunity and leukemia.  New insights into the role of PI3K in lymphocyte biol. have been derived from gene-targeting studies, which have identified the PI3K subunits that are involved in B-cell and T-cell signaling.  In particular, the catalytic subunit p110δ seems to be adapted to transmit antigen receptor signaling in B and T cells.  Addnl. recent work has provided new insights into the mol. interactions that lead to PI3K activation and the signaling pathways that are regulated by PI3K.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqMNzLr_tCL7Vg90H21EOLACvtfcHk0lggHtDVJTsPHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisFWku70%253D&md5=97161849a1a965ce48f2641ec19c7941</span></div><a href="/servlet/linkout?suffix=cit5d&amp;dbid=16384&amp;doi=10.1038%2Fnri1056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1056%26sid%3Dliteratum%253Aachs%26aulast%3DOkkenhaug%26aufirst%3DK.%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26atitle%3DPI3K%2520in%2520Lymphocyte%2520Development%252C%2520Differentiation%252C%2520and%2520Activation%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2003%26volume%3D3%26spage%3D317%26epage%3D330%26doi%3D10.1038%2Fnri1056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Rommel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camps, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span> </span><span class="NLM_article-title">PI3Kδ and PI3Kγ: Partners in Crime in Inflammation in Rheumatoid Arthritis and Beyond?</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">201</span><span class="refDoi"> DOI: 10.1038/nri2036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1038%2Fnri2036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=17290298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=191-201&author=C.+Rommelauthor=M.+Campsauthor=H.+Ji&title=PI3K%CE%B4+and+PI3K%CE%B3%3A+Partners+in+Crime+in+Inflammation+in+Rheumatoid+Arthritis+and+Beyond%3F&doi=10.1038%2Fnri2036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5eR"><div class="casContent"><span class="casTitleNuber">5e</span><div class="casTitle"><span class="NLM_cas:atitle">PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond?</span></div><div class="casAuthors">Rommel, Christian; Camps, Montserrat; Ji, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">191-201</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Dysregulated signal transduction in innate and adaptive immune cells is known to be assocd. with the development of various autoimmune and inflammatory diseases.  Consequently, targeting intracellular signaling of the pro-inflammatory cytokine network heralds hope for the next generation of anti-inflammatory drugs.  Phosphoinositide 3-kinases (PI3Ks) generate lipid-based second messengers that control an array of intracellular signaling pathways that are known to have important roles in leukocytes.  In light of the recent progress in the development of selective PI3K inhibitors, and the beneficial effects of these inhibitors in models of acute and chronic inflammatory disorders, the authors discuss the therapeutic potential of blocking PI3K isoforms for the treatment of rheumatoid arthritis and other immune-mediated diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKSAduhwUrPrVg90H21EOLACvtfcHk0lggHtDVJTsPHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrtbk%253D&md5=2fdb3507d06ddf7d5485185f4573790f</span></div><a href="/servlet/linkout?suffix=cit5e&amp;dbid=16384&amp;doi=10.1038%2Fnri2036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2036%26sid%3Dliteratum%253Aachs%26aulast%3DRommel%26aufirst%3DC.%26aulast%3DCamps%26aufirst%3DM.%26aulast%3DJi%26aufirst%3DH.%26atitle%3DPI3K%25CE%25B4%2520and%2520PI3K%25CE%25B3%253A%2520Partners%2520in%2520Crime%2520in%2520Inflammation%2520in%2520Rheumatoid%2520Arthritis%2520and%2520Beyond%253F%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2007%26volume%3D7%26spage%3D191%26epage%3D201%26doi%3D10.1038%2Fnri2036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Ameriks, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venable, J. D.</span><span> </span><span class="NLM_article-title">Small Molecule Inhibitors of Phosphoinositide 3-Kinase (PI3K) δ and γ</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">738</span><span class="NLM_x">–</span> <span class="NLM_lpage">753</span><span class="refDoi"> DOI: 10.2174/156802609789044434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.2174%2F156802609789044434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=19689378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFehsLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=738-753&author=M.+K.+Ameriksauthor=J.+D.+Venable&title=Small+Molecule+Inhibitors+of+Phosphoinositide+3-Kinase+%28PI3K%29+%CE%B4+and+%CE%B3&doi=10.2174%2F156802609789044434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5fR"><div class="casContent"><span class="casTitleNuber">5f</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule inhibitors of phosphoinositide 3-kinase (PI3K) δ and γ</span></div><div class="casAuthors">Ameriks, Michael K.; Venable, Jennifer D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">738-753</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  In recent years, pharmaceutical companies have increasingly focused on phosphoinositide 3-kinases delta (PI3Kδ) and gamma (PI3Kγ) as therapeutic targets for the treatment of inflammatory and autoimmune diseases.  All class 1 PI3-kinases (α/β/γ/δ) generate phospholipid second messengers that help govern cellular processes such as migration, proliferation, and apoptosis.  PI3K δ/γ lipid kinases are mainly restricted to the hematopoetic system whereas PI3Kα/β are ubiquitously expressed, thus raising potential toxicity concerns for chronic indications such as asthma and rheumatoid arthritis.  Therefore, the challenge in developing a small mol. inhibitor of PI3K is to define and attain the appropriate isoform selectivity profile.  Significant advances in the design of such compds. have been achieved by utilizing x-ray crystal structures of various inhibitors bound to PI3Kγ in conjunction with pharmacophore modeling and high-throughput screening.  Herein, we review the history and challenges involved with the discovery of small mol. isoform-specific PI3K inhibitors.  Recent progress in the design of selective PI3Kδ, PI3Kγ, and PI3Kδ/γ dual inhibitors will be presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeoiBWisF3T7Vg90H21EOLACvtfcHk0liL-cSR7RPF0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFehsLnP&md5=1cae29b32c03158fe8b933fabe8b7a2b</span></div><a href="/servlet/linkout?suffix=cit5f&amp;dbid=16384&amp;doi=10.2174%2F156802609789044434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802609789044434%26sid%3Dliteratum%253Aachs%26aulast%3DAmeriks%26aufirst%3DM.%2BK.%26aulast%3DVenable%26aufirst%3DJ.%2BD.%26atitle%3DSmall%2520Molecule%2520Inhibitors%2520of%2520Phosphoinositide%25203-Kinase%2520%2528PI3K%2529%2520%25CE%25B4%2520and%2520%25CE%25B3%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D738%26epage%3D753%26doi%3D10.2174%2F156802609789044434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ruckle, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rommel, C.</span><span> </span><span class="NLM_article-title">PI3Kγ Inhibition: Towards an Aspirin for the 21st Century?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">903</span><span class="NLM_x">–</span> <span class="NLM_lpage">918</span><span class="refDoi"> DOI: 10.1038/nrd2145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1038%2Fnrd2145" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=903-918&author=T.+Ruckleauthor=M.+K.+Schwarzauthor=C.+Rommel&title=PI3K%CE%B3+Inhibition%3A+Towards+an+Aspirin+for+the+21st+Century%3F&doi=10.1038%2Fnrd2145"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1038%2Fnrd2145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2145%26sid%3Dliteratum%253Aachs%26aulast%3DRuckle%26aufirst%3DT.%26aulast%3DSchwarz%26aufirst%3DM.%2BK.%26aulast%3DRommel%26aufirst%3DC.%26atitle%3DPI3K%25CE%25B3%2520Inhibition%253A%2520Towards%2520an%2520Aspirin%2520for%2520the%252021st%2520Century%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D903%26epage%3D918%26doi%3D10.1038%2Fnrd2145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Barber, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartolome, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redondo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez-Arias, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camps, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruckle, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez-A, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balomenos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rommel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrera, A. C.</span><span> </span><span class="NLM_article-title">PI3Kγ Inhibition Blocks Glomerulonephritis and Extends Lifespan in a Mouse Model of Systemic Lupus</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">933</span><span class="NLM_x">–</span> <span class="NLM_lpage">935</span><span class="refDoi"> DOI: 10.1038/nm1291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1038%2Fnm1291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=16127435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpslelurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=933-935&author=D.+F.+Barberauthor=A.+Bartolomeauthor=C.+Hernandezauthor=J.+M.+Floresauthor=C.+Redondoauthor=C.+Fernandez-Ariasauthor=M.+Campsauthor=T.+Ruckleauthor=M.+K.+Schwarzauthor=S.+Rodriguezauthor=C.+Martinez-Aauthor=D.+Balomenosauthor=C.+Rommelauthor=A.+C.+Carrera&title=PI3K%CE%B3+Inhibition+Blocks+Glomerulonephritis+and+Extends+Lifespan+in+a+Mouse+Model+of+Systemic+Lupus&doi=10.1038%2Fnm1291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">PI3Kγ inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus</span></div><div class="casAuthors">Barber, Domingo F.; Bartolome, Almira; Hernandez, Carmen; Flores, Juana M.; Redondo, Clara; Fernandez-Arias, Cristina; Camps, Montserrat; Rueckle, Thomas; Schwarz, Matthias K.; Rodriguez, Santiago; Martinez-A, Carlos; Balomenos, Dimitrios; Rommel, Christian; Carrera, Ana C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">933-935</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Systemic lupus erythematosus (SLE) is a chronic inflammatory disease generated by deregulation of T cell-mediated B-cell activation, which results in glomerulonephritis and renal failure.  Disease is treated with immunosuppressants and cytostatic agents that have numerous side effects.  Here the authors examine the use of inhibitors of phosphoinositide 3-kinase (PI3K) γ, a lipid kinase that regulates inflammation, in the MRL-lpr mouse model of SLE.  Treatment reduced glomerulonephritis and prolonged lifespan, suggesting that P13Kγ may be a useful target in the treatment of chronic inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd9Xak5Gdl_rVg90H21EOLACvtfcHk0liL-cSR7RPF0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpslelurk%253D&md5=95434bc2c945d81c940c1b959599d89b</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1038%2Fnm1291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1291%26sid%3Dliteratum%253Aachs%26aulast%3DBarber%26aufirst%3DD.%2BF.%26aulast%3DBartolome%26aufirst%3DA.%26aulast%3DHernandez%26aufirst%3DC.%26aulast%3DFlores%26aufirst%3DJ.%2BM.%26aulast%3DRedondo%26aufirst%3DC.%26aulast%3DFernandez-Arias%26aufirst%3DC.%26aulast%3DCamps%26aufirst%3DM.%26aulast%3DRuckle%26aufirst%3DT.%26aulast%3DSchwarz%26aufirst%3DM.%2BK.%26aulast%3DRodriguez%26aufirst%3DS.%26aulast%3DMartinez-A%26aufirst%3DC.%26aulast%3DBalomenos%26aufirst%3DD.%26aulast%3DRommel%26aufirst%3DC.%26aulast%3DCarrera%26aufirst%3DA.%2BC.%26atitle%3DPI3K%25CE%25B3%2520Inhibition%2520Blocks%2520Glomerulonephritis%2520and%2520Extends%2520Lifespan%2520in%2520a%2520Mouse%2520Model%2520of%2520Systemic%2520Lupus%26jtitle%3DNat.%2520Med.%26date%3D2005%26volume%3D11%26spage%3D933%26epage%3D935%26doi%3D10.1038%2Fnm1291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Wymann, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjorklof, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomast, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trifilieff, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altruda, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laffargue, M.</span><span> </span><span class="NLM_article-title">Phosphoinositide 3-Kinase γ: A Key Modulator in Inflammation and Allergy</span> <span class="citation_source-journal">Biochem. Soc. Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">275</span><span class="NLM_x">–</span> <span class="NLM_lpage">280</span><span class="refDoi"> DOI: 10.1042/bst0310275</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1042%2Fbst0310275" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=12546701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptF2qtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2003&pages=275-280&author=M.+P.+Wymannauthor=K.+Bjorklofauthor=R.+Calvezauthor=P.+Finanauthor=M.+Thomastauthor=A.+Trifilieffauthor=M.+Barbierauthor=F.+Altrudaauthor=E.+Hirschauthor=M.+Laffargue&title=Phosphoinositide+3-Kinase+%CE%B3%3A+A+Key+Modulator+in+Inflammation+and+Allergy&doi=10.1042%2Fbst0310275"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6cR"><div class="casContent"><span class="casTitleNuber">6c</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide 3-kinase γ: a key modulator in inflammation and allergy</span></div><div class="casAuthors">Wymann, M. P.; Bjoerkloef, K.; Calvez, R.; Finan, P.; Thomast, M.; Trifilieff, A.; Barbier, M.; Altruda, F.; Hirsch, E.; Laffargue, M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">275-280</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Chronic inflammation and allergy involve the activation of tissue-resident cells and, later on, the invasion of effector cells.  We have previously shown that the loss of phosphoinositide 3-kinase (PI3K) γ impairs chemokine-dependent migration of neutrophils and macrophages both in vitro and in vivo .  On the other hand, PI3Kγ is not required either during phagocytic processes or in the activation of bactericidal activities like granule secretion and particle-mediated respiratory burst in neutrophils.  Tissue mast cells are key regulators in allergy and inflammation and release histamine upon clustering of their IgE receptors.  We have demonstrated that murine mast cell responses are exacerbated in vitro and in vivo by autocrine signals, and require functional PI3Kγ.  Adenosine, acting through the A3 adenosine receptor, as well as other agonists of Gαi-coupled receptors, transiently increased PtdIns(3,4,5) P 3 exclusively via PI3Kγ.  PI3Kγ-derived PtdIns(3,4,5) P 3 was instrumental for initiation of a sustained influx of external Ca2+ and degranulation.  Mice that lacked PI3Kγ did not form edema when challenged by passive systemic anaphylaxis.  PI3Kγ thus relays inflammatory signals through various GPCRs, and is thus central to mast cell function.  Taken together, this suggests that pharmaceutical targeting of PI3Kγ might alleviate inflammation at both early and late stages of the allergic response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSxvbIu0vVf7Vg90H21EOLACvtfcHk0liL-cSR7RPF0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptF2qtw%253D%253D&md5=5163ba45e24d7304db751f5beb16556f</span></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1042%2Fbst0310275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbst0310275%26sid%3Dliteratum%253Aachs%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DBjorklof%26aufirst%3DK.%26aulast%3DCalvez%26aufirst%3DR.%26aulast%3DFinan%26aufirst%3DP.%26aulast%3DThomast%26aufirst%3DM.%26aulast%3DTrifilieff%26aufirst%3DA.%26aulast%3DBarbier%26aufirst%3DM.%26aulast%3DAltruda%26aufirst%3DF.%26aulast%3DHirsch%26aufirst%3DE.%26aulast%3DLaffargue%26aufirst%3DM.%26atitle%3DPhosphoinositide%25203-Kinase%2520%25CE%25B3%253A%2520A%2520Key%2520Modulator%2520in%2520Inflammation%2520and%2520Allergy%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2003%26volume%3D31%26spage%3D275%26epage%3D280%26doi%3D10.1042%2Fbst0310275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Hirsch, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katanaev, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garlanda, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azzolino, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirola, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silengo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sozzani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantovani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altruda, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wymann, M. P.</span><span> </span><span class="NLM_article-title">Central role for G protein-coupled phosphoinositide 3-kinase γ in inflammation</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">287</span><span class="NLM_x">, </span> <span class="NLM_fpage">1049</span><span class="NLM_x">–</span> <span class="NLM_lpage">1053</span><span class="refDoi"> DOI: 10.1126/science.287.5455.1049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1126%2Fscience.287.5455.1049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10669418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtFyqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2000&pages=1049-1053&author=E.+Hirschauthor=V.+L.+Katanaevauthor=C.+Garlandaauthor=O.+Azzolinoauthor=L.+Pirolaauthor=L.+Silengoauthor=S.+Sozzaniauthor=A.+Mantovaniauthor=F.+Altrudaauthor=M.+P.+Wymann&title=Central+role+for+G+protein-coupled+phosphoinositide+3-kinase+%CE%B3+in+inflammation&doi=10.1126%2Fscience.287.5455.1049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6dR"><div class="casContent"><span class="casTitleNuber">6d</span><div class="casTitle"><span class="NLM_cas:atitle">Central role for G protein-coupled phosphoinositide 3-kinase γ in inflammation</span></div><div class="casAuthors">Hirsch, Emilio; Katanaev, Vladimir L.; Garlanda, Cecilia; Azzolino, Ornella; Pirola, Luciano; Silengo, Lorenzo; Sozzani, Silvano; Mantovani, Alberto; Altruda, Fiorella; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">5455</span>),
    <span class="NLM_cas:pages">1049-1053</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinase (PI3K) activity is crucial for leukocyte function, but the roles of the 4 receptor-activated isoforms are unclear.  Mice lacking heterotrimeric guanine nucleotide-binding protein (G protein)-coupled PI3Kγ were viable and had fully differentiated neutrophils and macrophages.  Chemoattractant-stimulated PI3Kγ-/- neutrophils did not produce phosphatidylinositol 3,4,5-trisphosphate, did not activate protein kinase B, and displayed impaired respiratory burst and motility.  Peritoneal PI3Kγ-null macrophages showed a reduced migration toward a wide range of chemotactic stimuli and a severely defective accumulation in a septic peritonitis model.  Thus, PI3Kγ is a crucial signaling mol. required for macrophage accumulation in inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovE06YS7tEErVg90H21EOLACvtfcHk0liAGa8b1g_0Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtFyqtbs%253D&md5=8594ff672743c7873560576b00cd96db</span></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=10.1126%2Fscience.287.5455.1049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.287.5455.1049%26sid%3Dliteratum%253Aachs%26aulast%3DHirsch%26aufirst%3DE.%26aulast%3DKatanaev%26aufirst%3DV.%2BL.%26aulast%3DGarlanda%26aufirst%3DC.%26aulast%3DAzzolino%26aufirst%3DO.%26aulast%3DPirola%26aufirst%3DL.%26aulast%3DSilengo%26aufirst%3DL.%26aulast%3DSozzani%26aufirst%3DS.%26aulast%3DMantovani%26aufirst%3DA.%26aulast%3DAltruda%26aufirst%3DF.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DCentral%2520role%2520for%2520G%2520protein-coupled%2520phosphoinositide%25203-kinase%2520%25CE%25B3%2520in%2520inflammation%26jtitle%3DScience%26date%3D2000%26volume%3D287%26spage%3D1049%26epage%3D1053%26doi%3D10.1126%2Fscience.287.5455.1049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Camps, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rückle, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardissone, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rintelen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrandi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillieron, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gretener, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leroy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitte, P.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wymann, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirillo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rommel, C.</span><span> </span><span class="NLM_article-title">Blockade of PI3Kγ Suppresses Joint Inflammation and Damage in Mouse Models of Rheumatoid Arthritis</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">936</span><span class="NLM_x">–</span> <span class="NLM_lpage">943</span><span class="refDoi"> DOI: 10.1038/nm1284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1038%2Fnm1284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=16127437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpslelur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=936-943&author=M.+Campsauthor=T.+R%C3%BCckleauthor=H.+Jiauthor=V.+Ardissoneauthor=F.+Rintelenauthor=J.+Shawauthor=C.+Ferrandiauthor=C.+Chabertauthor=C.+Gillieronauthor=B.+Franconauthor=T.+Martinauthor=D.+Gretenerauthor=D.+Perrinauthor=D.+Leroyauthor=P.-A.+Vitteauthor=E.+Hirschauthor=M.+P.+Wymannauthor=R.+Cirilloauthor=M.+K.+Schwarzauthor=C.+Rommel&title=Blockade+of+PI3K%CE%B3+Suppresses+Joint+Inflammation+and+Damage+in+Mouse+Models+of+Rheumatoid+Arthritis&doi=10.1038%2Fnm1284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6eR"><div class="casContent"><span class="casTitleNuber">6e</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis</span></div><div class="casAuthors">Camps, Montserrat; Rueckle, Thomas; Ji, Hong; Ardissone, Vittoria; Rintelen, Felix; Shaw, Jeffrey; Ferrandi, Chiara; Chabert, Christian; Gillieron, Corine; Francon, Bernard; Martin, Thierry; Gretener, Denise; Perrin, Dominique; Leroy, Didier; Vitte, Pierre-Alain; Hirsch, Emilio; Wymann, Matthias P.; Cirillo, Rocco; Schwarz, Matthias K.; Rommel, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">936-943</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinases (PI3K) have long been considered promising drug targets for the treatment of inflammatory and autoimmune disorders as well as cancer and cardiovascular diseases.  But the lack of specificity, isoform selectivity and poor biopharmaceutical profile of PI3K inhibitors have so far hampered rigorous disease-relevant target validation.  Here we describe the identification and development of specific, selective and orally active small-mol. inhibitors of PI3Kγ (encoded by Pik3cg).  We show that Pik3cg-/- mice are largely protected in mouse models of rheumatoid arthritis; this protection correlates with defective neutrophil migration, further validating PI3Kγ as a therapeutic target.  We also describe that oral treatment with a PI3Kγ inhibitor suppresses the progression of joint inflammation and damage in two distinct mouse models of rheumatoid arthritis, reproducing the protective effects shown by Pik3cg-/- mice.  Our results identify selective PI3Kγ inhibitors as potential therapeutic mols. for the treatment of chronic inflammatory disorders such as rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEyzzdnR3FXLVg90H21EOLACvtfcHk0liAGa8b1g_0Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpslelur8%253D&md5=1fed7126427b519a4a457a8bf31ade7d</span></div><a href="/servlet/linkout?suffix=cit6e&amp;dbid=16384&amp;doi=10.1038%2Fnm1284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1284%26sid%3Dliteratum%253Aachs%26aulast%3DCamps%26aufirst%3DM.%26aulast%3DR%25C3%25BCckle%26aufirst%3DT.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DArdissone%26aufirst%3DV.%26aulast%3DRintelen%26aufirst%3DF.%26aulast%3DShaw%26aufirst%3DJ.%26aulast%3DFerrandi%26aufirst%3DC.%26aulast%3DChabert%26aufirst%3DC.%26aulast%3DGillieron%26aufirst%3DC.%26aulast%3DFrancon%26aufirst%3DB.%26aulast%3DMartin%26aufirst%3DT.%26aulast%3DGretener%26aufirst%3DD.%26aulast%3DPerrin%26aufirst%3DD.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DVitte%26aufirst%3DP.-A.%26aulast%3DHirsch%26aufirst%3DE.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DCirillo%26aufirst%3DR.%26aulast%3DSchwarz%26aufirst%3DM.%2BK.%26aulast%3DRommel%26aufirst%3DC.%26atitle%3DBlockade%2520of%2520PI3K%25CE%25B3%2520Suppresses%2520Joint%2520Inflammation%2520and%2520Damage%2520in%2520Mouse%2520Models%2520of%2520Rheumatoid%2520Arthritis%26jtitle%3DNat.%2520Med.%26date%3D2005%26volume%3D11%26spage%3D936%26epage%3D943%26doi%3D10.1038%2Fnm1284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Pomel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klicic, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covini, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Church, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roulin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgat-Charvillon, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valognes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camps, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillieron, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leroy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gretener, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitte, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carboni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rommel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rückle, T.</span><span> </span><span class="NLM_article-title">Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase γ</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">3857</span><span class="NLM_x">–</span> <span class="NLM_lpage">3871</span><span class="refDoi"> DOI: 10.1021/jm0601598</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0601598" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=3857-3871&author=V.+Pomelauthor=J.+Klicicauthor=D.+Coviniauthor=D.+D.+Churchauthor=J.+P.+Shawauthor=K.+Roulinauthor=F.+Burgat-Charvillonauthor=D.+Valognesauthor=M.+Campsauthor=C.+Chabertauthor=C.+Gillieronauthor=B.+Franconauthor=D.+Perrinauthor=D.+Leroyauthor=D.+Gretenerauthor=A.+Nicholsauthor=P.+A.+Vitteauthor=S.+Carboniauthor=C.+Rommelauthor=M.+K.+Schwarzauthor=T.+R%C3%BCckle&title=Furan-2-ylmethylene+thiazolidinediones+as+novel%2C+potent%2C+and+selective+inhibitors+of+phosphoinositide+3-kinase+%CE%B3&doi=10.1021%2Fjm0601598"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6f&amp;dbid=16384&amp;doi=10.1021%2Fjm0601598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0601598%26sid%3Dliteratum%253Aachs%26aulast%3DPomel%26aufirst%3DV.%26aulast%3DKlicic%26aufirst%3DJ.%26aulast%3DCovini%26aufirst%3DD.%26aulast%3DChurch%26aufirst%3DD.%2BD.%26aulast%3DShaw%26aufirst%3DJ.%2BP.%26aulast%3DRoulin%26aufirst%3DK.%26aulast%3DBurgat-Charvillon%26aufirst%3DF.%26aulast%3DValognes%26aufirst%3DD.%26aulast%3DCamps%26aufirst%3DM.%26aulast%3DChabert%26aufirst%3DC.%26aulast%3DGillieron%26aufirst%3DC.%26aulast%3DFrancon%26aufirst%3DB.%26aulast%3DPerrin%26aufirst%3DD.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DGretener%26aufirst%3DD.%26aulast%3DNichols%26aufirst%3DA.%26aulast%3DVitte%26aufirst%3DP.%2BA.%26aulast%3DCarboni%26aufirst%3DS.%26aulast%3DRommel%26aufirst%3DC.%26aulast%3DSchwarz%26aufirst%3DM.%2BK.%26aulast%3DR%25C3%25BCckle%26aufirst%3DT.%26atitle%3DFuran-2-ylmethylene%2520thiazolidinediones%2520as%2520novel%252C%2520potent%252C%2520and%2520selective%2520inhibitors%2520of%2520phosphoinositide%25203-kinase%2520%25CE%25B3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D3857%26epage%3D3871%26doi%3D10.1021%2Fjm0601598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Pereira, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strangman, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marion, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldberg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roll, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersen, R. J.</span><span> </span><span class="NLM_article-title">Synthesis of Phosphatidylinositol 3-Kinase (PI3K) Inhibitory Analogues of the Sponge Meroterpenoid Liphagal</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8523</span><span class="NLM_x">–</span> <span class="NLM_lpage">8533</span><span class="refDoi"> DOI: 10.1021/jm100531u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100531u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFShtb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8523-8533&author=A.+R.+Pereiraauthor=W.+K.+Strangmanauthor=F.+Marionauthor=L.+Feldbergauthor=D.+Rollauthor=R.+Mallonauthor=I.+Hollanderauthor=R.+J.+Andersen&title=Synthesis+of+Phosphatidylinositol+3-Kinase+%28PI3K%29+Inhibitory+Analogues+of+the+Sponge+Meroterpenoid+Liphagal&doi=10.1021%2Fjm100531u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6gR"><div class="casContent"><span class="casTitleNuber">6g</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Phosphatidylinositol 3-Kinase (PI3K) Inhibitory Analogues of the Sponge Meroterpenoid Liphagal</span></div><div class="casAuthors">Pereira, Alban R.; Strangman, Wendy K.; Marion, Frederic; Feldberg, Larry; Roll, Deborah; Mallon, Robert; Hollander, Irwin; Andersen, Raymond J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8523-8533</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The sponge meroterpenoid liphagal (+)-I and racemic and nonracemic analogs such as (±)-II were prepd. and their inhibition of phosphatidylinositol-3-kinases α and γ (PI3Kα and PI3Kγ, resp.) was detd.  II inhibited PI3Kα and PI3Kγ with IC50 values of 66 nM and 1840 nM, resp., showing a 27-fold preference for PI3Kα; in addn., II exhibited enhanced chem. stability and modestly enhanced potency and selectivity compared with those of I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-dJ0WNMQ0nrVg90H21EOLACvtfcHk0lj5wcYUXBRGww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFShtb7F&md5=fe31011bbe5e502c62daf12167cea734</span></div><a href="/servlet/linkout?suffix=cit6g&amp;dbid=16384&amp;doi=10.1021%2Fjm100531u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100531u%26sid%3Dliteratum%253Aachs%26aulast%3DPereira%26aufirst%3DA.%2BR.%26aulast%3DStrangman%26aufirst%3DW.%2BK.%26aulast%3DMarion%26aufirst%3DF.%26aulast%3DFeldberg%26aufirst%3DL.%26aulast%3DRoll%26aufirst%3DD.%26aulast%3DMallon%26aufirst%3DR.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DAndersen%26aufirst%3DR.%2BJ.%26atitle%3DSynthesis%2520of%2520Phosphatidylinositol%25203-Kinase%2520%2528PI3K%2529%2520Inhibitory%2520Analogues%2520of%2520the%2520Sponge%2520Meroterpenoid%2520Liphagal%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8523%26epage%3D8533%26doi%3D10.1021%2Fjm100531u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Leahy, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhr, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baik, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cannoy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forsyth, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeong, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuss, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heald, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holst, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaeger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lougheed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plonowski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stout, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakes, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raeber, O.</span><span> </span><span class="NLM_article-title">Discovery of a Novel Series of Potent and Orally Bioavailable Phosphoinositide 3-Kinase γ Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">5467</span><span class="NLM_x">–</span> <span class="NLM_lpage">5482</span><span class="refDoi"> DOI: 10.1021/jm300403a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300403a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1OqtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5467-5482&author=J.+W.+Leahyauthor=C.+A.+Buhrauthor=H.+W.+Johnsonauthor=B.+G.+Kimauthor=T.+Baikauthor=J.+Cannoyauthor=T.+P.+Forsythauthor=J.+W.+Jeongauthor=M.+S.+Leeauthor=S.+Maauthor=K.+Nosonauthor=L.+Wangauthor=M.+Williamsauthor=J.+M.+Nussauthor=E.+Brooksauthor=P.+Fosterauthor=L.+Goonauthor=N.+Healdauthor=C.+Holstauthor=C.+Jaegerauthor=S.+Lamauthor=J.+Lougheedauthor=L.+Nguyenauthor=A.+Plonowskiauthor=J.+Songauthor=T.+Stoutauthor=X.+Wuauthor=M.+F.+Yakesauthor=P.+Yuauthor=W.+Zhangauthor=P.+Lambauthor=O.+Raeber&title=Discovery+of+a+Novel+Series+of+Potent+and+Orally+Bioavailable+Phosphoinositide+3-Kinase+%CE%B3+Inhibitors&doi=10.1021%2Fjm300403a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6hR"><div class="casContent"><span class="casTitleNuber">6h</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel Series of Potent and Orally Bioavailable Phosphoinositide 3-Kinase γ Inhibitors</span></div><div class="casAuthors">Leahy, James W.; Buhr, Chris A.; Johnson, Henry W. B.; Kim, Byung Gyu; Baik, TaeGon; Cannoy, Jonah; Forsyth, Timothy P.; Jeong, Joon Won; Lee, Matthew S.; Ma, Sunghoon; Noson, Kevin; Wang, Longcheng; Williams, Matthew; Nuss, John M.; Brooks, Eric; Foster, Paul; Goon, Leanne; Heald, Nathan; Holst, Charles; Jaeger, Christopher; Lam, Scott; Lougheed, Julie; Nguyen, Lam; Plonowski, Arthur; Song, Joanne; Stout, Thomas; Wu, Xiang; Yakes, Michael F.; Yu, Peiwen; Zhang, Wentao; Lamb, Peter; Raeber, Olivia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5467-5482</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The phosphoinositide 3-kinases (PI3Ks) have been linked to an extraordinarily diversified group of cellular functions making these enzymes compelling targets for the treatment of disease.  A large body of evidence has linked PI3Kγ to the modulation of autoimmune and inflammatory processes making it an intriguing target for drug discovery.  A high-throughput screening (HTS) campaign revealed two hits that were nominated for further optimization studies.  The in vitro activity of the first HTS hit, I, designated as the sulfonylpiperazine scaffold, was optimized utilizing structure-based design.  However, nonoptimal pharmacokinetic properties precluded this series from further studies.  An overlay of the x-ray structures of the sulfonylpiperazine scaffold and the second HTS hit, II, within their complexes with PI3Kγ revealed a high degree of overlap.  This feature was utilized to design a series of hybrid analogs including advanced leads such as III with desirable potency, selectivity, and oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxapmg3cIbmLVg90H21EOLACvtfcHk0lj5wcYUXBRGww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1OqtrY%253D&md5=c9986a8e80b1188c52a9d36d3f1d24f3</span></div><a href="/servlet/linkout?suffix=cit6h&amp;dbid=16384&amp;doi=10.1021%2Fjm300403a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300403a%26sid%3Dliteratum%253Aachs%26aulast%3DLeahy%26aufirst%3DJ.%2BW.%26aulast%3DBuhr%26aufirst%3DC.%2BA.%26aulast%3DJohnson%26aufirst%3DH.%2BW.%26aulast%3DKim%26aufirst%3DB.%2BG.%26aulast%3DBaik%26aufirst%3DT.%26aulast%3DCannoy%26aufirst%3DJ.%26aulast%3DForsyth%26aufirst%3DT.%2BP.%26aulast%3DJeong%26aufirst%3DJ.%2BW.%26aulast%3DLee%26aufirst%3DM.%2BS.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DNoson%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DNuss%26aufirst%3DJ.%2BM.%26aulast%3DBrooks%26aufirst%3DE.%26aulast%3DFoster%26aufirst%3DP.%26aulast%3DGoon%26aufirst%3DL.%26aulast%3DHeald%26aufirst%3DN.%26aulast%3DHolst%26aufirst%3DC.%26aulast%3DJaeger%26aufirst%3DC.%26aulast%3DLam%26aufirst%3DS.%26aulast%3DLougheed%26aufirst%3DJ.%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DPlonowski%26aufirst%3DA.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DStout%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DYakes%26aufirst%3DM.%2BF.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DLamb%26aufirst%3DP.%26aulast%3DRaeber%26aufirst%3DO.%26atitle%3DDiscovery%2520of%2520a%2520Novel%2520Series%2520of%2520Potent%2520and%2520Orally%2520Bioavailable%2520Phosphoinositide%25203-Kinase%2520%25CE%25B3%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5467%26epage%3D5482%26doi%3D10.1021%2Fjm300403a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group">Collier, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez-Botella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornebise, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cottrell, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doran, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahajan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maltais, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moody, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huck, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aronov, A. M.</span><span> </span><span class="NLM_article-title">Structural Basis for Isoform Selectivity in a Class of Benzothiazole Inhibitors of Phosphoinositide 3-Kinase γ</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">517</span><span class="NLM_x">–</span> <span class="NLM_lpage">521</span><span class="refDoi"> DOI: 10.1021/jm500362j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500362j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6i&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsFWnsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=517-521&author=P.+N.+Collierauthor=G.+Martinez-Botellaauthor=M.+Cornebiseauthor=K.+M.+Cottrellauthor=J.+D.+Doranauthor=J.+P.+Griffithauthor=S.+Mahajanauthor=F.+Maltaisauthor=C.+S.+Moodyauthor=E.+P.+Huckauthor=T.+Wangauthor=A.+M.+Aronov&title=Structural+Basis+for+Isoform+Selectivity+in+a+Class+of+Benzothiazole+Inhibitors+of+Phosphoinositide+3-Kinase+%CE%B3&doi=10.1021%2Fjm500362j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6iR"><div class="casContent"><span class="casTitleNuber">6i</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for Isoform Selectivity in a Class of Benzothiazole Inhibitors of Phosphoinositide 3-Kinase γ</span></div><div class="casAuthors">Collier, Philip N.; Martinez-Botella, Gabriel; Cornebise, Mark; Cottrell, Kevin M.; Doran, John D.; Griffith, James P.; Mahajan, Sudipta; Maltais, Francois; Moody, Cameron S.; Huck, Emilie Porter; Wang, Tiansheng; Aronov, Alex M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">517-521</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinase γ (PI3Kγ) is an attractive target to potentially treat a range of disease states.  Herein, we describe the evolution of a reported phenylthiazole pan-PI3K inhibitor into a family of potent and selective benzothiazole inhibitors.  Using x-ray crystallog., we discovered that compd. I occupies a previously unreported hydrophobic binding cleft adjacent to the ATP binding site of PI3Kγ, and achieves its selectivity by exploiting natural sequence differences among PI3K isoforms in this region.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDVpUaz7njz7Vg90H21EOLACvtfcHk0liwfP7z2MPwJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsFWnsrk%253D&md5=dd5ce3f9e524747d10d094c9f9b9127c</span></div><a href="/servlet/linkout?suffix=cit6i&amp;dbid=16384&amp;doi=10.1021%2Fjm500362j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500362j%26sid%3Dliteratum%253Aachs%26aulast%3DCollier%26aufirst%3DP.%2BN.%26aulast%3DMartinez-Botella%26aufirst%3DG.%26aulast%3DCornebise%26aufirst%3DM.%26aulast%3DCottrell%26aufirst%3DK.%2BM.%26aulast%3DDoran%26aufirst%3DJ.%2BD.%26aulast%3DGriffith%26aufirst%3DJ.%2BP.%26aulast%3DMahajan%26aufirst%3DS.%26aulast%3DMaltais%26aufirst%3DF.%26aulast%3DMoody%26aufirst%3DC.%2BS.%26aulast%3DHuck%26aufirst%3DE.%2BP.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DAronov%26aufirst%3DA.%2BM.%26atitle%3DStructural%2520Basis%2520for%2520Isoform%2520Selectivity%2520in%2520a%2520Class%2520of%2520Benzothiazole%2520Inhibitors%2520of%2520Phosphoinositide%25203-Kinase%2520%25CE%25B3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D517%26epage%3D521%26doi%3D10.1021%2Fjm500362j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6j"><span><span class="NLM_label">(j) </span><span class="NLM_contrib-group">Oka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yabuuchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakahara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sekiguchi, Y.</span><span> </span><span class="NLM_article-title">Discovery and optimization of a series of 2-aminothiazole-oxazoles as potent phosphoinositide 3-kinase γ inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">7534</span><span class="NLM_x">–</span> <span class="NLM_lpage">7538</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.10.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6j&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.bmcl.2012.10.028" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=7534-7538&author=Y.+Okaauthor=T.+Yabuuchiauthor=Y.+Fujiiauthor=H.+Ohtakeauthor=S.+Wakaharaauthor=K.+Matsumotoauthor=M.+Endoauthor=Y.+Tamuraauthor=Y.+Sekiguchi&title=Discovery+and+optimization+of+a+series+of+2-aminothiazole-oxazoles+as+potent+phosphoinositide+3-kinase+%CE%B3+inhibitors&doi=10.1016%2Fj.bmcl.2012.10.028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6j&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.10.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.10.028%26sid%3Dliteratum%253Aachs%26aulast%3DOka%26aufirst%3DY.%26aulast%3DYabuuchi%26aufirst%3DT.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DOhtake%26aufirst%3DH.%26aulast%3DWakahara%26aufirst%3DS.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DEndo%26aufirst%3DM.%26aulast%3DTamura%26aufirst%3DY.%26aulast%3DSekiguchi%26aufirst%3DY.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520a%2520series%2520of%25202-aminothiazole-oxazoles%2520as%2520potent%2520phosphoinositide%25203-kinase%2520%25CE%25B3%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D7534%26epage%3D7538%26doi%3D10.1016%2Fj.bmcl.2012.10.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fruman, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rommel, C.</span><span> </span><span class="NLM_article-title">ΠI3Kδ Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">562</span><span class="NLM_x">–</span> <span class="NLM_lpage">572</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-11-0249</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1158%2F2159-8290.CD-11-0249" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=562-572&author=D.+A.+Frumanauthor=C.+Rommel&title=%CE%A0I3K%CE%B4+Inhibitors+in+Cancer%3A+Rationale+and+Serendipity+Merge+in+the+Clinic&doi=10.1158%2F2159-8290.CD-11-0249"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-11-0249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-11-0249%26sid%3Dliteratum%253Aachs%26aulast%3DFruman%26aufirst%3DD.%2BA.%26aulast%3DRommel%26aufirst%3DC.%26atitle%3D%25CE%25A0I3K%25CE%25B4%2520Inhibitors%2520in%2520Cancer%253A%2520Rationale%2520and%2520Serendipity%2520Merge%2520in%2520the%2520Clinic%26jtitle%3DCancer%2520Discovery%26date%3D2011%26volume%3D1%26spage%3D562%26epage%3D572%26doi%3D10.1158%2F2159-8290.CD-11-0249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lannutti, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meadows, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, S. E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashishian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrd, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loriaux, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puri, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulrich, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giese, N. A.</span><span> </span><span class="NLM_article-title">CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">594</span><span class="refDoi"> DOI: 10.1182/blood-2010-03-275305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1182%2Fblood-2010-03-275305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=20959606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1aqtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=591-594&author=B.+J.+Lannuttiauthor=S.+A.+Meadowsauthor=S.+E.+M.+Hermanauthor=A.+Kashishianauthor=B.+Steinerauthor=A.+J.+Johnsonauthor=J.+C.+Byrdauthor=J.+W.+Tynerauthor=M.+M.+Loriauxauthor=M.+Deiningerauthor=B.+J.+Drukerauthor=K.+J.+Puriauthor=R.+G.+Ulrichauthor=N.+A.+Giese&title=CAL-101%2C+a+p110delta+selective+phosphatidylinositol-3-kinase+inhibitor+for+the+treatment+of+B-cell+malignancies%2C+inhibits+PI3K+signaling+and+cellular+viability&doi=10.1182%2Fblood-2010-03-275305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability</span></div><div class="casAuthors">Lannutti, Brian J.; Meadows, Sarah A.; Herman, Sarah E. M.; Kashishian, Adam; Steiner, Bart; Johnson, Amy J.; Byrd, John C.; Tyner, Jeffrey W.; Loriaux, Marc M.; Deininger, Mike; Druker, Brian J.; Puri, Kamal D.; Ulrich, Roger G.; Giese, Neill A.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">591-594</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-kinase p110δ serves as a central integration point for signaling from cell surface receptors known to promote malignant B-cell proliferation and survival.  This provides a rationale for the development of small mol. inhibitors that selectively target p110δ as a treatment approach for patients with B-cell malignancies.  We thus identified 5-fluoro-3-phenyl-2-[(S)-1-(9H-purin-6-ylamino)-propyl]-3H-quinazolin-4-one (CAL-101), a highly selective and potent p110δ small mol. inhibitor (half-maximal effective concn. [EC50] = 8nM).  Using tumor cell lines and primary patient samples representing multiple B-cell malignancies, we have demonstrated that constitutive phosphatidylinositol-3-kinase pathway activation is p110δ-dependent.  CAL-101 blocked constitutive phosphatidylinositol-3-kinase signaling, resulting in decreased phosphorylation of Akt and other downstream effectors, an increase in poly(ADP-ribose) polymerase and caspase cleavage and an induction of apoptosis.  These effects have been obsd. across a broad range of immature and mature B-cell malignancies, thereby providing a rationale for the ongoing clin. evaluation of CAL-101.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrID8zgXRVmvbVg90H21EOLACvtfcHk0liwfP7z2MPwJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1aqtro%253D&md5=423bf1fbea274424db3b818fdc6733b0</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-03-275305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-03-275305%26sid%3Dliteratum%253Aachs%26aulast%3DLannutti%26aufirst%3DB.%2BJ.%26aulast%3DMeadows%26aufirst%3DS.%2BA.%26aulast%3DHerman%26aufirst%3DS.%2BE.%2BM.%26aulast%3DKashishian%26aufirst%3DA.%26aulast%3DSteiner%26aufirst%3DB.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DDeininger%26aufirst%3DM.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DPuri%26aufirst%3DK.%2BJ.%26aulast%3DUlrich%26aufirst%3DR.%2BG.%26aulast%3DGiese%26aufirst%3DN.%2BA.%26atitle%3DCAL-101%252C%2520a%2520p110delta%2520selective%2520phosphatidylinositol-3-kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520B-cell%2520malignancies%252C%2520inhibits%2520PI3K%2520signaling%2520and%2520cellular%2520viability%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26spage%3D591%26epage%3D594%26doi%3D10.1182%2Fblood-2010-03-275305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Subramaniam, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whye, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Efimenko, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tosello, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Keersmaecker, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashishian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castillo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordon-Cardo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davé, U. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrando, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lannutti, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diacovo, T. G.</span><span> </span><span class="NLM_article-title">Targeting Nonclassical Oncogenes for Therapy in T-ALL</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">459</span><span class="NLM_x">–</span> <span class="NLM_lpage">472</span><span class="refDoi"> DOI: 10.1016/j.ccr.2012.02.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.ccr.2012.02.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=22516257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvVSnsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=459-472&author=P.+S.+Subramaniamauthor=D.+W.+Whyeauthor=E.+Efimenkoauthor=J.+Chenauthor=V.+Toselloauthor=K.+De+Keersmaeckerauthor=A.+Kashishianauthor=M.+A.+Thompsonauthor=M.+Castilloauthor=C.+Cordon-Cardoauthor=U.+P.+Dav%C3%A9author=A.+Ferrandoauthor=B.+J.+Lannuttiauthor=T.+G.+Diacovo&title=Targeting+Nonclassical+Oncogenes+for+Therapy+in+T-ALL&doi=10.1016%2Fj.ccr.2012.02.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Nonclassical Oncogenes for Therapy in T-ALL</span></div><div class="casAuthors">Subramaniam, Prem S.; Whye, Dosh W.; Efimenko, Evgeni; Chen, Jianchung; Tosello, Valeria; De Keersmaecker, Kim; Kashishian, Adam; Thompson, Mary Ann; Castillo, Mireia; Cordon-Cardo, Carlos; Dave, Utpal P.; Ferrando, Adolfo; Lannutti, Brian J.; Diacovo, Thomas G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">459-472</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Constitutive phosphoinositide 3-kinase (PI3K)/Akt activation is common in T cell acute lymphoblastic leukemia (T-ALL).  Although four distinct class I PI3K isoforms (α, β, γ, δ) could participate in T-ALL pathogenesis, none has been implicated in this process.  We report that in the absence of PTEN phosphatase tumor suppressor function, PI3Kγ or PI3Kδ alone can support leukemogenesis, whereas inactivation of both isoforms suppressed tumor formation.  The reliance of PTEN null T-ALL on the combined activities of PI3Kγ/δ was further demonstrated by the ability of a dual inhibitor to reduce disease burden and prolong survival in mice as well as prevent proliferation and promote activation of proapoptotic pathways in human tumors.  These results support combined inhibition of PI3Kγ/δ as therapy for T-ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosNmXI2hkyJLVg90H21EOLACvtfcHk0liLX3R7fPQKNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvVSnsr8%253D&md5=398af95a5213dd668b882bf33b222a8c</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2012.02.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2012.02.029%26sid%3Dliteratum%253Aachs%26aulast%3DSubramaniam%26aufirst%3DP.%2BS.%26aulast%3DWhye%26aufirst%3DD.%2BW.%26aulast%3DEfimenko%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTosello%26aufirst%3DV.%26aulast%3DDe%2BKeersmaecker%26aufirst%3DK.%26aulast%3DKashishian%26aufirst%3DA.%26aulast%3DThompson%26aufirst%3DM.%2BA.%26aulast%3DCastillo%26aufirst%3DM.%26aulast%3DCordon-Cardo%26aufirst%3DC.%26aulast%3DDav%25C3%25A9%26aufirst%3DU.%2BP.%26aulast%3DFerrando%26aufirst%3DA.%26aulast%3DLannutti%26aufirst%3DB.%2BJ.%26aulast%3DDiacovo%26aufirst%3DT.%2BG.%26atitle%3DTargeting%2520Nonclassical%2520Oncogenes%2520for%2520Therapy%2520in%2520T-ALL%26jtitle%3DCancer%2520Cell%26date%3D2012%26volume%3D21%26spage%3D459%26epage%3D472%26doi%3D10.1016%2Fj.ccr.2012.02.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Schmid, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avraamides, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dippold, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foubert, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellies, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acevedo, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manglicmot, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrasidlo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginsberg, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheresh, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Field, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varner, J. A.</span><span> </span><span class="NLM_article-title">Receptor Tyrosine Kinases and TLR/IL1Rs Unexpectedly Activate Myeloid Cell PI3Kγ, A Single Convergent Point Promoting Tumor Inflammation and Progression</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">715</span><span class="NLM_x">–</span> <span class="NLM_lpage">727</span><span class="refDoi"> DOI: 10.1016/j.ccr.2011.04.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.ccr.2011.04.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=715-727&author=M.+C.+Schmidauthor=C.+J.+Avraamidesauthor=H.+C.+Dippoldauthor=I.+Francoauthor=P.+Foubertauthor=L.+G.+Elliesauthor=L.+M.+Acevedoauthor=J.+R.+Manglicmotauthor=X.+Songauthor=W.+Wrasidloauthor=S.+L.+Blairauthor=M.+H.+Ginsbergauthor=D.+A.+Chereshauthor=E.+Hirschauthor=S.+J.+Fieldauthor=J.+A.+Varner&title=Receptor+Tyrosine+Kinases+and+TLR%2FIL1Rs+Unexpectedly+Activate+Myeloid+Cell+PI3K%CE%B3%2C+A+Single+Convergent+Point+Promoting+Tumor+Inflammation+and+Progression&doi=10.1016%2Fj.ccr.2011.04.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2011.04.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2011.04.016%26sid%3Dliteratum%253Aachs%26aulast%3DSchmid%26aufirst%3DM.%2BC.%26aulast%3DAvraamides%26aufirst%3DC.%2BJ.%26aulast%3DDippold%26aufirst%3DH.%2BC.%26aulast%3DFranco%26aufirst%3DI.%26aulast%3DFoubert%26aufirst%3DP.%26aulast%3DEllies%26aufirst%3DL.%2BG.%26aulast%3DAcevedo%26aufirst%3DL.%2BM.%26aulast%3DManglicmot%26aufirst%3DJ.%2BR.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DWrasidlo%26aufirst%3DW.%26aulast%3DBlair%26aufirst%3DS.%2BL.%26aulast%3DGinsberg%26aufirst%3DM.%2BH.%26aulast%3DCheresh%26aufirst%3DD.%2BA.%26aulast%3DHirsch%26aufirst%3DE.%26aulast%3DField%26aufirst%3DS.%2BJ.%26aulast%3DVarner%26aufirst%3DJ.%2BA.%26atitle%3DReceptor%2520Tyrosine%2520Kinases%2520and%2520TLR%252FIL1Rs%2520Unexpectedly%2520Activate%2520Myeloid%2520Cell%2520PI3K%25CE%25B3%252C%2520A%2520Single%2520Convergent%2520Point%2520Promoting%2520Tumor%2520Inflammation%2520and%2520Progression%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26spage%3D715%26epage%3D727%26doi%3D10.1016%2Fj.ccr.2011.04.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm406387.htm" class="extLink">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm406387.htm</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm406387.htm."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="note"><p class="first last">Reviews of class I PI3K inhibitors under clinical evaluation:</p></div><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Carnero, A.</span><span> </span><span class="NLM_article-title">Novel Inhibitors of the PI3K Family</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1265</span><span class="NLM_x">–</span> <span class="NLM_lpage">1277</span><span class="refDoi"> DOI: 10.1517/13543780903066798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1517%2F13543780903066798" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=1265-1277&author=A.+Carnero&title=Novel+Inhibitors+of+the+PI3K+Family&doi=10.1517%2F13543780903066798"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1517%2F13543780903066798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543780903066798%26sid%3Dliteratum%253Aachs%26aulast%3DCarnero%26aufirst%3DA.%26atitle%3DNovel%2520Inhibitors%2520of%2520the%2520PI3K%2520Family%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2009%26volume%3D18%26spage%3D1265%26epage%3D1277%26doi%3D10.1517%2F13543780903066798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Courtney, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corcoran, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">The PI3K Pathway as a Drug Target in Human Cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1075</span><span class="refDoi"> DOI: 10.1200/JCO.2009.25.3641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1200%2FJCO.2009.25.3641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=20085938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktF2lt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=1075&author=K.+D.+Courtneyauthor=R.+B.+Corcoranauthor=J.+A.+Engelman&title=The+PI3K+Pathway+as+a+Drug+Target+in+Human+Cancer&doi=10.1200%2FJCO.2009.25.3641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">The PI3K pathway as drug target in human cancer</span></div><div class="casAuthors">Courtney, Kevin D.; Corcoran, Ryan B.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1075-1083</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The phosphatidylinositol 3-kinase (PI3K) signaling axis impacts on cancer cell growth, survival, motility, and metab.  This pathway is activated by several different mechanisms in cancers, including somatic mutation and amplification of genes encoding key components.  In addn., PI3K signaling may serve integral functions for noncancerous cells in the tumor microenvironment.  Consequently, therapeutics targeting the PI3K pathway are being developed at a rapid pace, and preclin. and early clin. studies are beginning to suggest specific strategies to effectively use them.  However, the central role of PI3K signaling in a large array of diverse biol. processes raises concerns about its use in therapeutics and increases the need to develop sophisticated strategies for its use.  In this review, we will discuss how PI3K signaling affects the growth and survival of tumor cells.  From this vantage, we will consider how inhibitors of the PI3K signaling cascade, either alone or in combination with other therapeutics, can most effectively be used for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpPqtk2bVl0rVg90H21EOLACvtfcHk0lgrNi8KZTnfcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktF2lt7w%253D&md5=b88b394919647e2eb47e7735355fde2a</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.25.3641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.25.3641%26sid%3Dliteratum%253Aachs%26aulast%3DCourtney%26aufirst%3DK.%2BD.%26aulast%3DCorcoran%26aufirst%3DR.%2BB.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520PI3K%2520Pathway%2520as%2520a%2520Drug%2520Target%2520in%2520Human%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D1075%26doi%3D10.1200%2FJCO.2009.25.3641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hixon, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paccagnella, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millham, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Olle, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gualberto, A.</span><span> </span><span class="NLM_article-title">Development of Inhibitors of the IGF-1R/PI3K/Akt/mTOR Pathway</span> <span class="citation_source-journal">Rev. Recent Clin. Trials</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">189</span><span class="NLM_x">–</span> <span class="NLM_lpage">208</span><span class="refDoi"> DOI: 10.2174/157488710792007329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.2174%2F157488710792007329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=20533896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFKqsrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=189-208&author=M.+L.+Hixonauthor=L.+Paccagnellaauthor=R.+Millhamauthor=R.+Perez-Olleauthor=A.+Gualberto&title=Development+of+Inhibitors+of+the+IGF-1R%2FPI3K%2FAkt%2FmTOR+Pathway&doi=10.2174%2F157488710792007329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10c</span><div class="casTitle"><span class="NLM_cas:atitle">Development of inhibitors of the IGF-IR/PI3K/Akt/mTOR pathway</span></div><div class="casAuthors">Hixon, Mary L.; Paccagnella, Luisa; Millham, Robert; Perez-Olle, Raul; Gualberto, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Reviews on Recent Clinical Trials</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">189-208</span>CODEN:
                <span class="NLM_cas:coden">RRCTB2</span>;
        ISSN:<span class="NLM_cas:issn">1574-8871</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Progress has been made towards the development of agents targeting tyrosine kinase receptors and other mols. involved in signalling pathways important for cell proliferation, motility, and apoptosis.  Inhibitor mols. designed to be highly specific with the aim of decreasing toxicity have proven to be generally well tolerated.  However, the efficacy of targeted agents may be impacted by cross-talk between pathways and downregulation of neg. feed-back loops.  That is the case of the IGF-IR/PI3K/Akt/mTOR pathway.  This issue raises the question of how these targeted agents could be combined to prevent or delay resistance without significantly increasing toxicity.  Several mTOR inhibitors have been approved for cancer therapy, and late-stage clin. trials of IGF-IR inhibitors are underway.  The outcome of ongoing clin. studies of IGF-IR, PI3K, Akt and mTOR inhibitors as well as further testing of the combination of these agents will be key for the development of therapeutic options in a wide range of oncol. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGootsaAecGArrVg90H21EOLACvtfcHk0lgrNi8KZTnfcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFKqsrfJ&md5=b2c1643995fec5371c54112057c9d920</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=10.2174%2F157488710792007329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157488710792007329%26sid%3Dliteratum%253Aachs%26aulast%3DHixon%26aufirst%3DM.%2BL.%26aulast%3DPaccagnella%26aufirst%3DL.%26aulast%3DMillham%26aufirst%3DR.%26aulast%3DPerez-Olle%26aufirst%3DR.%26aulast%3DGualberto%26aufirst%3DA.%26atitle%3DDevelopment%2520of%2520Inhibitors%2520of%2520the%2520IGF-1R%252FPI3K%252FAkt%252FmTOR%2520Pathway%26jtitle%3DRev.%2520Recent%2520Clin.%2520Trials%26date%3D2010%26volume%3D5%26spage%3D189%26epage%3D208%26doi%3D10.2174%2F157488710792007329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Shuttleworth, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cecil, A. R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomassi, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2686</span><span class="NLM_x">–</span> <span class="NLM_lpage">2714</span><span class="refDoi"> DOI: 10.2174/092986711796011229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.2174%2F092986711796011229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=21649578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Cit73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=2686-2714&author=S.+J.+Shuttleworthauthor=F.+A.+Silvaauthor=A.+R.+L.+Cecilauthor=C.+D.+Tomassiauthor=T.+J.+Hillauthor=F.+I.+Raynaudauthor=P.+A.+Clarkeauthor=P.+Workman&title=Progress+in+the+preclinical+discovery+and+clinical+development+of+class+I+and+dual+class+I%2FIV+phosphoinositide+3-kinase+%28PI3K%29+inhibitors&doi=10.2174%2F092986711796011229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10dR"><div class="casContent"><span class="casTitleNuber">10d</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors</span></div><div class="casAuthors">Shuttleworth, S. J.; Silva, F. A.; Cecil, A. R. L.; Tomassi, C. D.; Hill, T. J.; Raynaud, F. I.; Clarke, P. A.; Workman, P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2686-2714</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The phosphoinositide 3-kinases (PI3Ks) constitute an important family of lipid kinase enzymes that control a range of cellular processes through their regulation of a network of signal transduction pathways, and have emerged as important therapeutic targets in the context of cancer, inflammation and cardiovascular diseases.  Since the mid-late 1990s, considerable progress was made in the discovery and development of small mol. ATP-competitive PI3K inhibitors, a no. of which have entered early phase human trials over recent years from which key clin. results are now being disclosed.  This review summarizes progress made to date, primarily on the discovery and characterization of class I and dual class I/IV subtype inhibitors, together with advances that were made in translational and clin. research, notably in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpibTyG_ua2WLVg90H21EOLACvtfcHk0lgrNi8KZTnfcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Cit73M&md5=baf93d773ce18eb70ebc5549c14f422c</span></div><a href="/servlet/linkout?suffix=cit10d&amp;dbid=16384&amp;doi=10.2174%2F092986711796011229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711796011229%26sid%3Dliteratum%253Aachs%26aulast%3DShuttleworth%26aufirst%3DS.%2BJ.%26aulast%3DSilva%26aufirst%3DF.%2BA.%26aulast%3DCecil%26aufirst%3DA.%2BR.%2BL.%26aulast%3DTomassi%26aufirst%3DC.%2BD.%26aulast%3DHill%26aufirst%3DT.%2BJ.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DProgress%2520in%2520the%2520preclinical%2520discovery%2520and%2520clinical%2520development%2520of%2520class%2520I%2520and%2520dual%2520class%2520I%252FIV%2520phosphoinositide%25203-kinase%2520%2528PI3K%2529%2520inhibitors%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D2686%26epage%3D2714%26doi%3D10.2174%2F092986711796011229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Phosphoinositide 3-kinase α inhibitors: a patent review</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">789</span><span class="NLM_x">–</span> <span class="NLM_lpage">799</span><span class="refDoi"> DOI: 10.1517/13543776.2013.779673</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1517%2F13543776.2013.779673" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=23488930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslCks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=789-799&author=W.+A.+Denny&title=Phosphoinositide+3-kinase+%CE%B1+inhibitors%3A+a+patent+review&doi=10.1517%2F13543776.2013.779673"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10eR"><div class="casContent"><span class="casTitleNuber">10e</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide 3-kinase α inhibitors: a patent review</span></div><div class="casAuthors">Denny, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">789-799</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The alpha isoform of the class 1A family of phosphatidylinositol 3-kinases (PI3Kα) has been extensively studied and exploited as a target for cancer drugs.  A large no. of compds., from a wide variety of structural scaffolds, are in development.  There is an ongoing debate about the desirability for selectivity between PI3Kα and the other isoforms.  Areas covered: The article briefly outlines the nature and role of the class 1A PI3K in cell signalling and provides a table of representative inhibitors of these enzymes that have proceeded to clin. trial, with literature data on their isoform selectivity.  It covers the published patent literature from 2011 to 2012 (search completed in Dec. 2012), with a particular focus on compds. with a level of selective inhibition of PI3Kα.  In most cases, representative examples of claimed compds. and data on their inhibitory effects are provided.  Expert opinion: Features of the development of PI3K inhibitors to date have been the plasticity of the enzymes, which possess binding sites for a bewildering no. of small mol. scaffolds, and the need to det. the optimal patterns of selectivity between both the PI3K isoforms and the related downstream serine/threonine kinase mammalian target of rapamycin (mTOR) for therapeutic effect.  Both themes are apparent in the recent patents reviewed here, with a wide variety of drug types, including variations on existing scaffolds and completely new ones, being evident.  While many of these are dual PI3K/mTOR inhibitors, the PI3Kα-selective pyrido[2,3-b]pyrazine heterocycles reported by Intellikine and the (thiazolyl)pyrrolidinecarboxamides of Novartis are of particular interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0mWqyfPDxVbVg90H21EOLACvtfcHk0liY7U8thaiGrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslCks7Y%253D&md5=4e0f5604400d18d1b31d1134d8697fff</span></div><a href="/servlet/linkout?suffix=cit10e&amp;dbid=16384&amp;doi=10.1517%2F13543776.2013.779673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2013.779673%26sid%3Dliteratum%253Aachs%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DPhosphoinositide%25203-kinase%2520%25CE%25B1%2520inhibitors%253A%2520a%2520patent%2520review%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2013%26volume%3D23%26spage%3D789%26epage%3D799%26doi%3D10.1517%2F13543776.2013.779673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Yap, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjerke, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Drugging PI3K in cancer: refining targets and therapeutic strategies</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">98</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span><span class="refDoi"> DOI: 10.1016/j.coph.2015.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.coph.2015.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=26117819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWrt7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=98-107&author=T.+A.+Yapauthor=L.+Bjerkeauthor=P.+A.+Clarkeauthor=P.+Workman&title=Drugging+PI3K+in+cancer%3A+refining+targets+and+therapeutic+strategies&doi=10.1016%2Fj.coph.2015.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10fR"><div class="casContent"><span class="casTitleNuber">10f</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging PI3K in cancer: refining targets and therapeutic strategies</span></div><div class="casAuthors">Yap, Timothy A.; Bjerke, Lynn; Clarke, Paul A.; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">98-107</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The phosphatidylinositol-3 kinase (PI3K) pathway is one of the most frequently activated pathogenic signalling routes in human cancers, making it a rational and important target for innovative anticancer drug development and precision medicine.  The three main classes of PI3K inhibitors currently in clin. testing comprise dual pan-Class I PI3K/mTOR inhibitors, pan-Class I PI3K inhibitors lacking significant mTOR activity and isoform-selective PI3K inhibitors.  A major step forward in recent years is the progression of over 30 small mol. PI3K inhibitors into clin. trials and the first regulatory approval of the PI3Kδ inhibitor idelalisib for multiple B-cell malignancies.  This review article focuses on the progress made in the discovery and development of novel PI3K inhibitors, with an emphasis on antitumor activity and tolerability profiles for agents that have entered clin. trials.  We also discuss the key issues of drug resistance, patient selection approaches and rational targeted combinations.  Finally, we envision the future development and use of PI3K inhibitors for the treatment of patients with a range of malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDxyCAEREi_7Vg90H21EOLACvtfcHk0liY7U8thaiGrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWrt7bJ&md5=9a0238f97d8ecdc54e0c5b9b6ce4fc76</span></div><a href="/servlet/linkout?suffix=cit10f&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2015.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2015.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DBjerke%26aufirst%3DL.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DDrugging%2520PI3K%2520in%2520cancer%253A%2520refining%2520targets%2520and%2520therapeutic%2520strategies%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2015%26volume%3D23%26spage%3D98%26epage%3D107%26doi%3D10.1016%2Fj.coph.2015.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="note"><p class="first last">For PI3Kα isoform selective inhibitors in clinical trials, see:</p></div><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fritsch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatenay-Rivauday, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guthy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erdmann, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Pover, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferretti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trappe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brachmann, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maira, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chene, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cozens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlegel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caravatti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span> </span><span class="NLM_article-title">Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1117</span><span class="NLM_x">–</span> <span class="NLM_lpage">1129</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0865</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1158%2F1535-7163.MCT-13-0865" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=24608574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsFWjsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1117-1129&author=C.+Fritschauthor=A.+Huangauthor=C.+Chatenay-Rivaudayauthor=C.+Schnellauthor=A.+Reddyauthor=M.+Liuauthor=A.+Kauffmannauthor=D.+Guthyauthor=D.+Erdmannauthor=A.+De+Poverauthor=P.+Furetauthor=H.+Gaoauthor=S.+Ferrettiauthor=Y.+Wangauthor=J.+Trappeauthor=S.+M.+Brachmannauthor=S.+M.+Mairaauthor=C.+Wilsonauthor=M.+Boehmauthor=C.+Garcia-Echeverriaauthor=P.+Cheneauthor=M.+Wiesmannauthor=R.+Cozensauthor=J.+Leharauthor=R.+Schlegelauthor=G.+Caravattiauthor=F.+Hofmannauthor=W.+R.+Sellers&title=Characterization+of+the+novel+and+specific+PI3K%CE%B1+inhibitor+NVP-BYL719+and+development+of+the+patient+stratification+strategy+for+clinical+trials&doi=10.1158%2F1535-7163.MCT-13-0865"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials</span></div><div class="casAuthors">Fritsch, Christine; Huang, Alan; Chatenay-Rivauday, Christian; Schnell, Christian; Reddy, Anupama; Liu, Manway; Kauffmann, Audrey; Guthy, Daniel; Erdmann, Dirk; De Pover, Alain; Furet, Pascal; Gao, Hui; Ferretti, Stephane; Wang, Youzhen; Trappe, Joerg; Brachmann, Saskia M.; Maira, Sauveur-Michel; Wilson, Christopher; Boehm, Markus; Garcia-Echeverria, Carlos; Chene, Patrick; Wiesmann, Marion; Cozens, Robert; Lehar, Joseph; Schlegel, Robert; Caravatti, Giorgio; Hofmann, Francesco; Sellers, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1117-1129</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Somatic PIK3CA mutations are frequently found in solid tumors, raising the hypothesis that selective inhibition of PI3Kα may have robust efficacy in PIK3CA-mutant cancers while sparing patients the side-effects assocd. with broader inhibition of the class I phosphoinositide 3-kinase (PI3K) family.  Here, we report the biol. properties of the 2-aminothiazole deriv. NVP-BYL719, a selective inhibitor of PI3Kα and its most common oncogenic mutant forms.  The compd. selectivity combined with excellent drug-like properties translates to dose- and time-dependent inhibition of PI3Kα signaling in vivo, resulting in robust therapeutic efficacy and tolerability in PIK3CA-dependent tumors.  Novel targeted therapeutics such as NVP-BYL719, designed to modulate aberrant functions elicited by cancer-specific genetic alterations upon which the disease depends, require well-defined patient stratification strategies in order to maximize their therapeutic impact and benefit for the patients.  Here, we also describe the application of the Cancer Cell Line Encyclopedia as a preclin. platform to refine the patient stratification strategy for NVP-BYL719 and found that PIK3CA mutation was the foremost pos. predictor of sensitivity while revealing addnl. pos. and neg. assocns. such as PIK3CA amplification and PTEN mutation, resp.  These patient selection determinants are being assayed in the ongoing NVP-BYL719 clin. trials.  Mol Cancer Ther; 13(5); 1117-29. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzBW6u023PF7Vg90H21EOLACvtfcHk0liY7U8thaiGrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsFWjsb4%253D&md5=58d9132052dd9d430361021b0f877475</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0865&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0865%26sid%3Dliteratum%253Aachs%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DChatenay-Rivauday%26aufirst%3DC.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DReddy%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DKauffmann%26aufirst%3DA.%26aulast%3DGuthy%26aufirst%3DD.%26aulast%3DErdmann%26aufirst%3DD.%26aulast%3DDe%2BPover%26aufirst%3DA.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DFerretti%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DTrappe%26aufirst%3DJ.%26aulast%3DBrachmann%26aufirst%3DS.%2BM.%26aulast%3DMaira%26aufirst%3DS.%2BM.%26aulast%3DWilson%26aufirst%3DC.%26aulast%3DBoehm%26aufirst%3DM.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DChene%26aufirst%3DP.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DLehar%26aufirst%3DJ.%26aulast%3DSchlegel%26aufirst%3DR.%26aulast%3DCaravatti%26aufirst%3DG.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26atitle%3DCharacterization%2520of%2520the%2520novel%2520and%2520specific%2520PI3K%25CE%25B1%2520inhibitor%2520NVP-BYL719%2520and%2520development%2520of%2520the%2520patient%2520stratification%2520strategy%2520for%2520clinical%2520trials%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D1117%26epage%3D1129%26doi%3D10.1158%2F1535-7163.MCT-13-0865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Barlaam, B.; Cosulich, S.; Delouvrie, B.; Fitzek, M.; Germain, H.; Green, S.; Harris, C. S.; Hudson, K.; Lambert-van der Brempt, C.; Lamorlette, M.; Antoine, L. G.; Morgentin, R.; Ouvry, G.; Page, K.; Pasquet, G.; Ruston, L.; Saleh, T.; Vautier, M.; Ward, L.</span><span> </span><span class="NLM_article-title">Discovery of AZD8835, a potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of PIK3CA-dependent cancers</span>.  <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span>, <span class="NLM_issue">suppl</span>, abstract  <span class="NLM_fpage">2830</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2015-2830</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1158%2F1538-7445.AM2015-2830" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=2830&issue=suppl&author=B.+Barlaam&author=S.+Cosulich&author=B.+Delouvrie&author=M.+Fitzek&author=H.+Germain&author=S.+Green&author=C.+S.+Harris&author=K.+Hudson&author=C.+Lambert-van+der+Brempt&author=M.+Lamorlette&author=L.+G.+Antoine&author=R.+Morgentin&author=G.+Ouvry&author=K.+Page&author=G.+Pasquet&author=L.+Ruston&author=T.+Saleh&author=M.+Vautier&author=L.+Ward&title=Discovery+of+AZD8835%2C+a+potent+and+selective+inhibitor+of+PI3K%CE%B1+and+PI3K%CE%B4+for+the+treatment+of+PIK3CA-dependent+cancers&doi=10.1158%2F1538-7445.AM2015-2830"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2015-2830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2015-2830%26sid%3Dliteratum%253Aachs%26aulast%3DBarlaam%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520AZD8835%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520PI3K%25CE%25B1%2520and%2520PI3K%25CE%25B4%2520for%2520the%2520treatment%2520of%2520PIK3CA-dependent%2520cancers%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26issue%3Dsuppl%26spage%3D2830%26doi%3D10.1158%2F1538-7445.AM2015-2830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="note"><p class="first last">For recent reviews of isoform selective PI3K inhibitors, see:</p></div><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Marone, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cmiljanovic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giese, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wymann, M. P.</span><span> </span><span class="NLM_article-title">Targeting Phosphoinositide 3-Kinase—Moving Towards Therapy</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Proteins Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">1784</span><span class="NLM_x">, </span> <span class="NLM_fpage">159</span><span class="NLM_x">–</span> <span class="NLM_lpage">185</span><span class="refDoi"> DOI: 10.1016/j.bbapap.2007.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.bbapap.2007.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=17997386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlerug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1784&publication_year=2008&pages=159-185&author=R.+Maroneauthor=V.+Cmiljanovicauthor=B.+Gieseauthor=M.+P.+Wymann&title=Targeting+Phosphoinositide+3-Kinase%E2%80%94Moving+Towards+Therapy&doi=10.1016%2Fj.bbapap.2007.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting phosphoinositide 3-kinase-Moving towards therapy</span></div><div class="casAuthors">Marone, Romina; Cmiljanovic, Vladimir; Giese, Bernd; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1784</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">159-185</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Phosphoinositide 3-kinases (PI3K) orchestrate cell responses including mitogenic signaling, cell survival and growth, metabolic control, vesicular trafficking, degranulation, cytoskeletal rearrangement and migration.  Deregulation of the PI3K pathway occurs by activating mutations in growth factor receptors or the PIK3CA locus coding for PI3Kα, by loss of function of the lipid phosphatase and tensin homolog deleted in chromosome ten (PTEN/MMAC/TEP1), by the up-regulation of protein kinase B (PKB/Akt), or the impairment of the tuberous sclerosis complex (TSC1/2).  All these events are linked to growth and proliferation, and have thus prompted a significant interest in the pharmaceutical targeting of the PI3K pathway in cancer.  Genetic targeting of PI3Kγ (p110γ) and PI3Kδ (p110δ) in mice has underlined a central role of these PI3K isoforms in inflammation and allergy, as they modulate chemotaxis of leukocytes and degranulation in mast cells.  Proof-of-concept mols. selective for PI3Kγ have already successfully alleviated disease progress in murine models of rheumatoid arthritis and lupus erythematosus.  As targeting PI3K moves forward to therapy of chronic, non-fatal disease, safety concerns for PI3K inhibitors increase.  Many of the present inhibitor series interfere with target of rapamycin (TOR), DNA-dependent protein kinase (DNA-PKcs) and activity of the ataxia telangiectasia mutated gene product (ATM).  Here we review the current disease-relevant knowledge for isoform-specific PI3K function in the above mentioned diseases, and review the progress of > 400 recent patents covering pharmaceutical targeting of PI3K.  Currently, several drugs targeting the PI3K pathway have entered clin. trials (phase I) for solid tumors and suppression of tissue damage after myocardial infarction (phases I,II).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwrI_aSA632bVg90H21EOLACvtfcHk0lgKkJvRkGx6Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlerug%253D%253D&md5=bf9f259b3da61067631823656658e0f7</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2007.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2007.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DMarone%26aufirst%3DR.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DGiese%26aufirst%3DB.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DTargeting%2520Phosphoinositide%25203-Kinase%25E2%2580%2594Moving%2520Towards%2520Therapy%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2008%26volume%3D1784%26spage%3D159%26epage%3D185%26doi%3D10.1016%2Fj.bbapap.2007.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Chemically Targetting the PI3K Family</span> <span class="citation_source-journal">Biochem. Soc. Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">–</span> <span class="NLM_lpage">249</span><span class="refDoi"> DOI: 10.1042/BST0350245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1042%2FBST0350245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=17371250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt1Wrsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=245-249&author=Z.+A.+Knightauthor=K.+M.+Shokat&title=Chemically+Targetting+the+PI3K+Family&doi=10.1042%2FBST0350245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically targeting the PI3K family</span></div><div class="casAuthors">Knight, Z. A.; Shokat, K. M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">245-249</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  PI3K (phosphoinositide 3-kinase) is a key regulator of cell growth, metab., and survival.  The frequent activation of the PI3K pathway in cancer has stimulated widespread interest in identifying potent and selective inhibitors of PI3K isoforms.  The present paper highlights recent progress in identifying such mols. and the challenges that remain for efforts to pharmacol. target the PI3K family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtmivxnuTfQ7Vg90H21EOLACvtfcHk0lgKkJvRkGx6Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt1Wrsb4%253D&md5=b7243ad076ba15f65214acc8a3b09d65</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1042%2FBST0350245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST0350245%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DChemically%2520Targetting%2520the%2520PI3K%2520Family%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2007%26volume%3D35%26spage%3D245%26epage%3D249%26doi%3D10.1042%2FBST0350245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ward, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finan, P.</span><span> </span><span class="NLM_article-title">Isoform-specific Phosphoinositide 3-Kinase Inhibitors as Therapeutic Agents</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">426</span><span class="NLM_x">–</span> <span class="NLM_lpage">434</span><span class="refDoi"> DOI: 10.1016/S1471-4892(03)00078-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2FS1471-4892%2803%2900078-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=12901953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlvFGju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=426-434&author=S.+G.+Wardauthor=P.+Finan&title=Isoform-specific+Phosphoinositide+3-Kinase+Inhibitors+as+Therapeutic+Agents&doi=10.1016%2FS1471-4892%2803%2900078-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12cR"><div class="casContent"><span class="casTitleNuber">12c</span><div class="casTitle"><span class="NLM_cas:atitle">Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents</span></div><div class="casAuthors">Ward, Stephen G.; Finan, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">426-434</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The phosphoinositide 3-kinase (PI3K) family of enzymes consists of several closely related isoforms that are thought to have distinct biol. roles.  Until now, researchers have been frustrated by poor selectivity of the available pharmacol. inhibitors, which are unable to distinguish adequately the activities of different PI3K isoforms.  Recently published patent specifications describe new PI3K inhibitors, including several that are selective for the PI3Kδ isoform.  There is now cautious optimism that isoform-selective PI3K inhibitors will provide new avenues for therapeutic applications in a range of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoooGyT_yJeLLVg90H21EOLACvtfcHk0lgKkJvRkGx6Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlvFGju7c%253D&md5=301655ddf3635b506ddb01a95d608f1d</span></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1016%2FS1471-4892%2803%2900078-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1471-4892%252803%252900078-X%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DS.%2BG.%26aulast%3DFinan%26aufirst%3DP.%26atitle%3DIsoform-specific%2520Phosphoinositide%25203-Kinase%2520Inhibitors%2520as%2520Therapeutic%2520Agents%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2003%26volume%3D3%26spage%3D426%26epage%3D434%26doi%3D10.1016%2FS1471-4892%2803%2900078-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Sundstrom, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, D. L.</span><span> </span><span class="NLM_article-title">Inhibitors of Phosphoinositide-3-Kinase: A Structure-Based Approach to Understanding Potency and Selectivity</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">840</span><span class="NLM_x">–</span> <span class="NLM_lpage">850</span><span class="refDoi"> DOI: 10.1039/b819067b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1039%2Fb819067b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=19225663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvFGru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=840-850&author=T.+J.+Sundstromauthor=A.+C.+Andersonauthor=D.+L.+Wright&title=Inhibitors+of+Phosphoinositide-3-Kinase%3A+A+Structure-Based+Approach+to+Understanding+Potency+and+Selectivity&doi=10.1039%2Fb819067b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12dR"><div class="casContent"><span class="casTitleNuber">12d</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of phosphoinositide-3-kinase: a structure-based approach to understanding potency and selectivity</span></div><div class="casAuthors">Sundstrom, Teather J.; Anderson, Amy C.; Wright, Dennis L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">840-850</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Phosphoinositide-3-kinase is a pivotal protein involved in a wide variety of signaling cascades and there has been a great deal of interest in the development of potent and selective inhibitors of this enzyme.  In this review, the potency and selectivity of the known inhibitors is presented along with key structural information that helps rationalize the obsd. trends.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1X1C0qBQxy7Vg90H21EOLACvtfcHk0ljMTe1F3Im6vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvFGru70%253D&md5=77356f92a07e4314aa2bd90e2382c7c0</span></div><a href="/servlet/linkout?suffix=cit12d&amp;dbid=16384&amp;doi=10.1039%2Fb819067b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb819067b%26sid%3Dliteratum%253Aachs%26aulast%3DSundstrom%26aufirst%3DT.%2BJ.%26aulast%3DAnderson%26aufirst%3DA.%2BC.%26aulast%3DWright%26aufirst%3DD.%2BL.%26atitle%3DInhibitors%2520of%2520Phosphoinositide-3-Kinase%253A%2520A%2520Structure-Based%2520Approach%2520to%2520Understanding%2520Potency%2520and%2520Selectivity%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2009%26volume%3D7%26spage%3D840%26epage%3D850%26doi%3D10.1039%2Fb819067b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hayakawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaizawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koizumi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohishi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterfield, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of imidazo[1,2-<i>a</i>]pyridine derivatives as novel PI3 kinase p110α inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">403</span><span class="NLM_x">–</span> <span class="NLM_lpage">412</span><span class="refDoi"> DOI: 10.1016/j.bmc.2006.09.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.bmc.2006.09.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=17049248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Cmt77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=403-412&author=M.+Hayakawaauthor=H.+Kaizawaauthor=K.+Kawaguchiauthor=N.+Ishikawaauthor=T.+Koizumiauthor=T.+Ohishiauthor=M.+Yamanoauthor=M.+Okadaauthor=M.+Ohtaauthor=S.+Tsukamotoauthor=F.+I.+Raynaudauthor=M.+D.+Waterfieldauthor=P.+Parkerauthor=P.+Workman&title=Synthesis+and+biological+evaluation+of+imidazo%5B1%2C2-a%5Dpyridine+derivatives+as+novel+PI3+kinase+p110%CE%B1+inhibitors&doi=10.1016%2Fj.bmc.2006.09.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110α inhibitors</span></div><div class="casAuthors">Hayakawa, Masahiko; Kaizawa, Hiroyuki; Kawaguchi, Ken-ichi; Ishikawa, Noriko; Koizumi, Tomonobu; Ohishi, Takahide; Yamano, Mayumi; Okada, Minoru; Ohta, Mitsuaki; Tsukamoto, Shin-ichi; Raynaud, Florence I.; Waterfield, Michael D.; Parker, Peter; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">403-412</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">3-{1-[(4-Fluorophenyl)sulfonyl]-1H-pyrazol-3-yl}-2-methylimidazo[1,2-a]pyridine, 2a, was discovered in our chem. library as a novel p110α inhibitor with an IC50 of 0.67 μM, through screening in a scintillation proximity assay.  Optimization of the substituents of 2a increased the p110α inhibitory activity by more than 300-fold (2g: IC50 = 0.0018 μM).  Further structural modification of 2g afforded thiazole deriv. 12 (I), which has potent p110α inhibitory activity (IC50 of 0.0028 μM) and is highly selective for p110α over other PI3K isoforms.  Compd. 12 also inhibited serum-induced cell proliferation of A375 and HeLa cells in vitro with IC50 values of 0.14 μM and 0.21 μM, resp., and suppressed tumor growth by 37% in a mouse HeLa xenograft model when dosed i.p. at 25 mg/kg.  These results suggest that selective p110α inhibitors may have potential as cancer therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtD0faWirHM7Vg90H21EOLACvtfcHk0ljMTe1F3Im6vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Cmt77L&md5=775c2f4e69fd565d13df597610ec44dd</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.09.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.09.047%26sid%3Dliteratum%253Aachs%26aulast%3DHayakawa%26aufirst%3DM.%26aulast%3DKaizawa%26aufirst%3DH.%26aulast%3DKawaguchi%26aufirst%3DK.%26aulast%3DIshikawa%26aufirst%3DN.%26aulast%3DKoizumi%26aufirst%3DT.%26aulast%3DOhishi%26aufirst%3DT.%26aulast%3DYamano%26aufirst%3DM.%26aulast%3DOkada%26aufirst%3DM.%26aulast%3DOhta%26aufirst%3DM.%26aulast%3DTsukamoto%26aufirst%3DS.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DWaterfield%26aufirst%3DM.%2BD.%26aulast%3DParker%26aufirst%3DP.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520imidazo%255B1%252C2-a%255Dpyridine%2520derivatives%2520as%2520novel%2520PI3%2520kinase%2520p110%25CE%25B1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D403%26epage%3D412%26doi%3D10.1016%2Fj.bmc.2006.09.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pereira, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strangman, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marion, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldberg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roll, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersen, R.</span><span> </span><span class="NLM_article-title">Synthesis of Phosphatidylinositol 3-Kinase (PI3K) Inhibitory Analogues of the Sponge Meroterpenoid Liphagal. J</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8523</span><span class="NLM_x">–</span> <span class="NLM_lpage">8533</span><span class="refDoi"> DOI: 10.1021/jm100531u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100531u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8523-8533&author=A.+R.+Pereiraauthor=W.+K.+Strangmanauthor=F.+Marionauthor=L.+Feldbergauthor=D.+Rollauthor=R.+Mallonauthor=I.+Hollanderauthor=R.+Andersen&title=Synthesis+of+Phosphatidylinositol+3-Kinase+%28PI3K%29+Inhibitory+Analogues+of+the+Sponge+Meroterpenoid+Liphagal.+J&doi=10.1021%2Fjm100531u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1021%2Fjm100531u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100531u%26sid%3Dliteratum%253Aachs%26aulast%3DPereira%26aufirst%3DA.%2BR.%26aulast%3DStrangman%26aufirst%3DW.%2BK.%26aulast%3DMarion%26aufirst%3DF.%26aulast%3DFeldberg%26aufirst%3DL.%26aulast%3DRoll%26aufirst%3DD.%26aulast%3DMallon%26aufirst%3DR.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DAndersen%26aufirst%3DR.%26atitle%3DSynthesis%2520of%2520Phosphatidylinositol%25203-Kinase%2520%2528PI3K%2529%2520Inhibitory%2520Analogues%2520of%2520the%2520Sponge%2520Meroterpenoid%2520Liphagal.%2520J%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8523%26epage%3D8533%26doi%3D10.1021%2Fjm100531u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Gilbert, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bursavich, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehnhardt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delos Santos, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldberg, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatesan, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallon, R.</span><span> </span><span class="NLM_article-title">Novel Purine and Pyrazolo[3,4-d]pyrimidine Inhibitors of PI3 Kinase-a: Hit to Lead Studies</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">636</span><span class="NLM_x">–</span> <span class="NLM_lpage">639</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.11.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.bmcl.2009.11.051" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=636-639&author=A.+M.+Gilbertauthor=P.+Nowakauthor=N.+Brooijmansauthor=M.+G.+Bursavichauthor=C.+Dehnhardtauthor=E.+Delos+Santosauthor=L.+R.+Feldbergauthor=I.+Hollanderauthor=S.+Kimauthor=S.+Lombardiauthor=K.+Parkauthor=A.+M.+Venkatesanauthor=R.+Mallon&title=Novel+Purine+and+Pyrazolo%5B3%2C4-d%5Dpyrimidine+Inhibitors+of+PI3+Kinase-a%3A+Hit+to+Lead+Studies&doi=10.1016%2Fj.bmcl.2009.11.051"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.11.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.11.051%26sid%3Dliteratum%253Aachs%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DNowak%26aufirst%3DP.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DBursavich%26aufirst%3DM.%2BG.%26aulast%3DDehnhardt%26aufirst%3DC.%26aulast%3DDelos%2BSantos%26aufirst%3DE.%26aulast%3DFeldberg%26aufirst%3DL.%2BR.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLombardi%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DVenkatesan%26aufirst%3DA.%2BM.%26aulast%3DMallon%26aufirst%3DR.%26atitle%3DNovel%2520Purine%2520and%2520Pyrazolo%255B3%252C4-d%255Dpyrimidine%2520Inhibitors%2520of%2520PI3%2520Kinase-a%253A%2520Hit%2520to%2520Lead%2520Studies%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D636%26epage%3D639%26doi%3D10.1016%2Fj.bmcl.2009.11.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Kendall, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederick, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mawson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baguley, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaussade, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, P. R.</span><span> </span><span class="NLM_article-title">Synthesis, biological evaluation and molecular modeling of sulfonohydrazides as selective PI3K p110α inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">7677</span><span class="NLM_x">–</span> <span class="NLM_lpage">7687</span><span class="refDoi"> DOI: 10.1016/j.bmc.2007.08.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.bmc.2007.08.062" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=7677-7687&author=J.+D.+Kendallauthor=G.+W.+Rewcastleauthor=R.+Frederickauthor=C.+Mawsonauthor=W.+A.+Dennyauthor=E.+S.+Marshallauthor=B.+C.+Baguleyauthor=C.+Chaussadeauthor=S.+P.+Jacksonauthor=P.+R.+Shepherd&title=Synthesis%2C+biological+evaluation+and+molecular+modeling+of+sulfonohydrazides+as+selective+PI3K+p110%CE%B1+inhibitors&doi=10.1016%2Fj.bmc.2007.08.062"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13d&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2007.08.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2007.08.062%26sid%3Dliteratum%253Aachs%26aulast%3DKendall%26aufirst%3DJ.%2BD.%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DFrederick%26aufirst%3DR.%26aulast%3DMawson%26aufirst%3DC.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DMarshall%26aufirst%3DE.%2BS.%26aulast%3DBaguley%26aufirst%3DB.%2BC.%26aulast%3DChaussade%26aufirst%3DC.%26aulast%3DJackson%26aufirst%3DS.%2BP.%26aulast%3DShepherd%26aufirst%3DP.%2BR.%26atitle%3DSynthesis%252C%2520biological%2520evaluation%2520and%2520molecular%2520modeling%2520of%2520sulfonohydrazides%2520as%2520selective%2520PI3K%2520p110%25CE%25B1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D7677%26epage%3D7687%26doi%3D10.1016%2Fj.bmc.2007.08.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zunder, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loewith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokoe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toth, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balla, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">733</span><span class="NLM_x">–</span> <span class="NLM_lpage">747</span><span class="refDoi"> DOI: 10.1016/j.cell.2006.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.cell.2006.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=16647110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD28XltlSkt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2006&pages=733-747&author=Z.+A.+Knightauthor=B.+Gonzalezauthor=M.+E.+Feldmanauthor=E.+R.+Zunderauthor=D.+D.+Goldenbergauthor=O.+Williamsauthor=R.+Loewithauthor=D.+Stokoeauthor=A.+Ballaauthor=B.+Tothauthor=T.+Ballaauthor=W.+A.+Weissauthor=R.+L.+Williamsauthor=K.+M.+Shokat&title=A+Pharmacological+Map+of+the+PI3-K+Family+Defines+a+Role+for+p110%CE%B1+in+Insulin+Signaling&doi=10.1016%2Fj.cell.2006.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13eR"><div class="casContent"><span class="casTitleNuber">13e</span><div class="casTitle"><span class="NLM_cas:atitle">A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling</span></div><div class="casAuthors">Knight, Zachary A.; Gonzalez, Beatriz; Feldman, Morri E.; Zunder, Eli R.; Goldenberg, David D.; Williams, Olusegun; Loewith, Robbie; Stokoe, David; Balla, Andras; Toth, Balazs; Balla, Tamas; Weiss, William A.; Williams, Roger L.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">733-747</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinases (PI3-Ks) are an important emerging class of drug targets, but the unique roles of PI3-K isoforms remain poorly defined.  We describe here an approach to pharmacol. interrogate the PI3-K family.  A chem. diverse panel of PI3-K inhibitors was synthesized, and their target selectivity was biochem. enumerated, revealing cryptic homologies across targets and chemotypes.  Crystal structures of three inhibitors bound to p110γ identify a conformationally mobile region that is uniquely exploited by selective compds.  This chem. array was then used to define the PI3-K isoforms required for insulin signaling.  We find that p110α is the primary insulin-responsive PI3-K in cultured cells, whereas p110β is dispensable but sets a phenotypic threshold for p110α activity.  Compds. targeting p110α block the acute effects of insulin treatment in vivo, whereas a p110β inhibitor has no effect.  These results illustrate systematic target validation using a matrix of inhibitors that span a protein family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrozjvOeMXP3bVg90H21EOLACvtfcHk0lgYyFZD3lP78Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltlSkt7o%253D&md5=b95a8cb433927ff9a75b33fc4ac2c8a0</span></div><a href="/servlet/linkout?suffix=cit13e&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DGonzalez%26aufirst%3DB.%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DZunder%26aufirst%3DE.%2BR.%26aulast%3DGoldenberg%26aufirst%3DD.%2BD.%26aulast%3DWilliams%26aufirst%3DO.%26aulast%3DLoewith%26aufirst%3DR.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DBalla%26aufirst%3DA.%26aulast%3DToth%26aufirst%3DB.%26aulast%3DBalla%26aufirst%3DT.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DA%2520Pharmacological%2520Map%2520of%2520the%2520PI3-K%2520Family%2520Defines%2520a%2520Role%2520for%2520p110%25CE%25B1%2520in%2520Insulin%2520Signaling%26jtitle%3DCell%26date%3D2006%26volume%3D125%26spage%3D733%26epage%3D747%26doi%3D10.1016%2Fj.cell.2006.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Jamieson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, J. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolekar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchanan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baguley, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, P. R.</span><span> </span><span class="NLM_article-title">A drug targeting only p110α can block phosphoinositide 3-kinase signaling and tumour growth in certain cell types</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">438</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span><span class="refDoi"> DOI: 10.1042/BJ20110502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1042%2FBJ20110502" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=438&publication_year=2011&pages=53-62&author=S.+Jamiesonauthor=J.+U.+Flanaganauthor=S.+Kolekarauthor=S.+Buchananauthor=J.+D.+Kendallauthor=W.-J.+Leeauthor=G.+W.+Rewcastleauthor=W.+A.+Dennyauthor=R.+Singhauthor=J.+Dicksonauthor=B.+C.+Baguleyauthor=P.+R.+Shepherd&title=A+drug+targeting+only+p110%CE%B1+can+block+phosphoinositide+3-kinase+signaling+and+tumour+growth+in+certain+cell+types&doi=10.1042%2FBJ20110502"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1042%2FBJ20110502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20110502%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DS.%26aulast%3DFlanagan%26aufirst%3DJ.%2BU.%26aulast%3DKolekar%26aufirst%3DS.%26aulast%3DBuchanan%26aufirst%3DS.%26aulast%3DKendall%26aufirst%3DJ.%2BD.%26aulast%3DLee%26aufirst%3DW.-J.%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DDickson%26aufirst%3DJ.%26aulast%3DBaguley%26aufirst%3DB.%2BC.%26aulast%3DShepherd%26aufirst%3DP.%2BR.%26atitle%3DA%2520drug%2520targeting%2520only%2520p110%25CE%25B1%2520can%2520block%2520phosphoinositide%25203-kinase%2520signaling%2520and%2520tumour%2520growth%2520in%2520certain%2520cell%2520types%26jtitle%3DBiochem.%2520J.%26date%3D2011%26volume%3D438%26spage%3D53%26epage%3D62%26doi%3D10.1042%2FBJ20110502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guagnano, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairhurst, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imbach-Weese, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruce, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritsch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blasco, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aichholz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caravatti, G.</span><span> </span><span class="NLM_article-title">Discovery of NVP-BYL719 a Potent and Selective Phosphatidylinositol-3 Kinase Alpha Inhibitor Selected for Clinical Evaluation</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3741</span><span class="NLM_x">–</span> <span class="NLM_lpage">3748</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.bmcl.2013.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=23726034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosFaisrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3741-3748&author=P.+Furetauthor=V.+Guagnanoauthor=R.+A.+Fairhurstauthor=P.+Imbach-Weeseauthor=I.+Bruceauthor=M.+Knappauthor=C.+Fritschauthor=F.+Blascoauthor=J.+Blanzauthor=R.+Aichholzauthor=J.+Hamonauthor=D.+Fabbroauthor=G.+Caravatti&title=Discovery+of+NVP-BYL719+a+Potent+and+Selective+Phosphatidylinositol-3+Kinase+Alpha+Inhibitor+Selected+for+Clinical+Evaluation&doi=10.1016%2Fj.bmcl.2013.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation</span></div><div class="casAuthors">Furet, Pascal; Guagnano, Vito; Fairhurst, Robin A.; Imbach-Weese, Patricia; Bruce, Ian; Knapp, Mark; Fritsch, Christine; Blasco, Francesca; Blanz, Joachim; Aichholz, Reiner; Hamon, Jacques; Fabbro, Doriano; Caravatti, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3741-3748</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-kinase α (PI3Kα) is a therapeutic target of high interest in anticancer drug research.  On the basis of a binding model rationalizing the high selectivity and potency of a particular series of 2-aminothiazole compds. in inhibiting PI3Kα, a medicinal chem. program has led to the discovery of the clin. candidate NVP-BYL719 I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraN93Vwrfb4bVg90H21EOLACvtfcHk0lhCt9Fc11U9fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosFaisrY%253D&md5=a0d2d69e01e7a82a5fed04114105925e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DImbach-Weese%26aufirst%3DP.%26aulast%3DBruce%26aufirst%3DI.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DBlasco%26aufirst%3DF.%26aulast%3DBlanz%26aufirst%3DJ.%26aulast%3DAichholz%26aufirst%3DR.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DCaravatti%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520NVP-BYL719%2520a%2520Potent%2520and%2520Selective%2520Phosphatidylinositol-3%2520Kinase%2520Alpha%2520Inhibitor%2520Selected%2520for%2520Clinical%2520Evaluation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3741%26epage%3D3748%26doi%3D10.1016%2Fj.bmcl.2013.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Bruce, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akhlaq, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloomfield, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Budd, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuenoud, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gedeck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayler, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Head, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leblanc, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Grand, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oza, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilgrim, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Press, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sviridenko, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitehead, L.</span><span> </span><span class="NLM_article-title">Development of Isoform Selective PI3-Kinase Inhibitors as Pharmacological Tools for Elucidating the PI3K Pathway</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">5445</span><span class="NLM_x">–</span> <span class="NLM_lpage">5450</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.07.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.bmcl.2012.07.042" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=5445-5450&author=I.+Bruceauthor=M.+Akhlaqauthor=G.+C.+Bloomfieldauthor=E.+Buddauthor=B.+Coxauthor=B.+Cuenoudauthor=P.+Finanauthor=P.+Gedeckauthor=J.+Hattoauthor=J.+F.+Haylerauthor=D.+Headauthor=T.+Kellerauthor=L.+Kirmanauthor=C.+Leblancauthor=D.+Le+Grandauthor=C.+McCarthyauthor=D.+O%E2%80%99Connorauthor=C.+Owenauthor=M.+S.+Ozaauthor=G.+Pilgrimauthor=N.+E.+Pressauthor=L.+Sviridenkoauthor=L.+Whitehead&title=Development+of+Isoform+Selective+PI3-Kinase+Inhibitors+as+Pharmacological+Tools+for+Elucidating+the+PI3K+Pathway&doi=10.1016%2Fj.bmcl.2012.07.042"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.07.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.07.042%26sid%3Dliteratum%253Aachs%26aulast%3DBruce%26aufirst%3DI.%26aulast%3DAkhlaq%26aufirst%3DM.%26aulast%3DBloomfield%26aufirst%3DG.%2BC.%26aulast%3DBudd%26aufirst%3DE.%26aulast%3DCox%26aufirst%3DB.%26aulast%3DCuenoud%26aufirst%3DB.%26aulast%3DFinan%26aufirst%3DP.%26aulast%3DGedeck%26aufirst%3DP.%26aulast%3DHatto%26aufirst%3DJ.%26aulast%3DHayler%26aufirst%3DJ.%2BF.%26aulast%3DHead%26aufirst%3DD.%26aulast%3DKeller%26aufirst%3DT.%26aulast%3DKirman%26aufirst%3DL.%26aulast%3DLeblanc%26aufirst%3DC.%26aulast%3DLe%2BGrand%26aufirst%3DD.%26aulast%3DMcCarthy%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DD.%26aulast%3DOwen%26aufirst%3DC.%26aulast%3DOza%26aufirst%3DM.%2BS.%26aulast%3DPilgrim%26aufirst%3DG.%26aulast%3DPress%26aufirst%3DN.%2BE.%26aulast%3DSviridenko%26aufirst%3DL.%26aulast%3DWhitehead%26aufirst%3DL.%26atitle%3DDevelopment%2520of%2520Isoform%2520Selective%2520PI3-Kinase%2520Inhibitors%2520as%2520Pharmacological%2520Tools%2520for%2520Elucidating%2520the%2520PI3K%2520Pathway%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D5445%26epage%3D5450%26doi%3D10.1016%2Fj.bmcl.2012.07.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staben, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B.-Y.</span><span> </span><span class="NLM_article-title">The Rational Design of PI3 Kinase Inhibitors Exhibiting Selectivity Over the PI3K-β Isoform</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7815</span><span class="NLM_x">–</span> <span class="NLM_lpage">7833</span><span class="refDoi"> DOI: 10.1021/jm2007084</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007084" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7815-7833&author=T.+P.+Heffronauthor=B.+Weiauthor=A.+Oliveroauthor=S.+T.+Stabenauthor=V.+Tsuiauthor=S.+Doauthor=J.+Dotsonauthor=A.+Folkesauthor=P.+Goldsmithauthor=P.+Goldsmithauthor=J.+Gunznerauthor=J.+Lesnickauthor=C.+Lewisauthor=S.+Mathieuauthor=J.+Nonomiyaauthor=S.+Shuttleworthauthor=D.+P.+Sutherlinauthor=N.+C.+Wanauthor=S.+Wangauthor=C.+Wiesmannauthor=B.-Y.+Zhu&title=The+Rational+Design+of+PI3+Kinase+Inhibitors+Exhibiting+Selectivity+Over+the+PI3K-%CE%B2+Isoform&doi=10.1021%2Fjm2007084"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm2007084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007084%26sid%3Dliteratum%253Aachs%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DOlivero%26aufirst%3DA.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DFolkes%26aufirst%3DA.%26aulast%3DGoldsmith%26aufirst%3DP.%26aulast%3DGoldsmith%26aufirst%3DP.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DShuttleworth%26aufirst%3DS.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DB.-Y.%26atitle%3DThe%2520Rational%2520Design%2520of%2520PI3%2520Kinase%2520Inhibitors%2520Exhibiting%2520Selectivity%2520Over%2520the%2520PI3K-%25CE%25B2%2520Isoform%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7815%26epage%3D7833%26doi%3D10.1021%2Fjm2007084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Staben, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ndubaku, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaquiere, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bull, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edgar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heald, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolesnikov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLean, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ord, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouge, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weismann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P.</span><span> </span><span class="NLM_article-title">Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase β isoform</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">2606</span><span class="NLM_x">–</span> <span class="NLM_lpage">2613</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.02.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.bmcl.2013.02.102" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=2606-2613&author=S.+T.+Stabenauthor=C.+Ndubakuauthor=N.+Blaquiereauthor=M.+Belvinauthor=R.+J.+Bullauthor=D.+Dudleyauthor=K.+Edgarauthor=D.+Grayauthor=R.+Healdauthor=T.+P.+Heffronauthor=G.+E.+Jonesauthor=M.+Jonesauthor=A.+Kolesnikovauthor=L.+Leeauthor=J.+Lesnickauthor=C.+Lewisauthor=J.+Murrayauthor=N.+J.+McLeanauthor=J.+Nonomiyaauthor=A.+G.+Oliveroauthor=R.+Ordauthor=J.+Pangauthor=S.+Priceauthor=W.+W.+Priorauthor=L.+Rougeauthor=L.+Salphatiauthor=D.+Sampathauthor=J.+Wallinauthor=L.+Wangauthor=B.+Weiauthor=C.+Weismannauthor=P.+Wu&title=Discovery+of+thiazolobenzoxepin+PI3-kinase+inhibitors+that+spare+the+PI3-kinase+%CE%B2+isoform&doi=10.1016%2Fj.bmcl.2013.02.102"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.02.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.02.102%26sid%3Dliteratum%253Aachs%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DNdubaku%26aufirst%3DC.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DBull%26aufirst%3DR.%2BJ.%26aulast%3DDudley%26aufirst%3DD.%26aulast%3DEdgar%26aufirst%3DK.%26aulast%3DGray%26aufirst%3DD.%26aulast%3DHeald%26aufirst%3DR.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DJones%26aufirst%3DG.%2BE.%26aulast%3DJones%26aufirst%3DM.%26aulast%3DKolesnikov%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DMcLean%26aufirst%3DN.%2BJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DOrd%26aufirst%3DR.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DRouge%26aufirst%3DL.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DWallin%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWeismann%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520thiazolobenzoxepin%2520PI3-kinase%2520inhibitors%2520that%2520spare%2520the%2520PI3-kinase%2520%25CE%25B2%2520isoform%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D2606%26epage%3D2613%26doi%3D10.1016%2Fj.bmcl.2013.02.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Folkes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmadi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alderton, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alix, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuckowree, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depledge, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancox, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kugendradas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lensun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pergl-Wilson, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saghir, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallweber, H. J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhyvoloup, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvelebil, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S. J.</span><span> </span><span class="NLM_article-title">The Identification of 2-(1<i>H</i>-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5522</span><span class="NLM_x">–</span> <span class="NLM_lpage">5532</span><span class="refDoi"> DOI: 10.1021/jm800295d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800295d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVCmsr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5522-5532&author=A.+J.+Folkesauthor=K.+Ahmadiauthor=W.+K.+Aldertonauthor=S.+Alixauthor=S.+J.+Bakerauthor=G.+Boxauthor=I.+S.+Chuckowreeauthor=P.+A.+Clarkeauthor=P.+Depledgeauthor=S.+A.+Ecclesauthor=L.+S.+Friedmanauthor=A.+Hayesauthor=T.+C.+Hancoxauthor=A.+Kugendradasauthor=L.+Lensunauthor=P.+Mooreauthor=A.+G.+Oliveroauthor=J.+Pangauthor=S.+Patelauthor=G.+H.+Pergl-Wilsonauthor=F.+I.+Raynaudauthor=A.+Robsonauthor=N.+Saghirauthor=L.+Salphatiauthor=S.+Sohalauthor=M.+H.+Ultschauthor=M.+Valentiauthor=H.+J.+A.+Wallweberauthor=N.+C.+Wanauthor=C.+Wiesmannauthor=P.+Workmanauthor=P.+Zhyvoloupauthor=M.+J.+Zvelebilauthor=S.+J.+Shuttleworth&title=The+Identification+of+2-%281H-Indazol-4-yl%29-6-%284-methanesulfonyl-piperazin-1-ylmethyl%29-4-morpholin-4-yl-thieno%5B3%2C2-d%5Dpyrimidine+%28GDC-0941%29+as+a+Potent%2C+Selective%2C+Orally+Bioavailable+Inhibitor+of+Class+I+PI3+Kinase+for+the+Treatment+of+Cancer&doi=10.1021%2Fjm800295d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer</span></div><div class="casAuthors">Folkes, Adrian J.; Ahmadi, Khatereh; Alderton, Wendy K.; Alix, Sonia; Baker, Stewart J.; Box, Gary; Chuckowree, Irina S.; Clarke, Paul A.; Depledge, Paul; Eccles, Suzanne A.; Friedman, Lori S.; Hayes, Angela; Hancox, Timothy C.; Kugendradas, Arumugam; Lensun, Letitia; Moore, Pauline; Olivero, Alan G.; Pang, Jodie; Patel, Sonal; Pergl-Wilson, Giles H.; Raynaud, Florence I.; Robson, Anthony; Saghir, Nahid; Salphati, Laurent; Sohal, Sukhjit; Ultsch, Mark H.; Valenti, Melanie; Wallweber, Heidi J. A.; Wan, Nan Chi; Wiesmann, Christian; Workman, Paul; Zhyvoloup, Alexander; Zvelebil, Marketa J.; Shuttleworth, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5522-5532</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-kinase (PI3K) is an important target in cancer due to the deregulation of the PI3K/Akt signaling pathway in a wide variety of tumors.  A series of thieno[3,2-d]pyrimidine derivs. were prepd. and evaluated as inhibitors of PI3 kinase p110α.  The synthesis, biol. activity, and further profiling of these compds. are described.  This work resulted in the discovery of GDC-0941 (I) which is a potent, selective, orally bioavailable inhibitor of PI3K and is currently being evaluated in human clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojkFv29FXqO7Vg90H21EOLACvtfcHk0lhtIy0aKi8FnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVCmsr7E&md5=742084954685353ceaf18660ab3a0703</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm800295d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800295d%26sid%3Dliteratum%253Aachs%26aulast%3DFolkes%26aufirst%3DA.%2BJ.%26aulast%3DAhmadi%26aufirst%3DK.%26aulast%3DAlderton%26aufirst%3DW.%2BK.%26aulast%3DAlix%26aufirst%3DS.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%2BS.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DDepledge%26aufirst%3DP.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHancox%26aufirst%3DT.%2BC.%26aulast%3DKugendradas%26aufirst%3DA.%26aulast%3DLensun%26aufirst%3DL.%26aulast%3DMoore%26aufirst%3DP.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DPergl-Wilson%26aufirst%3DG.%2BH.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DRobson%26aufirst%3DA.%26aulast%3DSaghir%26aufirst%3DN.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSohal%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%2BH.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%2BA.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DZhyvoloup%26aufirst%3DP.%26aulast%3DZvelebil%26aufirst%3DM.%2BJ.%26aulast%3DShuttleworth%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520Identification%2520of%25202-%25281H-Indazol-4-yl%2529-6-%25284-methanesulfonyl-piperazin-1-ylmethyl%2529-4-morpholin-4-yl-thieno%255B3%252C2-d%255Dpyrimidine%2520%2528GDC-0941%2529%2520as%2520a%2520Potent%252C%2520Selective%252C%2520Orally%2520Bioavailable%2520Inhibitor%2520of%2520Class%2520I%2520PI3%2520Kinase%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5522%26epage%3D5532%26doi%3D10.1021%2Fjm800295d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castanedo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuckowree, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folks, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pegg, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouge, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A.</span><span> </span><span class="NLM_article-title">Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7579</span><span class="NLM_x">–</span> <span class="NLM_lpage">7587</span><span class="refDoi"> DOI: 10.1021/jm2009327</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2009327" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Ort7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7579-7587&author=D.+P.+Sutherlinauthor=L.+Baoauthor=M.+Berryauthor=G.+Castanedoauthor=I.+Chuckowreeauthor=J.+Dotsonauthor=A.+Folksauthor=L.+Friedmanauthor=R.+Goldsmithauthor=J.+Gunznerauthor=T.+Heffronauthor=J.+Lesnickauthor=C.+Lewisauthor=S.+Mathieuauthor=J.+Murrayauthor=J.+Nonomiyaauthor=J.+Pangauthor=N.+Peggauthor=W.+W.+Priorauthor=L.+Rougeauthor=L.+Salphatiauthor=D.+Sampathauthor=Q.+Tianauthor=V.+Tsuiauthor=N.+C.+Wanauthor=S.+Wangauthor=B.+Q.+Weiauthor=C.+Wiesmannauthor=P.+Wuauthor=B.-Y.+Zhuauthor=A.+Olivero&title=Discovery+of+a+Potent%2C+Selective%2C+and+Orally+Available+Class+I+Phosphatidylinositol+3-Kinase+%28PI3K%29%2FMammalian+Target+of+Rapamycin+%28mTOR%29+Kinase+Inhibitor+%28GDC-0980%29+for+the+Treatment+of+Cancer&doi=10.1021%2Fjm2009327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer</span></div><div class="casAuthors">Sutherlin, Daniel P.; Bao, Linda; Berry, Megan; Castanedo, Georgette; Chuckowree, Irina; Dotson, Jenna; Folks, Adrian; Friedman, Lori; Goldsmith, Richard; Gunzner, Janet; Heffron, Timothy; Lesnick, John; Lewis, Cristina; Mathieu, Simon; Murray, Jeremy; Nonomiya, Jim; Pang, Jodie; Pegg, Niel; Prior, Wei Wei; Rouge, Lionel; Salphati, Laurent; Sampath, Deepak; Tian, Qingping; Tsui, Vickie; Wan, Nan Chi; Wang, Shumei; Wei, Bin Qing; Wiesmann, Christian; Wu, Ping; Zhu, Bing-Yan; Olivero, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7579-7587</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of 2 (GDC-0980, I), a class I PI3K and mTOR kinase inhibitor for oncol. indications, is described. mTOR inhibition was added to the class I PI3K inhibitor 1 (GDC-0941) scaffold primarily through the substitution of the indazole in 1 for a 2-aminopyrimidine.  This substitution also increased the microsomal stability and the free fraction of compds. as evidenced through a pairwise comparison of mols. that were otherwise identical.  Highlighted in detail are analogs of an advanced compd. 4 that were designed to improve soly., resulting in 2.  This compd., is potent across PI3K class I isoforms with IC50s of 5, 27, 7, and 14 nM for PI3Kα, β, δ, and γ, resp., inhibits mTOR with a Ki of 17 nM yet is highly selective vs. a large panel of kinases including others in the PIKK family.  On the basis of the cell potency, low clearance in mouse, and high free fraction, 2 demonstrated significant efficacy in mouse xenografts when dosed as low as 1 mg/kg orally and is currently in phase I clin. trials for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-3-5KDI509bVg90H21EOLACvtfcHk0lhtIy0aKi8FnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Ort7%252FJ&md5=ba7ede710885b51fffa63977fc64d3f5</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm2009327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2009327%26sid%3Dliteratum%253Aachs%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DBao%26aufirst%3DL.%26aulast%3DBerry%26aufirst%3DM.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DFolks%26aufirst%3DA.%26aulast%3DFriedman%26aufirst%3DL.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DHeffron%26aufirst%3DT.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPegg%26aufirst%3DN.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DRouge%26aufirst%3DL.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DTian%26aufirst%3DQ.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DB.%2BQ.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DB.-Y.%26aulast%3DOlivero%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Available%2520Class%2520I%2520Phosphatidylinositol%25203-Kinase%2520%2528PI3K%2529%252FMammalian%2520Target%2520of%2520Rapamycin%2520%2528mTOR%2529%2520Kinase%2520Inhibitor%2520%2528GDC-0980%2529%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7579%26epage%3D7587%26doi%3D10.1021%2Fjm2009327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Ndubaku, C. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staben, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgardner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaquiere, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bull, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edgar, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heald, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolesnikov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nannini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span> </span><span class="NLM_article-title">Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1<i>H</i>-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-<i>d</i>][1,4]oxazepin-9-yl]-1<i>H</i>-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">4597</span><span class="NLM_x">–</span> <span class="NLM_lpage">4610</span><span class="refDoi"> DOI: 10.1021/jm4003632</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4003632" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVWjur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4597-4610&author=C.+O.+Ndubakuauthor=T.+P.+Heffronauthor=S.+T.+Stabenauthor=M.+Baumgardnerauthor=N.+Blaquiereauthor=E.+Bradleyauthor=R.+Bullauthor=S.+Doauthor=J.+Dotsonauthor=D.+Dudleyauthor=K.+A.+Edgarauthor=L.+S.+Friedmanauthor=R.+Goldsmithauthor=R.+A.+Healdauthor=A.+Kolesnikovauthor=L.+Leeauthor=C.+Lewisauthor=M.+Nanniniauthor=J.+Nonomiyaauthor=J.+Pangauthor=S.+Priceauthor=W.+W.+Priorauthor=L.+Salphatiauthor=S.+Siderisauthor=J.+J.+Wallinauthor=L.+Wangauthor=B.+Weiauthor=D.+Sampathauthor=A.+G.+Olivero&title=Discovery+of+2-%7B3-%5B2-%281-Isopropyl-3-methyl-1H-1%2C2%E2%80%934-triazol-5-yl%29-5%2C6-dihydrobenzo%5Bf%5Dimidazo%5B1%2C2-d%5D%5B1%2C4%5Doxazepin-9-yl%5D-1H-pyrazol-1-yl%7D-2-methylpropanamide+%28GDC-0032%29%3A+A+%CE%B2-Sparing+Phosphoinositide+3-Kinase+Inhibitor+with+High+Unbound+Exposure+and+Robust+in+Vivo+Antitumor+Activity&doi=10.1021%2Fjm4003632"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity</span></div><div class="casAuthors">Ndubaku, Chudi O.; Heffron, Timothy P.; Staben, Steven T.; Baumgardner, Matthew; Blaquiere, Nicole; Bradley, Erin; Bull, Richard; Do, Steven; Dotson, Jennafer; Dudley, Danette; Edgar, Kyle A.; Friedman, Lori S.; Goldsmith, Richard; Heald, Robert A.; Kolesnikov, Aleksandr; Lee, Leslie; Lewis, Cristina; Nannini, Michelle; Nonomiya, Jim; Pang, Jodie; Price, Steve; Prior, Wei Wei; Salphati, Laurent; Sideris, Steve; Wallin, Jeffery J.; Wang, Lan; Wei, BinQing; Sampath, Deepak; Olivero, Alan G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4597-4610</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dysfunctional signaling through the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway leads to uncontrolled tumor proliferation.  In the course of the discovery of novel benzoxepin PI3K inhibitors, we obsd. a strong dependency of in vivo antitumor activity on the free-drug exposure.  By lowering the intrinsic clearance, we derived a set of imidazobenzoxazepin compds. that showed improved unbound drug exposure and effectively suppressed growth of tumors in a mouse xenograft model at low drug dose levels.  One of these compds., GDC-0032 (I), was progressed to clin. trials and is currently under phase I evaluation as a potential treatment for human malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvaWg9tu7Zv7Vg90H21EOLACvtfcHk0lhVenF6HvXKbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVWjur8%253D&md5=f9c169c99757708a9d327ad0b022fde9</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm4003632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4003632%26sid%3Dliteratum%253Aachs%26aulast%3DNdubaku%26aufirst%3DC.%2BO.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DBaumgardner%26aufirst%3DM.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DBradley%26aufirst%3DE.%26aulast%3DBull%26aufirst%3DR.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DDudley%26aufirst%3DD.%26aulast%3DEdgar%26aufirst%3DK.%2BA.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DHeald%26aufirst%3DR.%2BA.%26aulast%3DKolesnikov%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DWallin%26aufirst%3DJ.%2BJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26atitle%3DDiscovery%2520of%25202-%257B3-%255B2-%25281-Isopropyl-3-methyl-1H-1%252C2%25E2%2580%25934-triazol-5-yl%2529-5%252C6-dihydrobenzo%255Bf%255Dimidazo%255B1%252C2-d%255D%255B1%252C4%255Doxazepin-9-yl%255D-1H-pyrazol-1-yl%257D-2-methylpropanamide%2520%2528GDC-0032%2529%253A%2520A%2520%25CE%25B2-Sparing%2520Phosphoinositide%25203-Kinase%2520Inhibitor%2520with%2520High%2520Unbound%2520Exposure%2520and%2520Robust%2520in%2520Vivo%2520Antitumor%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4597%26epage%3D4610%26doi%3D10.1021%2Fjm4003632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="note"><p class="first last">A depiction of a crystal structure of a benzoxepin bound to PI3Kγ (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3R7R">3R7R</a>) where residues are labeled to highlight differences between PI3Kα and the other isoforms within the active site can be found as <a href="/doi/suppl/10.1021/acs.jmedchem.5b01483/suppl_file/jm5b01483_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Staben, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdick, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouge, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P.</span><span> </span><span class="NLM_article-title">Structure-based design of thienobenzoxepin inhibitors of PI3-kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4054</span><span class="NLM_x">–</span> <span class="NLM_lpage">4058</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.04.124</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1016%2Fj.bmcl.2011.04.124" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=4054-4058&author=S.+T.+Stabenauthor=M.+Siuauthor=R.+Goldsmithauthor=A.+G.+Oliveroauthor=S.+Doauthor=D.+J.+Burdickauthor=T.+P.+Heffronauthor=J.+Dotsonauthor=D.+P.+Sutherlinauthor=B.-Y.+Zhuauthor=V.+Tsuiauthor=H.+Leauthor=L.+Leeauthor=J.+Lesnickauthor=C.+Lewisauthor=J.+M.+Murrayauthor=J.+Nonomiyaauthor=J.+Pangauthor=W.+W.+Priorauthor=L.+Salphatiauthor=L.+Rougeauthor=D.+Sampathauthor=S.+Siderisauthor=C.+Wiesmannauthor=P.+Wu&title=Structure-based+design+of+thienobenzoxepin+inhibitors+of+PI3-kinase&doi=10.1016%2Fj.bmcl.2011.04.124"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.04.124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.04.124%26sid%3Dliteratum%253Aachs%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DSiu%26aufirst%3DM.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DBurdick%26aufirst%3DD.%2BJ.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DZhu%26aufirst%3DB.-Y.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DLe%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DRouge%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DP.%26atitle%3DStructure-based%2520design%2520of%2520thienobenzoxepin%2520inhibitors%2520of%2520PI3-kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D4054%26epage%3D4058%26doi%3D10.1016%2Fj.bmcl.2011.04.124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Huang, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandelker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt-Kittler, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuels, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velculescu, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinzler, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogelstein, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabelli, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amzel, L. M.</span><span> </span><span class="NLM_article-title">The Structure of Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">318</span><span class="NLM_x">, </span> <span class="NLM_fpage">1744</span><span class="NLM_x">–</span> <span class="NLM_lpage">1748</span><span class="refDoi"> DOI: 10.1126/science.1150799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1126%2Fscience.1150799" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2007&pages=1744-1748&author=C.-H.+Huangauthor=D.+Mandelkerauthor=O.+Schmidt-Kittlerauthor=Y.+Samuelsauthor=V.+E.+Velculescuauthor=K.+W.+Kinzlerauthor=B.+Vogelsteinauthor=S.+B.+Gabelliauthor=L.+M.+Amzel&title=The+Structure+of+Human+p110%CE%B1%2Fp85%CE%B1+Complex+Elucidates+the+Effects+of+Oncogenic+PI3K%CE%B1+Mutations&doi=10.1126%2Fscience.1150799"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1126%2Fscience.1150799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1150799%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DC.-H.%26aulast%3DMandelker%26aufirst%3DD.%26aulast%3DSchmidt-Kittler%26aufirst%3DO.%26aulast%3DSamuels%26aufirst%3DY.%26aulast%3DVelculescu%26aufirst%3DV.%2BE.%26aulast%3DKinzler%26aufirst%3DK.%2BW.%26aulast%3DVogelstein%26aufirst%3DB.%26aulast%3DGabelli%26aufirst%3DS.%2BB.%26aulast%3DAmzel%26aufirst%3DL.%2BM.%26atitle%3DThe%2520Structure%2520of%2520Human%2520p110%25CE%25B1%252Fp85%25CE%25B1%2520Complex%2520Elucidates%2520the%2520Effects%2520of%2520Oncogenic%2520PI3K%25CE%25B1%2520Mutations%26jtitle%3DScience%26date%3D2007%26volume%3D318%26spage%3D1744%26epage%3D1748%26doi%3D10.1126%2Fscience.1150799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="note"><p class="first last">After the conclusion of our research efforts, a report suggesting the importance of hydrogen bonding with Gln859 to achieve PI3Kα specificity in a different series of molecules. See refs <a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">15, 16</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="note"><p class="first last">A figure depicting the computational Link/Grow strategy is included as <a href="/doi/suppl/10.1021/acs.jmedchem.5b01483/suppl_file/jm5b01483_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Li, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, C. K.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hank, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murry, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobiassen, H.</span><span> </span><span class="NLM_article-title">An Optimized Process for Formation of 2,4-Disubstituted Imidazoles from Condensation of Amidines and α-Haloketones</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">682</span><span class="NLM_x">–</span> <span class="NLM_lpage">683</span><span class="refDoi"> DOI: 10.1021/op025552b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op025552b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2002&pages=682-683&author=B.+Liauthor=C.+K.-F.+Chiuauthor=R.+F.+Hankauthor=J.+Murryauthor=J.+Rothauthor=H.+Tobiassen&title=An+Optimized+Process+for+Formation+of+2%2C4-Disubstituted+Imidazoles+from+Condensation+of+Amidines+and+%CE%B1-Haloketones&doi=10.1021%2Fop025552b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fop025552b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop025552b%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DB.%26aulast%3DChiu%26aufirst%3DC.%2BK.-F.%26aulast%3DHank%26aufirst%3DR.%2BF.%26aulast%3DMurry%26aufirst%3DJ.%26aulast%3DRoth%26aufirst%3DJ.%26aulast%3DTobiassen%26aufirst%3DH.%26atitle%3DAn%2520Optimized%2520Process%2520for%2520Formation%2520of%25202%252C4-Disubstituted%2520Imidazoles%2520from%2520Condensation%2520of%2520Amidines%2520and%2520%25CE%25B1-Haloketones%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2002%26volume%3D6%26spage%3D682%26epage%3D683%26doi%3D10.1021%2Fop025552b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><div class="note"><p class="first last">There are multiple reported values for liver blood flow of a rat. One estimate is 55.2 mL/min/kg:</p></div><span class="NLM_contrib-group">Tschida, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vance-Bryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaske, D. E.</span><span> </span><span class="NLM_article-title">Anti-infective agents and hepatic disease</span> <span class="citation_source-journal">Med. Clin. North Am.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">895</span><span class="NLM_x">–</span> <span class="NLM_lpage">917</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=7791429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADyaK2MXntVagtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=1995&pages=895-917&author=S.+J.+Tschidaauthor=K.+Vance-Bryanauthor=D.+E.+Zaske&title=Anti-infective+agents+and+hepatic+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-infective agents and hepatic disease</span></div><div class="casAuthors">Tschida, Suzanne J.; Vance-Bryan, Kyle; Zaske, Darwin E.</div><div class="citationInfo"><span class="NLM_cas:title">Medical Clinics of North America</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">895-917</span>CODEN:
                <span class="NLM_cas:coden">MCNAA9</span>;
        ISSN:<span class="NLM_cas:issn">0025-7125</span>.
    </div><div class="casAbstract">A review with 72 refs. on the pharmacokinetic principles related to antibacterial drug disposition in patient with hepatic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquHFfsK-S1ubVg90H21EOLACvtfcHk0ljy7HQFT3xhGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXntVagtrY%253D&md5=e6dbb44eae3a3e7fc682ea35674242cf</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTschida%26aufirst%3DS.%2BJ.%26aulast%3DVance-Bryan%26aufirst%3DK.%26aulast%3DZaske%26aufirst%3DD.%2BE.%26atitle%3DAnti-infective%2520agents%2520and%2520hepatic%2520disease%26jtitle%3DMed.%2520Clin.%2520North%2520Am.%26date%3D1995%26volume%3D79%26spage%3D895%26epage%3D917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liston, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silber, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacIntyre, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rance, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wastall, P.</span><span> </span><span class="NLM_article-title">The prediction of humanpharmacokinetic parameters from preclinical and in vitro metabolism data</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">46</span><span class="NLM_x">–</span> <span class="NLM_lpage">58</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=9336307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADyaK2sXmslCltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1997&pages=46-58&author=R.+S.+Obachauthor=J.+G.+Baxterauthor=T.+E.+Listonauthor=B.+M.+Silberauthor=B.+C.+Jonesauthor=F.+MacIntyreauthor=D.+J.+Ranceauthor=P.+Wastall&title=The+prediction+of+humanpharmacokinetic+parameters+from+preclinical+and+in+vitro+metabolism+data"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data</span></div><div class="casAuthors">Obach, R. Scott; Baxter, James G.; Liston, Theodore E.; Silber, B. Michael; Jones, Barry C.; Macintyre, Flona; Rance, David J.; Wastall, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-58</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">A review with 35 refs.  We describe a comprehensive retrospective anal. in which the abilities of several methods by which human pharmacokinetic parameters are predicted from preclin. pharmacokinetic data and/or in vitro metab. data were assessed.  The prediction methods examd. included both methods from the scientific literature as well as some described in this report for the first time.  Four methods were examd. for their ability to predict human vol. of distribution.  Three were highly predictive, yielding, on av., predictions that were within 60% to 90% of actual values.  Twelve methods were assessed for their utility in predicting clearance.  The most successful allometric scaling method yielded clearance predictions that were, on av., within 80% of actual values.  The best methods in which in vitro metab. data from human liver microsomes were scaled to in vivo clearance values yielded predicted clearance values that were, on av., within 70% to 80% of actual values.  Human t1/2 was predicted by combining predictions of human vol. of distribution and clearance.  The best t1/2 prediction methods successfully assigned compds. to appropriate dosing regimen categories (e.g., once daily, twice daily and so forth) 70% to 80% of the time.  In addn., correlations between human t1/2 and t1/2 values from preclin. species were also generally successful (72-87%) when used to predict human dosing regimens.  In summary, this retrospective anal. has identified several approaches by which human pharmacokinetic data can be predicted from preclin. data.  Such approaches should find utility in the drug discovery and development processes in the identification and selection of compds. that will possess appropriate pharmacokinetic characteristics in humans for progression to clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppAngniZ4izLVg90H21EOLACvtfcHk0ljy7HQFT3xhGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmslCltr0%253D&md5=68d1910d925e26ec4a8ef23043ffb1ed</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DBaxter%26aufirst%3DJ.%2BG.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DSilber%26aufirst%3DB.%2BM.%26aulast%3DJones%26aufirst%3DB.%2BC.%26aulast%3DMacIntyre%26aufirst%3DF.%26aulast%3DRance%26aufirst%3DD.%2BJ.%26aulast%3DWastall%26aufirst%3DP.%26atitle%3DThe%2520prediction%2520of%2520humanpharmacokinetic%2520parameters%2520from%2520preclinical%2520and%2520in%2520vitro%2520metabolism%2520data%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D283%26spage%3D46%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Pryde, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T.-D.</span><span> </span><span class="NLM_article-title">Aldehyde Oxidase: An Enzyme of Emerging Importance in Drug Discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8441</span><span class="NLM_x">–</span> <span class="NLM_lpage">8460</span><span class="refDoi"> DOI: 10.1021/jm100888d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100888d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFygt73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8441-8460&author=D.+C.+Prydeauthor=D.+Dalvieauthor=Q.+Huauthor=P.+Jonesauthor=R.+S.+Obachauthor=T.-D.+Tran&title=Aldehyde+Oxidase%3A+An+Enzyme+of+Emerging+Importance+in+Drug+Discovery&doi=10.1021%2Fjm100888d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Aldehyde Oxidase: An Enzyme of Emerging Importance in Drug Discovery</span></div><div class="casAuthors">Pryde, David C.; Dalvie, Deepak; Hu, Qiyue; Jones, Peter; Obach, R. Scott; Tran, Thien-Duc</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8441-8460</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Aldehyde oxidase has for many years been recognized as a metabolizing enzyme contained within the cytosolic compartment of many tissues and in many species.  The first literature ref. to AO dates from the 1930s, but literature citations to this enzyme have been steadily growing ever since, esp. in the past decade.  It has been increasingly recognized in this past decade that AO, through its unique structure, distribution, and substrate recognition, has an important role to play in the metab. of drugs.  In this timely Perspective, we present the current knowledge of the enzyme's expression, its structure, and its distribution across species.  We offer an anal. of substrates recognized by AO and highlight clin. examples where metab. by this enzyme has had significant clin. impact or led to the termination of a drug development program.  Finally, through anal. of the structure of known substrates, we present data to suggest the significant impact AO could play on future drug discovery programs along with strategies that could be employed to mitigate this.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqALwFS70G6tLVg90H21EOLACvtfcHk0lhk046YLJ8pqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFygt73N&md5=972eb9862a7dc7bff024b530ab40de7f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm100888d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100888d%26sid%3Dliteratum%253Aachs%26aulast%3DPryde%26aufirst%3DD.%2BC.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DTran%26aufirst%3DT.-D.%26atitle%3DAldehyde%2520Oxidase%253A%2520An%2520Enzyme%2520of%2520Emerging%2520Importance%2520in%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8441%26epage%3D8460%26doi%3D10.1021%2Fjm100888d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Edgar, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span> </span><span class="NLM_article-title">Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">1164</span><span class="NLM_x">–</span> <span class="NLM_lpage">1172</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-2525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.1158%2F0008-5472.CAN-09-2525" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=1164-1172&author=K.+A.+Edgarauthor=J.+J.+Wallinauthor=M.+Berryauthor=L.+B.+Leeauthor=W.+W.+Priorauthor=D.+Sampathauthor=L.+S.+Friedmanauthor=M.+Belvin&title=Isoform-Specific+Phosphoinositide+3-Kinase+Inhibitors+Exert+Distinct+Effects+in+Solid+Tumors&doi=10.1158%2F0008-5472.CAN-09-2525"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-2525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-2525%26sid%3Dliteratum%253Aachs%26aulast%3DEdgar%26aufirst%3DK.%2BA.%26aulast%3DWallin%26aufirst%3DJ.%2BJ.%26aulast%3DBerry%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DL.%2BB.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DBelvin%26aufirst%3DM.%26atitle%3DIsoform-Specific%2520Phosphoinositide%25203-Kinase%2520Inhibitors%2520Exert%2520Distinct%2520Effects%2520in%2520Solid%2520Tumors%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D1164%26epage%3D1172%26doi%3D10.1158%2F0008-5472.CAN-09-2525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="note"><p class="first last">Enzymatic IC<sub>50</sub> values were determined by Invitrogen for <b>4</b> against the following kinases, PI3KC2b (IC<sub>50</sub> = 261 nM), PI3KC2a (IC<sub>50</sub> > 10 μM), hVPS34 (IC<sub>50</sub> = 2.84 μM). <i>K</i><sub>i,app</sub> for mTOR was determined to be 4.3 μM. A complete list of kinases tested at Invitrogen is included as <a href="/doi/suppl/10.1021/acs.jmedchem.5b01483/suppl_file/jm5b01483_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="note"><p class="first last">The in vitro EC<sub>50</sub> values for inhibition of pAKT in MCF7-neo/HER2 cells are 4 and 10 nM for <b>3</b> and <b>4</b>, respectively.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="note"><p class="first last">Hepatic CL was predicted to be 5 mL/min/kg by microsomal incubations. Allometric scaling projected a plasma CL of 3 mL/min/kg (based on the rule of exponents).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Halladay, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaffer, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinhababu, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khojasteh-Bakht, S. C.</span><span> </span><span class="NLM_article-title">Metabolic Stability Screen for Drug Discovery Using Cassette Analysis and Column Switching</span> <span class="citation_source-journal">Drug Metab. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">67</span><span class="NLM_x">–</span> <span class="NLM_lpage">72</span><span class="refDoi"> DOI: 10.2174/187231207779814364</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=10.2174%2F187231207779814364" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=19356021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtleru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2007&pages=67-72&author=J.+S.+Halladayauthor=S.+Wongauthor=S.+M.+Jafferauthor=A.+K.+Sinhababuauthor=S.+C.+Khojasteh-Bakht&title=Metabolic+Stability+Screen+for+Drug+Discovery+Using+Cassette+Analysis+and+Column+Switching&doi=10.2174%2F187231207779814364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic stability screen for drug discovery using cassette analysis and column switching</span></div><div class="casAuthors">Halladay, Jason S.; Wong, Susan; Jaffer, Sharmin M.; Sinhababu, Achintya K.; Khojasteh-Bakht, S. Cyrus</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-72</span>CODEN:
                <span class="NLM_cas:coden">DMLRBM</span>;
        ISSN:<span class="NLM_cas:issn">1872-3128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">In vitro metabolic stability assays are used to screen compds. for stability in the presence of various drug metabolizing enzymes, usually cytochrome P 450 in liver prepns. (e.g., liver microsomes).  High-throughput metabolic stability assays using pooling methods have been developed to keep pace with screening requirements at the lead ADME optimization stage.  In our lab., we have improved the metabolic stability assay using the cassette anal. method, column switching, and incorporated time saving techniques in method development to yield a robust method which reduces data turnaround time, increases compd. throughput, and maximizes mass spectrometer usage.  This method can det. metabolic stability using microsomes or hepatocytes from any species.  We describe our findings following incubation of 40 different compds. with human liver microsomes and anal. by the cassette and discrete anal. methods.  Similar metabolic stability results were obtained using the cassette anal. and discrete anal. method.  An overall 70% time savings was achieved by pooling four new compds. into one sample for method development/MS optimization, cassetting four samples into one sample to minimize the no. of injections on LC/MS/MS anal., and using a column switching system to analyze the samples, which results in a two-fold decrease in the LC/MS/MS anal. time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKzVSm6sBe1bVg90H21EOLACvtfcHk0lhk046YLJ8pqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtleru74%253D&md5=e00c66b3ca6a1eaee107c4eb81e07bf5</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.2174%2F187231207779814364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187231207779814364%26sid%3Dliteratum%253Aachs%26aulast%3DHalladay%26aufirst%3DJ.%2BS.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DJaffer%26aufirst%3DS.%2BM.%26aulast%3DSinhababu%26aufirst%3DA.%2BK.%26aulast%3DKhojasteh-Bakht%26aufirst%3DS.%2BC.%26atitle%3DMetabolic%2520Stability%2520Screen%2520for%2520Drug%2520Discovery%2520Using%2520Cassette%2520Analysis%2520and%2520Column%2520Switching%26jtitle%3DDrug%2520Metab.%2520Lett.%26date%3D2007%26volume%3D1%26spage%3D67%26epage%3D72%26doi%3D10.2174%2F187231207779814364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DXH" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DXH','PDB','5DXH'); return false;">PDB: 5DXH</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RD0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RD0','PDB','2RD0'); return false;">PDB: 2RD0</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DXT" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DXT','PDB','5DXT'); return false;">PDB: 5DXT</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DXU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DXU','PDB','5DXU'); return false;">PDB: 5DXU</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3R7R" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3R7R','PDB','3R7R'); return false;">PDB: 3R7R</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i56"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01483">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_34102"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b01483">10.1021/acs.jmedchem.5b01483</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">A kinase selectivity panel for <b>4</b>, a figure explaining the Link and Grow strategies used to design PI3Kα specific inhibitors, crystal structure metrics as well as a depiction of a crystal structure of a benzoxepin bound to PI3Kγ (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3R7R">3R7R</a>) where residues are labeled to highlight differences between PI3Kα and the other isoforms within the active site (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01483/suppl_file/jm5b01483_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01483/suppl_file/jm5b01483_si_001.pdf">jm5b01483_si_001.pdf (556.85 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The coordinates of <b>5</b> in PI3Kα have been deposited with PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DXH">5DXH</a>. The coordinates of <b>4</b> in PI3Kα and PI3Kδ have been deposited with PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DXT">5DXT</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DXU">5DXU</a>, respectively.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b01483&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-3%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01483%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b01483" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6798ffc6dd3d3bf2","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
